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Abstracts	  
	   Receptor	   tyrosine	   kinases	   (RTKs)	   are	   key	   regulators	   of	   critical	   cellular	  processes,	   such	   as	   cell	   cycle,	   differentiation,	   proliferation,	   apoptosis	   and	   survival.	  Mutations,	  hyperactivity	  and	  loss	  of	  function	  of	  RTKs	  are	  responsible	  for	  numerous	  diseases.	  Because	  of	  the	  therapeutic	   importance	  of	  RTK	  signaling,	   intensive	  studies	  have	  been	  devoted	  to	  understanding	  the	  signaling	  mechanisms	  of	  RTKs,	  and	  the	  key	  components	  in	  their	  signaling	  networks.	  However,	  studying	  the	  cellular	  responses	  to	  RTK	  stimulation	  in	  a	  native	  cellular	  context	  is	  technically	  challenging.	  Consequently,	  many	  details	  of	  RTK	  signaling	  kinetics,	  and	  the	  underlying	  molecular	  mechanisms	  of	  action,	  remain	  unclear.	  	   The	  RET	  receptor	  tyrosine	  kinase	  is	  important	  for	  neuronal	  cell	  survival	  and	  function,	   and	   for	   the	   development	   of	   the	   kidneys	   and	   nervous	   system.	   Gain	   of	  function	   of	   RET	   leads	   to	   tumor	   formation,	   while	   loss	   of	   function	   in	   RET’s	   kinase	  activity	   is	  associated	  with	  the	  developmental	  kidney	  defect	  Hirschsprung’s	  disease.	  
	  	  vii	  
RET	   is	   activated	   by	   ligands	   of	   glial	   cell	   line-­‐derived	   neurotrophic	   factor	   (GDNF)	  family,	   which	   consist	   of	   four	   homologs—GDNF,	   Neuturin,	   Artemin	   (ART)	   and	  Persephin.	  GDNF	  family	  ligands	  activate	  RET	  only	  in	  the	  presence	  of	  GPI-­‐linked	  co-­‐receptors	   (GFRα1–4).	   Formation	   of	   the	   pentameric	   ligand/co-­‐receptor2/RET2	  complex	   leads	   to	   dimerization	   of	   RET	   and	   autophosphrylation	   of	   its	   cytoplasmic	  kinase	   domain.	   RET	   phosphorylation	   results	   in	   the	   activation	   of	   multiple	  downstream	   signaling	   pathways,	   including	   the	   Ras-­‐Raf-­‐MEK-­‐ERK	   and	   PI3K-­‐Akt	  pathways.	   The	  ERK	   and	  Akt	   signaling	   pathways	   participate	   in	   a	   variety	   of	   cellular	  activities,	  including	  cell	  survival,	  proliferation,	  and	  differentiation.	  
	   My	   project	   addresses	   the	   following	   questions:	   (1)	  What	   are	   the	   kinetics	   of	  RET	   activation	   and	   deactivation	   processes	   after	   ART	   stimulation?	   (2)	  How	   is	   RET	  activation	  coupled	  to	  the	  phosphorylation	  of	  ERK1/2	  and	  Akt?	  (3)	  How	  does	  ligand-­‐induced	  internalization	  of	  RET	  affect	  RET	  signaling?	  (4)	  How	  does	  each	  step	  in	  the	  RET-­‐Ras-­‐Raf-­‐MEK-­‐ERK	  cascade	  quantitatively	  regulate	  ERK	  phosphorylation	  levels?	  The	  results	  will	  elucidate	  the	  spatial	  and	  temporal	  dynamics	  of	  RET	  signaling	  upon	  stimulation	  by	  ART,	  and	  to	  determine	  how	  downstream	  signaling	  is	  regulated	  by	  the	  amplitude	   and	   timing	   of	   RET	   activation.	   Overall,	   the	   thesis	   aims	   to	   advance	   our	  understanding	   of	   RTK	   signaling,	   by	   establishing	   methods	   and	   principles	   that	   can	  potentially	  be	  applied	  to	  other	  RTK	  systems.	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Chapter	  1. Introduction:	  Structure	  and	  Functions	  of	  RET	  
1.1. Receptor	  Tyrosine	  Kinases	  
Receptor	   tyrosine	   kinases	   (RTKs)	   received	   their	   name	   due	   to	   their	   two	  essential	   properties,	   being	   on	   the	   cell	   membrane	   where	   they	   sense	   extracellular	  stimulation	   through	   binding	   cytokine	   or	   growth	   factor	   (GF)	   ligands	   and,	   upon	  activation,	   exhibiting	   kinase	   activity	   specific	   for	   tyrosine	   residues	   on	   intracellular	  target	   substrates.1	   Analysis	   of	   the	   human	   genome	   has	   confirmed	   that	   humans	  possess	  58	  RTKs,	  categorized	  into	  20	  subfamilies	  that	  include	  the	  EGFR-­‐ErbB	  family,	  insulin	  receptor	  (IR)	  family,	  Trks,	  FGFRs,	  PDGFRs,	  VEGFRs,	  RET,	  Met,	  and	  the	  ephrin	  receptors.2	   RTKs	   regulate	   normal	   cell	   proliferation,	   differentiation,	   and	   survival.	  Changes	  in	  the	  activity	  or	  expression	  levels	  of	  RTKs	  are	  associated	  with	  unregulated	  cells	   growth	   and	   apoptosis.	   Accordingly,	   significant	   effort	   has	   been	   invested	   in	  understanding	   RTK	   signaling	   mechanisms,	   in	   part	   to	   inform	   the	   development	   of	  RTK-­‐targeting	  anti-­‐cancer	  therapeutics.	  	  
RTKs	  were	   firstly	   discovered	   as	   cell	   surface	   receptors	   for	   insulin,	   and	   GFs	  such	  as	  epidermal	  growth	  factor	  (EGF)	  and	  nerve	  growth	  factor	  (NGF),	  in	  the	  1960s,	  before	   being	   recognized	   as	   a	   family	   and	   receiving	   their	   kinase-­‐activity	   related	  name.3,4	  GFs	  play	  important	  roles	  in	  regulating	  cell	  proliferation	  and	  differentiation,	  via	  binding	  to	   their	  cell	  surface	  receptors,	  many	  of	  which	  are	  RTKs.	   Initially,	  RTKs	  were	   proposed	   to	   function	   as	   passive	   carriers	   for	   GFs,	   to	   deliver	   them	   into	   the	  
	  	  
2	  
cytoplasm	   to	   interact	   with	   downstream	   signaling	   molecules.	   In	   the	   late	   1970s,	  however,	   experiments	   showing	   that	   a	   bivalent	   anti-­‐IR	   antibody	   could	   successfully	  mimic	  the	  functions	  of	  insulin	  proved	  that	  IR	  is	  more	  than	  just	  a	  passive	  carrier	  for	  insulin.5,6	  The	  fact	  that	  monovalent	  fragment	  antigen-­‐binding	  (Fab)	  fragments	  of	  the	  same	   antibody	   failed	   to	   induce	   the	   insulin-­‐like	   responses	   strongly	   suggested	   that	  receptor	  dimerization	  plays	  an	  important	  role	  in	  IR-­‐mediated	  signaling.7	  Kasuga	  et	  
al.	  first	  discovered	  the	  kinase	  activity	  of	  IR	  by	  showing	  that	  incubation	  of	  insulin	  and	  IR	  with	  ATP,	   in	  a	  cell-­‐free	  environment,	   caused	  phosphorylation	  of	   the	   IR	  α	  and	  β	  subunits.8	  Discovery	  of	  the	  kinase	  activity	  of	  RTKs,	  and	  the	  essential	  role	  of	  receptor	  dimerization,	   provided	   a	   basic	   framework	   for	   understanding	   the	   activation	  mechanism	  of	  ligand-­‐induced	  RTK	  activation.	  	  
RTKs	  share	  a	  common	  structural	  topology	  consisting	  of	  a	  large	  glycosylated	  extracellular	   domain,	   a	   helical	   transmembrane	   domain,	   and	   a	   cytoplasmic	   region	  containing	  a	  catalytic	  kinase	  domain,	  as	  illustrated	  in	  Figure	  1.1.9	  Ligand	  binding	  to	  
	  
Figure 1.1 Schematic illustration of the structure of the receptor tyrosine kinase (RTK) family 
and its activation upon ligand binding.  
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the	   receptor’s	   extracellular	   domain	   triggers	   rearrangement	   of	   the	   interacting	  receptors	  in	  the	  cytoplasmic	  region,	  and	  enhances	  the	  intrinsic	  kinase	  activity	  of	  the	  kinase	  domain.	  The	  activated	  kinase	  domain	  of	  one	  receptor	  catalyzes	  the	  transfer	  of	   the	   gamma-­‐phosphate	   (PO3-­‐)	   from	  ATP	   to	   tyrosine	   residues	   in	   the	   cytoplasmic	  domain	   of	   the	   other	   receptor	   in	   the	   dimer.	   These	   phosphorylation	   events	   further	  activate	  the	  catalytic	  activity	  of	  the	  receptor	  kinase	  domain,	  and	  also	  create	  docking	  sites	   for	   phosphotyrosine	   binding	   proteins	   such	   as	   scaffold	   proteins,	   leading	   to	  recruitment	   of	   other	   signaling	   molecules	   to	   initiate	   the	   signaling	   cascade.	   Some	  RTKs	  exist	  mainly	  as	  inactive	  monomers	  on	  the	  cell	  membrane,	  and	  dimerize	  upon	  ligand	   stimulation.	   The	   observation	   that,	   without	   insulin	   stimulation,	   most	   cell	  surface	  IR	  molecules	  exist	  as	  inactive	  dimers	  suggests	  that	  receptor	  dimerization	  is	  necessary	  but	  not	  sufficient	  for	  RTK	  activation.	  10	  




1.2. Introduction	  to	  RET	  
This	   thesis	   focuses	   on	   the	   RTK	   family	   member	   RET,	   a	   transmembrane	  receptor	   tyrosine	   kinase,	   which	   plays	   important	   roles	   in	   the	   development	   and	  maintenance	  of	  the	  nervous	  system	  and	  the	  kidneys.	  Abnormality	  in	  RET	  activity	  or	  expression	   causes	  dysregulated	   cell	   proliferation,	   differentiation	   and	   survival,	   and	  results	   in	   numerous	   diseases	   such	   as	   the	   kidney	   condition	   Hirschsprung	   disease,	  multiple	   endocrine	   neoplasia	   type	   2	   (MEN2),	   and	   papillary	   thyroid	   carcinoma	  (PTC).11	  
1.2.1. RET,	  Its	  Co-­‐receptors	  and	  Ligands	  
	   RET	   is	   encoded	   by	   the	   proto-­‐oncogene	   ret,	   standing	   for	   rearranged	  during	  
transfection.12,13	   As	   a	   typical	   receptor	   tyrosine	   kinase,	   RET	   contains	   a	   large	  extracellular	   domain,	   a	   helical	   transmembrane	   region,	   and	   an	   intracellular	   or	  cytoplasmic	  domain	  (Figure	  1.2).	  Mature	  RET	  has	  a	  mass	  of	  approximately	  175	  kDa.	  The	   glycosylated	   extracellular	   region	   of	   RET	   contains	   four	   cadherin-­‐like	   domains	  (CLD1-­‐4)	  of	  about	  110	  residues	  each	  and	  a	  cysteine-­‐rich	  domain	  of	  120	  residues.14	  There	  is	  also	  a	  Ca2+-­‐binding	  domain	  between	  CLD2	  and	  CLD3,	  and	  Ca2+	  is	  essential	  for	   RET	   signaling	   and	   stabilizes	   the	   ligand-­‐receptor	   complex.15	   The	   intracellular	  domain	   contains	   a	   juxtamembrane	   region	   of	   50	   residues,	   a	   kinase	   domain,	   and	  isoform-­‐specific	   tails.	   There	   are	   three	   isoforms	   of	   RET	   resulting	   from	   alternative	  splicing	  at	  3’	  exons:	  RET9,	  RET43	  and	  RET	  51,	  which	  contain	  unique	  sequences	  of	  9,	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43	   and	   51	   amino	   acids,	   respectively,	   in	   the	   C-­‐terminal	   tail	   after	   residue	   glycine	  1063.16,17	  	  RET	   is	   activated	   by	   the	   glial	   cell	   line-­‐derived	   neurotrophic	   factor	   (GDNF)	  family	   of	   ligands,	   which	   includes	   GDNF,	   neurturin	   (NTN),	   artemin	   (ART)	   and	  persephin	   (PSP).18	   GDNF	   family	   ligands	   (GFLs)	   are	   soluble,	   covalently	   dimeric	  proteins	  of	  approximately	  30	  kDa.	  GDNF	  was	   first	  discovered	   in	  1993	  as	  a	   trophic	  factor	   for	  a	  subset	  of	  neurons,	  such	  as	  midbrain	  dopaminergic	  neurons	  and	  motor	  neurons.19,20	   Later,	   GDNF	   was	   found	   to	   play	   important	   roles	   in	   neuronal	  
	   	  
Figure 1.2 Structural scheme of RET, GDNF family ligands and GFRα co-receptors. RET is a 
transmembrane receptor, consisting of an extracellular domain comprising 4 cadherin-like 
domains (CLDs), a Ca2+ binding domain and a cysteine-rich region (CRD), and an intracellular 
domain containing a kinase domain. GDNF family ligands (GFLs) (GDNF, NTN, ART and 
PSP) can activate RET only in the presence of a GPI-anchored GFRα co-receptor (GFRα1–
GFRα4). The preferred, although not exclusive, specificity between ligands and co-receptors is 
indicated with arrows. Upon ligand stimulation, RET is recruited to the cholesterol-rich 
regions in the plasma membrane (PM) called lipid rafts and form the active complex 
ligand/co-receptor2/RET2. RET is activated upon crossphosphorylation of its kinase domain, 
which then triggers downstream signaling cascades.  
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development	  in	  the	  central	  and	  peripheral	  nervous	  systems,	  by	  regulating	  neuronal	  cell	   survival,	   differentiation,	   and	   migration.21	   NTN,	   discovered	   in	   1996,	   has	  neurotrophic	   and	   mitogenic	   effects	   on	   sympathetic	   neurons	   and	   nasal	   sensory	  neurons.	   NTN	   is	   structurally	   similar	   to	   GDNF,22	   and	   thus	   defined	   a	   new	  neurotrophic	  factor	  family	  together	  with	  GDNF,	  and	  prompted	  the	  later	  discovery	  of	  ART	  and	  NTN	  based	  on	  sequence	  homology.	  Besides	  their	  pronounced	  effects	  on	  the	  nervous	   system,	   GDNF	   family	   ligands	   also	   regulate	   kidney	   development	   and	  spermatogonia	  differentiation.23	  	  
Different	  from	  most	  RTKs,	  RET	  is	  incapable	  of	  binding	  directly	  to	  its	  growth	  factor	  ligands	  on	  its	  own.	  RET	  can	  be	  activated	  by	  GFLs	  only	  in	  conjunction	  with	  one	  of	  the	  four	  glycosylphosphatidylinositol	  (GPI)-­‐anchored	  co-­‐receptors	  GFRα1–GFRα4	  on	   the	   cell	   membrane.	   Each	   GFL	   has	   its	   preferred	   co-­‐receptor	   (GDNF/GFRα1,	  NTN/GFRα2,	  ART/GFRα3,	  PSP/GFRα4),	  with	  which	   it	  binds	  with	  high	  affinity	   and	  specificity.	   Together,	   each	   GFL-­‐GFRα	   combination	   can	   bind	   to	   the	   extracellular	  domain	  of	  RET	  and	  recruit	  it	  to	  lipid	  rafts,	  the	  cholesterol-­‐rich	  regions	  in	  the	  plasma	  membrane,	  where	   the	   five-­‐member	  active	  complex	  comprising	  GFL/(GFRα)2/RET2	  is	   formed,	   as	   illustrated	   in	   Figure	   1.2.24	   Upon	   dimerization,	   RET	   becomes	   auto-­‐phosphorylated	   at	   multiple	   tyrosine	   residues	   in	   its	   intracellular	   kinase	   domain,	  which	   provide	   docking	   sites	   for	   phosphoprotein-­‐binding	   signaling	   proteins	   to	  initiate	  downstream	  signaling	  cascades.	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Due	   to	   the	   involvement	   of	   multiple	   components	   in	   the	   receptor	   activation	  process,	  the	  kinetic	  mechanism	  of	  RET	  activation	  is	  not	  yet	  completely	  understood.	  Jing	   et	   al.25	   proposed	   a	   stepwise	   binding	  mechanism	   suggesting	   that	   GDNF	   binds	  first	   to	   either	  monomeric	  or	  dimeric	  GFRα1,	   and	   then	   this	   complex	   interacts	  with	  two	  molecules	  of	  RET	  to	  induce	  RET	  dimerization.	  Experiments	  conducted	  by	  Schlee	  
et	  al.	  suggest	  that	  ART	  binds	  to	  one	  monomeric	  GFRα3	  molecule	  first,	  and	  then	  one	  recruits	  RET,	  followed	  by	  a	  second	  GFRα3	  and	  finally	  a	  second	  RET.26	  
	  Although	   each	   GFL	   has	   its	   preferred	   co-­‐receptor	   that	   it	   binds	   with	   high	  affinity,	   the	   ligand/co-­‐receptor	   interactions	   are	   not	   entirely	   exclusive.	   Additional	  interactions	  that	  have	  been	  discovered	  up	  to	  now	  are	  shown	  in	  Figure	  1.3.	  In	  vitro	  studies	  show	  that	  GFRα1	  can	  bind	  to	  both	  GDNF	  and	  NTN,	  and	  GFRα2	  can	  bind	  to	  GDNF	   in	   the	  presence	  of	  RET.27,28	  GFRα1	  and	  GFRα2	  can	  mediate	  both	  GDNF-­‐	  and	  NTN-­‐induced	  RET	  signaling	  in	  the	  cells.29	  In	  vivo	  studies	  show	  that	  ART	  can	  activate
	   	  
Figure 1.3 Scheme illustrating known interaction between GDNF family ligands (GFLs) and 
GFRα co-receptors. Main interactions are indicated with solid arrows, and cross-talks are 
indicated with dashed arrows.  
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  the	  GFRα1-­‐RET	  complex,30	  and	   that	  GFRα330	  and	  GFRα431	  can	   likely	  only	  activate	  RET	  via	  their	  paired	  ligands,	  ART	  and	  PSP,	  respectively.	  	  
Studies	   have	   shown	   that	   RET	   can	   be	   activated	   by	   GFLs	   with	   either	   cell	  membrane	  anchored	  GFRα,	  or	  with	  soluble	  GFRα.32	  GFRα	  co-­‐receptors	  are	  usually	  expressed	  as	  GPI-­‐anchored	  cell	  surface	  proteins	  located	  in	  the	  lipid	  rafts.	  When	  RET	  is	   activated	   by	   soluble	   GFLs	   and	   anchored	   GFRα,	   called	   activation	   in	   cis,	   RET	   is	  recruited	  to	  and	  activated	  in	  lipid	  rafts.	  Alternatively,	  when	  RET	  is	  activated	  by	  GFLs	  plus	   soluble	   GFRα,	   called	   in	   trans	   activation33,	   the	   resulting	   activated	   RET	   can	  interact	  with	  adaptor	  proteins	  outside	  of	  the	  lipid	  rafts.	  Activation	  of	  RET	  by	  soluble	  GFRα	  also	  increases	  the	  flexibility	  of	  how	  RET	  signaling	  can	  be	  regulated,	  by	  having	  two	  soluble	  signaling	  components,	  instead	  of	  only	  GFL	  as	  is	  the	  case	  for	  activation	  in	  
cis.	   In	   addition,	   the	  GFL-­‐GFRα	  gradient	   created	  by	  GFRα	   cleavage	  might	   cause	   the	  cells	   to	   receive	   different	   levels	   of	   RET	   stimulus	   and	   therefore	   develop	   differently,	  based	  on	   the	  distance	   to	   the	  GFRα-­‐shedding	  source.	  However,	   the	  extent	   to	  which	  RET	  activation	  differs	  qualitatively	  or	  quantitatively	  between	  activation	  in	  cis	  and	  in	  
trans	  is	  currently	  not	  fully	  known.24,33,34,35	  
Like	   other	   RTKs,	   RET	   signaling	   outcomes	   are	   dictated	   by	   ligand-­‐induced	  activation,	   phosphatase-­‐regulated	   deactivation,	   ubiquitination-­‐dependent	  degradation	   via	   the	   proteasome,	   and	   endosome-­‐dependent	   recycling	   and	  degradation.	   Protein	   tyrosine	   phosphatases	   (PTPs)	   directly	   deactivate	   RTKs	   by	  dephosphorylating	   the	   tyrosine	   residues.36	   Ligand-­‐induced	   receptor	   endocytosis	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regulates	  RTK	  signaling	  amplitude	  by	  reducing	  the	  cell	  surface	  receptor	  population,	  and	   also	   provides	   additional	   signaling	   platforms	   in	   endosomes.37,38	   (Additional	  background	   information	   on	   the	   detailed	   regulatory	   mechanisms	   and	   effects	   of	  endocytosis	  on	  RTK	  signaling	  is	  provided	  in	  Chapter	  4.)	  Comprehensive	  analysis	  of	  RTK	  signaling	  regulation	  has	  been	  performed	  on	  several	  RTK	  families	  such	  as	  ErbB,	  VEGFR	   and	   Trk.39,40,41,42	   The	   results	   show	   that	   mechanisms	   and	   dynamics	   in	   the	  regulation	   of	   PTP,	   endocytosis	   and	   degradation	   are	   highly	   conditional	   to	   the	  receptor	  system	  and	  cellular	  environment.	  
1.2.2. Signaling	  Pathways	  Downstream	  of	  RET	  
Once	   activated,	   RET	   is	   phosphorylated	   at	   multiple	   tyrosine	   residues	   and	   one	  serine	  residue	  in	  the	  intracellular	  domain,	  which	  serve	  as	  docking	  sites	  for	  a	  variety	  of	   adaptor	   proteins,	   shown	   in	  Figure	   1.4.	   Recruitment	   of	   these	   adaptor	   proteins	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 1.4 RET phosphorylation sites and their interacting adaptor proteins. 
	  	  
10	  
leads	   to	   activation	   of	   multiple	   downstream	   signaling	   pathways	   such	   as	   the	  PI3K/Akt,	  mitogen	  activated	  protein	  kinase	  (MAPK)	  (Ras/Raf/MEK/ERK),	  and	  c-­‐Jun	  N-­‐terminal	   kinase	   (JNK)	   pathways,	   shown	   in	   Figure	   1.5.43	   Four	   phosphorylated	  tyrosine	  residues	  (Tyr905,	  Tyr1015,	  Tyr	  1062	  and	  Tyr1096)	  in	  the	  RET	  cytoplasmic	  domain	  serve	  as	  binding	  sites	  for	  adaptor	  proteins	  containing	  a	  Src	  homolog	  2	  (SH2)	  or	  phosphotyrosine-­‐binding	  (PTB)	  domain.43	  Phosphorylated	  Tyr905,	  Tyr1015	  and	  Tyr1096	   can	   interact	   with	   the	   SH2	   containing	   proteins	   GRB2,	   GRB7,	   GRB10,	   and	  PLCγ.	   Phosphorylated	   Tyr1062	   interacts	   with	   multiple	   scaffold	   proteins	   such	   as	  SHC1,	  FRS2,	  IRS1/2	  and	  DOK1/2/4/5/6	  via	  their	  PTB	  domains.44	  Binding	  of	  SHC1	  to	  phospho-­‐Tyr1062	  leads	  to	  recruitment	  of	  GRB2	  and	  SOS	  leading	  to	  activation	  of	  the	  Ras/MAPK	   pathway,	   and	   recruitment	   of	   GRB2,	   GRB2	   and	   p85PI3K	   leading	   to	  
	  




activation	  of	  the	  PI3K/Akt	  pathway.45	  Although	  not	  the	  only	  route	  to	  activating	  ERK	  and	   Akt,	   Tyr1062	   is	   the	   most	   important	   site	   for	   initiating	   these	   events	   and	   is	  required	  for	  the	  cell-­‐survival	  signaling	  effects	  of	  RET	  activation.46	  Tyr1062	  is	  shared	  by	  all	  three	  RET	  isoforms	  (RET9,	  RET43	  and	  RET51),	  being	  the	  last	  residue	  before	  the	  distinct	  carboxyl	  tails	  begin	  to	  diverge.	  Tyr1096,	  also	  capable	  of	  interacting	  with	  GRB247	  and	  activating	  Akt,	  only	  exists	  in	  the	  long	  isoform	  RET51.	  	  
	   The	   pathways	   mentioned	   above	   are	   critical	   for	   the	   biological	   functions	   of	  RET	   in	  promoting	  cell	  survival	  and	  regulating	  cell	  growth	  and	  differentiation.	  ERK	  and	   Akt	   pathways,	   in	   particular,	   are	   critical	   regulators48	   of	   several	   important	  biological	   processes,	   such	   as	   cell	   differentiation,	   proliferation,	   survival	   and	  apoptosis.48	  
Extracellular-­‐signal-­‐regulated	  kinase	  (ERK)	  is	  a	  protein	  serine/threonine	  kinase	  that	  transduces	  extracellular	  stimuli	  to	  intracellular	  signaling	  events	  in	  response	  to	  stimulation	  by	   GFs	   and	   cytokines.49	   ERK1	   and	   ERK2	   are	   two	   isoforms	   of	   ERK,	   and	   share	   extensive	  sequence	   identity	   and	   similar	   functions.50	   ERK1	   and	   ERK2	   belong	   to	   the	   MAPK	   family.49	  Because	  the	  activities	  of	  these	  two	  kinases	  are	  largely	  redundant,	  often	  they	  are	  collectively	  referred	  to	  as	  ERK1/2	  or	  simply	  ERK,	  as	  we	  do	  here.	  ERK	  is	  activated	  by	  MEK	  in	  the	  Ras-­‐Raf-­‐MEK-­‐ERK	  signaling	  cascade,	  also	  called	  the	  MAPK/ERK	  pathway,	  shown	  in	  Figure	  1.5.	  When	  activated	  by	  MEK,	  human	  ERK1	  is	  phosphorylated	  at	  Tyr204	  and	  then	  Thr202,	  which	  correspond	  to	  Tyr187	  and	  Thr185	  in	  ERK2.	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When	  RET	  is	  activated,	  its	  phosphorylated	  kinase	  domain	  provides	  binding	  sites	  for	  scaffold	  proteins	  containing	  a	  phosphotyrosine	  binding	  domain	  and/or	  a	  SH2	  domain,	  such	  as	   SHC.51	   SHC	   then	   recruits	   GRB2	   and	   SOS	   to	   the	   plasma	  membrane.52	   SOS	   is	   a	   guanine	  exchange	   factor	   and	   induces	   the	   exchange	  of	  GDP	  bound	   to	   inactive	  Ras	  with	  GTP,	  which	  converts	   Ras	   (rat	   sarcoma)	   to	   its	   active	   conformation.53	   Activated	   GTP-­‐Ras	   binds	   to	   the	  cytoplasmic	  Ser/Thr	  kinase	  Raf	  with	  high	  affinity	  and	  recruits	  Raf	  to	  the	  plasma	  membrane,	  where	   it	   is	   activated	   via	   a	   multi-­‐step	   process.54	   Upon	   binding	   to	   Ras,	   inactive	   Raf	   is	  dephosphorylated	  at	  several	  residues	  including	  Ser259,	  dimerizes,	  dissociates	  from	  the	  Raf	  kinase	   inhibitory	   protein	   (RKIP)	   and	   chaperonin	   proteins	   such	   as	   14-­‐3-­‐3,	   and	   then	   is	  phosphorylated	  at	  several	  residues	  to	  achieve	  activation.55,56	  Activated	  Raf	  dissociates	  from	  membrane-­‐attached	   Ras	   and	   translocates	   into	   the	   cytoplasm.	   MEK1	   and	   MEK2	   are	   then	  activated	  by	  Raf	  via	  phosphorylation	  on	  Serine	  residues	  in	  their	  catalytic	  domain.57	  MEK,	  in	  turn,	   activates	   ERK1/2	   by	   phosphorylating	   at	   Thr202/185	   and	   Tyr204/187.49	   The	  observation	   of	   similar	   levels	   of	   ERK1	   and	   ERK2	   activation	   in	   the	   same	   cells	   upon	  stimulation	   in	  vivo	   suggests	   that	  ERK1	  and	  ERK2	  are	   activated	   in	  parallel.58	   In	   this	   study,	  ERK	  activation	  levels	  are	  determined	  using	  an	  antibody	  that	  detects	  activated	  ERK1	  through	  phospho-­‐Thr202	   and	  phospho-­‐Tyr204,	   and	   activated	  ERK2	   through	  phospho-­‐Thr185	   and	  phospho-­‐Tyr187.	  Activated	  ERK	  catalyzes	   the	  phosphorylation	  of	   its	   substrate	  proteins	   in	  the	   cytoplasm,	   which	   include	   phosphatases,	   ribosomal	   s6	   kinase	   (RSK)	   family	   protein	  kinases,	  apoptotic	  proteins,	  and	  other	  signaling	  molecules.59	  ERK	  can	  also	  translocate	  from	  the	   cytoplasm	   to	   the	   nucleus,	   where	   it	   can	   activate	   transcription	   factors	   and	   their	  regulators,	   such	   as	   Elk160	   and	   c-­‐Fos,61	   responsible	   for	   activating	   cell-­‐survival-­‐promoting	  genes.59,62	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PI3K/Akt	   pathway	   is	   another	   important	   signaling	   pathway	   downstream	   of	   most	  RTKs,	   parallel	   to	   the	   MAPK	   pathway.	   Akt,	   also	   known	   as	   protein	   kinase	   B	   (PKB),	   is	   a	  ubiquitously	  expressed	  cytoplasmic	   signaling	  kinase.	  There	  are	   three	   isoforms	   in	   the	  PKB	  family,	   Akt1/PKBα,	   Akt2/PKBβ,	   and	   Akt3/PKBγ.63	   We	   examined	   the	   activation	   of	   Akt1	  downstream	  of	  RET,	  which	   is	   referred	   to	   as	  Akt	   in	   this	   thesis	   unless	   otherwise	   specified.	  When	  RTKs	  are	  activated,	  PI3K	  can	  be	  activated	  by	  RTK	  via	  binding	  to	  its	  SH2	  domain	  via	  the	   p85-­‐PI3K	   subunit,	   or	   activated	   by	   Ras-­‐GTP.64,65,66	   Activated	   PI3K	   phosphorylates	  phosphatidylinositol-­‐4,5-­‐biphosphate	   (PIP2)	   to	   phosphatidylinositol-­‐3,4,5-­‐triphosphate	  (PIP3),	  which	  can	  in	  turn	  recruit	  and	  activate	  3-­‐phosphoinositide-­‐dependent	  kinase	  1	  (PDK1)	  and	   the	  mammalian	   target	   of	   rapamycin	   (mTOR)	   in	  mTOR	   complex	  2	   (mTORC2).67,68	   Full	  activation	   of	   Akt	   requires	   phosphorylation	   on	   Thr308	   by	   PDK169,70,	   and	   on	   Ser473	   by	  mTORC271	  or	  by	  DNA-­‐dependent	  protein	  kinase	   (DNA-­‐PK)72.	  DNA-­‐PK	   is	   a	  nuclear	  protein	  kinase	   that	   can	   activate	  Akt	   on	   the	   cell	  membrane	   in	   a	  PI3K-­‐dependent	  manner.72	   In	   this	  study,	  we	  monitored	   the	   phosphorylation	   levels	   of	   Ser473	   using	   an	   anti-­‐phospho-­‐Ser473	  Akt1	  antibody,	  to	  detect	  Akt	  activation	  levels	  downstream	  of	  RET	  signaling.	  	  
Two	  main	  functions	  of	  Akt	  are	  promoting	  cell	  survival	  and	  cell	  proliferation.	  Akt	  can	  phosphorylate	  one	  of	  the	  Bcl-­‐2	  family	  proteins,	  BAD,	  to	  inhibit	  its	  pro-­‐apoptotic	  activity	  and	  in	   turn	  promote	  cell	   survival.	  Akt	  can	  also	  phosphorylate	  and	  deactivate	   the	   transcription	  factors	  FOXO	  and	  p53,	  which	  in	  turn	  negatively	  regulate	  the	  expression	  of	  FOXO-­‐	  and	  p51-­‐mediated	   pro-­‐apoptotic	   genes.73,74	   Akt	   can	   additionally	   phosphorylate	   pro-­‐caspase-­‐9	   to	  decrease	   its	   protease	   activity,	   which	   directly	   decreases	   caspase-­‐9	   initiated	   cell	   death.75	  Another	   substrate	   of	   Akt	   is	   mTOR	   complex	   1,	   which	   regulates	   components	   in	   the	   gene	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translation	  and	  protein	  synthesis	  machinery.	  The	  PI3K/Akt	  pathway	  thus	  contributes	  to	  cell	  growth	  and	  survival	  by	  inhibiting	  apoptosis	  and	  maintaining	  protein	  synthesis.76	  
Due	  to	  the	  essential	  roles	  of	  ERK	  and	  Akt	  in	  regulating	  cell	  proliferation,	  survival	  and	  differentiation,	   in	   this	   study	   we	   chose	   ERK	   and	   Akt	   as	   two	   representative	   intracellular	  signaling	   molecules	   downstream	   of	   RET,	   to	   study	   how	   extracellular	   stimulation	   is	  transduced	  to	  intracellular	  signaling	  in	  the	  RET	  system.	  	  
1.2.3. GFL-­‐dependent	  Signaling	  of	  RET	  
	   Four	  different	  GFLs	  signal	  through	  RET	  and	  activate	  similar	  sets	  of	  tyrosine	  residues	  in	  the	  RET	  intracellular	  domain,	  but	  trigger	  different	  biological	  responses	  according	  to	  the	  different	  phenotypes	  of	  the	  respective	  gene-­‐knock-­‐out	  mice.77	  Even	  for	   the	   same	  GFL,	   activation	   in	  cis	   and	   in	  trans	   can	   trigger	  different	  RET	   signaling	  dynamics.	  Paratcha	  et	  al.33	  showed	  that	  RET	  activated	  in	  trans	  by	  soluble	  GDNF	  and	  GFRα1	   caused	   slower	   RET	   phosphorylation	   compared	   to	   activation	   in	   cis.	   As	   a	  result,	   RET	   activated	   in	   cis	   in	   lipid	   rafts	   could	   immediately	   interact	   with	   FRS2,	   a	  substrate	   for	   pTyr1062	   in	   RET	   residing	   in	   lipid	   rafts78,	  whereas	   RET	   activated	   in	  
trans	  showed	  a	  delayed	  recruitment	  to	  lipid	  rafts	  to	  interact	  with	  FRS2.	  In	  addition,	  RET	   activated	   in	   trans	  showed	   a	   stronger	   interaction	  with	   SHC	   outside	   lipid	   rafts	  compared	   to	   RET	   activated	   in	   cis.	   The	   above	   evidence	   of	   RET	   signaling	   diversity	  raises	  the	  possibility	  that	  RET	  signaling	  is	  dictated	  by	  differences	  in	  the	  structure	  of	  the	   RET	   dimer	   brought	   about	   by	   binding	   of	   GFL/GFRα,	   and/or	   by	   the	  membrane	  region	  in	  which	  RET	  activation	  occurs.	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   It	   is	   still	   unclear	   how	   four	   different	   GFLs	   achieve	   different	   biological	  outcomes	  when	  they	  act	  through	  a	  common	  receptor.	  It	  is	  been	  shown	  that,	  in	  a	  cell	  line	   expressing	  RET	  and	  GFRα1,	  NTN	   triggered	  neuronal	   cell	   differentiation	  while	  stimulation	  of	  the	  same	  cells	  with	  GDNF	  instead	  promoted	  cell	  survival.79	  The	  same	  study	  revealed	  that	  NTN	  induced	  sustained	  activation	  of	  MAPK	  and	  PLCγ	  pathways,	  whereas	   GDNF	   induced	   only	   transient	   activation	   of	   both.	   Furthermore,	   NTN-­‐dependent	   cell	   differentiation	   could	   be	   blocked	   by	   inhibiting	   PLCγ,	   while	   GDNF-­‐dependent	  cell	  survival	  could	  be	  blocked	  by	  inhibiting	  MAPK.	  These	  results	  showed	  that	   the	   functional	  outcome	  of	  RET	  signaling	  can	  be	  different	  even	  when	  activated	  via	   the	   same	   GFRα	   co-­‐receptor	   and	   triggering	   the	   same	   set	   of	   downstream	  pathways.	   Since	   GFRα1	   is	   not	   the	   primary	   co-­‐receptor	   for	   NTN,	   it	   is	   not	   clear	  whether	   the	   difference	   in	   signaling	   is	   due	   to	   NTN	   activating	   RET	   via	   a	   distinct	  mechanism,	  or	  because	  NTN	  is	  a	  weaker	  binder	  to	  GFRα1	  and	  RET.	  	  
	   In	  addition	   to	   the	  above	   functional	  evidence	   for	  differences	   in	   the	  way	   that	  different	  GFL/GFRα	  combinations	  activate	  RET,	  X-­‐ray	  structural	  analyses	  of	  GDNF-­‐GFRα1	   and	   ART-­‐GFRα3	   pairs	   have	   suggested	   that	   the	   distance	   between	   the	   two	  ligand-­‐bound	  GFRαs	  is	  dependent	  on	  the	  geometry	  and	  the	  flexibility	  of	  the	  ligand,	  which	  differ	  between	  these	   two	  GFLs.80	  The	  authors	  suggested	  that	   this	  geometric	  difference	   could	   affect	   the	   dimerization	   mode	   of	   RET	   in	   ways	   that	   control	   the	  signaling	  and	  functional	  effects	  of	  RET	  activation.	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The	  most	  compelling	  evidence	  that	  different	  GFL/GFRα	  pairs	  have	  different	  biological	  functions	  is	  provided	  by	  analysis	  of	  gene	  knockout	  mice.	  RET	  is	  expressed	  mostly	   in	   the	   nervous	   system	   and	   urogenital	   system,	  with	   high	   expression	   levels	  during	   embryonic	   development	   and	   lower	   expression	   levels	   in	   adult	   tissues.81,82	  RET	  is	  required	  for	  the	  proliferation	  and	  differentiation	  of	  the	  ureteric	  bud	  in	  kidney	  development,	  neural-­‐crest-­‐derived	  enteric	  precursors	  in	  the	  enteric	  nervous	  system,	  peripheral	  neurons	  of	   the	  sympathetic	  and	  parasympathetic	  nervous	  systems,	  and	  spermatogonia	  stem	  cells	  (precursor	  of	  sperm	  cells).21	  Gene	  knockout	  experiments	  with	   RET,	   GDNF,	   or	   GFRα1	   showed	   similar	   lethal	   deficits	   in	   kidneys,	   the	  parasympathetic	   nervous	   system	   and	   the	   enteric	   nervous	   system,	   suggesting	   that	  the	   biological	   function	   of	   RET	   during	   embryogenesis	   is	   primarily	   GDNF-­‐dependent.18	  NTN	  or	  GFRα2	  knock-­‐out	  mice	   showed	  milder	  phenotypes	   involving	  defects	  in	  development	  of	  the	  enteric	  and	  parasympathetic	  nervous	  systems.83	  ART	  and	   GFRα3	   knock-­‐out	   mice	   also	   showed	   a	   non-­‐lethal	   phenotype,	   indicating	   that	  ART-­‐GFRα3	   signaling	   is	   important	   for	   the	   development	   of	   superior	   cervical	  ganglion.84	  
Due	   to	   the	   essential	   functions	   of	   RET	   signaling,	   RET	   loss	   of	   function	  mutations	   in	   humans	   are	   associated	   with	   the	   kidney	   condition	   known	   as	  Hirschsprung	  disease,	  with	   kidney	   agenesis,	   and	  with	   congenital	   anomalies	   of	   the	  kidney	  and	  urinary	   tract	   (CAKUT).85	  Gain	  of	   function	  mutations	  of	  RET	   in	  humans	  cause	   multiple	   diseases	   due	   to	   uncontrolled	   cell	   proliferation,	   such	   as	   multiple	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endocrine	   neoplasia	   type	   2A	   (MEN2A)	   and	   2B	   (MEN2B),	   and	   familial	   medullary	  thyroid	   carcinoma	   (FMTC).	   MEN2A	   and	   FMTC	   mutations	   are	   found	   as	   cysteine	  residues	  mutated	  to	  non-­‐cysteine	  residues	   in	  the	  extracellular	  domain	  of	  RET,	  and	  they	  are	  believed	  to	  leave	  other	  cysteine	  residues	  unpaired,	  leading	  to	  the	  formation	  of	   aberrant	   disulfide	   bonds	   between	   two	   RET	   receptors	   that	   cause	   ligand-­‐independent	   dimerization	   and	   activation	   of	   RET.86,87	   FMTC	   mutations	   in	   the	  intracellular	  domain	  of	  RET,	  such	  as	  Y791F	  or	  S891A,	  lead	  RET	  to	  become	  activated	  without	   dimerization.88,89	  MEN2B	  mutations	   are	   found	   in	   the	  RET	   kinase	   domain,	  and	  cause	  the	  mutant	  RET	  to	  become	  constitutively	  active	  with	  an	   increased	  ART-­‐binding	  affinity,	  and	  to	  be	   further	  activated	  by	  GFLs.90	  Gain	  of	   function	  of	  RET	  can	  also	  result	   from	  the	  chromosomal	  rearrangement	  of	  RET,	   in	  which	  the	  RET	  kinase	  domain	   fuses	   with	   another	   gene	   that	   encodes	   a	   protein	   with	   a	   high	   tendency	   to	  dimerize.	   In	   this	   fusion	   two	  RET	  kinase	  domains	  are	  brought	   together	  and	  exhibit	  constitutive	  activation.	  Several	  RET	  rearrangements	  of	  this	  kind	  are	  responsible	  for	  papillary	  thyroid	  carcinoma	  (PTC).91	  	  
	  
1.3. Overview	  of	  this	  Thesis,	  and	  Goals	  of	  the	  Current	  Work	  
	   The	   ultimate	   goal	   of	  my	   thesis	   research	  was	   to	   elucidate	   the	   spatial	   and	   temporal	  dynamics	   of	   RET	   signaling	   upon	   stimulation	   by	   ART	   with	   GFRα3,	   and	   to	   determine	   how	  downstream	   signaling	   is	   regulated	   by	   the	   amplitude	   and	   timing	   of	   RET	   activation.	   This	  thesis	   focuses	   on	   addressing	   the	   following	   questions:	   (1)	   What	   are	   the	   kinetics	   of	   RET	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activation	   and	   deactivation	   processes	   upon	   ART	   stimulation?	   (2)	   How	   is	   RET	   activation	  coupled	  to	  activation	  of	  the	  Raf/MEK/ERK	  and	  PI3K/Akt	  signaling	  pathways?	  (3)	  How	  does	  ligand-­‐induced	   internalization	  of	  RET	  affect	  RET	   signaling?	   (4)	  How	  does	   each	   step	   in	   the	  RET/Ras/Raf/MEK/ERK	   signaling	   cascade	   quantitatively	   regulate	   ERK	   phosphorylation	  levels?	  	   Chapter	   2	   focuses	   on	   (1)	   developing	  methods	   to	   quantify	   cellular	   phosphorylation	  levels	  of	  RET,	  ERK	  and	  Akt	  upon	  ART	  stimulation	  using	  quantitative	  biochemical	  assays,	  and	  (2)	  analyzing	  signaling	  amplification	  and	  sensitization	  from	  RET	  to	  its	  downstream	  signaling	  effectors	   ERK	   and	   Akt	   under	   different	   ART	   stimulation	   conditions.	   This	   study	   provides	  insights	   into	   how	   receptor-­‐effector	   coupling	   efficiency	   varies	   as	   a	   function	   of	   stimulation	  strength	   and	   time	   after	   stimulation,	   and	  how	   it	   relates	   to	   the	   functional	   outcomes	   of	  RET	  signaling.	   My	   work	   in	   this	   chapter	   was	   recently	   published	   in	   the	   Journal	   of	   Biological	  Chemistry.	  The	  chapter	  was	  adapted	  from	  the	  manuscript	  of	  the	  published	  paper.92	  	  	   Chapter	  3	  describes	   the	   analysis	  of	  RET	  activation	  and	  deactivation	  kinetics	   in	   the	  initial	  10	  min	  after	  ART	  stimulation,	  and	  the	  development	  of	  a	  mechanistic	  model	   for	  how	  ART	  binding	  triggers	  the	  phosphorylation	  of	  RET.	  By	  applying	  simple	  biochemical	  methods	  with	  unmodified	  RET,	  in	  combination	  with	  computational	  analysis,	  we	  were	  able	  to	  identify	  the	  rate-­‐limiting	  step	  in	  the	  RET	  activation	  process.	  	  	   Chapter	  4	  describes	  a	  systemic	  study	  of	  how	  ligand-­‐induced	  receptor	  internalization	  affects	  the	  signaling	  capacity	  of	  RET,	  using	  a	  set	  of	  tools	  such	  as	  ELISA,	  flow	  cytometry	  and	  immunofluorescence	  microscopy.	  This	  work	  describes	  the	  discovery	  and	  characterization	  of	  a	  phosphorylated	  but	  signaling-­‐incompetent	  form	  of	  RET.	  Also	  reported	  is	  a	  computational	  model	  to	  describe	  RET	  signaling	  and	  trafficking	  kinetics,	  with	  evidence	  that	  this	  model	  can	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accurately	  predict	  the	  behavior	  of	  the	  system	  under	  conditions	  that	  differ	  from	  those	  used	  to	  obtain	  the	  data	  on	  which	  the	  model	  was	  trained.	  	   In	  Chapter	  5,	  studies	  of	  ERK	  deactivation	  kinetics	  are	  performed	  to	  investigate	  how	  each	   step	   contributes	   to	   ERK	   phosphorylation	   levels	   in	   the	   RET/Ras/Raf/MEK/ERK	  signaling	  cascade,	  using	  small	  molecule	   inhibitors	  targeting	  different	  steps	  of	   the	  pathway.	  Also	  described	  are	  similar	  studies	  on	  Akt	  activation	  in	  the	  PI3K/Akt	  pathway,	  and	  I	  address	  the	  question	  of	  whether	  there	  are	  feedback	  effects	  regulated	  by	  ERK	  and	  Akt	  activation,	  or	  cross-­‐talk	  between	  the	  ERK	  and	  Akt	  pathways.	  	  	   Overall,	   the	   results	   described	   in	   this	   thesis	   elucidate	   the	   spatial	   and	   temporal	  dynamics	  of	  RET	  signaling	  upon	  stimulation	  by	  ART,	  describe	  how	  downstream	  signaling	  is	  regulated	   by	   the	   amplitude	   and	   timing	   of	   RET	   activation,	   and	   thereby	   advance	   our	  understanding	  of	  RTK	  signaling.	  They	  additionally	  establish	  methods	  and	  principles	  that	  can	  potentially	  be	  applied	  to	  other	  RTK	  systems.	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Chapter	  2. Analysis	  of	  the	  Coupling	  Efficiency	  of	  RET	  to	  ERK	  and	  Akt	  
	   (This	   chapter	   is	   a	  modified	   version	   of	   Li,	   et	   al.,	   “Quantitative	   Analysis	   of	  
Receptor	  Tyrosine	  Kinase-­‐Effector	  Coupling	  at	  Functionally	  Relevant	  Stimulus	  
Levels”,	  Journal	  of	  Biological	  Chemistry	  (2015)	  10018-­‐10036.) 
	  
2.1. Key	   Questions	   about	   how	   RET	   Activation	   Couples	   to	   Downstream	  
Signaling	  
Our	  quantitative	  understanding	  of	   the	  activation	  and	  signaling	  mechanisms	  of	   cytokine	  and	  growth	   factor	   (GF)	   receptors	  has	  advanced	  substantially	   in	   recent	  years.93,94,95,96,97,98,99,100,101	   Yet	   because	   of	   the	   high	   complexity	   of	   the	   problem,	   and	  the	   often	   context-­‐dependent	   behavior	   of	   many	   intracellular	   signaling	   events	   and	  processes,	   progress	   toward	   a	   quantitative	   understanding	   of	   how	   cells	   orchestrate	  their	   response	   to	   external	   stimuli	   remains	   in	   its	   infancy.	   Experimental	   difficulties	  abound	   also.	   For	   example,	   functional	   cellular	   responses	   often	   occur	   at	   very	   low	  concentrations	   of	   stimulating	   GF,	   involving	   activation	   of	   only	   a	   tiny	   fraction	   of	  receptor	   molecules,	   whereas	   substantially	   higher	   stimulation	   levels	   are	   typically	  required	   to	  achieve	   robust	   levels	  of	   receptor	  activation	  and	   intracellular	   signaling	  that	   can	   easily	   be	   measured.102,103,104,105,106,107.	   Consequently,	   much	   of	   our	  knowledge	  about	   the	   timing	  and	  amplitude	  of	   receptor	   signaling	   responses	  comes	  from	  experiments	  using	  GF	  concentrations	  far	  above	  those	  at	  which	  biology	  occurs.	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Another	   experimental	   dilemma	   concerns	   whether	   to	   use	   approaches	   that	  aggregate	  responses	  from	  many	  cells,	  or	  instead	  to	  measure	  events	  occurring	  within	  individual	   cells.	   Single	   cell	  methods	   typically	   involve	   exogenously	   expressing,	   and	  often	   overexpressing,	   a	   signaling	   protein	   fused	   to	   a	   fluorescent	   partner	   that	  provides	   an	   optical	   readout	   for	   its	   activation	   state	   and/or	   intracellular	  location.108,109,110	   Such	   approaches,	   although	   uniquely	   informative	   in	   many	  important	  respects,	  carry	  the	  risk	  that	  the	  non-­‐native	  structure	  or	  expression	  level	  of	   the	   exogenous	   protein	   might	   qualitatively	   or	   quantitatively	   alter	   its	   behavior.	  Alternative	  methods,	   such	   as	   quantitative	  mass	   spectrometry-­‐based	  proteomics111	  or	   traditional	  Western	   blots	   or	   immunoassays112,	   can	   be	   applied	   to	   endogenously	  expressed	   proteins	   present	   at	   their	   natural	   expression	   levels,	   but	   they	   involve	  analysis	   of	   lysates	   generated	   from	   large	   populations	   of	   cells,	   thus	   obscuring	  potentially	   important	  cell-­‐to-­‐cell	  differences	   in	  behavior.	  Each	  of	   these	  approaches	  thus	  has	  its	  advantages	  and	  drawbacks.	  
The	   role	   of	   signaling	   dynamics	   in	   translating	   extracellular	   stimuli	   into	  functional	   cellular	   responses	   is	   emerging	   as	   an	   important	   field	   of	  study.113,114,115,116,117,118,119,120	   Many	   studies	   have	   reported	   data	   on	   the	   timing	   of	  various	  signaling	  events	  after	  activation	  of	  cells	  with	  a	  given	  growth	  factor,	  although	  quantitative	  and	  systematic	  studies	  of	  signaling	  dynamics	  are	  more	  rare.121,122,123	  In	  interpreting	  the	  functional	  role	  of	  dynamics,	  most	  work	  to	  date	  has	  focused	  on	  the	  role	  of	  network	  topology,	  for	  example	  through	  feedback	  activation	  or	  inhibition	  that	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can	   extend	   or	   truncate	   the	   duration	   of	   particular	   signaling	  events.101,113,114,115,116,118,119	   Molecular	   kinetic	   factors,	   involving	   the	   formation	   and	  decay	  kinetics	  of	  individual	  molecular	  species,	  have	  been	  invoked	  more	  rarely.	  For	  example,	   Albeck	   et	   al.	   have	   argued	   that	   the	   very	   slow	   decay	   rate	   of	   the	   ERK	  substrate	  Fra-­‐1	  serves	  to	  integrate	  over	  time	  the	  cumulative	  effect	  of	  multiple	  short	  pulses	  of	  ERK	  activation.124	   In	   the	  same	  vein,	  Fujita	  et	  al.	  have	  proposed	   that,	   in	  a	  system	  involving	  consecutive	  first-­‐order	  reactions,	  a	  kinetically	  slow	  step	  will	  act	  as	  a	   “low-­‐pass	   filter”	   to	   selectively	   dampen	   the	   transmission	   of	   rapidly	   changing	  upstream	  signals	   in	   favor	  of	  signals	  that	  are	  sustained	  or	   fluctuate	  more	  slowly.125	  However,	  how	  the	  dynamics	  of	  intracellular	  signaling	  processes	  and	  the	  kinetics	  of	  the	   individual	  molecular	   steps	   relate	   to	   the	   cell’s	   ability	   to	   sense	   and	   respond	   to	  external	  stimuli	  remains	  poorly	  understood.	  
	   Here,	   we	   address	   how	   activation	   of	   the	   receptor	   tyrosine	   kinase	   RET	   is	  quantitatively	  coupled	  to	  signaling	  events	   in	  divergent	  downstream	  pathways.	  Our	  laboratory	   has	   previously	   proposed	   a	   mechanism	   for	   the	   assembly	   of	   the	  multicomponent	   activated	   RET	   receptor	   complex	   on	   NB41A3-­‐mGFRα3	   mouse	  neuroblastoma	  cells,	  which	  express	  RET	  endogenously	  and	  were	  stably	  transfected	  with	  GFRα3.126	   This	   prior	  work	   established	   the	   quantitative	   relationship	   between	  the	   concentration	   of	   stimulating	   ART	   and	   the	   number	   of	   activated	   RET	   receptor	  complexes	   that	  result	  on	   the	  cell.	  Here,	  we	  address	  how	  assembly	  of	   the	  activated	  RET	   receptor	   complex	   on	   these	   same	   cells	   is	   quantitatively	   coupled	   to	  molecular	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events	   in	   divergent	   signaling	   pathways	   downstream	   of	   RET	   and	   to	   the	   functional	  response	  of	  neurite	  outgrowth.	  We	   focus	  on	  how	  RET	  activation	   is	   coupled	   to	   the	  phosphorylation	  of	  ERK	  and	  Akt,	  which	  are	  key	  mediators	  of	  cell	  survival,	  growth,	  and	  differentiation.63,49	  Our	  aim	  is	  to	  elucidate	  how	  the	  amplitude	  and	  timing	  of	  RET	  activation	   relate	   to	   the	   strength	   and	   character	   of	   intracellular	   signaling	   and	   to	   a	  functional	   cellular	   outcome.	   To	   address	   this	   question,	   we	   developed	   quantitative	  immunoassays	   to	   measure	   the	   absolute	   numbers	   of	   pRET,	   pERK,	   and	   pAkt	  molecules	  produced	   in	  cells	  by	  ART	  stimulation,	  and	  we	  used	   them	  to	  analyze	   the	  concentration	   dependence	   and	   time	   dependence	   of	   the	   receptor-­‐effector	  relationships.	  
	  
2.2. Quantification	   of	   Cellular	   RET,	   ERK	   and	   Akt	   Phosphorylation	   Levels	  
After	  ART	  Stimulation	  
2.2.1. Validation	  of	  ELISA	  Assays	  	  
ERK	  and	  Akt	  are	  critical	  downstream	  regulators	  that	  help	  fulfill	  the	  biological	  functions	   of	   RET.	   To	   fully	   understand	   the	   quantitative	   relationships	   between	  extracellular	   stimulation,	   RET	   activation	   levels,	   and	   downstream	   signaling	   events,	  we	   needed	   to	   quantify	   the	   number	   of	   molecules	   of	   each	   effector	   that	   become	  activated	   upon	   stimulation	   of	   cells	   by	   ART.	   The	   mouse	   neuroblastoma	   cell	   line	  (NB41A3-­‐mGFRα3)	  used	   in	   this	   study	  endogenously	  expresses	  RET,	  and	  had	  been	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stably	  transfected	  with	  GFRα3.	  The	  method	  of	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  was	  used	  to	  detect	  the	  concentrations	  of	  the	  phosphoproteins	  of	  interest	  in	  cell	   lysate	   after	   ART	   stimulation,	   as	   described	   in	   Experimental	   Methods.	   Taking	  phospho-­‐RET	  (pRET)	  detection	  (Figure	  2.1A),	   for	  instance,	  cells	  stimulated	  with	  a	  given	   concentration	   of	   ART	   for	   a	   given	   time	  were	   lysed,	   the	   solubilized	   RET	  was	  captured	   onto	   an	   assay	   plate	   using	   an	   antibody	   specific	   for	   the	   RET	   extracellular	  
	  
Figure 2.1 Illustration and validation of KIRA ELISA for pRET detection.A. Scheme 
illustrating experimental protocol for measuring phosphoprotein levels using quantitative 
immunoassay. B. KIRA ELISA assay validation. Cells were treated with various amount of 
ART for 20 min, followed with KIRA ELISA assay. “No C” (no capture antibody), “No D” 
(no detection antibody) and “LB” (lysis buffer as sample) were used as negative controls.	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domain,	  and	  the	  amount	  of	  phosphorylated	  RET	  was	  quantified	  using	  a	  horseradish	  peroxidase-­‐coupled	   anti-­‐phosphotyrosine	   antibody.	   Figure	   2.1B	   shows	   that	  stimulating	  the	  cells	  with	  4	  nM	  or	  10	  nM	  ART,	  for	  20	  min,	  gives	  a	  robust	  signal	  in	  the	  pRET	   ELISA	   compared	   to	   untreated	   cells.	   Three	   additional	   negative	   controls	   are	  used	   in	   the	   ELISA	   assay,	   comprising	   ELISA	   wells	   with	   capture	   antibody	   (No	   C),	  detection	  antibody	  (No	  D)	  or	  cell	  lysate	  (LB)	  omitted.	  Low	  signals	  from	  “No	  D”	  and	  “LB”	   suggest	   low	  nonspecific	   binding	  of	   the	  detection	   antibody	   to	   the	   assay	  plate.	  Comparable	  low	  signals	  between	  the	  “No	  C”	  control	  and	  lysates	  from	  untreated	  cells	  indicate	  that	  the	  basal	  signal	   in	  untreated	  cells	   is	  a	  result	  of	  nonspecific	  binding	  of	  proteins	   with	   phosphorylated	   tyrosine,	   rather	   than	   indicating	   a	   basal	   level	   of	  phosphorylated	  RET	  existing	  in	  untreated	  cells.	  





2.2.2. Standardizing	  Cellular	  pERK	  and	  pAkt	  Assays	  	  
In	  order	  to	  draw	  quantitative	  connections	  between	  RET	  activation	  levels	  and	  downstream	  signaling	  events,	  we	  needed	  to	  quantify	  how	  many	  molecules	  of	  RET,	  ERK	  and	  Akt	  per	  cell	  are	  activated	  under	  various	  stimulation	  conditions.	  Shown	  in	  
Figure	   2.3,	   we	   constructed	   standard	   curves	   using	   activated	   recombinant	   mouse	  pERK,	   or	   activated	   recombinant	   human	   pAkt,	   as	   standards.	   The	   capture	   and	  detection	   antibodies	   for	  pERK	  do	  not	  discriminate	  between	  pERK1	  and	  pERK2127,	  
	  
Figure 2.2 Validation of pERK and pAkt ELISAs. A. ELISA data for pERK (left) and pAkt 
(right) showing that, in each case, lysate from cells treated with 4 nM ART for 10 min gives a 
strong positive signal, whereas negative controls in which capture antibody (No C), detection 
antibody (No D), or cell lysate (LB) was omitted gave only a low background signal. Plots 
show the averaged data from duplicate wells. Error bars are the difference between the 
duplicates. Results are representative of at least three independent experiments. B. Dose-
response data for activation of ERK (left) and Akt (right) measured by Western blotting. Cell 
lysates were obtained by stimulating the cells with the stated concentration of ART for 10 min. 
α-Tubulin was used as loading control. 
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and	  those	  used	  for	  the	  pAkt	  ELISA	  detect	  both	  human	  and	  mouse	  pAkt.128	  We	  fitted	  the	   data	   points	   in	   the	   pERK	   standard	   curve	   to	   a	   linear	   equation,	   to	   obtain	   the	  relationships	  between	  the	  measured	  absorbance	  and	  the	  pERK	  concentration	  in	  the	  lysate.	  A	  hyperbolic	  equation	  was	  used	  to	  fit	  the	  pAkt	  standard	  curve.	  By	  reference	  to	   these	   standard	   curves,	  we	   estimate	   that	   stimulation	  of	   6	  ×	  105	   cells	  with	  4	  nM	  ART	  for	  10	  min	  resulted	  in	  cell	  lysate	  (600	  μL)	  containing	  9.9	  ±	  2.0	  ng/mL	  pERK	  and	  9.4	  ±	  1.2	  ng/mL	  pAkt	  (n	  =	  3),	  which	  corresponds	  to	  formation	  of	  142,000	  ±	  33,000	  pERK	  molecules	  and	  95,000	  ±	  12,000	  pAkt	  molecules	  per	  cell.	  The	  error	  limits	  are	  standard	   deviations	   from	   three	   replicates.	   These	   stimulation	   conditions	   result	   in	  maximal	   responses	   for	   both	   pERK	   and	   pAkt,	   indicating	   that	   the	   above	   numbers	  reflect	  the	  maximum	  number	  of	  ERK	  or	  Akt	  molecules	  per	  cell	  that	  are	  available	  for	  
	  
Figure 2.3 Calibration data for pERK and pAkt ELISAs. Calibration curves constructed using 
purified recombinant activated mouse ERK2 (A) in the pERK ELISA or human pAkt1 (B) in 
the pAkt ELISA, added to cell lysate from unstimulated cells. Data points show the averaged 
data from duplicate wells, shown as absorbance at 450 nm. Solid lines show the best fit of the 
data points to a linear (pERK) or hyperbolic (pAkt) equation. Error bars are the difference 
between the duplicates. The dashed lines show the signal detected in lysates from NB41A3-
mGFRα3 cells stimulated with 4 nM ART for 10 min in the same experiment. Results show 




activation	  by	  ART	  stimulation.	  These	  calibrations	  were	  used	  to	  scale	  the	  ELISA	  data	  from	  subsequent	  experiments	  to	  give	  an	  estimate	  of	  absolute	  pERK	  and	  pAkt	  levels,	  by	   including	   in	   each	  experiment	   control	  wells	   containing	   lysate	   from	  cells	   treated	  with	  4	  nM	  ART	  for	  10	  min.	  
2.2.3. Quantification	  of	  Cellular	  pRET	  Levels	  	  
Due	  to	   the	  difficulty	   in	  obtaining	  purified	  recombinant	  phosphorylated	  RET	  protein,	  we	  were	  not	  able	  to	  construct	  a	  standard	  curve	  to	  calibrate	  the	  pRET	  ELISA	  data	  to	  quantify	  the	  number	  of	  molecules	  of	  RET	  being	  activated	  in	  the	  cells.	  It	  has	  been	   reported	   that	   NB41A3-­‐mGFRα3	   cells	   express	   approximately	   6500	   RET	  molecules	  per	   cell.126	   If	  we	   could	  establish	  what	   fraction	  of	  6500	   cell	   surface	  RET	  molecules	   become	   phosphorylated	   under	  maximal	   ART	   stimulation	   condition,	   we	  could	  use	  this	  number	  to	  calibrate	  the	  pRET	  ELISA.	  	  To	  do	  this	  we	  treated	  the	  cells	  with	  4	  nM	  ART	  for	  20	  min,	  and	  then	  divided	  the	  resulting	  cell	  lysate	  into	  two	  parts.	  One	   part	   we	   treated	   with	   sepharose	   beads	   coated	   with	   anti-­‐pTyr	   antibody,	   to	  partially	  deplete	  pTyr-­‐containing	  proteins	  including	  pRET	  from	  the	  lysate.	  The	  other	  portion	   of	   the	   lysate	  we	   treated	   similarly	   but	   using	   beads	   coated	  with	   an	   isotype	  control	   antibody	   instead	   of	   anti-­‐pTyr.	   We	   then	   assayed	   both	   the	   pTyr-­‐depleted	  lysate	  and	  the	  control	  lysate	  to	  measure	  the	  concentration	  of	  pRET	  remaining	  and,	  separately,	   to	  measure	   total	  RET	  protein	   regardless	   of	   phosphorylation	   state.	   The	  total	  RET	  ELISA	  was	  performed	  similarly	  to	  the	  KIRA	  assay	  described	  above,	  except	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detecting	  with	   a	   polyclonal	   anti-­‐RET	   antibody	   in	   place	   of	   the	   anti-­‐pTyr	   detection	  antibody.	  	  
The	  results	  (Figure	  2.4)	  show	  that	  treatment	  of	  the	  cell	  lysate	  with	  the	  anti-­‐pTyr	  beads	  reduced	  pRET	  levels	  by	  58%,	  and	  reduced	  total	  RET	  by	  28%.	  Thus,	  the	  fraction	  of	   total	  RET	   that	  was	  phosphorylated	   in	   this	   experiment	  =	  28%	  /	  58%	  ×	  100	  =	  49%.	  	  The	  average	  of	  three	  independent	  experiments	  showed	  that	  stimulation	  by	   4	   nM	   ART	   for	   20	   min	   causes	   49%	   ±	   5%	   of	   total	   cellular	   RET	   to	   be	  phosphorylated.	   Given	   6500	   RET	  molecules	   per	   cell,	   this	   amount	   is	   equivalent	   to	  
	  
Figure 2.4 Fraction of total cellular RET that becomes phosphorylated upon activation with 4 
nM ART for 20 min. ELISA analysis showed that treatment of cell lysate with anti-pTyr-
coated beads reduced pRET levels by 58 ± 5% (A) but reduced total RET levels by only 28 ± 
1% (B), compared to treatment of the lysates with unconjugated control beads, indicating that 
ART treatment had resulted in phosphorylation of 28 × 100/58 = 49 ± 4% of total cellular 
RET. The negative controls are analysis of lysate from ART-treated cells but omitting either 
the anti-RET capture antibody (“ART, no capture”) or the anti-pTyr or anti-RET detection 
antibody (“ART, no detection”), or analysis of lysis buffer only instead of cell lysate. Results 
shown are averaged data from duplicate measurements from a single experiment. Error bars 
are the differences between the duplicates. Results shown are representative of three 
independent replicate experiments, and quoted uncertainty limits are standard deviations of 
the three independent results.  
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6500	  ×	  49%	  =	  3200	  RET	  molecules	  per	  cell	  that	  become	  activated	  upon	  stimulation	  with	  4	  nM	  ART	  for	  20	  min.	  	  
Dose-­‐response	  experiments	  under	  identical	  conditions	  showed	  saturating	  ART	  concentrations	   can	   activate	   higher	   pRET	   levels	   than	   that	   induced	   by	   4	   nM	   ART	  (Figure	  2.5).	  We	  determined	  the	  maximum	  pRET	  level	  as	  131%	  of	  that	  induced	  by	  4	  nM	   ART,	   by	   fitting	   the	   dose-­‐response	   data	   to	   a	   logistic	   equation,	  
∆𝑝𝑅𝐸𝑇 =    !"#!"#$!!(!"!"/[!!"])!"#$%.	  Thus,	  the	  fraction	  of	  RET	  that	  can	  become	  phosphorylated	  in	   response	   to	   fully	   saturating	  ART	   is	   (49	  ±	  5%)	  ×	  1.31	  =	  64	  ±	  6%.	  We	   therefore	  conclude	   that,	   in	  NB41A3-­‐mGFRα3	  cells,	  up	   to	   two-­‐thirds	  of	   the	   total	  RET	  present	  
	  
Figure 2.5 Dose-response data for activation of pRET after stimulation of NB41A3-mGFRα3 
cells with the stated concentration of ART for 20 min. The ordinate shows the pRET levels as 
a percent of that induced by 4 nM ART stimulation for 20 min. The plot shows the averaged 
data from at least three independent experiments. Error bars are standard deviations among the 




on	  the	  cell	  can	  be	  phosphorylated	  upon	  treatment	  with	  ART,	  corresponding	  to	  up	  to	  ~4200	  out	  of	  the	  6500	  RET	  molecules	  present,	  on	  average,	  per	  cell.	  
	  	  
2.3. Analysis	  of	  ART	  Dose-­‐response	  relationships	  for	  Activation	  of	  RET,	  ERK	  
and	  Akt	  	  
2.3.1. Quantification	   of	   ART	   Dose-­‐responses	   for	   Activation	   of	   RET,	   ERK	   and	  
Akt	  at	  Various	  Time	  Points	  
As	  a	  first	  step	  to	  characterize	  how	  pERK	  and	  pAkt	  levels	  relate	  to	  the	  amount	  of	   activated	   RET	   receptor	   on	   the	   cell,	   we	   used	   the	   quantitative	   immunoassays	  described	   above	   to	   measure	   pRET,	   pERK	   and	   pAkt	   levels	   after	   stimulation	   of	  NB41A3-­‐mGFRα3	  cells	  for	  various	  periods	  of	  time	  (10,	  30	  or	  60	  min)	  with	  various	  concentrations	   of	   ART.	   Figure	   2.6	   shows	   that	   ART	   caused	   dose-­‐dependent	  increases	   in	  pRET,	  pERK	  and	  pAkt,	  with	  half-­‐maximal	   responses	   (EC50)	  depending	  on	   the	   stimulation	   time	  and	   the	  phosphoprotein	  being	  measured.	  The	  EC50	   values	  were	  obtained	  by	  fitting	  the	  dose-­‐response	  data	  to	  the	  logistic	  equation	  described	  in	  
Eq	  2.1,	  	  
Eq. 2.1 ∆𝒑𝑿 =    𝑿𝒕𝒐𝒕𝟏!(𝑬𝑪𝟓𝟎/[𝑨𝑹𝑻])𝒔𝒍𝒐𝒑𝒆	  
where	   pX	   =	   pRET,	   pERK,	   or	   pAkt;	   Xtot	   is	   the	   total	   number	   of	   RET,	   ERK,	   or	   Akt	  molecules	  available	  for	  activation	  upon	  stimulation	  of	  RET	  by	  ART;	  EC50	  is	  the	  ART	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concentration	   giving	   half-­‐maximal	   ΔpX;	   and	   slope	   is	   a	   factor	   representing	   the	  steepness	   of	   the	   curve.	   The	   EC50	   values	   obtained	   from	   the	   best	   fits	   are	   listed	   in	  
Table	  2.1.	  	  
	  
	  
Figure 2.6 ART dose-dependent activation of RET, ERK and Akt. Data show levels of pRET 
(A), pERK (B) and pAkt (C) after stimulation of NB41A3-mGFRα3 cells with the stated 
concentration of ART for 10 min (red), 30 min (blue) or 60 min (green).The ordinate shows 
the average number of 1000 phosphoprotein molecules per cell. Plots show the averaged data 
from at least three independent experiments. Error bars are standard deviations among the 
separate experiments. Solid lines represent the best fits to a logistic equation (Eq. 2.1). The 




As	   shown	   in	  Table	   2.1,	   at	   10	  min,	   ART	   activates	   RET	  with	   a	   half-­‐maximal	  response	   at	   1.97	   ±	   0.07	   nM.	   The	   EC50	   value	   for	   RET	   decreases	   as	   the	   stimulation	  time	  increases,	  indicating	  that	  the	  sensitivity	  of	  RET	  responding	  to	  ART	  stimulation	  increases	   with	   time.	   Compared	   with	   pRET	   at	   all	   three	   tested	   time	   periods,	   both	  pERK	   and	   pAkt	   were	  more	   sensitive	   to	   ART	   stimulation.	   For	   instance,	   pERK	   and	  pAkt	   show	   EC50	   values	   of	   0.35	   ±	   0.02	   and	   0.66	   ±	   0.03	   nM	   (n	   =	   4),	   respectively,	  whereas	  EC50	  for	  pRET	  is	  1.97	  ±	  0.07	  nM.	  To	  better	  visualize	  this	  shift	  in	  sensitivity,	  the	   dose-­‐response	   curves	   for	   pRET,	   pERK	   and	   pAkt	   were	   each	   plotted	   as	   a	  percentage	  of	  its	  own	  maximal	  amplitude	  from	  the	  best	  logistic	  fits	  (Figure	  2.7B).	  	  
The	  pERK	  and	  pAkt	  dose	  responses	  also	  displayed	  somewhat	  steeper	  slopes	  than	   was	   seen	   for	   pRET.	   As	   stated	   above,	   NB41A3-­‐mGFRα3	   cells	   express	   ~6500	  RET	  molecules	  per	   cell,	   and	  only	  ~4200	   can	  be	  phosphorylation	  when	   stimulated	  with	  saturating	  ART.	  Figure	  2.7A	  shows	  that	  stimulation	  with	  saturating	  ART	  for	  10	  min	  resulted	  in	  the	  formation	  of	  much	  higher	  numbers	  of	  pERK	  (~140,000/cell)	  and	  pAkt	   (~95,000/cell).	   Our	   results	   show	   that	   there	   is	   a	   large	   amplification	   of	   the	  
Table 2.1 EC50 values for RET, ERK and Akt activation under various stimulation periods 
(10, 30 or 60 min). Results are averaged data of four independent measurements. Error limits 




signal	   between	   initial	   activation	   of	   the	   receptor	   and	   these	   intermediate	   steps	   in	  downstream	  signaling.	  	  
	  
2.3.2. Analysis	  of	  Receptor-­‐Effector	  Coupling	  Efficiency	  for	  ERK	  and	  Akt	  
How	  pERK	  and	  pAkt	  levels	  relate	  to	  the	  number	  of	  pRET	  molecules	  present	  at	  10	  min	  after	  stimulation	  can	  be	  examined	  further	  by	  calculating	  the	  pERK/pRET	  and	  pAkt/pRET	  ratios	  observed	  at	  each	  ART	  concentration,	  as	  shown	  in	  Figure	  2.7.	  The	  ratio	  of	  pEffector/pReceptor,	  sometimes	  called	  the	  signal	  “amplification”	  or	  “gain,”	  represents	   the	   efficiency	   with	   which	   activation	   of	   the	   receptor	   is	   coupled	   to	  activation	  of	  a	  given	  step	  in	  a	  downstream	  pathway.	  The	  dose-­‐response	  curves	  for	  the	  ART-­‐dependent	   induction	  of	  pRET,	  pERK,	  and	  pAkt	   in	  Figure	   2.7	   can	  each	  be	  
 
Figure 2.7 Comparison of ART dose-dependent activation of RET, ERK and Akt. A. Dose-
response data for activation of RET (circles), ERK (squares), and Akt (triangles) after 
stimulation of NB41A3-mGFRα3 cells with the stated concentration of ART for 10 min. The 
ordinate shows the average number of phosphoprotein molecules per cell. Plots show the 
averaged data from at least three independent experiments. Error bars are standard deviations 
among the separate experiments. Solid lines represent the best fits to a logistic equation (Eq. 
2.1). B. The same dose-response data plotted as percent maximum value determined by each 
fit, to highlight the different EC50 values for the three phosphoproteins.  
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well	  described	  by	  the	  standard	  logistic	  Eq.	  2.1,	  as	  shown	  earlier.	  Although	  entirely	  empirical,	   Eq.	   2.1	   can	   be	   seen	   to	   describe	   the	   dose-­‐response	   behavior	   quite	  precisely	   over	   the	   full	   measurable	   dose	   range.	   Therefore,	   although	   this	   empirical	  curve	   fit	   cannot	   be	   used	   to	   extrapolate	   to	   ART	   concentrations	   lying	   outside	   the	  range	  that	  was	  measured	  experimentally,	  it	  can	  be	  used	  to	  establish	  a	  quantitative,	  if	  model-­‐free,	   description	   of	   how	   phosphoprotein	   levels	   and	   phosphoprotein	   ratios	  vary	   over	   the	   measured	   ART	   range.	   For	   dose-­‐response	   curves	   that	   are	   well	  described	  by	  a	  logistic	  equation,	  the	  ratio	  of	  activated	  effector	  (pX)	  (X	  =	  ERK	  or	  Akt)	  to	  phosphorylated	  receptor	  (pR)	  at	  a	  given	  time	  after	  stimulation	  can	  be	  calculated	  simply	  by	  taking	  the	  ratio	  of	  the	  logistic	  equations	  that	  describe	  their	  separate	  dose-­‐response	  behavior	  which,	  rearranged	  into	  a	  convenient	  form,	  is	  shown	  below	  in	  Eq.	  
2.2.	  Eq.	  2.2	  can	  be	  used	  to	  estimate	  how	  the	  ratio	  of	  pX	  to	  pR	  varies	  as	  a	  function	  of	  the	  concentration	  of	  the	  activating	  growth	  factor	  ligand	  (ART)	  for	  pX	  and	  pR	  dose-­‐response	  curves	  with	  given	  EC50	  values	  and	  slopes.	  The	  calculated	  ratios	  for	  pERK	  and	  pAkt	  are	  shown	  in	  Figure	  2.8.	  For	  the	  ratios	  pERK/pRET	  and	  pAkt/pRET,	  the	  uncertainty	   in	   each	   data	   point	   was	   determined	   by	   propagating	   the	   standard	  deviations	  for	  the	  individual	  measurements	  according	  to	  Equation	  2.3.	  
Eq. 2.2  𝒑𝑿𝒑𝑹 =   𝑿𝒕𝒐𝒕𝑹𝒐𝒕 . 𝟏! 𝑬𝑪𝟓𝟎 𝒑𝑹𝑨𝑹𝑻 𝒔𝒍𝒐𝒑𝒆(𝒑𝑹)𝟏!   𝑬𝑪𝟓𝟎 𝒑𝑿𝑨𝑹𝑻 𝒔𝒍𝒐𝒑𝒆(𝒑𝑿) 
Eq. 2.3 
𝝈 𝒂𝒃𝒂𝒃 =    𝝈𝒂𝒂 𝟐 + 𝝈𝒃𝒃 𝟐 
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  Our	   results	   show	   that	   pERK/pRET	   is	   low	   at	   maximal	   ART	   stimulation,	   and	  increases	  sharply	  at	   lower	  concentrations	  of	  ART,	  up	  to	  a	  high	  of	  ~260	  pERKs	  per	  pRET	   at	   ~100	   pM	   ART.	   The	   data	   for	   pAkt	   show	   similar	   behavior	   but	   with	   a	  maximum	   pAkt/pRET	   ratio	   of	   ~100:1.	   Although	   this	   treatment	   is	   empirical,	   and	  thus	   does	   not	   embody	   any	   hypothesis	   concerning	   the	   molecular	   mechanism	   or	  network	  topology	  that	  links	  pRET	  to	  ERK	  or	  Akt,	   it	  nevertheless	  reveals	  important	  features	   of	   how	   receptor-­‐effector	   coupling	   varies	   with	   the	   strength	   of	   receptor	  stimulus,	  as	  described	  below.	  	  
	  
	  
Figure 2.8 Ratio of pERK/pRET (squares) or pAkt/pRET (triangles) for each ART 
concentration tested. Solid lines represent expected values derived from the curve fits in 
Figure 2.7A as described in the text. Error bars are the standard deviations, propagated from 
the errors in Figure 2.7A as described in Eq. 2.3. Data are shown for [ART] ≥ 0.1 nM only, as 
at lower ART the propagated errors were very large. Inset plot shows the same data but with a 
logarithmic concentration axis, to better show the data at low ART concentrations. Data points 
indicated * or ** are values that are significantly greater than the corresponding value for 10 
nM ART at the level of p < 0.05 or < 0.01, respectively, as determined using an unpaired two-
tailed Student’s t test. The dashed line indicates value of zero. 
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2.4. Quantification	  of	  Time-­‐dependent	  ART-­‐induced	  Activation	  of	  RET,	  ERK	  
and	  Akt	  
2.4.1. Time-­‐Courses	  for	  Activation	  of	  RET	  	  
Cell	   signaling	   is	   a	  dynamic	  process.	  Therefore,	   to	  understand	  how	  receptor	  activation	   is	  coupled	   to	  downstream	  signaling,	   it	   is	  necessary	   to	  measure	  how	  the	  events	   of	   interest	   evolve	   over	   time.	   To	   this	   end,	   we	   used	   the	   immunoassays	  described	  above	  to	  characterize	  pRET,	  pERK,	  and	  pAkt	  levels	  at	  various	  times	  from	  0	  to	  90	  min	  after	  ART	  stimulation.	  Focusing	  first	  on	  events	  that	  occur	  in	  the	  first	  10	  min	  after	  stimulation,	  Figure	  2.9A	  shows	  that	  pRET	  levels	  begin	  to	  rise	  immediately	  upon	   treatment	   of	   the	   cells	   with	   ART.	   The	   amplitude	   of	   RET	   increases	  with	   ART	  concentrations	  over	  the	  range	  0.1–10	  nM	  ART.	  The	  lack	  of	  any	  observable	  saturation	  in	  this	  relationship	  is	  consistent	  with	  the	  previous	  proposal	  from	  our	  group	  that	  the	  KD	  value	  for	  the	  initial	  binding	  of	  ART	  to	  NB41A3-­‐mGFRα3	  cells	  is	  >	  10	  nM.126	  The	  evolution	  of	  pRET	  shows	  a	  linear	  initial	  rate	  that	  persists	  for	  >	  10	  min	  at	  low	  ART,	  but	  at	  high	  ART	  the	  rate	  begins	  to	  level	  off	  after	  just	  a	  few	  minutes.	  The	  initial	  rate	  of	  pRET	   formation	   is	   proportional	   to	   the	   concentration	   of	   stimulating	   ART	   over	   the	  range	  [ART]	  =	  0.1–10	  nM	  (Figure	  2.9B).	  	  
Extending	   the	   time-­‐course	   measurements	   out	   to	   90	   min	   after	   ART	  stimulation	  shows	  that,	  at	  moderate	  to	  high	  ART	  concentrations,	  pRET	  increases	  to	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a	  maximum	   and	   then	   slowly	   decreases	   (Figure	   2.9C).	   The	   time	   corresponding	   to	  maximum	  pRET	   shows	   a	   strong	   inverse	  dependence	  on	   [ART],	   such	   that	   at	   lower	  ART	  concentrations	  pRET	  levels	  were	  steady	  or	  even	  still	  slowly	  rising	  at	  90	  min.	  
	  
	  
Figure 2.9 Time-courses for RET activation over 0-10 min and 0-90 min.Time-course data 
show how the levels of pRET change after treatment of cells with the stated concentration of 
ART for 0-10 min (A) or 0-90 min (B). Data are the average of at least three independent 
experiments. Solid lines are smoothed interpolations of the data. Error bars are standard 
deviations between the independent experiments. C. Rates of pRET formation in the first 2 
min after stimulation plotted against ART concentration. The solid line is a linear least squares 
fit passing through the origin. The inset plot shows the same data and curve fit, but using 
logarithmic axes to better show the data at low [ART]. Errors bars stand for the propagated 
errors from data in Figure 2.9A. 
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2.4.2. Time-­‐courses	  for	  Activation	  of	  ERK	  
We	  examined	  the	  time-­‐dependent	  activation	  of	  ERK	  over	  10	  min	  and	  90	  min	  after	  ART	   stimulation	   in	   a	   similar	  way.	  Figure	   2.10A	   shows	   that	  pERK	   formation	  displays	  a	  pronounced	  lag,	  indicating	  that	  the	  molecular	  events	  subsequent	  to	  RET	  phosphorylation	   that	   culminate	   in	   activation	   of	   ERK	   take	   a	   few	  minutes	   to	   occur.	  The	  lag	  time	  decreases	  with	  increasing	  ART,	  from	  ~4	  min	  at	  0.1	  nM	  ART	  to	  <	  2	  min	  at	  10	  nM	  ART.	  Plotting	  accumulated	  pRET	  levels	  at	  the	  time	  pERK	  began	  to	  rise,	  for	  each	   ART	   concentration,	   shows	   that	   different	   numbers	   of	   pRET	   molecules	  accumulated	  within	  those	  time	  windows	  (Figure	  2.10B).	  The	  accumulated	  amounts	  of	  pRET	  during	  the	  lag	  periods	  in	  ERK	  activation	  were	  highly	  dependent	  on	  [ART].	  For	   instance,	  with	  4	  nM	  of	  ART,	   the	   lag	   time	   for	  ERK	  activation	   is	  <	  2	  min,	  within	  which	  <	  1000	  RET	  molecules	  had	  been	  activated.	  However,	  the	  lag	  time	  at	  1	  nM	  ART	  is	  extended	  to	  around	  2	  min,	  and	  only	  ~250	  molecules	  of	  pRET	  accumulated	  within	  that	   time.	   Comparing	   the	   accumulated	   levels	   of	   pRET	   for	   each	   tested	   ART	  concentrations	  suggests	  that	  the	  lag	  does	  not	  reflect	  the	  time	  required	  to	  surpass	  a	  fixed	  threshold	  level	  of	  pRET.	  	  
Examining	   how	   pERK/pRET	   coupling	   evolves	   over	   time	   (Figure	   2.10C)	  shows	   that	   the	   signal	   gain	   increases	   over	   the	   first	   few	  minutes	   after	   stimulation,	  before	  achieving	  a	  steady	  state	  level	  that	  persists	  for	  several	  minutes.	  The	  maximum	  gain,	  observed	  between	  6	  and	  10	  min,	  decreases	  as	  ART	  is	  increased	  from	  0.4	  to	  10	  nM.	  In	  Figure	  2.10C,	  we	  omitted	  the	  pERK/pRET	  data	  set	  with	  0.1	  nM	  ART	  because	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of	  the	  high	  errors	  due	  to	  low	  signals.	  The	  inverse	  dependence	  of	  signal	  gain	  on	  ART	  concentration	   is	   consistent	   with	   the	   results	   obtained	   in	   the	   dose-­‐response	  experiments	  shown	  in	  Figure	  2.6,	  which	  showed	  that	  lower	  ART	  concentration	  are	  associated	  with	  higher	  Effector/Receptor	  coupling	  efficiency.	  	  
	  
Figure 2.10 Time-courses for ERK activation over 0-10 min. A. Time-course data showing 
how the levels of pERK change after treatment of cells with the stated concentration of ART 
for 0, 2, 4, 6, 8, or 10 min. Data are the average of at least three independent experiments. 
Solid lines are smoothed interpolations of the data. Error bars are standard deviations between 
the independent experiments. B. Numbers of pRET accumulated within the approximate 
lagging time in ERK activation with the stated concentration of ART. C. Ratios of 
pERK/pRET plotted against time after stimulation, calculated using the data from Figure 
2.9A and Figure 2.10A. 
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Shown	  in	  Figure	  2.11A,	  the	  0–90	  min	  time-­‐course	  for	  pERK	  shows	  an	  initial,	  transient	  phase	  of	  activation	  followed	  by	  a	  lower,	  sustained	  response	  that	  persists	  to	  >	  90	  min.	  Sustained	  ERK	  activation	  has	  previously	  been	  well	  documented	  in	  multiple	  growth	   factor	   systems,	   such	   as	   NGF	   stimulating	   PC12	   cells	   and	   EGF	   stimulating	  human	  mammary	   epithelial	   cells.129,130	  Our	   results	   show	   that	   the	  maximum	  of	   the	  transient	  pERK	  response	  occurs	  at	  ~10	  min	  at	  all	  ART	  doses	  tested.	  Comparison	  of	  pERK	  dose-­‐response	  curves	  measured	  at	  10	  and	  60	  min	  shows	  that	  the	  amplitudes	  of	   the	   transient	   and	   sustained	   responses	   are	   roughly	   proportional	   over	   the	   entire	  dose	   range	   (Figure	   2.11B),	   such	   that	   at	   any	   ART	   dose	   the	   pERK	   level	   observed	  during	   the	   sustained	   response	   is	   a	   more	   or	   less	   constant	   fraction	   of	   the	   peak	  transient	  response. 
	  
	  
Figure 2.11 Time-courses of ERK activation over 0–90 min. A. Time-course data showing 
how the levels of pERK change after treatment of cells with the stated concentration of ART 
for 0–90 min. Data are the average of at least three independent experiments. Solid lines are 
smoothed interpolations of the data. Errors are omitted for clarity. B. Levels of pERK 
observed after 60 min plotted against the pERK levels seen at 10 min, over a range of ART 
concentrations from 0.001–10 nM. Each data point represents a pair of measurements made at 




Interestingly,	   at	   [ART]	   =	   4	   nM,	   pERK	   shows	   a	   reproducible	   pattern	   of	  oscillations	  extending	  from	  10	  to	  60	  min	  or	  so	  (Figure	  2.11A).	  Our	  assay	  method,	  using	  0.1%	  Triton	  X-­‐100131	  to	  lyse	  the	  cells,	  only	  detected	  cytoplasmic	  pERK	  and	  not	  nuclear	   pERK.	   So	   these	   oscillations	   could	   reflect	   cyclic	   variation	   in	   total	   cellular	  pERK	  levels,	  or	  possibly	  cycling	  pERK	  between	  cytoplasm	  and	  nucleus	  as	  has	  been	  observed	   previously.124,132,133,134	   These	   oscillations	   in	   pERK	   are	   averaged	   over	   the	  many	   cells	   that	   contribute	   to	   the	   cell	   lysate,	   and	   therefore	   reflect	   a	   remarkable	  degree	  of	  synchronization	  across	  the	  different	  cells	  in	  the	  population.	  No	  significant	  oscillations	   are	   seen	   in	   individual	   experiments	   performed	   at	   ART	   concentrations	  just	   a	   few	   fold	  higher	  or	   lower,	   perhaps	  due	   to	   a	   loss	   of	   synchronization	   in	  pERK	  oscillations	  between	  the	  many	  cells	  that	  contribute	  to	  each	  sample	  of	  cell	  lysate.	  
2.4.3. Time-­‐courses	  for	  Activation	  of	  Akt	  




For	  pAkt,	  the	  0–90	  min	  time-­‐course	  also	  shows	  a	  transient	  response,	  peaking	  at	  5–10	  min	  after	  stimulation,	  followed	  by	  a	  sustained	  response	  that	  holds	  steady	  or	  decays	   gradually	   over	   >	   1	   h	   (Figure	   2.12B).	   The	   pAkt	   response	   differs	   from	   the	  pERK	   response	   in	   that	   the	   transient	   and	   sustained	  phases	   are	   not	   separated	   by	   a	  pronounced	  minimum,	  as	  was	  seen	  for	  pERK,	  but	   instead	  simply	   involve	  a	  sudden	  
	  
Figure 2.12 Time-courses for Akt activation over 0-10 min and 0-90 min. Time-course data 
show how the levels of pAkt change after treatment of cells with the stated concentration of 
ART for 0–10 min (A) or 0–90 min (B). Data are the average of at least three independent 
experiments. Solid lines are smoothed interpolations of the data. Error bars in A are standard 
deviations between the independent experiments. Error bars in B are omitted for clarity. C. 
Ratio of pAkt/pRET plotted against time after stimulation, calculated using the data from 
Figure 2.9A and Figure 2.12A. 
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decrease	   in	   the	  net	  pAkt	  decay	   rate.	  Also,	  where	   the	   sustained	  phase	  of	   the	  pERK	  response	   showed	   stable	   or	   even	   slightly	   increasing	  pERK	   levels	   out	   to	   at	   least	   60	  min,	   for	   pAkt	   the	   sustained	   phase	   shows	   a	   marked	   decline	   at	   higher	   ART	  concentrations.	  
2.4.4. Comparison	  of	  Coupling	  Efficiency	  of	  RET	  with	  ERK	  and	  Akt	  
Our	  analysis	  of	  the	  receptor-­‐effector	  coupling	  efficiency	  after	  10	  min	  of	  ART	  stimulation	  in	  Section	  2.3.2	  shows	  that	  both	  ERK	  and	  Akt	  pathways	  exhibit	  maximal	  signal	  gain	  at	   low	  ART	  concentration.	  Our	  examination	  of	   the	  pERK/pRET	  (Figure	  
2.10C)	  and	  pAkt/pRET	  (Figure	  2.12C)	  ratios	  in	  the	  first	  10	  min	  of	  ART	  stimulation	  shows	   that	   signal	   amplification	   for	   Akt	   peaks	   earlier	   than	   that	   of	   ERK.	   To	   further	  investigate	   the	   long-­‐term	   evolution	   of	   receptor-­‐effector	   coupling	   efficiency,	   we	  compared	   the	   pERK/pRET	   and	   pAkt/pRET	   coupling	   ratios	   during	   the	   sustained	  phase,	   after	   stimulation	  of	   cells	  with	  0.4	  nM	  ART.	   Shown	   in	  Figure	   2.13,	   for	   both	  
	  
Figure 2.13 Ratio of pERK/pRET (squares) or pAkt/pRET (triangles). The ratio is plotted as a 
function of time after stimulation with 0.4 nM ART. Error bars were omitted for clarity.	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phosphoproteins	   the	   coupling	   ratios	   fall	   from	   the	   high	   values	   seen	   during	   the	  transient	   response	   to	   stabilize	   at	  ~3-­‐fold	   lower	   levels	   during	   the	   sustained	  phase.	  Specifically,	  over	  the	  period	  40–90	  min,	  0.4	  nM	  ART	  induces	  an	  average	  of	  ~28	  pERK	  molecules	   for	   each	   pRET	  present	   on	   the	   cells	   and	   about	   half	   that	   number	   of	   pAkt	  molecules	  per	  pRET.	  The	  nearly	  2-­‐fold	  difference	  in	  the	  coupling	  efficiency	  at	  10	  min	  suggests	   that,	   at	   low	   ART	   concentrations,	   ERK	   activation	   is	   favored	   over	   Akt	  activation.	  
	  
2.5. Discussion	  
2.5.1. [ART]-­‐dependent	  Coupling	  Efficiency	  in	  RET	  Signaling	  
The	  goals	  of	  the	  work	  described	  in	  this	  chapter	  were	  to	  quantify	  the	  cellular	  RET	  activation	  levels	  and	  the	  intracellular	  ERK	  and	  Akt	  activation	  levels	  upon	  ART	  stimulation,	   and	   then	   to	   obtain	   quantitative	   insight	   into	   how	   activation	   of	   RET	   is	  coupled	   to	   these	   two	   key	   downstream	   signaling	   events.	   In	   particular,	   we	   are	  interested	   in	  how	  the	  strength	  and	  duration	  of	  extracellular	  stimulus	  relate	   to	   the	  absolute	  amplitude	  and	  duration	  of	  signaling	  at	  the	  level	  of	  ERK	  and	  Akt.	  	  
Our	   results	   show	   that	   the	   efficiency	   of	   receptor-­‐effector	   coupling	   is	   highly	  conditional;	  it	  varies	  with	  the	  strength	  of	  the	  extracellular	  stimulus,	  it	  evolves	  over	  time	  after	   stimulation,	   and	   it	  differs	   for	  different	  downstream	  signaling	  pathways.	  When	  attempting	  to	  develop	  a	  molecular	  level	  understanding	  of	  these	  behaviors,	  it	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is	  important	  to	  keep	  in	  mind	  that,	  like	  all	  signaling	  studies	  based	  on	  analysis	  of	  cell	  lysates	   or	   pooled	   cell	   populations,	   our	   measurements	   reflect	   changes	   in	  phosphoprotein	   levels	  averaged	  over	  many	  cells.	  Thus,	  what	  appear	   to	  be	  smooth,	  dose-­‐	   or	   time-­‐	   dependent	   changes	   when	   viewed	   in	   aggregate	   can	   result	   from	  changes	   in	   the	   proportion	   of	   cells	   experiencing	   more	   sudden	   or	   discontinuous	  changes	  at	   the	  single	  cell	   level.	   In	  particular,	   it	  has	  been	  shown	  that	   in	  single	  cells	  pERK	   levels	   do	   not	   vary	   continuously,	   but	   instead	   they	   manifest	   bi-­‐stable	  fluctuations	   between	   minimal	   and	   maximal	   pERK,	   with	   higher	   levels	   of	   stimulus	  causing	   an	   increase	   in	   the	   frequency	   and	   duration	   of	   these	   spikes	   of	   ERK	  activation.124,133	  The	   same	  does	  not	  appear	   to	  be	   the	   case	   for	  Akt,	  however;	   it	  has	  been	  shown	  that	  pAkt	  levels	  in	  individual	  cells	  are	  distributed	  stochastically	  around	  the	  mean.135	   Nevertheless,	   because	   of	   the	   limitations	   arising	   from	   averaging	   over	  many	   cells,	   we	   focus	   here	   on	   identifying	   quantitative,	   empirical	   relationships	  between	   key	   factors	   and	   events,	   rather	   than	   proposing	   detailed	   mechanistic	   or	  network	  models.	  
One	   striking	   result	   from	   our	   study	   is	   that	   pERK/pRET	   and	   pAkt/pRET	  coupling	  efficiencies	  are	  strongly	  dose-­‐dependent,	  rising	  dramatically	  as	  the	  level	  of	  GF	  stimulation	  decreases	  (Figure	  2.8).	  When	  pERK/pAkt	  is	  at	  its	  peak	  at	  ~10	  min	  after	   ART	   stimulation,	   0.1	   nM	   ART	   gave	   an	   average	   of	   ~260	   pERK	  molecules	   for	  each	   pRET	   molecule,	   whereas	   at	   higher	   ART	   concentrations,	   the	   ratio	   decreased	  toward	  a	  minimum	  of	  only	  ~50	  pERKs	  per	  pRET.	  A	  similar	  trend	  was	  seen	  for	  pAkt,	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although	   pAkt/pRET	   coupling	  was	   lower	   than	   for	   pERK	   at	   all	   concentrations.	  My	  colleague	  Jennifer	  M.	  Chow	  investigated	  what	  level	  of	  ART	  stimulation	  was	  required	  for	   a	   functional	   response,	   by	   evaluating	   the	   ART-­‐dependent	   neurite	   outgrowth	   in	  the	   same	  NB41A3-­‐mGFRα3	   cells.	  Neurite	   outgrowth	   is	   one	   of	   the	  main	   functional	  consequences	   of	   neuronal	   differentiation	   in	   response	   to	   RET	  activation.136,137,138,139,140,141	  Chow	  observed	  that	  the	  maximum	  response	  occurs	  over	  a	  concentration	  range	  of	  10–100	  pM	  ART,	  coinciding	  with	   the	  ART	  concentrations	  for	   maximal	   signal	   gain	   for	   both	   the	   ERK	   and	   Akt	   pathways.	   Thus,	   over	   the	  functionally	  relevant	  ART	  concentration	  range	  of	  10–100	  pM,	  at	  which	  the	  absolute	  signal	   amplitudes	   are	   very	   low,	   receptor-­‐effector	   coupling	   is	   highly	   efficient,	   i.e.	  there	   is	   a	   large	  amplification	  between	   receptor	  and	  effector,	  but	   it	  becomes	  much	  less	   efficient	   at	   higher	   stimulus	   levels	   that	   give	   more	   robust	   overall	   signaling.	  Interpreted	  in	  terms	  of	  a	  bi-­‐stable	  pERK	  response,	  the	  dose	  dependence	  of	  receptor-­‐effector	  coupling	  efficiency	  is	  even	  greater.	  For	  example,	  after	  10	  min	  of	  stimulation	  with	  0.1	  nM	  ART,	  the	  pERK	  signal	  is	  at	  15%	  of	  the	  maximum.	  If	  the	  pERK	  response	  is	  bi-­‐stable,	  this	  result	  corresponds	  to	  ~15%	  of	  cells	  being	  in	  the	  high	  pERK	  state	  and	  ~85%	   in	   the	   low	   pERK	   state	   at	   any	   given	   time.	   That	   subset	   of	   high	   pERK	   cells	  contains	  ~142,000	  pERK	  molecules	  per	  cell	  (i.e.	  all	  RET-­‐activatable	  ERK	  molecules	  in	  the	  cell),	  against	  an	  average	  of	  only	  ~90	  pRET	  molecules	  per	  cell	  (from	  the	  pRET	  dose	   response	   in	   Figure	   2.7A),	   corresponding	   to	   a	   coupling	   efficiency	   of	   ~1600	  pERKs/pRET	   in	   the	   high	   pERK	   cells.	   In	   contrast,	   at	   saturating	   ART	   essentially	   all	  cells	  have	  maximal	  pERK	  more	  or	  less	  all	  the	  time124	  while	  possessing	  an	  average	  of	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~4200	   activated	   RET	   receptors,	   giving	   a	   per-­‐cell	   coupling	   efficiency	   of	   only	  142,000/4200	   =	   ~34,	   representing	   an	   ~46-­‐fold	   decrease	   in	   coupling	   efficiency	  compared	   with	   low	   ART.	   Our	   observation	   that	   average	   pERK/pRET	   coupling	  efficiency	  increases	  as	  ART	  is	  lowered	  from	  saturating	  levels	  to	  functionally	  relevant	  concentrations	   is	   therefore	   likely	  even	  more	  pronounced	  at	   the	   level	  of	   individual	  cells.	  One	  possibility	  to	  explain	  such	  decreased	  receptor/effector	  coupling	  efficiency	  at	  high	  GF	  concentrations	  is	  that	  the	  activation	  of	  downstream	  effectors	  is	  saturated	  at	  low	  GF	  concentration,	  but	  receptor	  activation	  is	  not	  saturated	  yet.	  In	  this	  case,	  the	  amplitude	   of	   activated	   receptors	   will	   increase	   as	   the	   GF	   concentration	   increases,	  whereas	   effector	   activation	   levels	   will	   not.	   Therefore,	   the	   calculated	   ratio	   of	  activated	   downstream	   effector	   over	   activated	   receptor	   will	   decrease	   at	   high	   GF	  concentrations.	  
It	   is	   broadly	   true	   that	   intracellular	   signaling	   events	   saturate	   at	   stimulus	  levels	   at	   which	   only	   a	   fraction	   of	   receptors	   are	   activated.102,104,105,106,142	   Our	  observation	   that	   receptor-­‐effector	   coupling	   ratios	   are	   dose-­‐dependent,	   and	   are	  maximal	  at	  low	  stimulus	  levels,	  is	  therefore	  likely	  true	  for	  many	  such	  systems.	  The	  coupling	  of	  receptor	  activation	  to	  intracellular	  signaling	  events	  has	  previously	  been	  examined	  for	  the	  epidermal	  growth	  factor	  (EGF)	  receptor.104	  Similar	  to	  our	  findings	  here,	  the	  authors	  observed	  that	  the	  degree	  of	  signal	  amplification	  for	  pERK	  and	  for	  pAkt	  passed	  through	  a	  maximum	  at	  EGF	  concentrations	  well	  below	  the	  KD	  value	  for	  receptor	  binding.	  This	  earlier	  study	  did	  not	  address	  how	  receptor-­‐effector	  coupling	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efficiency	  relates	  to	  functional	  cellular	  responses,	  nor	  did	  they	  discuss	  how	  coupling	  efficiency	  or	  the	  balance	  of	  signaling	  flux	  between	  divergent	  pathways	  evolves	  over	  time.	  
2.5.2. Relative	  Coupling	  Efficiency	  to	  ERK	  Versus	  Akt	  




A	  particularly	   interesting	  finding	  is	  that	  the	  ART	  concentration	  that	  gives	  the	  highest	  observed	  pERK/pRET	  and	  pAkt/	  pRET	  coupling	  ratios,	  and	  also	  the	  greatest	  degree	  of	  discrimination	  between	  pERK	  and	  pAkt	  signal	  amplitudes,	  coincides	  with	  that	   required	   for	   the	   functional	   response	   of	   neurite	   outgrowth	   in	   the	   same	   cells.	  This	  result	  raises	  the	  intriguing	  possibility	  that	  the	  signaling	  system	  has	  evolved	  to	  be	  at	  its	  most	  efficient	  with	  respect	  to	  receptor-­‐effector	  coupling,	  and	  also	  its	  most	  discriminating	   with	   respect	   to	   the	   relative	   strength	   of	   signaling	   via	   different	  pathways	  downstream	  of	  the	  receptor,	  over	  the	  range	  of	  GF	  levels	  where	  biological	  function	  occurs.  
 
	  
Figure 2.14 Ratio of pERK/pAkt measured as a function of ART concentration after 10 min 
of stimulation. Data points show the ratio between the pERK and pAkt data in Figure 2.7A. 
Solid lines show the calculated ratio between the best fits of pERK and pAkt dose-responsive 
curves, using a modified form of Eq. 2.2. Error bars showed propagated standard deviations in 
pERK and pAkt dose-responsive data, based on Eq. 2.3. Data points indicated * or ** are 
values that are significantly greater than the corresponding values under 10 nM ART 
stimulation at the levels of p < 0.07 or p < 0.02, as determined by unpaired Students’ t-test. 
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2.5.3. Biological	  Advantages	  of	  High	  Receptor-­‐Effector	  Coupling	  Efficiency 
It	  is	  pertinent	  to	  ask	  why	  it	  might	  be	  advantageous	  for	  a	  cell	  to	  display	  high	  receptor-­‐effector	   coupling	   ratios	   at	   biologically	   relevant	   GF	   concentrations,	   other	  than	  a	  putative	  evolutionary	  drive	  for	  parsimony.	  A	  functional	  response	  presumably	  requires	   only	   that	   threshold	   levels	   of	   activation	   of	   key	   down-­‐stream	   effector	  molecules	   be	   achieved,	   with	   the	   role	   of	   receptor	   activation	   and	   other	   upstream	  signaling	   events	   being	   simply	   to	   bring	   this	   about.	   It	  would	   seem	   that	   a	   cell	   could	  achieve	   these	   threshold	   levels	   of	   effector	   activation	   either	   through	   the	   action	  of	   a	  small	  number	  of	  receptors	  working	  with	  high	  receptor-­‐effector	  coupling	  efficiency	  or	  equally	  well	  through	  a	  larger	  number	  of	  receptors	  working	  with	  lower	  coupling	  efficiency,	  as	  illustrated	  in	  Figure.	  2.15	  A	  and	  B.	  Thus,	  one	  might	  imagine	  that	  any	  level	  of	  coupling	  efficiency	  could	  be	  adequate	  for	  function,	  provided	  that	  a	  sufficient	  number	  of	  receptors	  are	  present	  and	  can	  become	  activated	  so	  as	  to	  bring	  about	  the	  required	  levels	  of	  effector	  activation.	  However,	  unlike	  our	  in	  vitro	  cell	  culture	  assays,	  in	  which	  monolayers	  of	  cells	  are	  bathed	   in	  a	   substantial	  volume	  of	   culture	  medium,	   in	  vivo	   adherent	  cells	  often	  exist	   in	  densely	  packed	  three-­‐dimensional	  structures	  where	  most	  of	   the	  volume	   is	  taken	  up	  by	  the	  cells	  themselves,	  and	  thus	  the	  volume	  of	  extracellular	  fluid	  per	  cell	  is	  much	  lower.	  Even	  in	  our	  experimental	  system	  a	  concentration	  of	  0.01–0.1	  nM	  ART	  represents	  only	  a	  roughly	  1–10-­‐fold	  stoichiometric	  excess	  over	  the	  number	  of	  RET	  molecules	   present.	   Therefore,	   in	   vivo	   it	   is	   likely	   that	   at	   these	   low	   functional	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concentrations	  ART	  itself	  is	  stoichiometrically	  limiting	  with	  respect	  to	  RET	  (Figure	  
2.15C).	   We	   therefore	   speculate	   that	   a	   high	   receptor-­‐effector	   coupling	   efficiency	  might	  be	  important	  in	  some	  instances	  of	  signaling	  by	  highly	  potent	  GFs	  such	  as	  ART	  that	  act	  on	  cells	  outside	  of	  the	  circulatory	  and	  lymphatic	  systems,	  where	  the	  volume	  of	   extracellular	   fluid	   is	   limited,	   and	   therefore	   a	   functional	   concentration	   of	   GF	  represents	  relatively	  few	  molecules	  per	  responsive	  cell.	  	  
We	   hypothesized	   that	   a	   high	   RET/ERK	   coupling	   efficiency	  would	   preserve	  the	  sensitivity	  of	  cellular	  responses	  even	  at	  high	  cell	  densities,	  when	  the	  volume	  of	  extracellular	   fluid,	   and	   thus	   the	   available	   number	   of	   ART	  molecules	   per	   cell,	   was	  
	  
Figure 2.15 Schematic illustrating circumstances under which a high receptor-effector 
coupling efficiency might be important for function. Under conditions where the 
concentration of activating GF (blue circles) is not limiting with respect to receptor, a given 
level of activated effector (orange lozenges) can be generated either by activation of a small 
number of receptors that display high receptor-effector coupling (A) or, alternatively, by 
activating a larger number of receptors that display lower receptor-effector coupling (B). 
However, if the GF concentration is stoichiometrically limiting, as for example in the case of a 
highly potent GF that is present at its very low functional concentration in a restricted volume 
of extracellular fluid space (C), the number of activated receptors will be limited by the 
number of available GF molecules. Under these conditions, achieving the necessary level of 
activated effectors will require a high receptor-effector coupling efficiency, no matter how 
many receptor molecules are present, because the number of activated receptors at a given 
time is limited by the low available GF concentrations.  
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limited.	  To	   further	  validate	   this	  hypothesis,	  we	  quantified	  EC50(pERK)	  values	  with	  cells	  in	  various	  densities	  stimulted	  by	  ART	  for	  10	  min.	  In	  support	  of	  this	  notion,	  we	  found	  that	  increasing	  the	  cell	  density	  in	  our	  experiments	  by	  5-­‐,	  10-­‐,	  or	  25-­‐fold,	  up	  to	  the	   highest	   density	   we	   could	   achieve	   experimentally,	   as	   expected	   had	   no	  measurable	  effect	  on	  EC50(pERK)	  for	  10	  min	  ART	  stimulation	  (Figure	  2.16).	  Usually,	  the	   cell	   stimulation	   is	   performed	   by	   incubating	   3	   ×	   105	   cells	  with	   250	   μL	   of	   ART	  solution	   in	   each	   well	   of	   the	   tissue	   culture	   plate.	   To	   increase	   the	   cell	   density,	   we	  decreased	   the	   volume	   of	   ART	   solution	   by	   5-­‐,	   10-­‐,	   or	   25-­‐fold	   while	   keeping	   the	  number	  of	  cells	  constant.	  This	  result	  is	  consistent	  with	  our	  hypothesis,	  illustrated	  in	  
	  
Figure 2.16 EC50 Values for pERK plotted as a function of cell density. NB41A3-mGFRα3 
cells were treated with ART (0.01–10 nM) in the stated ultimate cell density for 10 min. Data 
points show the average EC50 values of three independent experiments and EC50 value in each 
experiment was obtained by fitting the dose-response curves to a logistic equation (Eq. 2.1). 
Error bars stand for the standard deviation of three independent experiments. The solid line 
represent the expected relationship for normal NB41A3-mGFRα3 cells with low RET 
expression and high coupling efficiency, while the dashed line represents the result expected 
for hypothetical cells with high 100-fold higher RET expression and 100-fold reduced 
coupling efficiency, as described in the text. 	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Figure	   2.15,	   that	  a	  high	  RET/ERK	  coupling	  efficiency	  enables	   the	  cells	   to	  activate	  downstream	  molecules	   efficiency	   when	   the	   number	   of	   ART	   molecules	   per	   cell	   is	  limited.	   In	   contrast,	   a	   simple	   calculation	   shows	   that,	   if	   a	   cell	   line	  had	  much	   lower	  RET/ERK	  coupling	  efficiency,	  but	  compensated	   for	  by	  correspondingly	  higher	  RET	  expression,	  it	  would	  require	  substantially	  higher	  ART	  concentrations	  to	  occupy	  and	  activate	   sufficient	   RET	   receptors	   to	   achieve	   the	   same	   level	   of	   intracellular	   pERK.	  Based	  on	  the	  definition	  of	  dissociation	  constant	  (Eq.	  2.4–Eq.	  2.6),	  the	  relationship	  between	  the	  amount	  of	  ligand-­‐bound	  RET	  at	  steady	  state	  and	  the	  ART	  concentration	  can	  be	  expressed	  by	  a	  quadratic	  equation	  (Eq.	   2.7).	   In	  Eq.	   2.4–Eq.	   2.7,	  RT,	  R,	  LT,	  L	  and	  RL	   stand	   for	   total	   RET	   available	   for	   activation,	   unbound	   RET,	   total	   ART,	   free	  ART,	   and	   RET-­‐ART	   complex,	   respectively,	   and	   K	   is	   the	   apparent	   dissociation	  constant	   for	  ART	  binding	   to	   receptor	  on	   the	  cells.	  We	  have	  previously	  shown	   that	  ART	  can	  only	  activate	  a	  maximum	  of	  4200	  RET	  out	  of	  6500,	  and	  therefore	  we	  set	  RT	  =	  4200	  in	  normal	  NB41A3-­‐mGFRα3	  cells.	  The	  concentration	  of	  total	  RET	  in	  a	  given	  stimulation	  condition	  can	  be	  calculated	  based	  on	  the	  RET	  expression	   level	  per	  cell	  and	   the	   number	   of	   cells	   per	   volume.	  We	   assume	   that,	   at	   steady	   state,	   ART-­‐bound	  RET	  is	  activated	  and	  capable	  of	  activating	  ERK.	  
Eq. 2.4 𝑲 =    [𝑹]×[𝑳][𝑹𝑳]  
Eq. 2.5 [𝑹] =    [𝑹𝑻] − [𝑹𝑳] 
Eq. 2.6 [𝑳] =    [𝑳𝑻] − [𝑹𝑳] 
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Eq. 2.7 𝑲 =    ([𝑹𝑻]![𝑹𝑳])×([𝑳𝑻]![𝑹𝑳])[𝑹𝑳]  The	  relationship	  between	  ART	  concentration,	  the	  total	  amount	  of	  RET,	  and	  RET-­‐ART	  complex	   is	   shown	   in	   Eq.	   2.8,	   obtained	   by	   rearranging	   Eq.	   2.7.	   The	   relationship	  between	  ART	  concentration,	  the	  total	  amount	  of	  RET	  and	  the	  fraction	  of	  ART-­‐bound	  RET	  (f	  =	  [RL]	  /	  [RT])	  is	  shown	  in	  Eq.	  2.9.	  
Eq. 2.8 [𝐋𝑻] =   𝑲![𝑹𝑻]![𝑹𝑳][𝑹𝑻][𝑹𝑳]  !  𝟏  
Eq. 2.9 [𝑳𝑻] =   𝑲! 𝑹𝑻 ×(𝟏!𝒇)𝟏𝒇  !𝟏 	  We	   previously	   showed	   that	   the	   EC50	   for	   ERK	   activation	   at	   10	   min	   was	   0.35	   nM,	  which	  means	  0.35	  nM	  ART	  stimulation	  for	  10	  min	  activated	  50%	  of	  142,000	  pERK.	  With	  RET/ERK	   coupling	   efficiency	  of	  ~260,	   in	   order	   to	   activate	  142,000	  ×	  50%	  =	  71,000	  pERK	  we	  would	  need	  71,000	  ⁄	  260	  =	  273	  pRET.	  The	  fraction	  of	  ART-­‐bound	  RET	   (f)	   at	   EC50(pERK)	   can	   be	   calculated	   as	   f	   =	   273	   /	   4200	   =	   0.065.	   When	   we	  stimulated	   the	   same	   cells	   with	   ART	   but	   used	   different	   cell	   densities,	   EC50(pERK)	  would	   increase	   because	   [RT]	   increased	   with	   cell	   density.	   Based	   on	   Eq.	   2.9,	   we	  calculated	  that	  increasing	  cell	  density	  from	  6	  ×	  105	  cells/mL	  to	  6	  ×	  107	  cells/mL	  only	  changed	  EC50	   from	  0.35	  nM	  to	  0.	  38	  nM.	  This	  change	   is	   insignificant	  and	  would	  be	  too	   small	   to	   be	  detected	   experimentally.	   The	   calculated	   expected	  EC50	   values	   as	   a	  function	   of	   cell	   density	   in	   cells	   with	   low	   RET	   expression	   levels	   and	   high	  Receptor/Effector	   coupling	   efficiency	   are	   shown	   as	   the	   solid	   line	   in	  Figure	   2.16.	  However,	  the	  effects	  of	  increasing	  cell	  density	  in	  EC50(pERK)	  would	  be	  magnified	  if	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the	   cells	   possessed	   higher	   amount	   of	   RET	   with	   lower	   coupling	   efficiency.	   For	  example,	  one	  might	  consider	  cells	  containing	  a	  hypothetical	  RET	  that	  signaled	  with	  100-­‐fold	   lower	  RET/ERK	  coupling	  efficiency	  but	  was	  expressed	  at	  100-­‐fold	  higher	  levels	  to	  compensate	  for	  its	  inefficient	  signaling.	  In	  this	  case,	  100-­‐fold	  more	  bound-­‐RET	   (27,300)	   would	   be	   needed	   in	   order	   to	   activation	   the	   same	   amount	   of	   ERK	  (71,000).	   Since	   both	   bound-­‐RET	   (27,300)	   and	   total	   RET	   (650,000)	   increased	   by	  100-­‐fold	  compared	  to	  normal	  cells,	  ART-­‐bound	  fraction	  of	  RET	  f	  remained	  the	  same	  to	   achieve	   EC50(pERK)	   (f	   =	   273000	   /	   650000	   =	   0.065).	   Based	   on	  Eq.	   2.9,	   higher	  EC50(pERK)	  will	   be	  expected	   in	   these	  hypothetical	   cells	   compared	   to	  normal	   cells,	  when	  f	  remained	  the	  same	  as	  in	  normal	  cells	  but	  [RT]	  increased	  by	  100-­‐fold	  due	  to	  increase	   of	   the	   RET	   expression	   level.	   In	   such	   hypothetical	   cells,	   expected	  EC50(pERK)	  at	  the	  density	  of	  6	  ×	  107	  cell/mL	  is	  calculated	  as	  3.1	  nM,	  which	  is	  over	  8	  fold	   higher	   than	   EC50(pERK)	   (0.38	   nM)	   in	   normal	   cells	   at	   the	   same	   density.	   The	  calculated	  hypothetical	  EC50	  values	  as	  a	  function	  of	  cell	  density	  in	  cells	  with	  different	  RET	  expression	  levels	  are	  shown	  as	  the	  dashed	  line	  in	  Figure	  2.16.	  The	  calculation	  indicates	   that,	   at	   the	   cell	   density	   we	   estimate	   for	   a	   solid	   tissue	   (~5–10	   ×	   107	  cells/mL),143	   cells	   expressing	   650,000	   RET/cell	   with	   low	   coupling	   efficiency	  (pRET/pERK	   =	   2.6)	  would	   require	   up	   to	   13-­‐fold	   higher	   concentrations	   of	   ART	   to	  achieve	   the	  same	   level	  of	  pERK	  activation	  seen	   for	  cells	  expressing	  normal	  RET	  at	  normal	  levels.	  High	  ART	  concentrations	  would	  be	  required	  to	  ensure	  that	  there	  are	  a	  sufficient	  number	  of	  ART	  molecules	  present,	  in	  the	  limited	  extracellular	  fluid	  space	  around	   each	   cell,	   to	   engage	   and	   activate	   enough	   of	   the	   inefficiently	   coupled	   RET	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receptors	   to	   achieve	   the	   required	   levels	   of	   intracellular	   effector	   activation.	  Therefore,	  without	  high	  Receptor/Effector	  coupling	  efficiencies,	  the	  cells	  might	  fail	  to	   activate	   enough	  downstream	  molecules	   at	   low	  physiological	  GF	   concentrations.	  We	   cannot,	   of	   course,	   exclude	   the	   possibility	   that	   the	   high	   coupling	   efficiency	  we	  observed	   for	   RET	   at	   functional	   ART	   concentrations	   is	   merely	   coincidental,	   or	  reflects	   an	   arbitrary	   property	   of	   the	   system	   that	   is	   not	   important	   for	   the	   proper	  response	   of	   cells	   to	   ART.	   However,	   the	   above	   argument	   shows	   that	   reasonable	  circumstances	   can	   be	   conceived	  where	   receptor-­‐effector	   coupling	   efficiency	   could	  be	   functionally	   important,	   supporting	   the	   notion	   that	   this	   quantitative	   feature	   of	  receptor	  signaling	  is	  worthy	  of	  further	  study.  	  
2.5.4. Signal	  Sensitization	  and	  Amplification	  in	  RET	  Signaling	  
	   Our	   results	   also	   shed	   light	   on	   broader	   design	   principles	   governing	   how	  receptors	  and	  their	  associated	  signaling	  machinery	  decode	  an	  extracellular	  signal	  to	  trigger	   a	   functional	   outcome.	   The	   relationship	   EC50(receptor)	   >	   EC50(effector)	   >	  EC50(functional	   response)	   that	  we	   see	   for	   stimulation	   of	   cells	  with	   ART	   is	   not	   an	  uncommon	   pattern.103,104,105	   Our	   analysis	   provides	   insight	   into	   the	   functional	  consequences	  of	  such	  progressive,	  stepwise	  sensitization	  of	  signaling.	  In	  this	  context	  it	   is	   important	   to	   distinguish	   signal	   sensitization	   from	   the	   related	   but	   distinct	  phenomenon	  of	  signal	  amplification.	  Signal	  sensitization	  describes	  a	  decrease	  in	  the	  GF	  concentration	  required	  to	  activate	  successive	  steps	  in	  the	  transduction	  process,	  whereas	   signal	  amplification	  concerns	   the	  numbers	  of	  effector	  molecules	   involved	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Figure 2.17 Functional implications of receptor-effector coupling efficiency. A. Plots of Eq. 
2.1 and Eq. 2.2, for hypothetical receptor (red line) and effector (blue line) dose-response 
curves, showing that if EC50(effector) < EC50(receptor) then the receptor-effector coupling 
ratio (dashed line) will necessarily increase with decreasing GF concentrations, reaching a 
maximum at [GF] < EC50(effector). The GF concentration range giving maximal (> 90%) 
receptor-effector coupling is shaded in grey. If the system is one for which, for whatever 
reason, a functional response requires maximal receptor-effector coupling, then the dose-
response curve for function will lie around or to the left of the black line. B. Corresponds to A 
but plotted using the curve fits for the experimental data shown in Figure 2.6 (but omitting the 
experimental data points, for clarity) to illustrate the behavior observed experimentally in this 
study for pRET (red line), pERK (blue line), pAkt (green line), Dose-response data of neurite 
outgrowth induced by ART in the same cells measured by colleague Jennifer M. Chow is 
shown as the black line. C. Plots based on Eq. 2.1 and Eq. 2.2 showing the expected behavior 
for a hypothetical receptor (EC50 = 10 nM, red line) that activates effectors in two divergent 
signaling pathways with very different EC50 values (1 nM, blue line, and 0.033 nM, green 
line). The plot shows that pEffector/pReceptor coupling for the two effectors (dashed blue and 
green lines) is maximal at correspondingly different GF concentrations, such that functional 





In	  this	  study,	  we	  found	  that	  pERK	  and	  pAkt	  had	  fairly	  similar	  EC50	  values,	  and	  thus	   showed	   maximal	   receptor-­‐effector	   coupling	   efficiency	   over	   essentially	   the	  same	   ART	   concentration	   range	   (Figure	   2.17B).	  We	   speculate	   that	   a	   common	   GF	  concentration	   range	   for	   high	   receptor-­‐effector	   coupling	   might	   be	   expected	   for	  effectors	   that	  occupy	  similar	  positions	   in	   their	   respective	  signaling	  cascades	  when	  they	   participate	   in	   a	   common	   functional	   outcome.	   However,	   it	   is	   possible	   to	  conceive	   of	   situations	   in	   which	   a	   receptor	   might	   activate	   different	   downstream	  effectors	   with	   very	   different	   EC50	   values,	   such	   that	   the	   GF	   concentrations	   giving	  maximal	   coupling	   efficiency	   are	   dissimilar	   (Figure	   2.17C).	   Such	   a	   situation	  might	  arise	   if	   the	   different	   signaling	   events	   are	   associated	   with	   different	   functional	  responses	  that	  occur	  over	  distinct	  GF	  concentration	  ranges,	  as	  is	  known	  to	  occur	  for	  example	  with	  morphogens144	  and	  some	  growth	  factors145.	  	  
	  
2.6. Conclusions	  
In	  this	  study,	  we	  quantified	  the	  cellular	  activation	  levels	  of	  RET,	  ERK	  and	  Akt	  upon	  ART	  stimulation.	  ART	  Stimulation	  can	  maximally	  induce	  an	  average	  of	  140,000	  ±	   17,000	   phosphorylated	   ERK	  per	   cell,	   105,000	   ±	   10,000	   phosphorylated	  Akt	   per	  cell,	  and	  4200	  phosphorylated	  RET	  per	  cell.	  The	  latter	  number	  represents	  ~65%	  of	  total	   cellular	   RET.	   Our	   analysis	   of	   the	   receptor-­‐effector	   coupling	   efficiency	   in	   the	  RET	  system	  shows	  that	  maximal	  coupling	  efficiency	  coincides	  with	  the	  biologically	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relevant	   GF	   concentrations.	   We	   speculate	   that	   a	   high	   receptor-­‐effector	   coupling	  efficiency	   might	   be	   advantages	   in	   situations	   where	   the	   GF	   concentration	   is	  stoichiometrically	   limiting	   compared	   to	   the	   receptor	  expression	   levels,	  due	   to	   low	  fluid	  volume	   in	  dense	   tissue,	  such	   that	  high	   levels	  of	   intracellular	  signal	  activation	  must	  be	  achieved	  even	  though	  only	  a	   few	  receptors	  per	  cell	  can	  become	  activated.	  The	  comparison	  between	  the	  ERK	  and	  Akt	  pathways	  showed	  that	  receptor-­‐effector	  coupling	   efficiency	   is	   not	   only	   dependent	   on	  GF	   concentrations,	   but	   can	   differ	   for	  different	  pathways.	  The	  very	  low	  ART	  doses	  that	  are	  required	  for	  functional	  activity	  in	  addition	  to	  inducing	  maximal	  receptor-­‐effector	  coupling	  efficiencies,	  also	  showed	  the	   greatest	   discrimination	   between	   ERK	   and	   Akt	   pathways.	   These	   observations	  suggest	   that	   the	  RET	  system	  may	  have	  evolved	   to	   function	  with	  highest	   efficiency	  and	  pathway	  selectivity	  at	  functionally	  relevant	  levels	  of	  ART	  stimulation.	  	  	  
Our	   analysis	   of	   the	   ART	   dose-­‐dependent	   and	   time-­‐dependent	   signaling	  provides	  a	  quantitative	  picture	  of	  how	  receptor-­‐effector	  coupling	  efficiency	  relates	  to	  signaling,	  when	  measured	  at	   the	   level	  of	   receptor	  activation	  versus	  intracellular	  signaling	   events	   versus	   the	   ultimate	   cellular	   functional	   response.	   These	   findings	  advance	  our	  understanding	  of	  how	   the	   intracellular	   signaling	  machinery	  serves	   to	  decode	  the	  information	  contained	  in	  the	  concentration	  and	  timing	  of	  GF	  stimulation	  to	  achieve	  an	  appropriate	  functional	  outcome.	  	  
It	  will	   be	   interesting	   to	   see	  how	   the	   coupling	  efficiency	  of	  RET/ERK	   is	   in	   a	  single	  stimulated	  with	  ART	  and	  how	  it	  will	  be	  affected	  by	  surface	  expression	  levels	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2.7. Experimental	  Methods	  
Materials 
All	   salts,	   Nonidet	   P-­‐40,	   phenylmethanesulfonyl	   fluoride	   (PMSF),	   bovine	  serum	  albumin,	  sulfuric	  acid,	  3,3’,5,5’-­‐tetramethylbenzidine	  dihydrochloride	  (TMB),	  Dulbecco’s	  PBS,	   SDS-­‐PAGE	  gel	   and	  nitrocellulose	  membrane	  were	  purchased	   from	  Sigma-­‐Aldrich	   (St.	   Louis,	   MO)	   or	   Thermo	   Fisher	   (Waltham,	   MA).	   Rat	   artemin147,	  hamster	   anti-­‐rat	   RET	   antibody	   AA.GE7.3148,	   and	   the	   NB41A3-­‐mGFRα3	   cell	   line149	  were	   generous	   gifts	   from	   Biogen	   Idec	   (Cambridge,	   MA).	   For	   tissue	   culture,	  Dulbecco’s	   modified	   Eagle’s	   medium	   (DMEM)	   (catalog	   no.	   11965-­‐092)	   and	  Dulbecco’s	   phosphate-­‐buffered	   saline	   (PBS)	   (catalog	   no.	   10010-­‐023)	   were	  purchased	  from	  Theromo	  Fisher.	  Hygromycin	  B	  was	  from	  EMD	  Millipore	  (Billerica,	  MA).	   For	   ELISA,	   anti-­‐phospho-­‐p44/42	  MAPK	   rabbit	   capture	   antibody	   (catalog	   no.	  7246s),	   anti-­‐p44/42	   MAPK	   mouse	   detection	   antibody	   (catalog	   no.	   7246s),	   anti-­‐	  phospho-­‐Akt	   (Ser-­‐473)	   rabbit	   capture	   antibody	   (catalog	   no.	   7143s),	   anti-­‐Akt1	  mouse	  detection	  antibody	  (catalog	  no.	  7143s)	  and	  HRP-­‐conjugated	  anti-­‐mouse	  IgG	  antibody	   (catalog	   no.	   7076P2)	   were	   purchased	   from	   Cell	   Signaling	   Technology	  (Danvers,	  MA).	  HRP-­‐conjugated	  mouse	  anti-­‐phosphotyrosine	  antibody	  (catalog	  no.	  03-­‐7720)	   was	   purchased	   from	   Thermo	   Fisher.	   Anti-­‐C	   terminus	   RET	   antibody	  (catalog	   no.	   134100)	   and	   HRP-­‐conjugated	   anti-­‐rabbit	   IgG	   antibody	   (catalog	   no.	  6721)	   were	   purchased	   from	   Abcam	   (Cambridge,	   MA).	   Purified	   recombinant	  activated	   mouse	   ERK2	   (catalog	   no.	   14-­‐173)	   was	   purchased	   from	   EMD	   Millipore	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(Billerica,	  MA).	  Recombinant	  human	  activated	  Akt1	  protein	  (catalog	  no.	  2999)	  was	  purchased	   from	   Invitrogen.	   For	   Western	   blotting,	   anti-­‐pAkt	   (Ser-­‐473)	   rabbit	  antibody	   (catalog	   no.	   4060P),	   anti-­‐p44/42	   MAPK	   (Thr-­‐202/Tyr-­‐204)	   rabbit	  antibody	   (catalog	   no.	   4370P),	   HRP-­‐conjugated	   anti-­‐α-­‐tubulin	   mouse	   antibody	  (catalog	   no.	   12351S),	   and	   HRP-­‐conjugated	   anti-­‐rabbit	   IgG	   antibody	   (catalog	   no.	  7074P2)	   were	   purchased	   from	   Cell	   Signaling	   Technologies	   (Danvers,	   MA).	  Chemiluminescent	   substrate	   (catalog	   no.	   34076)	   was	   purchased	   from	   Thermo	  Fisher.	  For	   immunoprecipitation	  Pierce	  crosslink	   immunoprecipitation	  kit	   (catalog	  no.	   26147)	   was	   purchased	   from	   Thermo	   Fisher.	   Pierce™	   BCA	   protein	   assay	   kit	  (catalog	  no.	  23225)	  was	  purchased	  from	  Thermo	  Fisher.	  	  
Cell Culture  
NB41A3-­‐mGFRα3	  cells	  were	  cultured	  in	  Dulbecco’s	  modified	  Eagle’s	  medium	  (DMEM)	  supplemented	  with	  10%	   fetal	  bovine	   serum,	  2	  mM	  L-­‐glutamine,	   and	  500	  μg/mL	  hygromycin	  B	  in	  a	  humidified	  chamber	  with	  5%	  CO2	  at	  37	  °C.	  	  
pRET and total RET ELISAs 
The	   kinase	   receptor	   activation	   (KIRA)	   ELISA	   used	   to	   quantify	   RET	  phosphorylation	   levels	   was	   used	   as	   reported	   previously.126,149	   Briefly,	   NB41A3-­‐mGFRα3	   cells	   were	   seeded	   overnight	   in	   12-­‐well	   plates	   (Corning	   Glass)	   at	   a	  concentration	  of	  6	  ×	  105	   cells/mL	   in	  1	  ml	  of	  growth	  medium.	  To	  activate	   the	  RET	  receptor,	  ART	  was	  added	  to	  the	  cells	  in	  500	  μl	  of	  DMEM	  with	  2	  mM	  L-­‐glutamine.	  For	  
	  	  
65	  
the	  dose-­‐response	  experiments,	  cells	  were	  incubated	  with	  ART	  (0,	  0.005,	  0.02,	  0.1,	  0.2,	  0.4,	  1,	  2,	  4	  or	  10	  nM)	  for10,	  30,	  or	  60	  min.	  For	  the	  time-­‐course	  experiments,	  cells	  were	  incubated	  with	  a	  fixed	  concentration	  of	  ART	  (0.1,	  0.4,	  1,	  4,	  or	  10	  nM)	  for	  0,	  2,	  4,	  6,	  8,	  or	  10	  min	  (10-­‐min	  time-­‐course)	  or	  for	  0,	  5,	  10,	  20,	  30,	  40,	  50,	  60,	  70,	  80,	  or	  90	  min	   (90-­‐min	   time-­‐course).	   After	   incubation	   with	   ART	   at	   37	   °C,	   to	   quench	   the	  reaction,	  the	  cells	  were	  washed	  with	  ice-­‐cold	  Dulbecco’s	  phosphate-­‐buffered	  saline	  (PBS)	  and	  lysed	  for	  1	  h	  on	  ice	  in	  KIRA	  lysis	  buffer	  (10	  mM	  Tris,	  0.5%	  Nonidet	  P-­‐40,	  0.2%	  sodium	  deoxycholate,	  50	  mM	  NaF,	  0.1	  mM	  Na3VO4,	  1	  mM	  PMSF,	  pH	  8.0)	  with	  gentle	   shaking.	  Meanwhile,	   the	   96-­‐well	   ELISA	   plate	  was	   coated	  with	   100	   μL	   of	   5	  μg/mL	  anti-­‐rat	  RET	  antibody	  AA.GE7.3	   in	  50	  mM	  bicarbonate	  buffer,	  pH	  9.6,	  over-­‐night	  at	  4	   °C	  and then	   incubated	   for	  1	  h	  at	   room	   temperature	  with	  KIRA	  blocking	  buffer	  consisting	  of	  PBS	  with	  0.05%	  Tween	  20	  (PBST),	  3%	  bovine	  serum	  albumin,	  and	   1%	   fetal	   bovine	   serum.	   For	   each	   stimulation	   condition,	   a	   260-­‐μL	   aliquot	   of	  clarified	   cell	   lysate	   was	   added	   to	   each	  well	   of	   the	   assay	   plate,	   and	   the	   plate	   was	  incubated	  for	  2	  h	  at	  room	  temperature	  with	  gentle	  shaking.	  The	  plate	  was	  washed	  with	  PBST	  followed	  by	  incubation	  with	  100	  μL	  of	  0.5	  μg/mL	  HRP-­‐conjugated	  mouse	  anti-­‐phosphotyrosine	   antibody	   in	   blocking	   buffer	   for	   1.5	   h.	   After	   another	   PBST	  wash,	  the	  plate	  was	  incubated	  with	  the	  HRP	  substrate,	  TMB.	  The	  color	  reaction	  was	  quenched	  with	  1	  M	  H2SO4,	  and	  the	  absorbance	  from	  the	  wells	  was	  recorded	  at	  450	  nm	  using	  a	  SpectraMax	  M5	  microplate	   reader	   (Molecular	  Devices,	   Sunnyvale,	  CA).	  We	   have	   previously	   shown	   that	   the	   observed	   absorbance,	   after	   background	  subtraction,	  is	  proportional	  to	  the	  quantity	  of	  phosphorylated	  RET.	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To	  detect	   total	  cellular	  RET	   in	  cell	   lysates,	  after	   incubation	  with	  cell	   lysates	  and	  washing,	   the	  ELISA	  plate	  was	   incubated	  with	   the	  primary	  detection	  antibody,	  anti-­‐C	  terminus	  RET	  antibody	  (1:2000)	  in	  blocking	  buffer	  for	  1	  h	  while	  shaking.	  The	  plate	   is	   then	   washed	   with	   PBST	   and	   incubated	   with	   the	   secondary	   detection	  antibody,	  goat	  anti-­‐rabbit	  IgG	  antibody	  (1:2000)	  in	  blocking	  buffer	  for	  0.5	  h	  before	  washing	  and	  reacting	  with	  HRP	  substrates.	  	  
pRET Immunoprecipitation 
Crosslinking	   of	   5	   μg	   anti-­‐phospho	   Tyrosine	   antibody	   to	   10	   μL	   protein	   A/G	   plus	  agarose	   (20	   μL	   resin	   slurry)	  was	   performed	   following	   the	   procedure	   provided	   by	  the	   Pierce	   crosslink	   IP	   kit.	   Briefly,	   20	   μL	   of	   the	   resin	   slurry	   was	   washed	   with	  coupling	  buffer	  (0.01	  Na3PO4,	  0.15	  NaCl,	  pH	  7.2)	  in	  a	  Pierce	  spin	  column,	  followed	  by	  incubation	  of	  10	  μg	  anti-­‐phospho	  Tyrosine	  antibody	  in	  100	  μL	  coupling	  buffer	  for	  1	  h	  at	  room	  temperature	  on	  a	  shaker.	  After	  discarding	  the	  flow	  through,	  the	  resin	  was	  washed	   twice	   with	   coupling	   buffer	   and	   incubated	  with	   50	   μL	   of	   450	   μM	   freshly-­‐made	  disuccinimidyl	   suberate	   (DSS)	  crosslinker	   in	  coupling	  buffer	   for	  1	  hour.	  The	  antibody-­‐crosslinked	  resin	  was	  then	  washed	  with	  provided	  elution	  buffer	  (pH	  =	  2.8)	  and	  cold	  KIRA	  lysis	  buffer,	  and	  stored	  in	  KIRA	  lysis	  buffer	  at	  4	  °C	  before	  use.	  	  NB41A3-­‐mGFRα3	   cells	   were	   seeded	   overnight	   in	   6-­‐well	   plates	   (Corning,	  Corning,	  NY)	   at	   a	   concentration	   of	   1	   ×	   106	   cells/mL	   in	   2	  mL	   growth	  media.	   After	  stimulation	  of	  4	  nM	  ART	  or	  DMEM	  for	  20	  min,	  the	  cells	  in	  each	  well	  were	  lysed	  with	  1	   mL	   of	   KIRA	   lysis	   buffer.	   Protein	   concentration	   of	   each	   lysate	   sample	   was	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determined	  by	  BCA	  assay	  with	  BSA	  standards.	  The	  cell	  lysate	  was	  then	  pre-­‐cleared	  by	  incubation	  with	  provided	  control	  agarose	  beads	  for	  30	  min	  at	  4	  °C	  (80	  μL	  of	  the	  control	  agarose	  beads	  slurry	   for	  1	  mg	  of	   lysate).	  300	  μL	  of	  pre-­‐cleared	   lysate	  was	  added	   to	   the	   antibody-­‐crosslinked	   resin	   or	   vehicle	   resin	   in	   the	   column,	   followed	  with	  2	   h	   of	   incubation	   at	   4	   °C	  while	   shaking.	   The	   flow-­‐through	  was	   collected	   and	  detected	  for	  pRET	  and	  total	  RET	  by	  ELISAs	  as	  previously	  described.	  A	  100	  μL	  aliquot	  of	   resin-­‐incubated	   lysate	   was	   added	   onto	   KIRA	   ELISA	   for	   the	   detection	   of	   RET	  phosphorylation	   levels	  with	   or	  without	   the	   crosslinked	   antibody.	  The	   same	   lysate	  sample	  was	  diluted	  by	  6-­‐fold	  before	   loading	   to	   total	  RET	  ELISA	   to	  detect	   the	   total	  RET	   change	   caused	   by	   the	   immunoprecipitation.	   Protein	   concentration	   of	   all	  samples	  was	  determined	  by	  BCA	  assay	  and	  used	  to	  normalize	  the	  ELISA	  responses.	  
ERK/Akt Phosphorylation ELISAs 
Cellular	  ERK1/2	  and	  Akt	  phosphorylation	  levels	  were	  determined	  by	  ELISAs	  with	  antibodies	  specific	  to	  phosphorylated	  ERK1/2	  or	  phosphorylated	  Akt.	  NB41A3-­‐mGFRα3	  cells	  were	  stimulated	  with	   specific	  doses	  of	  ART	  exactly	  as	  was	  done	   for	  the	  RET	  ELISA.	  The	  cells	  were	  then	  lysed	  for	  20	  min	  on	  ice	  in	  pERK/pAkt	  lysis	  buffer	  (20	  mM	  Tris,	   150	  mM	  NaCl,	   1	  mM	  EDTA,	   1	  mM	  EGTA,	   1%	  Triton	   X-­‐100,	   2.5	  mM	  sodium	  pyrophosphate,	  1	  mM	  β-­‐glycerophosphate,	  50	  mM	  NaF,	  1	  mM	  Na3VO4,	  1	  mM	  PMSF,	   pH	   7.5)	   with	   shaking.	   The	   96-­‐well	   ELISA	   plates	   were	   coated	   with	   anti-­‐phospho-­‐p44/42	  MAPK	   capture	   antibody	   or	   anti-­‐phospho-­‐Akt1	   (Ser-­‐473)	   capture	  antibody	  (100	  μL	  of	  a	  1:100	  dilution	  of	  antibody	  stock	  solution	  in	  PBS)	  overnight	  at	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4	  °C,	  followed	  by	  incubation	  for	  1	  h	  with	  pERK/pAkt	  blocking	  buffer	  (PBST	  with	  1%	  bovine	  serum	  albumin)	  at	  room	  temperature.	  A	  260-­‐μL	  aliquot	  of	  clarified	  cell	  lysate	  was	  added	   to	  each	  well,	   followed	  by	   incubation	   for	  2	  h	  at	   room	  temperature	  with	  shaking.	  All	  samples	  were	  measured	  in	  duplicate.	  The	  plate	  was	  washed	  with	  PBST	  and	   incubated	   for	   1	   h	   with	   either	   anti-­‐p44/42	  MAPK	   detection	   antibody	   or	   anti-­‐Akt1	   detection	   antibody,	   followed	   by	   a	   wash	   step	   and	   detection	   with	   HRP-­‐conjugated	   anti-­‐mouse	   IgG	   for	   0.5	   h.	   All further	   steps	   leading	   to	   the	   recording	   of	  absorbance	   at	   450	  nm	  were	   similar	   to	   the	  KIRA	  ELISA.	   The	   anti-­‐phospho-­‐p44/42	  MAPK	  rabbit	   capture	  antibody	   recognizes	  ERK1/2	  when	  dually	  phosphorylated	  at	  Thr-­‐202/Tyr-­‐204	   in	   ERK1	   or	   Thr-­‐185/Tyr-­‐187	   in	   ERK2,	   or	   when	   singly	  phosphorylated	   at	   Thr-­‐202	   in	   ERK1	   or	   Thr-­‐185	   in	   ERK2,	   as	   described	   by	   the	  manufacturer.	   The	   anti-­‐phospho-­‐Akt	   rabbit	   capture	   antibody	   recognizes	   Akt1	  phosphorylated	  at	  Ser-­‐473.	  
Assays	  were	  calibrated	  by	  constructing	  standard	  curves	  using	  duplicate	  wells	  containing	  activated	  recombinant	  mouse	  MAPK2	  (ERK2)	  or	  activated	  recombinant	  human	  Akt1	   as	   standards.	   The	   capture	   and	   detection	   antibodies	   for	   pERK	   do	   not	  discriminate	   between	   pERK1	   and	   pERK2,127	   and	   those	   used	   for	   the	   pAkt	   ELISA	  detect	  both	  human	  and	  mouse	  pAkt1128.	  The	  standard	  proteins	  were	  reconstituted	  in	  lysate	  from	  unstimulated	  cells	  at	  concentrations	  of	  0.1,	  1,	  4,	  8,	  10,	  12,	  15,	  20,	  30,	  and	  40	  ng/mL,	  and	   the	  resulting	  signals	  were	  measured	  using	   the	  standard	  ELISA	  protocols	  described	  above.	  Lysate	  from	  6	  ×	  105	  cells	  stimulated	  with	  4	  nM	  ART	  for	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10	  min	  was	   included	   in	   the	   same	   experiments,	   and	   the	   concentration	   of	   pERK	   or	  pAkt	   present	   in	   these	   samples	   was	   read	   from	   the	   standard	   curve.	   Three	  independent	  calibration	  experiments	  were	  done	  for	  each	  ELISA.	  
In	  experiments	  measuring	  pERK	  EC50	  values	  with	  various	  cell	  densities,	  3	  ×	  105	  cells	  were	  stimulated	  with	  ART	  of	  various	  concentrations	   in	  the	  volume	  of	  20,	  50	  or	  90	  μL	  for	  10	  min.	  The	  cell	  pallets	  were	  spun	  down	  by	  centrifugation	  at	  300	  g	  for	  5	  min	  and	  lysed	  for	  pERK	  detection	  in	  ELISA	  assays	  as	  described	  above.	  	  
Western Blotting 
After	   ART	   stimulation,	   the	   cell	   lysates	   were	   resolved	   to	   SDS-­‐PAGE	   gel	  electrophoresis	  and	  electroblotted	  onto	  nitrocellulose	  membranes.	  The	  membranes	  were	   blocked	   in	   5%	   non-­‐fat	  milk	   at	   4	   °C	   overnight,	   then	   incubated	  with	   primary	  antibody	  at	  room	  temperature	  for	  2	  h,	  washed	  and	  incubated	  with	  HRP-­‐conjugated	  secondary	   antibody	   for	   1.5	   h.	   The	   probed	   membrane	   was	   visualized	   by	  chemiluminescent	   substrate	   and	   then	   detected	   by	   Bio-­‐Rad	   imager	   (Bio-­‐Rad,	  Hercules,	  CA).	  	  
Data Analysis 
Each	  ELISA	  experiment	  included	  duplicate	  wells	  containing	  lysis	  buffer	  only	  instead	   of	   cell	   lysate,	   others	   that	   contained	   cell	   lysate	   but	   from	   which	   capture	  antibody	  had	  been	  omitted,	  and	  others	  containing	  lysate	  from	  unstimulated	  cells	  to	  serve	   as	   negative	   controls.	   All	   experiments	   additionally	   included	  wells	   containing	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lysate	  stimulated	  with	  4	  nM	  ART	   for	  either	  10	  or	  20	  min	  as	  a	  positive	  control.	  All	  lysate	   samples	  were	   analyzed	   in	   duplicate.	   The	   duplicate	   absorbance	   values	  were	  averaged,	   the	   “unstimulated	   cells”	   negative	   control	   value	  was	   subtracted,	   and	   the	  result	   was	   expressed	   as	   %	   of	   (positive	   control	   –	   unstimulated	   cells).	   Each	  independent	   experiment	   was	   normalized	   to	   the	   positive	   control	   in	   its	   own	  experiment	   and	   the	   average	   of	   at	   least	   three	   experiments	   was	   used	   for	   further	  analysis.	  	  
All	  curve	  fits	  were	  performed	  using	  ProFit	  6.1.10	  (Quantum	  Soft,	  Uetikon	  am	  see,	  Switzerland).	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Chapter	  3. Analysis	  of	  Kinetic	  Mechanisms	  of	  ART-­‐induced	  RET	  Activation	  in	  
the	  Initial	  10	  Minutes	  After	  Stimulation	  
3.1. Introduction	  
3.1.1. Mechanisms	  of	  Receptor	  Tyrosine	  Kinase	  Activation	  
As	   described	   in	   Chapter	   1,	   RTKs	   become	   activated	   when	   binding	   of	   a	  cytokine	  or	  growth	  factor	  ligand	  recruits	  two	  or	  more	  receptor	  molecules	  to	  form	  an	  active	   complex,	   leading	   to	   cross-­‐autophopshorylation	   of	   their	   intracellular	   kinase	  domains.150	  Different	  receptors	  display	  differences	  in	  the	  affinities	  between	  binding	  partners,151	   and	   likely	   also	   in	   the	   rate	   constants	   of	   the	   activation	   steps.	   A	  quantitative	  understanding	  of	  such	  affinities	  and	  rate	  constants	  is	  required	  for	  a	  full	  understanding	  of	  the	  kinetic	  mechanism	  by	  which	  extracellular	  ligand	  stimulation	  is	  linked	  to	  RTK	  activation	  levels	  and	  is	  transduced	  into	  downstream	  signaling	  events.	  However,	   the	   dynamics	   of	   receptor	   activation,	   and	   how	   it	   affects	   downstream	  signaling	  events	  and	  biological	  effects,	  remain	  largely	  unexplored.	  
Despite	  the	  structural	  similarity	  shared	  within	  the	  RTK	  family,	  the	  activation	  mechanism	  of	  RTKs	  can	  be	  very	  different	  in	  respect	  to	  what	  molecules	  are	  involved	  in	   the	   activated	   receptor	   complex,	   and	   how	   the	   assembly	   of	   this	   complex	   brings	  about	   activation	   of	   the	   RTK	   components.152	   The	   simplest	   case	   is	  when	   binding	   of	  one	  ligand	  to	  two	  identical	  RTK	  induces	  formation	  of	  an	  activated,	  dimeric	  receptor	  complex	  and	  subsequent	  phosphorylation	  of	  the	  receptors,	  as	  is	  seen,	  for	  example	  in	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receptor	   systems	   such	   as	   KIT,	   activated	   by	   stem	   cell	   factor	   (SCF),153	   and	   insulin	  receptor,	   activated	   by	   insulin,	   IGF-­‐1	   and	   IGF-­‐2154.	   Alternatively,	   an	   active	   ligand-­‐receptor	  complex	  can	  consist	  of	  two	  receptors	  with	  a	  ligand	  bound	  to	  each,	  such	  as	  the	   2:2	   complexes	   formed	  by	   the	   epidermal	   growth	   factor	   (EGF)	   receptor	   (EGFR)	  with	   EGF155	   and	   with	   transforming	   growth	   factor-­‐α	   (TGFα).156	   Other	   receptors	  require	  accessory	  signaling	  proteins	  to	  achieve	  activation.	  For	  example,	  activation	  of	  fibroblast	   growth	   factor	   (FGF)	   requires	   the	   crosslinking	   of	   two	   FGF:FGFR	   (1:1)	  complexes	  by	  heparin.157,158	  Full	  activation	  of	  RET	  also	  requires	  the	  participation	  of	  an	   accessory	   protein.	   As	   described	   in	   Chapter	   1,	   the	   activated	   receptor	   complex	  contains	   one	   copy	   of	   a	   GDNF	   family	   ligand	   (GNDF,	   ART,	   PSP	   or	   NTN),	   two	   RET	  molecules,	   and	   two	  molecules	   of	   a	   GPI-­‐linked	   co-­‐receptors	   (GFRα1,	   2,	   3,	   or	   4),	   to	  form	   a	   five-­‐member	   complex	   of	   composition	   ligand-­‐(GFRα)2-­‐RET2.18	   The	  employment	  of	  additional	  accessory	  molecules	  adds	  complexity	  and	  challenge	  to	  the	  study	  of	   the	  RET	  activation	  mechanism,	  by	   introducing	  extra	  components	   into	   the	  puzzle.	  	  
Besides	   the	  difference	   in	   the	   type	  and	  number	  of	  molecules	   involved	   in	   the	  RTK	  activation	  process,	  RTK	  activation	  mechanisms	  also	  differ	  in	  how	  the	  two	  RTK	  molecules	   are	   brought	   into	   the	   correct	   mutual	   orientation	   for	   trans-­‐autophosphorylation	   to	   occur.	   One	   straightforward	   mechanism,	   termed	   “ligand-­‐induced	  dimerization”,	  is	  when	  receptor	  dimerization	  is	  merely	  driven	  by	  binding	  of	  a	  bivalent	   ligand	   to	   two	  receptors,	  bringing	   them	   into	  a	   ternary	  complex	   in	  which	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the	   two	   receptor	   molecules	   are	   close	   together.150	   For	   instance,	   one	   molecule	   of	  nerve	  growth	  factor	  (NGF),	  a	  constitutive	  homodimer,	  binds	  to	  two	  molecules	  of	  its	  receptor,	   tropomyosin	   receptor	   kinase-­‐A	   (TrkA)	   independently	   and	   equivalently,	  bringing	   the	   two	   receptor	   molecules	   together	   into	   a	   functional	   complex.159	   In	  contrast,	   in	  some	  RTK	  systems,	  such	  as	  the	  ErbB	  receptor	  family160,	   the	  ligands	  do	  not	  directly	  contact	  both	  receptor	  chains	  in	  the	  final	  activated	  complex.	  	  In	  this	  case,	  exemplified	   by	   ErbB1,	   also	   known	   as	   EGFR,	   binding	   of	   the	   ligand	   EGF	   to	   a	   single	  EGFR	  molecule	   causes	   a	   conformational	   change	   in	   the	   EGFR	   extracellular	   domain	  that	   exposes	   a	   region	   of	   the	   receptor	   structure	   known	   as	   the	   “dimerization	   arm”,	  which	  mediates	  interaction	  with	  another	  ligand-­‐bound	  EGFR	  to	  form	  the	  functional,	  EGF2-­‐EGFR2	   complex.161,162	   Some	   other	   receptors	   are	   activated	   by	   mechanisms	  involving	  a	  combination	  of	  bivalent	  ligand	  binding,	  receptor-­‐mediated	  dimerization,	  and	   the	  use	  of	  additional	  binding	  components.	  GDNF	   family	   ligands	   (GFLs)	  do	  not	  bind	  measurably	   to	  RET	   alone,	   and	   thus	  must	   bind	   to	   a	  GFRα	   co-­‐receptor	   first	   in	  order	   to	   recruit	  RET	   into	  a	   complex.	   Schlee	  et	  al.	   proposed	   that	   the	  GFL	  ART	   first	  binds	   to	   a	   co-­‐receptor	   GFRα3,	   then	   recruits	   one	  molecule	   of	   RET	   to	   form	   a	   1:1:1	  ART-­‐GFRα3-­‐RET	  complex,	  then	  recruits	  a	  second	  GFRα3	  followed	  by	  a	  second	  RET	  to	   form	   the	   active	   five-­‐member	   complex.126	   The	   molecular	   mechanisms	   of	   RET	  activation	  and	  the	  kinetics	  of	  key	  binding	  and	  phosphorylation	  steps	  are	  still	  under	  investigation.	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Substantial	  knowledge	  has	  been	  gained	  concerning	  the	  structure	  of	  the	  RET	  ligand-­‐coreceptor	  complexes,	  the	  locations	  of	  phosphorylation	  sites	  on	  RET,	  and	  the	  physiological	  functions	  of	  RET.	  However,	  it	  remains	  unclear	  exactly	  how	  binding	  of	  the	   ligand	   to	   the	   receptor’s	   extracellular	   domain	   causes	   the	   rearrangement	   of	   the	  receptor’s	   intracellular	   domains	   to	   enhance	   RET’s	   kinase	   activity.	   Indeed,	   no	  detailed	  understanding	  exists	   for	   the	  kinetic	  mechanism	  of	   receptor	  activation	   for	  any	  RTK,	  at	  the	  level	  of	  experimentally	  determined	  rate	  constants	  for	  the	  individual,	  microscopic	   steps.	   It	   is	   important	   to	   gain	   a	   quantitative	   understanding	   of	   the	  molecular	   mechanism	   of	   RTK	   activation	   if	   one	   wants	   to	   predict	   how	   the	   system	  would	  behave	  under	  different	   conditions,	   for	  example	   in	  a	  different	   cell	   type	  with	  different	   levels	   of	   receptor	   and/or	   co-­‐receptor	   expression.	   Such	   information	   also	  aids	   the	   generalization	   of	   the	   knowledge	   and	   understanding	   gained	   through	  working	   on	   a	   given	   receptor	   system,	   by	   revealing	   fundamental	   principles	   and	  relationships	  that	  potentially	  can	  be	  applied	  to	  other	  receptors.	  
3.1.1. Key	  Questions	  and	  Main	  Challenges	  
Important	   progress	   towards	   achieving	   a	   quantitative	   understanding	   of	  receptor	   activation	   processes	   has	   been	  made	   using	   fluorescence-­‐based	   and	   other	  biophysical	  methods	  to	  characterize	  the	  interactions	  between	  receptor	  proteins	  on	  artificial	  membranes163,164	  	   or	   live	  cells165,166,167,168,169,170.	  Gavutis	  et	  al.	  developed	  a	  method	   to	   anchor	   receptors	   onto	   glass-­‐supported	   lipid	   bilayers,	   and	   applied	   it	   to	  detect	   ligand-­‐receptor	   interactions	   by	   simultaneous	   reflectance	   interferometry	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(RIF)	  and	  total	   internal	  reflection	  fluorescence	  spectroscopy	  (TIRFS).164,171	  Yang	  et	  
al.	  and	  Macdonald-­‐Obermann	  et	  al.	  used	  a	  luciferase	  fragment	  located	  in	  the	  EGFR	  C-­‐terminus	  to	  monitor	  its	  activation	  dynamics.168,169,172	  Wilkinson	  et	  al.	  measured	  EGF-­‐EGFR	   binding	   kinetics	   in	   live	   cells	   by	   monitoring	   the	   anisotropy	   change	   of	  fluorescently	  labeled	  EGF	  upon	  binding	  to	  EGFR-­‐expressing	  cells	  in	  a	  stopped-­‐flow	  assay.170	   However,	   these	   biophysical	   approaches	   generally	   involve	   labeling	   or	  modifying	  the	  receptor,	  and/or	  expressing	   it	  at	  unnaturally	  high	   levels,	  potentially	  affecting	  the	  quantitative	  behavior	  of	  the	  system.	  	  
It	  has	  been	  considered	  extremely	  daunting	  to	  attempt	  to	  directly	  measure	  the	  rate	   constants	   for	   ligand	   binding,	   complex	   assembly	   and	   receptor	  autophosphorylation	  in	  the	  native	  cellular	  context.	  The	  reasons	  are	  as	  follows:	  First,	  protein-­‐protein	   interactions	   and	   protein	   rearrangements	   often	   happen	   on	   a	   time	  scale	  of	   seconds	  or	   shorter173,	  which	  makes	   it	  hard	   to	   capture	   the	   ligand-­‐receptor	  binding	  kinetics	  during	   the	   critical	   time	  window	  without	   rapid	  detection	  methods	  that	  are	  difficult	  to	  apply	  to	  whole-­‐cell	  experimental	  systems.	  FRET	  has	  shown	  great	  advantages	   in	   revealing	   real-­‐time	   protein-­‐protein	   interactions	   with	   a	   time	  resolution	  of	  nanoseconds.174	  However,	  a	   limitation	   is	   that	   introducing	   fluorescent	  labels	   to	   the	   target	   proteins	   might	   perturb	   the	   affinity	   or	   kinetics	   of	   the	   ligand-­‐receptor	  interaction.	  Techniques	  such	  as	  SPR	  can	  monitor	  real-­‐time	  ligand-­‐receptor	  interaction	   dynamics,	   but	   can	   be	   done	   only	   with	   purified	   receptor	   extracellular	  domains.175	  As	  a	   result,	   contextual	   factors	   such	  as	   the	  movements	  of	   receptors	  on	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the	  cell	  surface	  important	  for	  the	  formation	  of	  higher	  order	  receptor	  clusters,176,177	  or	  recruitment	  to	  signal	  in	  certain	  cell	  membrane	  subdomains178,24,	  are	  eliminated.	  For	  instance,	  recruitment	  of	  RET	  into	  lipid	  rafts,	  where	  its	  co-­‐receptor	  GFRα	  resides,	  is	   essential	   to	   achieve	   full	   RET	   activation.24	   In	   addition,	   for	   a	   multicomponent	  ligand-­‐receptor	   system	  such	  as	  RET,	   it	   is	   also	   important	   to	   gain	  knowledge	  of	   the	  binding	  sequence	  of	  the	  different	  signaling	  components.	  In	  general,	   it	   is	  difficult	  to	  recapitulate	   the	   native	   cellular	   environment	   with	   artificial	   cell	   membranes	   and	  purified	  recombinant	  proteins.	  Due	  to	  these	  challenges,	  kinetic	  mechanistic	  studies	  of	   receptor	   activation	   using	   unmodified	   receptor	   proteins	   expressed	   on	   cells	   at	  endogenous	  levels	  are	  exceptionally	  rare.	  	  
We	   sought	   to	   establish	   a	   non-­‐perturbing	   approach	   to	   characterize	   the	  activation	  kinetics	  of	  a	  receptor	  tyrosine	  kinase,	  using	  RET	  as	  a	  model	  system.	  Here	  we	  characterize	  the	  kinetics	  of	  the	  assembly	  of	  the	  activated	  RET	  receptor	  complex	  with	  ART	  and	  GFRα3,	  and	   its	  subsequent	  phosphorylation	  and	  dephosphorylation,	  applying	  simple,	  direct	  methods	  that	  use	  unmodified	  RET	  expressed	  endogenously	  in	  cells.	  
	  
3.2. Analysis	  of	  RET	  Activation	  Kinetics	  at	  Steady	  State	  
	   As	  is	  typical	  for	  receptor	  tyrosine	  kinases,	  activation	  of	  RET	  results	  in	  auto-­‐phosphorylation	  of	  multiple	  sites	  in	  the	  cytoplasmic	  domain	  of	  the	  receptor,	  which	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further	  activates	  the	  kinase	  domains	  and	  also	  creates	  docking	  sites	  for	  pTyr-­‐binding	  signaling	   molecules.44	   We	   measured	   the	   rate	   and	   extent	   of	   RET	   phosphorylation	  stimulated	   by	   its	   natural	   ligand	   ART	   using	   our	   previously	   described	   pRET	   ELISA	  assay	   (see	  Chapter	   2	   Experimental	  Methods).	   The	  mouse	  neuroblastoma	   cell	   line	  (NB41A3-­‐mGFRα3)	   used	   in	   this	   study	   endogenously	   expresses	   RET	   and	   has	   been	  stably	   transfected	   with	   GFRα3.	   As	   we	   have	   shown	   previously	   (Figure	   2.9),	  stimulating	   cells	   for	   up	   to	   10	  min	  with	   0.1-­‐10	   nM	   ART	   caused	   a	   dose	   dependent	  increase	  in	  pRET.	  Figure	  3.1A	  shows	  that	  these	  time-­‐courses	  can	  be	  well	  described	  by	  a	  single	  exponential	  rate	  equation	  (Eq.	  3.1),	  	  
Eq. 3.1 𝛥𝑝𝑅𝐸𝑇 = 𝑅𝐸𝑇!"!  ×  (1 −   𝑒!!")	  where	  RETtot	   is	   the	   total	   amount	   of	   RET	   available	   for	   phosphorylation	   upon	   ART	  stimulation,	   and	   t	   is	   stimulation	   time.	   We	   have	   previously	   determined	   that	  
  
Figure 3.1 Time-courses of pRET formation over 0-10 min after stimulation. A. Time-courses 
for the evolution of pRET after treatment of cells with the stated concentration of ART, 
measured using the KIRA ELISA. Solid lines represent the best fit of each time-course to an 
exponential rate equation. Plots show averaged measurements from three independent 
experiments. Error bars are standard deviations of the independent replicate measurements. B. 
Initial rates for the time-courses shown in (A), determined from the exponential curve fits 
shown in that figure.  
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stimulation	   of	  ART	   can	  maximally	   induce	  ~4200	  phosphorylated	  RET	  per	   cell,	   on	  average,	   out	   of	   a	   total	   of	   ~6500	   RET	   molecules	   present,	   on	   average,	   per	   cell.	  Therefore	   we	   constrained	   RETtot	   in	   Eq.	   3.1	   to	   equal	   4.2	   (×	   1000	   molecules/cell)	  when	  fitting	  the	  data. 
The	  initial	  rate	  of	  pRET	  formation	  increases	  almost	  linearly	  with	  [ART]	  over	  this	  concentration	  range	  (Figure	  3.1B),	  indicating	  that	  pRET	  formation	  is	  kinetically	  first-­‐order	  in	  ART.	  Thus	  the	  rate-­‐limiting	  step	  in	  pRET	  formation	  could	  be	  the	  initial	  binding	   of	   ART	   to	   GFRα3,	   or	   any	   of	   the	   several	   subsequent	   steps	   involved	   in	   the	  recruitment	   of	   additional	   RET	   and	   GFRα3	   molecules	   into	   the	   activated	   receptor	  complex,126	   or	   could	   be	   RET	   autophosphorylation	   itself.	   The	   initial	   slope	   of	   the	  dependence	  seen	  in	  Figure	  3.1B	   indicates	  that	  the	  initial	  rate	  of	  pRET	  formation	  is	  160	  ±	  15	  molecules.	  min-­‐1.	  [ART]-­‐1.	  
	  
3.3. Analysis	  of	  RET	  Deactivation	  Kinetics	  	  
Having	  examined	  the	  rate	  of	  pRET	  formation	  and	  the	  maximal	  extent	  of	  pRET	  observed	  at	  steady	  state,	  we	  turned	  our	  attention	  to	  the	  rate	  of	  pRET	  degradation,	  which	   during	   the	   short,	   10	   min	   time	   frame	   of	   our	   experiments	   we	   expect	   is	  primarily	   through	   dephosphorylation	   by	   cellular	   phosphatases.	   We	   employed	   a	  small	   molecule	   inhibitor	   ZD6474	   (also	   known	   as	   vandetenib,	   structure	   shown	   in	  (Figure	  3.2)	  targeting	  the	  kinase	  domain	  of	  RET	  to	  examine	  the	  dephosphorylation	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rate	  of	  pRET	  by	  blocking	  RET	  phosphorylation.	  ZD6474	   is	  a	  selective	   inhibitor	   for	  RET,	  EGFR	  and	  VEGFR	  (vascular	  endothelial	  growth	  factor	  receptor),	  with	  IC50	  =	  100	  nM	  for	  RET.179,180	  Knowles	  et	  al.	  reported	  the	  crystal	  structure	  of	  ZD6474	  bound	  to	  the	  RET	  kinase	  domain,	  which	   shows	   that	  ZD6474	   inhibits	  RET	  kinase	   activity	  by	  occupying	  the	  ATP	  binding	  pocket.179	  
To	  establish	  the	  potency	  with	  which	  ZD6474	  inhibits	  RET	  phosphorylation	  in	  our	   experimental	   system,	   we	   first	   tested	   its	   inhibitory	   effects	   on	   RET	  phosphorylation	  when	  added	  prior	  to	  exposing	  the	  cells	  to	  ART	  stimulation.	  Figure	  
3.2	  shows	  that	  the	  IC50	  of	  ZD6474	  for	  RET	  in	  our	  system	  is	  ~0.41	  μM.	  These	  results	  also	  established	  that	  a	  concentration	  of	  50	  μM	  ZD6474	  was	  sufficient	  to	  essentially	  fully	  inhibit	  RET	  autophosphorylation.	  
  
  
Figure 3.2 Dose-dependent inhibition by ZD6474 of RET phosphorylation. Cells were 
incubated with ZD6474 at various concentrations (10 nM–2 µM) for 10 min, followed by 
incubation with 10 nM ART for 10 min in the continued presence of ZD6474. Experimental 
data show averaged measurements of two independent experiments, plotted as a percentage of 
that from uninhibited cells. Error bars indicate the difference between the duplicates. The solid 
line shows the best fit of the averaged data to a logistic equation. 
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To	  measure	  the	  rate	  of	  pRET	  degradation,	   I	  stimulated	  cells	  with	  4	  nM	  ART	  for	  6	  min	  to	  allow	  pRET	  to	  accumulate,	  added	  50	  μM	  ZD6474	  to	  block	  further	  RET	  autophosphorylation,	   and	   then	  monitored	   pRET	   levels	   as	   a	   function	   of	   time	   after	  ZD6474	   addition.	   The	   results	   (Figure	   3.3A)	   show	   that,	   upon	   addition	   of	   RET	  inhibitor,	  pRET	  levels	  fell	  rapidly	  to	  baseline	  with	  a	  half-­‐life	  of	  t1/2	  	  ~	  1	  min.	  Fitting	  the	  decay	  phase	  of	  this	  time-­‐course	  to	  a	  single	  exponential	  equation	  (Figure	  3.3B)	  indicates	  that	  pRET	  decays	  with	  rate	  constant	  of	  kdephos	  ≥	  0.7	  min-­‐1.	  The	  loss	  of	  pRET	  is	   very	   rapid	   compared	   to	   the	   time	   resolution	   of	   our	   assay	   method	   and	   so,	  conservatively,	  the	  fitted	  rate	  constant	  should	  be	  considered	  as	  a	  lower	  limit	  to	  the	  true	  value	  of	  kdephos.	  The	  short	  lifetime	  of	  pRET	  indicates	  that	  the	  gradual	  increase	  in	  pRET	  levels	  that	  is	  seen	  over	  the	  first	  10	  min	  after	  stimulation	  of	  the	  cells	  with	  ART	  
  
Figure 3.3 Intrinsic lifetime of pRET. A. Effect on pRET levels of adding 50 µM of the RET 
kinase domain inhibitor ZD6474 at 6 min after stimulation of cells with 4 nM ART. Error bars 
are differences between duplicate wells. B. Time-courses for pRET decay after ZD6474 (50 
µM) was added at 10 min after stimulation of cells with 4 nM ART. Solid lines represent the 
best fit of the average data to a single exponential equation. Plots show averaged 
measurements from four independent experiments. Error bars are standard deviations of the 
independent replicate measurements. 
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reflects	   an	   evolving	   balance	   between	   the	   rapid	   formation	   of	   pRET	   and	   its	  comparably	  rapid	  decay.	  	  
	  
3.4. Modeling	  of	  RET	  Activation	  Mechanisms	  
 The	   simplest	   mechanism	   for	   pRET	   formation	   would	   involve	   the	   activation	  and	   autophosphorylation	   of	   RET	   with	   rate	   constant	   k1,	   accompanied	   by	  dephosphorylation	   of	   the	   resulting	   pRET	  with	   rate	   constant	   k-­‐1	  (corresponding	   to	  
kdephos	   measured	   in	   Figure	   3.3A),	   leading	   to	   establishment	   of	   an	   equilibrium	  distribution	  of	  RET	  between	  phosphorylated	  and	  unphosphorylated	  forms	  (Figure	  
3.4A),	  as	  described	  below.	  	  
𝐴𝑅𝑇 + 𝑅𝐸𝑇 !! 𝑝𝑅𝐸𝑇 + 𝐴𝑅𝑇 
    𝑝𝑅𝐸𝑇   !_! 𝑅𝐸𝑇 
Such	  a	  model	   assumes	   that,	  within	   the	   first	  10	  min	  after	   stimulation	  of	   the	  cells,	  no	  significant	  feedback	  amplification	  or	  inhibition	  mechanisms	  on	  pRET	  have	  yet	  begun	  to	  exert	  their	  effects,	  so	  that	  k1	  and	  k-­‐1	  are	  invariant	  over	  this	  time-­‐frame,	  and	   also	   that	   the	   number	   of	   RET	   molecules	   available	   to	   participate	   in	   the	  phosphorylation	   and	   dephosphorylation	   processes	   remains	   roughly	   constant	   over	  this	  short	  period.	  We	  have	  previously	  shown	  that	  stimulation	  of	  10	  nM	  ART	  for	  10	  min	   activates	  ~4200	   RET	   out	   of	   6500	   cellular	   RET	  molecules,	   such	   that	  maximal	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stimulation	  by	  ART	  converts	  ~65%	  of	  total	  cellular	  RET	  to	  pRET	  (Chapter	  2,	  Figure	  
2.6,	  and	  Figure	  2.7).	  To	  test	  this	  simplified	  model,	  we	  first	  fitted	  the	  experimental	  time-­‐course	  data	   from	  Figure	   3.1A	   to	   this	  model,	  while	  keeping	  k-­‐1	  constrained	   to	  0.7	  min-­‐1	  as	  measured	  in	  Figure	  3.3A,	  and	  the	  ratio	  of	  pRET/RET	  after	  10	  nM	  ART	  for	  10	  min	  constrained	  to	  a	  value	  of	  2.0,	  corresponding	  to	  65%	  pRET.	  Figure	  3.4B	  shows	  a	  global	  nonlinear	  regression	  fit	  of	  the	  experimental	  time-­‐course	  data	  to	  this	  
  
                         
Figure 3.4 Simple kinetic mechanism for RET activation and phosphorylation. A. Simple 
model for pRET formation in which observed pRET levels represent the balance between 
pRET formation with rate constant k1 and pRET dephosphorylated with rate constant k-1. B 
and C. Global fit of the time-course data from Figure 3.1A to the mechanistic model from 
(A), performed by numerical nonlinear regression analysis using DynaFit, with the rate of 
pRET decay constrained to the value of k-1 = 0.7 min-1 measured in Figure 3.3A, and the 
pRET/RET ratio constrained to 2.0 at 10 min as measured in Figure 2.9C (B) or with the 
initial pRET formation rate constrained to the value measured in Figure 3.1B (C). Results 
show a poor fit in both cases, indicating that this simple kinetic model cannot accurately 
account for the experimental time-course data for pRET accumulation, and at the same time 
account for the measured, high rate of pRET degradation and the measured fraction of pRET 




model,  using	   the	  program	  DynaFit	   as	  described	   in	  Experimental	  Methods	   and	   in	  
Appendix	   I.181	  The	  results	  show	  that	  the	  experimental	  data	  cannot	  be	  successfully	  fitted	   using	   this	   simple	   model.	   Given	   the	   short	   lifetime	   of	   pRET,	   to	   build	   up	   the	  levels	  of	  this	  species	  shown	  in	  Figure	  3.1A	  would	  require	  pRET	  formation	  rates	  that	  are	  much	  higher	  than	  those	  observed	  experimentally.	  The	  discrepancy	  between	  the	  curve	   fits	   and	   the	   experimental	   data	   is	   further	   exacerbated	   if	  k-­‐1	  is	   assumed	   to	  be	  even	  greater	  than	  0.7	  min-­‐1,	  as	  the	  data	  from	  Figure	  3.3A	  allow.	  We	  then	  tried	  to	  fit	  the	   same	   experimental	   time-­‐course	   data	   for	   pRET	   formation,	   from	   Figure	   3.1A,	  while	   fixing	   the	   initial	   RET	   activation	   rate	   to	   that	   measured	   in	   Figure	   3.1B,	   but	  allowing	  the	  steady	  state	  pRET/RET	  ratio	  to	  vary.	  Our	  results	  show	  that,	  according	  to	   the	   simple	   kinetic	  model	   shown	   in	  Figure	   3.4A,	   the	   initial	   pRET	   accumulation	  rates	   that	   were	   measured	   in	   Figure	   3.1B	   would	   result	   in	   accumulation	   of	   much	  lower	   levels	   of	   pRET	   than	   as	   seen	   experimentally.	   In	   conclusion,	   the	   simplified	  model	   shown	   in	  Figure	   3.4A	   fails	   to	   simultaneously	   account	   for	   the	   rate	   (Figure	  
3.4B)	   and	   the	   extent	   of	   pRET	   accumulation	   (Figure	   3.4C)	   that	   is	   seen	  experimentally,	   if	   pRET	  degradation	   occurs	   at	   the	   high	   rate	   established	   in	  Figure	  
3.3.	  
The	   experimental	   time-­‐course	   data	   can	   be	   fitted	   essentially	   perfectly,	  however,	  if	  a	  modified	  mechanistic	  model	  is	  adopted	  in	  which	  the	  rate-­‐limiting	  step	  in	   pRET	   formation	   is	   the	   slow,	   reversible	   assembly	   of	   the	   activated	  RET	   receptor	  complex,	  with	  autophosphorylation	  occurring	  rapidly	  once	  this	  complex	  has	  formed	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(Figure	  3.5A),	  as	  described	  in	  the	  kinetic	  scheme	  shown	  below.	  In	  this	  scheme,	  RET	  stands	  for	  free	  receptor,	  RET’	  for	  ligand-­‐bound	  but	  unphosphorylated	  receptor,	  and	  pRET	  for	  phosphorylated	  RET.	  	  
𝐴𝑅𝑇 + 𝑅𝐸𝑇 !! 𝑅𝐸𝑇′ + 𝐴𝑅𝑇 
𝑅𝐸𝑇′ !! 𝑝𝑅𝐸𝑇 
𝑝𝑅𝐸𝑇 !!! 𝑅𝐸𝑇′ 
𝑅𝐸𝑇′ !!! 𝑅𝐸𝑇 
 
The	  fit	  (Appendix	   II)	  shown	  in	  Figure	  3.5B	  returns	  a	  best-­‐fit	  value	  for	  the	  rate	  of	  formation	  of	  the	  activated	  receptor	  complex	  of	  k0	  =	  4.6	  ±	  0.3	  ×	  107	  M-­‐1	  min-­‐1,	  which	  corresponds	  to	  a	  rate	  of	  210	  ±	  14	  pRET	  molecules.cell-­‐1.min-­‐1	  per	  nM	  ART,	  in	  
  
Figure 3.5 Optimized kinetic mechanism for RET activation and phosphorylation. A. 
Alternative model for pRET formation in which rate-limiting assembly of the activated 
complex comprising RET plus ART and GFRα3 is followed by rapid autophosphorylation to 
form pRET, with dephosphorylation of pRET reverting RET to the intact but 
unphosphorylated ART/(GFRα3)2/(RET)2 complex. B. Global fit of the time-course data from 
Figure 3.1A to the model from (A), with k-1 constrained to the experimentally determined 
value of 0.7 min-1. Results show a good fit that accurately captures both the rate and the extent 
of pRET accumulation. 
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good	  agreement	  with	  the	  value	  obtained	  from	  the	  slope	  of	  Figure	  3.1B.	  The	  value	  obtained	  for	  the	  rate	  of	  autophosphorylation	  within	  the	  assembled	  complex	  is	  k1	  =	  1.9	   ±	   0.3	  min-­‐1,	   though	   if	   k-­‐1	   is	   in	   fact	   higher	   than	   the	   lower	   limit	   of	   ≥	   0.7	  min-­‐1	  determined	   from	   Figure	   3.3A	   then	   k1	   would	   also	   be	   correspondingly	   higher	   to	  account	   for	   the	   large	   fraction	   of	   cellular	  RET	   that	   becomes	   phosphorylated.	   From	  this	  value	  for	  k1	   it	  can	  be	  seen	  that,	  even	  at	  the	  very	  high	  ART	  concentration	  of	  10	  nM,	  the	  rate	  of	  autophosphorylation	  is	  at	  least	  4-­‐fold	  higher	  than	  the	  rate	  for	  initial	  assembly	  of	  the	  activated	  receptor	  complex,	  which	  occurs	  with	  kobs	  =	  4.6	  x	  107	  M-­‐1	  min-­‐1	  ×	  10	  nM	  =	  0.46	  min-­‐1.	  Figure	  3.1B	  showed	  that	  the	  rate	  of	  complex	  assembly	  is	   first-­‐order	   in	   [ART],	   so	   at	   the	   much	   lower	   ART	   concentrations	   of	   <	   100	   pM	  required	   for	   a	   functional	   cellular	   response,92	   assembly	   of	   the	   activated	   receptor	  complex	   would	   be	   several	   orders	   of	   magnitude	   slower	   than	   the	   subsequent	  autophosphorylation	  step.	  
The	  fit	  shown	  in	  in	  Figure	  3.5B	  additionally	  returned	  a	  best	  fit	  value	  for	  the	  rate	  of	  complex	  dissociation	  of	  k-­‐0	  =	  0.16	  ±	  0.05	  min-­‐1.	  This	  rate	  constant	  is	  relatively	  poorly	   defined,	   however,	   because	   a	   reasonably	   good	   fit	   can	   be	   obtained	   for	   any	  value	  for	  k-­‐0	  that	  is	  low	  compared	  to	  k1,	  with	  minimal	  effect	  on	  the	  values	  returned	  for	  the	  other	  rate	  constants.	  
The	   key	   features	   of	   the	   model	   shown	   in	   Figure	   3.5A	   are	   as	   follows:	   (i)	  autophosphorylation	  of	  RET	  within	  the activated	  receptor	  complex	  is	  fast	  compared	  to	  the	  physical	  assembly	  of	  the	  complex;	  (ii)	  dephosphorylation	  of	  pRET	  regenerates	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the	   intact	   but	   now	   unphosphorylated	   receptor	   complex;	   and	   (iii)	  autophosphorylation	   of	   RET	   within	   this	   intermediate	   complex	   to	   reform	   pRET	   is	  fast	  compared	  to	  dissociation	  of	  the	  complex	  through	  loss	  of	  GFRα3	  and/or	  ART	  (i.e.	  
k1	  >>	  k-­‐1).	  Thus,	  while	  initial	  formation	  of	  pRET	  is	  rate-­‐limited	  by	  the	  slow	  assembly	  of	  the	  activated	  receptor	  complex,	  once	  this	  has	  occurred	  the	  majority	  of	  RET	  can	  be	  kept	  in	  a	  phosphorylated	  state	  because	  k1	  is	  greater	  than	  k-­‐0,	  ensuring	  that	  the	  RET	  that	  becomes	  dephosphorylated	  partitions	  predominantly	  forwards	  to	  reform	  pRET	  rather	   than	   backwards	   through	   dissociation	   of	   the	   complex	   into	   its	   separate	  components.	  	  
	  
3.5. Tests	  of	  the	  Proposed	  RET	  Activation	  Mechanism	  	  
 To	   directly	   test	   the	   hypothesis	   that	   assembly	   of	   the	   activated	   receptor	  complex	   is	   rate	   limiting	   for	   pRET	   formation,	   we	   examined	   the	   effect	   of	   the	   RET	  inhibitor	  ZD6474	  on	  the	  kinetics	  of	  pRET	  accumulation.	  If	  the	  autophosphorylation	  step	   were	   rate	   limiting,	   then	   slowing	   this	   step	   by	   adding	   partially	   inhibitory	  concentrations	   of	   ZD6474	  would	   reduce	   the	   rate	   constant	   for	   approach	   to	   steady	  state	  as	  well	  as	  reducing	  the	  maximum	  level	  of	  pRET	  achieved.	  However,	  if	  assembly	  of	   the	   activated	   receptor	   complex	   is	   rate	   limiting,	   then	   partially	   inhibiting	   the	  subsequent,	   fast	   phosphorylation	   step	   would	   reduce	   the	  maximum	   level	   of	   pRET	  formed,	  by	  shifting	  the	  balance	  between	  k1	  and	  k-­‐1,	  but	  would	  not	  affect	  the	  rate	  for	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reaching	  steady	  state.	  Figure	  3.6	  shows	  time-­‐course	  data	  for	  pRET	  formation	  in	  the	  presence	  of	  various	  partially	  inhibitory	  concentrations	  of	  ZD6474.	  The	  results	  show	  that	  the	  inhibitor	  reduces	  the	  maximum	  level	  of	  pRET	  observed,	  but	  has	  negligible	  effect	  on	  the	  exponential	  rate	  of	  approach	  to	  maximal	  pRET.	  We	  performed	  a	  global	  fit	  of	  the	  data	  in	  Figure	  3.6	  to	  the	  two-­‐step	  activation	  model	  from	  Figure	  3.5A,	  but	  with	   an	   additional	   step	   in	  which	   ZD6474	   can	   bind	   rapidly	   and	   reversibly	   to	   RET	  with	   affinity	   KI	   to	   form	   an	   inhibited	   RET-­‐ZD6474	   complex	   that	   cannot	   auto-­‐phosphorylate	   (Appendix	   III).	  Global	   fitting	  of	   the	  data	   to	   this	  model	   gave	   the	   fit	  shown	  in	  Figure	  3.6,	  returning	  values	  for	  k0	  and	  k1	  that	  are	  essentially	  identical	  to	  those	   found	   from	   Figure	   3.5B,	   and	   a	   value	   for	   KI	   of	   0.15	   ±	   0.01	   μM	   that	   is	   in	  reasonable	   agreement	   with	   that	  measured	   in	   Figure	   3.2,	   and	   also	   with	   reported	  values	   for	   the	  potency	  with	  which	  ZD6474	   inhibits	  RET.179,180	  This	  result	  confirms	  that	   autophosphorylation	   is	   fast	   compared	   with	   assembly	   of	   the	   activated	   RET	  receptor	  complex,	  as	  was	  deduced	  from	  the	  results	  shown	  in	  Figure	  3.5.	  	  
	   As	   a	   further	   test	   of	   our	   mechanism,	   my	   colleague	   Mariya	   Atanasova	  attempted	   to	   directly	  measure	   the	   lifetime	   of	   the	   assembled	   receptor	   complex,	   to	  determine	  whether	  its	  dissociation	  is	  indeed	  slow	  compared	  to	  k1	  as	  our	  proposed	  mechanism	  requires.	  ART	   is	  known	   to	  associate	  with	  cell	   surface	  glycoproteins182,	  and	  this	  large	  background	  of	  additional	  binding	  sites	  makes	  it	  impossible	  to	  directly	  measure	  specific	  binding	  of	  ART	  to	  RET	  on	  cells	  using	  conventional	  approaches.126	  Atanasova	   developed	   a	   real-­‐time	   flow	   cytometry	   assay	   using	   a	   fluorescein	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isothiocyanate	  (FITC)–labeled	  monoclonal	  antibody	  (FITC-­‐mAb2)	  with	  high	  affinity	  for	   RET	   on	   NB41A3-­‐mGFRα3	   cells.	   FITC-­‐mAb2	  might	   distinguish	   between	   bound	  and	   unbound	  RET	   therefore	  mAb2	   binding	   could	   serve	   us	   an	   indirect	  measure	   of	  RET	   occupying.	   Cells	   pre-­‐incubated	   with	   ART	   and	   thus	   bearing	   ART-­‐bound	   RET	  exhibited	   a	   slower	   binding	   to	   FITC-­‐mAb2.	   Such	   slow	   binding	   to	   cells	   with	   bound	  RET	  can	  be	  explained	  by	   that	  FITC-­‐mAb	  can	  only	  bind	   to	   free	  RET	  but	  not	  bound	  RET,	   or	   alternatively	   if	   FITC-­‐mAb	   binds	   to	   bound	   RET	   in	   a	   slower	   rate	   due	   to	  decreased	  accessibility	  to	  its	  binding	  epitope	  in	  bound	  RET.	  In	  both	  cases,	  FITC-­‐mAb	  binding	   to	   ART-­‐treated	   cells	   must	   be	   faster	   than	   dissociation	   of	   the	   activated	  
  
Figure 3.6 Experimental test of the proposed mechanism using a RET kinase domain 
inhibitor. Time-course for the evolution of pRET after stimulation of cells with 10 nM ART, 
after pre-treatment of the cells for 10 min with various concentrations of the RET kinase 
domain inhibitor ZD6474. Data are averaged results from three independent replicate 
experiments; error bars are standard deviations. Solid lines show a global fit of the 
experimental data to the model shown in Figure 3.5A, with k-1 constrained to the value of 0.7 
min-1 measured in Figure 3.3A, and k0, k-0, and k1 constrained to the values determined for the 
curve with no inhibitor, which were essentially identical to the values found from Figure 
3.5A. The rate of RET autophosphorylation was modified by the inhibitor ZD6474 according 
to the function k1(effective) = k1 ([I] / ([I] + KI). The fit returned a value of KI = 0.15 ± 0.01 µM, 
consistent with reported values for the potency with which ZD6474 inhibits RET.  
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receptor	  complex	  to	  release	  free	  RET.	  The	  observed	  rate	  constant	  kobs	  (0.37	  min-­‐1)	  of	  FITC-­‐mAb2	  binding	  to	  cells	  bearing	  ART-­‐RET	  complexes	  quantified	  by	  Atanasova	  in	  such	  slow	  binding	  process	  must	  be	  equal	  or	  bigger	  than	  dissociation	  of	  the	  activated	  receptor	   complex,	   k-­‐0,	   to	   release	   free	   RET.	   We	   concluded	   that	   the	   assembled	  receptor	  complex	  dissociated	  with	  a	  rate	  constant	  of	  k-­‐0	  ≤	  0.37	  min-­‐1.	  This	  process	  is	  significantly	   slower	   than	   the	   rate	   of	   autophosphorylation	   occurring	   within	   the	  assembled	   receptor	   complex	   (k1	  =	   1.9	   min-­‐1),	   in	   agreement	   with	   the	   mechanistic	  scheme	   shown	   in	  Figure	   3.5A.	   This	   result	   therefore	   supports	   the	   conclusion	   that	  the	   intact	  ART/(GFRα3)2/(RET)2	  complex	  persists	   for	   long	  enough	   that,	   upon	  RET	  dephosphorylation,	   it	   partitions	   mostly	   forward	   to	   reform	   pRET	   rather	   than	  backward	  to	  give	  free	  RET,	  GFRα3	  and	  ART	  (partitioning	  ratio	  k1/k-­‐0	  ≥	  6:1).	  	  
	  
3.6. Discussion	  
	   The	  term	  “systems	  biology”	  has	  become	  closely	  associated	  with	  the	  complex	  computational	  modeling	   of	  molecularly	   detailed	   signaling	   networks.	  However,	   the	  essence	   of	   the	   systems	   approach	   is	   simply	   that	   the	   behavior	   of	   biomolecular	  systems	   is	   inextricably	   linked	   to	   the	   cellular	   or	   organismal	   context	   in	   which	   the	  system	  operates.	  Therefore,	  removing	  biomolecules	  from	  their	  biological	  context	  to	  study	   them	   in	   isolation	   can	   obscure	   key	   “emergent”	   features	   of	   their	   functional	  behavior.	   History	   shows	   that	   both	   “reductionist”	   and	   systems	   approaches	   have	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important	   roles	   to	  play	   in	  advancing	  our	  understanding	  of	  biology.	  However,	  with	  respect	   to	   the	   activation	   and	   signaling	   mechanisms	   of	   multi-­‐component	   cytokine	  and	  growth	  factor	  receptors,	  of	  which	  RET	  is	  a	  representative	  example,	  preserving	  the	   functional	   context	   of	   full-­‐length	   receptor	   proteins	   in	   a	   native-­‐like	   biological	  membrane	   environment,	   and	  with	   the	   relevant	   phosphatases	   and	   other	   receptor-­‐interacting	   proteins	   present,	   is	   clearly	   key	   to	   achieving	   a	   quantitatively	   accurate	  understanding	  of	  their	  activation	  and	  signaling	  as	  it	  occurs	  in	  cells.	  Moreover,	  to	  the	  extent	  that	  receptor	  activation	  involves	  reversible	  interactions	  of	  components	  of	  the	  activated	  receptor	  complex	  with	  each	  other,	  or	  with	  cytoplasmic	  signaling	  proteins,	  over-­‐expression	   of	   the	   receptor	   can	   also	   affect	   its	   behavior	   quantitatively	   and	  perhaps	  even	  qualitatively.	  The	  perceived	  difficulty	  in	  making	  rigorous,	  quantitative	  measurements	   involving	   cytokine	   and	   growth	   factor	   receptors	   present	   on	   cells	   at	  endogenous	  levels	  and	  in	  unmodified	  form	  has	  been	  a	  significant	  hindrance	  to	  our	  ability	  to	  routinely	  achieve	  a	  detailed	  mechanistic	  understanding	  of	  how	  particular	  receptor	  systems	  function.	  	  
	   Here	  we	   describe	   just	   such	   an	   analysis	   of	   the	   activation	  mechanism	   of	   the	  RET	  receptor.	  Overall,	  our	  results	  show	  that	  the	  rate	   limiting	  step	  in	  RET	  receptor	  activation	   is	   the	   physical	   assembly	   of	   the	   activated	   receptor	   complex.	   Subsequent	  RET	  autophosphorylation	  within	  this	  complex	  is	  rapid	  in	  comparison,	  even	  at	  very	  high	   ART	   concentrations	   that	   are	   well	   above	   the	   concentrations	   required	   for	  function.	   Our	   results	   also	   establish	   values	   for	   the	   rate	   constants	   for	   receptor	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complex	  assembly,	  for	  the	  autophosphorylation	  step,	  and	  for	  the	  dephosphorylation	  of	   pRET,	   and	   show	   that	   pRET	   is	   short-­‐lived	   such	   that	   the	   presence	   of	   sustained	  levels	  on	  the	  cell	  reflects	  the	  evolving	  balance	  between	  the	  rapid	  formation	  of	  pRET	  and	  its	  rapid	  decay.	  The	  fact	  that	  our	  data	  fit	  well	  to	  this	  simple	  model	  supports	  our	  initial	  assumptions	  that	  processes	  downstream	  of	  RET	  that	   feed	  back	  to	  alter	  k1	  or	  
k-­‐1	  evolve	  relatively	  slowly,	  and	  do	  not	  significantly	  affect	  pRET	  levels	  over	  the	  first	  10	  min	  after	  stimulation.	   
	   Receptor	   tyrosine	   kinases,	   and	   particularly	   the	   epidermal	   growth	   factor	  receptor	  (EGFR),	  have	  been	  the	  subject	  of	  intense	  quantitative	  study	  in	  the	  context	  of	   systems	   biology	   analysis.183,184,185,186,187,188,189,190,191,192,193,194,195,196	   A	   number	   of	  these	   studies	   report	   estimates	   for	   the	   rate	   constants	   for	   EGF	   dimerization	  (analogous	   to	   k0	   in	   our	   system),	   receptor	   autophosphorylation	   (k1)	   or	  dephosphorylation	   (k-­‐1),	   or	   for	   the	   rate	   at	   which	   the	   activated	   receptor	   complex	  dissociates	   (k-­‐0).	  These	  estimates	  were	   invariably	  obtained	  by	   fitting	  experimental	  data	  to	  kinetic	  models	  containing	  a	  large	  number	  of	  variable	  parameters,	  including	  forward	  and	  reverse	  rate	  constants	  for	  very	  many	  individual	  steps	  as	  well	  as	  initial	  concentrations	   for	   a	   large	   number	   of	   species.	   In	   such	   an	   approach	   the	   values	   of	  many	   parameters	  must	   be	   assumed,	   or	   fixed	   by	   reference	   to	   literature	   values,	   to	  reduce	  the	  degrees	  of	   freedom	  sufficiently	  to	  enable	  a	  meaningful	   fit.	   It	   is	  perhaps	  not	   surprising,	   therefore,	   that	   the	   rate	   constants	   for	   EGFR	   activation	   and	  phosphorylation	  derived	   from	  this	  approach	  vary	  over	  a	  wide	  range.	  For	  example,	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estimates	   of	   the	   rate	   constant	   for	   autophosphorylation	  within	   the	   activated	   EGFR	  dimer	   vary	   from	  1.2–163	  min-­‐1.183,184,185,186,187,188,189,193	   Similarly,	   estimates	   for	   the	  dephosphorylation	  rate	  of	  phosphor-­‐EGFR	  range	  from	  0.06-­‐16	  min-­‐1,187,188,190,191,193	  and	   those	   for	   dissociation	   of	   the	   EGFR	   dimer	   range	   from	   0.51–10	  min-­‐1.183,184,185,186,188,191,193	   The	   rate	   of	   dephosphorylation	   will	   depend	   on	   the	  phosphatase	   levels	   present	   in	   the	   cell	   type	   under	   study,	   and	   so	   could	   potentially	  differ	   greatly	   in	   different	   studies,	   but	   k-­‐0	   and	   k1	   are	   intrinsic	   properties	   of	   the	  activated	  receptor	  complex	  that,	  to	  a	  first	  approximation,	  might	  be	  expected	  to	  have	  similar	  values	  for	  any	  cell	  type	  or	  context.	  	  
Interestingly,	   despite	   the	   large	   variations	   in	   the	   estimated	   values	   for	  individual	   rate	   constants,	   studies	   tend	   to	   agree	   that	   EGFR	   autophosphorylation	   is	  fast	   compared	   to	  EGFR	  dimerization	   at	   the	  EGF	   concentrations	   considered,	   and	   is	  also	   fast	   compared	   to	   dissociation	   of	   the	   activated	   receptor	   dimer.	   These	  observations	   imply	   that,	   as	  we	   directly	   observed	   here	   for	   RET,	   dephosphorylated	  EGFR	   dimers	   will	   tend	   to	   rephosphorylate	   rather	   than	   dissociate	   into	   receptor	  monomers,	  though	  this	  conclusion	  does	  not	  appear	  to	  have	  been	  explicitly	  noted.	   
Biophysical	  approaches	  using	   labeled	  receptors	  have	  been	  used	  to	  measure	  receptor	  oligomerization,	  and	  a	  few	  of	  these	  studies	  report	  kinetic	  rate	  constants	  for	  EGFR	  dimerization.	   For	   example,	   very	   recently	   Coban	   et	  al.197	   reported	   a	   pseudo-­‐first-­‐order	  rate	  constant	  with	  the	  high	  value	  of	  kobs	  =	  72	  min-­‐1	  for	  EGFR	  dimerization	  at	   the	   EGF	   concentrations	   used	   in	   their	   experiments.	   We	   could	   find	   no	   direct	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biophysical	  measurements	  of	  the	  EGFR	  autophosphorylation	  rate	  or	  of	  the	  lifetime	  of	   the	   EGFR	   dimer,	   however.	   Indeed,	   we	   can	   find	   no	   previous	  work	   that	   directly	  measures	  the	  kinetics	  of	  receptor	  activation	  and	  phosphorylation,	  as	  we	  have	  done	  here,	   for	  any	  growth	   factor	  or	   cytokine	   receptor.	  The	   lifetime	  of	   the	  RET	  receptor	  complex	   reported	   here,	   ≤	   0.37	   min-­‐1,	   can	   however	   be	   compared	   to	   the	   value	   of	  0.24−0.42	   min-­‐1	   reported	   for	   the	   activated	   type	   I	   interferon	   receptor	   complex,	   a	  cytokine	   receptor,	   with	   interferon-­‐α2,	   measured	   using	   purified	   recombinant	  receptor	  extracellular	  domain	  protein	  constructs	  associated	  with	  a	  lipid	  bilayer	  on	  a	  solid	  support.171 
  
3.7. Conclusions 
Achieving	  a	  detailed	  mechanistic	  understanding	  of	  how	   ligands	  bring	  about	  activation	  of	  their	  receptors	  is	  critical	  to	  the	  broad	  goal	  of	  achieving	  a	  quantitative	  understanding	   of	   cellular	   signaling	   and	   function.	   Progress	   towards	   this	   important	  goal	  is	  hindered	  by	  the	  relative	  technical	  difficulty	  involved	  in	  making	  quantitative	  measurements	  on	  growth	  factor	  receptors	  in	  their	  functional	  cellular	  context.	  In	  this	  respect,	   the	   situation	   starkly	   contrasts	   to	   the	   wealth	   of	   highly	   quantitative	   and	  sophisticated	   methods	   available	   for	   studying	   enzyme	   kinetics	   in	   solution,	   or	   the	  power	   of	   electrophysiological	   measurements	   for	   characterizing	   the	   detailed	  mechanistic	  properties	  of	  ion	  channels.	  We	  show	  here	  that	  it	  is	  possible	  to	  perform	  a	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direct	  kinetic	  analysis	  of	  the	  activation	  mechanism	  of	  a	  growth	  factor	  receptor,	  using	  unmodified	  and	  unlabeled	  receptors	  expressed	  endogenously	  on	  live	  cells,	  through	  the	   application	   of	   experimental	   methods	   that	   are	   themselves	   standard	   and	  technically	  straightforward.	  Importantly,	  the	  approach	  we	  describe	  does	  not	  require	  the	   application	   of	   highly	   complex	   mechanistic	   schemes	   that	   are	   grossly	   under-­‐determined	   by	   the	   experimental	   data,	   and	   thus	   for	   which	   the	   values	   of	   many	  concentration	   and	   rate	   constant	   parameters	   must	   be	   assumed	   or	   taken	   from	  literature	   studies	   that	   use	   different	   cell-­‐types	   or	   experimental	   conditions.	   This	  method	  enables	  the	  kinetic	  exploration	  of	  receptor	  mechanisms	  from	  a	  perspective	  akin	  to	  that	  employed	  in	  mechanistic	  enzymology.	  This	  “mechanistic	  receptorology”	  approach,	   though	  rarely	  employed,	   confers	   significant	  and	  unique	  advantages	   that	  complement	   the	   strengths	   and	   limitations	   of	   more	   elaborate	   biochemical	   and	  biophysical	   methods,	   and	   we	   believe	   it	   has	   an	   important	   role	   in	   the	   quest	   to	  understand	  the	  molecular	  details	  of	  receptor	  activation	  and	  signaling.	  	  
	  
3.8. Experimental	  Methods	  
Materials	  RET	  inhibitor	  Vandetanib	  (ZD6474)	  (catalog	  no.	  S1046)	  was	  purchased	  from	  Selleck	  Chemicals	  (Houston,	  TX).	  Materials	  used	  for	  pRET	  ELISAs,	  and	  all	  other	  cell	  lines	  and	  materials	  used,	  were	  exactly	  as	  described	  in	  Chapter	  2.	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Inhibitor	  Effects	  of	  ZD6474	  on	  RET	  Phosphorylation	  
NB41A3-­‐mGFRα3	   cells	   were	   stimulated	   with	   ZD6474	   at	   various	  concentrations,	   diluted	   in	   DMEM	   (DMSO	   v/v	   ≤	   0.03%),	   for	   10	   min,	   followed	   by	  stimulation	  with	  10	  nM	  ART	  for	  10	  min	  in	  the	  presence	  of	  the	  same	  concentration	  of	  ZD6474.	  The	  cells	  were	  lysed	  at	  the	  desired	  time	  after	  ZD6474	  addition,	  and	  pRET	  levels	  were	  measured	  using	  the	  KIRA	  ELISA,	  as	  described	  in	  detail	  in	  Chapter	  2.	  	  
Detection	  of	  pRET	  Decay	  Rate	  
NB41A3-­‐mGFRα3	  cells	  were	  stimulated	  with	  4	  nM	  ART	  in	  DMEM	  for	  6	  or	  10	  min	   before	   the	   medium	   were	   changed	   to	   4	   nM	   ART	   with	   ZD6474	   at	   the	   stated	  concentration	  (DMSO	  v/v	  ≤	  0.3%).	  Cells	  were	   lysed	  2,	  4,	  6,	  8,	  14,	  24,	  34,	  54,	  or	  84	  min	  after	  addition	  of	  ZD6474.	  Levels	  of	  phosphorylated	  RET	  in	  the	  cell	  lysate	  were	  measured	  by	  KIRA	  ELISA,	  as	  described	  in	  Chapter	  2.	  
RET	  Activation	  with	  Partial	  Inhibition	  by	  ZD6474	  
NB41A3-­‐mGFRα3	  cells	  were	  preincubated	  with	  0,	  0.2,	  0.4	  or	  0.8	  μM	  ZD6474	  in	  DMEM	  (DMSO	  v/v	  ≤	  0.07%)	  for	  10	  min	  before	  addition	  of	  ART.	  In	  order	  to	  avoid	  agitation	  by	  frequently	  changing	  medium	  in	  the	  tissue	  culture	  plate,	  a	  small	  volume	  of	  concentrated	  ART	  stock	  (1	  μM)	  was	  added	  into	  each	  well	  to	  achieve	  a	  final	  ART	  concentration	  of	  4	  nM	  (for	  example,	  1	  μL	  of	  1	  μM	  ART	  stock	  was	  added	  into	  250	  μL	  DMEM).	  The	  culture	  plate	  was	  gently	  swirled	  to	  ensure	  mixing	  to	  achieve	  a	  uniform	  concentration	  of	  ART.	  ART	  was	  added	  for	  2,	  4,	  6,	  8	  or	  10	  min	  before	  lysing	  the	  cells.	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Phosphorylated	  RET	  levels	  were	  detected	  in	  the	  cell	  lysate	  using	  the	  KIRA	  ELISA,	  as	  described	  in	  Chapter	  2.	  
Method	  for	  fitting	  
Experimental	  time-­‐courses	  for	  RET	  activation	  were	  fitted	  to	  the	  model	  based	  on	   the	   chemical	   reactions	   described	   in	   Section	   3.4,   using	   the	   program	   DynaFit	  (BioKin	   Ltd.,	   Watertown,	   MA).	   The	   scripts	   of	   the	   model	   encoding	   the	   chemical	  reactions	  used	  for	  fitting	  the	  time-­‐courses	  for	  RET	  activation	  stimulated	  by	  ART	  at	  various	   concentrations	   in	  Dynafit	   are	   described	   as	   below,	  where	  k	   represents	   the	  rate	   constant	   for	   each	   step.	   The	   value	   of	   k-­‐1	   was	   set	   at	   0.7	   min-­‐1.	   The	   initial	  concentration	  of	  RET	  was	  set	  at	  6500	  per	  cell,	  and	  the	  initial	  concentrations	  for	  RET’	  and	  pRET	  were	  set	  at	  zero.	  
RET	  +	  ART	  à	  RET'	  +	  ART	   	   k0	  	   RET'	  à	  RET	   	   	   	   k-­‐0	  	   RET'	  à	  pRET	   	   	   	   k1	  	   pRET	  à	  RET’	  	  	   	   	   k-­‐1	  
The	  scripts	  of	  the	  model	  encoding	  the	  chemical	  reactions	  used	  for	  fitting	  the	  time-­‐courses	   for	   RET	   activation	   stimulated	   by	   4	   nM	   ART	   in	   the	   presence	   of	   RET	  inhibitor	   ZD6474	   at	   various	   concentrations	   are	   described	   as	   below,	   where	   k	  represents	   the	  rate	  constant	   for	  each	  step.	  The	  value	  of	  k-­‐1	  was	  set	  at	  0.7	  min-­‐1.	   In	  this	  model,	  we	  assumed	  that	  RET	  inhibitor	  ZD6474	  did	  not	  distinguish	  free	  RET	  and	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ART-­‐bound	   RET.	   We	   also	   assumed	   the	   concentrations	   of	   ART	   and	   ZD6474	   were	  invariant.	  
RET	  +	  ART	  à	  RET'	  +	  ART	   	   k0	  	   RET'	  à	  RET	   	   	   	   k-­‐0	  	   RET'	  à	  pRET	   	   	   	   k1	  	   pRET	  à	  RET’	  	  	   	   	   k-­‐1	  RET	  +	  Inh	  à	  RET-­‐Inh	  +	  Inh	   	   ki	  	   RET-­‐Inh	  à	  RET	   	   	   k-­‐i	  	   RET'	  +	  Inh	  à	  RET’-­‐Inh	  +	  Inh	  	   ki	  	   RET-­‐Inh	  +	  ART	  à	  RET’-­‐Inh	  +	  ART	  	   k-­‐i	  RET’-­‐Inh	  à	  RET-­‐Inh	   	   	   ki	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Chapter	  4. Analysis	  of	  RET	  Activation,	  Deactivation	  and	  Trafficking	  
Dynamics	  and	  Underlying	  Molecular	  Mechanisms	  
4.1. Introduction	  	  
4.1.1. Regulation	  of	  Receptor	  Tyrosine	  Kinase	  Signaling	  	  
	   Given	   the	   essential	   biological	   roles	   of	   receptor	   tyrosine	   kinases	   (RTKs),	  discussed	  earlier,	   it	   is	   important	  to	  understand	  how	  RTK	  signaling	  is	  achieved	  and	  regulated.	   RTKs	   are	   activated	   upon	   binding	   of	   their	   ligands,	   becoming	  phosphorylated,	  which	  promotes	  interactions	  with	  a	  variety	  of	  substrates	  to	  turn	  on	  downstream	   signaling	   events.	   There	   are	   a	   number	   of	  mechanisms	   responsible	   for	  controlling	   the	   level	   and	   dynamics	   of	   RTK	   phosphorylation,	   including	  dephosphorylation	  by	  protein	  tyrosine	  phosphatases	  (PTPs),	  proteolysis	  directed	  by	  ubiquitination,	   and	   receptor-­‐mediated	   endocytosis	   and	   trafficking.	   PTPs	   directly	  dephosphorylate	   and	   deactivate	   the	   phosphorylated	   cytoplasmic	   domain	   in	   active	  RTKs.36	  Cytosolic	  PTPs	  contribute	  to	  the	  observed	  short	  half-­‐life	  of	  activated	  RTKs	  like	   EGFR198,199,	   as	   we	   also	   showed	   for	   RET	   (see	   Chapter	   3).	   PTPs	   also	   help	   to	  suppress	  ligand-­‐independent	  RTK	  activation	  to	  maintain	  basal	  RTK	  activities	  at	  low	  levels	   in	   the	   absence	   of	   specific	   ligand	   stimulations.	   For	   example,	   inhibiting	   PTPs	  was	  found	  to	  elevate	  basal	  phosphorylation	  levels	  of	  platelet-­‐derived	  growth	  factor	  receptor	   (PDGFR)200	   and	  EGFR201	   in	   the	   absence	  of	   any	   ligand	   stimulation,	   and	   to	  enhance	  signaling	  of	  TrkB	  and	  RET	  in	  response	  to	  their	  natural	  ligands.202	  Another	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essential	   RTK	   signaling	   regulator	   is	   ubiquitin	   (Ub).	   Like	   phosphorylation,	  ubiquitination	   is	   a	   characteristic	   posttranslational	   modification	   of	   RTKs.	  Ubiquitination	   facilitates	   trafficking	   of	   cell	  membrane	   RTK	   into	   proteasomes,	   and	  endosomal	   RTK	   into	   lysosomes,	   for	   proteolytic	   degradation.203	   RTKs	   are	  ubiquitinated	   upon	   ligand	   stimulation	   by	   different	   E3	   ligases,	   as	   shown	   for	  receptors	  such	  as	  EGFR,	  VEGFR,	  PDGFR,	  TrkA,	  TGFβ	  and	  RET.204,205,206,207,208,209,210	  It	  has	  been	   shown	   that	   recognition	  of	  Ub-­‐modified	  RTKs	  by	   the	  ESCRTs	   (endosomal	  sorting	   complexes	   required	   for	   transport)	   leads	   to	   RTK	   transport	   from	   early	  endosomes	   to	   multivesicular	   bodies	   (MVBs)	   and	   then	   to	   lysosomes	   for	  degradation.211,212	   Ub	  modification	   patterns	   and	   their	   regulatory	   roles	   depend	   on	  the	   receptor	   type,	   cell	   type,	   and	   stimulation	   strength	   by	   GFs.203	   Ligand-­‐induced	  receptor	  endocytosis	   is	  another	  mechanism	   for	   regulating	  RTK	  signaling,	   in	  which	  cell	   surface	   RTKs	   are	   internalized	   into	   cargo	   vesicles	   and	   delivered	   to	   other	  intracellular	   compartments.213	  The	   routes	  and	   roles	  of	   ligand-­‐induced	  endocytosis	  are	  diverse	  and	  complicated,	  and	  are	  discussed	  in	  detail	  in	  the	  following	  section.	  	  
4.1.2. Receptor-­‐Mediated	  Endocytosis	  and	  Its	  Roles	  in	  RTK	  Signaling	  
	   Plasma	   membrane	   RTKs	   constitutively	   undergo	   endocytosis	   via	   different	  internalization	   mechanisms	   simultaneously.	   This	   receptor	   internalization	   can	   be	  substantially	   enhanced	   by	   ligand	   stimulation.214	   Ligand-­‐induced	   endocytosis	  reduces	   the	   cell	   surface	   RTK	   population,	   transports	   activated	   RTKs	   to	   endosomal	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compartments	   where	   additional	   signaling	   can	   happen,	   and	   also	   delivers	   RTKs	   to	  lysosomes	  for	  degradation.215	  	  
	   The	   process	   of	   RTK	   endocytosis	   involves	   cellular	   compartments	   including	  internalization	  vesicles,	  early	  endosomes,	  late	  endosomes,	  lysosomes,	  and	  recycling	  vesicles	  (Figure	  4.1).213	  The	  first	  step	  in	  endocytosis,	  also	  called	  internalization,	   is	  the	  clustering	  and	  capturing	  of	  receptors	  into	  membrane	  vesicles.	  Numerous	  types	  
  
Figure 4.1 Schematic illustration of ligand-induced receptor tyrosine kinase (RTK) endocytic 
pathways. Upon extracellular stimulation, RTKs are internalized via various routes such 
clathrin-coated-pits and caveolae, and transported into early endosomes. Some ligand-receptor 
complexes remain intact and some dissociate in endosomes. RTKs can be recycled rapidly to 
the plasma membrane from early endosomes, or delivered into multivesicular bodies 
(MVBs)/late endosomes. From MVBs, RTKs are sorted to for recycling or to enter lysosomes 
for degradation.  
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of	   receptor-­‐mediated	   internalization	  processes	   have	  been	   characterized,	   including	  via	   clathrin-­‐coated	   pits	   (CCPs),	   caveolae,	   and	   other	   clathrin-­‐	   and	   caveolin-­‐independent	   vesicles.213	   Recruitment	   of	   RTKs	   into	   endocytic	   sites	   in	   the	   plasma	  membrane	   followed	   by	   formation	   of	   cargo	   vesicles	   is	   guided	   both	   by	   intrinsic	  internalization	   sequences	   in	   RTKs,	   and	   by	   posttranslational	   modifications	   of	   the	  receptor	   such	   as	   phosphorylation	   and	   ubiquitination.	   Internalization	   motifs	   in	  insulin	   receptor	   (IR)	   were	   found	   to	   directly	   bind	   to	   the	   clathrin	   adaptor	   protein	  complex	   adipocyte	   protein	   2	   (AP2),	   responsible	   for	   the	   clathrin-­‐dependent	  internalization	   of	   insulin	   receptor.216,217	   In	   addition,	   some	   phosphotyrosine-­‐containing	   motifs	   in	   phosphorylated	   IR218,	   EGFR219	   and	   PDGFRβ220	   are	   found	   to	  interact	   with	   components	   in	   CCPs	   upon	   receptor	   stimulation.	   Ubiquitination	   has	  also	  been	  shown	  to	  facilitate	  caveolin-­‐dependent	  internalization,	  for	  example	  in	  the	  case	   of	   EGFR.221	   Internalization	   cargo	   vesicles	   loaded	   with	   RTKs	   and	   ligand-­‐RTK	  complexes	  are	  formed	  by	  invagination	  of	  the	  plasma	  membrane,	  pinch	  off	  from	  the	  cell	  membrane,	  enter	  the	  cytoplasm,	  and	  fuse	  with	  early	  endosomes,	  as	  illustrated	  in	  
Figure	   4.1.222	   The	   internalized	   receptors	   are	   oriented	   in	   such	   way	   that	   the	  extracellular	   domain	   is	   contained	   inside	   the	   internalization	   vesicles	   and	   early	  endosomes,	   and	   the	   kinase	   domain	   is	   facing	   the	   cytosol.	   From	   early	   endosomes,	  receptors	   can	   either	   be	   recycled	   to	   the	   plasma	  membrane,	   or	   can	   be	   transported	  into	   late	   endosomes	   and	   then	   to	   lysosomes	   for	   proteolytic	   degradation.	   Late	  endosomes	   are	   also	   known	   as	   multivesicular	   bodies	   (MVBs),	   due	   to	   their	  characteristic	   morphology	   comprising	   small	   luminal	   vesicles	   inside	   of	   larger	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vesicular	  compartments.223	  Since	  the	  intraluminal	  vesicles	  inside	  MVBs	  are	  formed	  by	   invagination	   of	   the	   endosome	   membrane	   outwards	   from	   the	   cytosol224,225,	  internalized	  RTKs	  are	  completely	  compartmentalized	  within	  MVBs,	  with	  the	  kinase	  domain	   no	   longer	   exposed	   to	   the	   cytosol	   (illustrated	   in	  Figure	   4.1).	   Receptors	   in	  late	  endosomes	  can	  also	  be	  recycled	  back	  to	  the	  membrane.	  There	  are	  two	  types	  of	  recycling	   vesicles	   derived	   from	   endosomes.226	   The	   rapid	   recycling	   route	   is	   via	  peripheral	  early	  endosomes,	   from	  where	  receptors	  are	  recycled	  directly.	  The	  slow	  recycling	   from	   late	   endosomes	   is	   via	   perinuclear	   recycling	   endosomes.226	   Some	  internalized	   ligand-­‐receptor	   complexes	   remain	   intact	   and	   active	   in	   endosomes,	  whereas	  others	  tend	  to	  dissociate	  due	  to	  the	  acidic	  environment	   in	  the	  endosomal	  lumen.227,228,229	  
	   Intracellular	   transportation	   of	   internalized	   receptors	   is	   carried	   on	   by	  membrane	   fission	   and	   fusion	   between	   organelles	   in	   the	   endocytic	   pathway.	  Receptors	   in	   early	   endosomes	   can	   be	   sorted	   into	   membrane	   regions,	   which	   can	  invaginate	  away	   from	  cytosol	   to	   form	   intralumenal	  vesicles	   (ILVs).	  Those	   ILVs	  are	  usually	  formed	  in	  the	  vacuolar	  regions	  in	  early	  endosomes,	  which	  can	  evolve	  to	  fuse	  with	   late	   endosomes	   to	   form	  mature	   multivescular	   bodies.	   Vacuolar-­‐ATPases	   (V-­‐ATPase)	  predominately	   locate	   in	   the	  vacuolar	   regions	   in	  early	  endosomes	  and	  get	  more	  concentrated	  when	  transported	  into	  late	  endosomes	  and	  then	  lysosomes.230	  V-­‐ATPases	   function	   as	   ATP-­‐driven	   proton	   pumps	   and	   acidify	   the	   intracellular	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organelles.231	   Low	   pH	   is	   required	   for	   the	   activity	   of	   degradative	   enzymes	   in	  lysosomes.	  
	   	  One	   important	   role	  of	   receptor-­‐mediated	  endocytosis	   is	   to	  reduce	  receptor	  abundance	  on	   the	   cell	  membrane.	   Fewer	   receptors	  present	   on	   the	   cell	  membrane	  means	   lower	   RTK	   signaling	   at	   any	   given	   ligand	   concentration,	   leading	   to	  desensitization	  of	  the	  cell	  in	  response	  to	  initial	  stimulation.	  Receptor	  internalization	  and	  recycling	  enable	  the	  cells	  to	  adjust	  cell	  surface	  receptor	  levels	  in	  an	  economical	  way	   by	   storing	   the	   receptor	   in	   intracellular	   compartments.	   Another	   role	   of	   RTK	  endocytosis	   is	   to	   allow	   subcellular-­‐location	   specific	   signaling.	   Although	   removed	  from	  the	  cell	   surface,	   the	  activated	  receptors	  can	  continue	  signaling	   in	  endosomes	  by	   interacting	   with	   cytosolic	   substrates	   or	   with	   signaling	   molecules	   residing	   in	  endosomes.214,232,233,234	  For	  instance,	  the	  presence	  of	  a	  MAPK	  scaffold	  complex	  was	  found	   to	   be	   recruited	   to	   endosomes,	   supporting	   the	   observation	   that	   an	   intact	  clathrin-­‐dependent	   trafficking	   machinery	   was	   required	   for	   full	   ERK	   activation	  downstream	  of	  receptors	  such	  as	  EGFR	  and	  VEGFR-­‐2.235,236,237,238,239	  	  
	   The	   internalization	   route,	   or	   a	   combination	   of	   routes,	   and	   their	   effects	   on	  RTK	   signaling	   dynamics	   and	   biological	   outcomes	   are	   highly	   conditional	   to	   the	  nature	  of	  the	  receptor,	  the	  cell	  type,	  and	  the	  stimulation	  condition.213	  Sigismund	  et	  
al.	   showed	   that	   clathrin-­‐dependent	   endocytosis	   facilitated	   EGFR	   recycling	   and	  promoted	   sustained	   activation	   of	   the	   downstream	   signaling	   of	   EGFR	   at	   low,	  physiological	   EGF	   concentrations,	  whereas	   high	  EGF	   concentrations	   initiated	   both	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clathrin-­‐dependent	   and	   -­‐independent	   pathways,	   where	   the	   latter	   route	   facilitated	  EGFR	  degradation.238	  Over-­‐expression	   of	   an	   inactivate	  mutant	   form	  of	   dynamin,	   a	  GTPase	  required	  for	  the	  pinching-­‐off	  process	  of	  CCPs	  and	  caveolae	  from	  the	  plasma	  membrane240,	  was	   found	   to	   impair	   ERK	   activation	   upon	   stimulation	   of	  HeLa	   cells	  with	  4	  nM	  EGF236,	  whereas	  similar	  experiments	  by	  others	  showed	  no	  effects	  on	  ERK	  signaling	   in	   HeLa	   and	   Hep2	   cells	   stimulated	   with	   10	   nM	   EGF241.	   The	   kinetic	   and	  mechanistic	   complexity	   of	   RTK	   endocytosis	   and	   trafficking	   creates	   difficulties	   for	  the	   comprehensive	   analysis	   of	   a	   receptor’s	   signaling	   kinetics,	   and	   thus	   for	  understanding	   and	  predicting	   the	  quantitative	   relationships	  between	   extracellular	  stimulation,	  receptor	  activation	  and	  downstream	  signaling	  events.	  	  
	   RET	  internalization	  has	  been	  observed	  upon	  stimulation	  with	  GDNF	  in	  HeLa	  and	  HEK293	  cells	  transfected	  with	  RET	  and	  GFRα1,	  and	  in	  SH-­‐SY5Y	  neuroblastoma	  cells	   endogenously	   expressing	   RET.242,243,244,245	   Experiments	   showed	   that	   RET	  activated	  by	  GDNF	  was	  internalized	  primarily	  via	  CCPs	  shortly	  after	  activation,	  and	  travelled	   through	   endosomes	   in	   a	   kinase-­‐activity-­‐dependent	   manner.242,245	  Perturbation	  of	  clathrin-­‐dependent	  internalization	  showed	  that	  RET	  internalization	  was	  required	  to	  activate	  ERK	  in	  HEK293	  cells,	  but	  not	  to	  activate	  Akt.242	  Most	  of	  the	  experiments	  studying	  RET	  trafficking	  employed	  genetically	  or	  chemically	  modified	  RET,	   which	   raises	   questions	   about	   the	   applicability	   of	   the	   results	   for	   predicting	  trafficking	  kinetics	  of	  endogenous	  RET	  in	  vivo.	  To	  date,	  no	  integral	  analysis	  has	  been	  
	  	  
105	  
performed,	   using	   RET	   in	   its	   native	   cellular	   environment,	   to	   investigate	   how	   RET	  signaling	  is	  regulated	  by	  endocytosis.	  	  
4.1.3. Advantages	   of	   Computational	   Methods	   for	   Revealing	   RET	   Signaling	  
Dynamics	  at	  Low,	  Biologically	  Relevant	  ART	  Concentrations	  
	   It	  is	  extremely	  difficult	  to	  directly	  measure	  the	  kinetics	  of	  the	  RTK	  signaling	  network	   in	   the	   native	   cellular	   context	   in	   order	   to	   understand	   the	   mechanisms	  underlying	  RTK	  signal	  transduction,	  as	  discussed	  in	  Chapter	  3.	  Ligand-­‐induced	  RTK	  endocytosis	   adds	   more	   complexity	   by	   enabling	   different	   location-­‐specific	   RTK	  signaling	   dynamics.	  Mathematical	   and	   computational	  models	   can	   provide	   indirect	  ways	   to	   infer	   signaling	   parameters	   that	   are	   difficult	   to	   directly	  measure,	   and	   can	  allow	  prediction	   of	   the	   system’s	   behavior	   under	   conditions	   that	   differ	   from	   those	  that	  can	  be	  accessed	  experimentally.246	  Over	  recent	  decades,	  integral	  models	  of	  RTK	  signaling	  and	  trafficking	  have	  been	  built	  to	  advance	  our	  understanding	  of	  RTK	  signal	  transduction	   mechanisms.247,248,249,250,229,251,252,253,254,255	   These	   computational	  models	   reveal	   relationships	   between	   stimuli	   and	   cellular	   responses,	   and	   provide	  rate	  constants	  for	  the	  steps	  of	  ligand-­‐binding,	  receptor	  dimerization,	  receptor	  auto-­‐phosphorylation,	   phosphatase-­‐mediated	   dephosphorylation,	   and/or	   trafficking	  between	  intracellular	  compartments.	  	  
	   The	  main	  challenge	  in	  building	  such	  models	  is	  to	  gain	  accurate,	  quantitative	  experimental	  data	  about	   the	  behavior	  of	   the	   signaling	  network,	   to	  use	   to	  develop,	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validate	   and	   refine	   the	   model.	   Topological	   representation	   of	   the	   signaling	  components	  and	  the	  links	  among	  them	  form	  the	  structural	  basis	  of	  any	  model.	  The	  rate	   constants	   of	   the	   signaling	   steps,	   and	   the	   concentrations	   of	   the	   involved	  signaling	   molecules,	   add	   detail	   to	   the	   model	   that	   enables	   its	   use	   to	   generate	  predictions.	  In	  particular,	  the	  model	  enables	  us	  to	  analyze	  RTK	  signaling	  dynamics	  at	  stimulation	  concentrations	  that	  can	  be	  difficult	  to	  measure.	  
	   In	  this	  chapter,	  we	  aim	  to	  elucidate	  the	  dynamics	  of	  ART-­‐induced	  endocytosis	  of	  RET,	  and	  how	  RET	  endocytosis	  and	  trafficking	  affect	   its	  signaling	  dynamics	  and	  signal	  transduction	  to	  ERK	  and	  Akt.	  To	  address	  this	  question,	  we	  characterized	  how	  levels	   of	   RET	   on	   the	   cell	   surface	   and	   in	   early	   endosomes	   change	   as	   a	   function	   of	  stimulation	  time.	  We	  then	  employed	  small	  molecule	   inhibitors	  to	  perturb	  different	  steps	  in	  the	  endocytic	  pathway,	  and	  quantified	  how	  different	  perturbations	  affected	  ART-­‐stimulated	   RET	   phosphorylation	   and	   the	   signaling	   capacity	   of	   pRET	   in	  activating	   ERK	   and	   Akt.	   In	   the	   course	   of	   these	   experiments	   we	   discovered	   and	  characterized	   a	   form	   of	   phosphorylated	   but	   signaling-­‐incompetent	   RET	   resulting	  from	   ligand-­‐induced	   receptor	   internalization	   and	   trafficking	   to	   late	   endosomes.	  Using	   computational	   tools,	  we	   built	   a	   comprehensive	  model	   that	   could	   accurately	  predict	  the	  time-­‐dependent	  distribution	  of	  different	  forms	  of	  RET	  after	  stimulation	  of	  NB41A3-­‐mGFRα3	  cells	  by	  ART.	  The	  species	  considered	  included	  unoccupied	  RET,	  ART-­‐bound	  but	  unphosphorylated	  RET	  and	  phosphorylated	  RET	  located	  on	  the	  cell	  surface,	  plus	  various	  forms	  of	  phosphorylated	  and	  non-­‐phosphorylated	  RET	  in	  early	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endosomes,	   MVBs,	   lysosomes,	   and	   recycling	   vesicles.	   This	   model	   allowed	   us	   to	  analyze	   RET	   signaling	   and	   trafficking	   dynamics	   at	   low,	   but	   biologically	   functional	  ART	   stimulation	   conditions,	   as	   established	   in	  Chapter	   2.	   The	  model	   showed	   that,	  when	  stimulated	  by	  0.1	  nM	  ART,	  most	  activated	  RET	  was	  present	  on	  the	  cell	  surface	  during	   the	   initial	   10	   min	   of	   stimulation.	   This	   prediction	   suggested	   that,	   at	  biologically	   relevant	   ART	   doses,	   ART-­‐induced	   transient	   ERK	   responses,	   occurring	  after	  10	  min	  of	  stimulation,	  do	  not	  require	  RET	  internalization.	  
	  
4.2. Results	  
4.2.1. Rates	  of	  RET	  Internalization	  upon	  ART	  Stimulation	  
	   Internalization	  of	  RET	  upon	  stimulation	  of	  cells	  with	  GDNF	  has	  been	  shown	  in	   several	   cell	   lines.245	   To	   investigate	   whether	   stimulation	   with	   ART	   causes	   RET	  internalization	  in	  the	  mouse	  neuroblastoma	  cell	  line	  NB41A3-­‐mGFRα3,	  I	  measured	  cell	   surface	   RET	   levels	   by	   flow	   cytometry	   using	   a	  monoclonal	   anti-­‐RET	   antibody,	  after	   incubating	   NB41A3-­‐mGFRα3	   cells	   with	   different	   concentrations	   of	   ART	   for	  various	  times	  up	  to	  90	  min.	  The	  results	  (Figure	  4.2)	  showed	  that	  internalization	  of	  RET	   began	   immediately	   upon	   exposure	   to	   ART,	   with	   up	   to	   80%	   of	   RET	   being	  internalized	  within	   30	  min	   at	   high	   ART	   doses.	   The	   internalization	   rate	   increased	  with	  increasing	  ART	  concentration,	  over	  the	  range	  0.1–20	  nM,	  saturating	  at	  ~10	  nM	  ART.	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   To	  determine	  whether	  the	  internalized	  RET	  is	  trafficked	  through	  endosomal	  compartments,	   I	   used	   immunofluorescence	   microscopy	   to	   visualize	   the	   cellular	  localization	   of	   RET	   upon	   stimulation	   of	   the	   cells	   with	   4	   nM	   ART	   for	   60	   min,	  compared	  to	  the	  location	  of	  the	  early	  endosome	  marker	  Early	  Endosome	  Antigen	  1	  	  (EEA1)256.	  Shown	  in	  Figure	  4.3	  (red),	  a	  significant	  portion	  of	  the	  RET	  could	  be	  seen	  to	  translocate	  from	  the	  cell	  membrane	  to	  the	  cytoplasm	  after	  5	  min,	  and	  remained	  in	  the	  cytoplasm	  after	   internalization.	  Merged	   images	  of	  RET	  and	  EEA1	  (Figure	   4.3)	  showed	   that	   co-­‐localization	   of	   RET	   and	   EEA1	   increased	   upon	   ART	   stimulation,	  suggesting	  that	  RET	  traffics	  through	  early	  endosomes.	  	  
                                       
Figure 4.2 RET internalization upon ART stimulation. Surface RET levels in NB41A3-
mGFRα3 cells after stimulation with the stated concentrations of ART over 0-90 min, 
measured by flow cytometry. The ordinate shows the percentage of RET remaining on the cell 
membrane. The experimental points are averages of at least two independent replicates, after 
subtracting the background signal from untreated cells stained with hamster IgG isotype 
control. Error bars show standard deviations of the replicates. Solid lines show the best fit of 
each data set to a single exponential equation, assuming that all curves asymptote to the same final	  percentage	  of	  cell-­‐surface	  RET.	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   The	   co-­‐localization	   of	   RET	   and	   EEA1	   was	   quantified	   by	   calculating	   the	  Pearson’s	   correlation	   coefficient	   (PCC)257	   using	   ImageJ258,259.	   PCC	   quantifies	   the	  linear	   correlation	   between	   two	   variables,	   and	   how	   the	   change	   of	   one	   variable	   is	  dependent	   on	   the	   change	   of	   the	   other	   variable.257	   When	   used	   in	   colocalization	  analysis	   of	   immunofluorescence	   images,	   PCC	   describes	   how	   the	   fluorescence	  intensity	  measured	  in	  one	  detector	  channel	  (i.e.	  one	  color)	  for	  any	  given	  pixel	  in	  the	  image	   correlates	  with	   the	   fluorescence	   intensity	  measured	   in	   the	   second	  detector	  channel	   (i.e.	   the	   other	   color).	   When	   the	   cell	   sample	   is	   stained	   for	   two	   different	  molecules	  with	  different-­‐colored	  fluorophores,	  PCC	  gives	  values	   in	  the	  range	  of	  +1	  to	  -­‐1.	  A	  value	  of	  +1	  means	  that	  the	  two	  colors	  are	  perfectly	  correlated	  to	  each	  other,	  such	  that	  they	  invariably	  appear	  together	  in	  the	  same	  pixel	  of	  the	  image.	  A	  PCC	  value	  of	  -­‐1	  means	  two	  molecules	  are	  inversely	  related	  to	  each	  other,	  such	  that	  they	  never	  
  
Figure 4.3 Time-course for RET internalization and colocalization with the early endosome 
marker EEA1. NB41A3-mGFRα3 cells were incubated with 4 nM ART for the indicated 
times, fixed with PFA, permeablized, immunostained for RET (red) and EEA1 (green), and 




appear	  in	  the	  same	  pixel.	  A	  value	  of	  0	  indicates	  that	  the	  cellular	  locations	  of	  the	  two	  different-­‐colored	   fluorophores	   are	   uncorrelated,	   such	   that	   the	   extent	   of	   co-­‐localization	  is	  as	  predicted	  from	  statistical	  chance.	  The	  PCC	  of	  an	  image	  containing	  red	  and	  green	  channels	  can	  be	  calculated	  as	  
𝑃𝐶𝐶 =    𝑅! − 𝑅 × 𝐺! − 𝐺!𝑅! − 𝑅 !× 𝐺! − 𝐺 !! 	  
where	  Ri	  and	  Gi	  are	  the	  fluorescent	  intensities	  of	  the	  red	  and	  green	  channels	  of	  pixel	  
i,	   and	  𝑅	  and	  𝐺	  are	   the	  mean	   intensities	   of	   the	   two	   channels	   over	   the	   entire	   image.	  The	   advantage	   of	   using	   PCC	   for	   colocalization	   analysis	   in	   immunofluorescence	  images	   is	   that	   it	   is	   independent	   of	   fluorescence	   intensity	   levels	   and	   signal	  background.	  	  




4.2.2. Discovery	  of	  Long-­‐Lived	  pRET	  
	   In	  Chapter	  2	  we	  showed	  that	  stimulating	  NB41A3-­‐mGFRα3	  cells	  with	  4	  nM	  ART	   triggers	   RET	   phosphorylation,	   which	   peaks	   around	   20	   min	   followed	   by	   a	  gradual	  decay	  (Figure	  2.9).	   In	  Chapter	  3,	  we	  showed	  that	  the	   intrinsic	   lifetime	  of	  pRET	   is	   ≤1	  min,	   suggesting	   that	   the	   observed	   pRET	   levels	   result	   from	   a	   dynamic	  
	  
Figure 4.4 Colocalization analysis of RET with the early endosome marker EEA1 after ART 
stimulation. Pearson’s correlation coefficients (PCC) were calculated from images obtained by 
immunostaining for RET and EEA1, using Image J software, and are plotted as a function of 
time after ART stimulation. Data points show average PCC values over five images from each 
coverslip. Error bars show standard deviations among the five images. Data in panel A 
correspond to the co-localization analysis of the images presented in Figure 4.3. Data points 
indicated with ** or * are values that are significantly greater than the corresponding values 
for untreated cells at the levels of p < 0.0001 or p < 0.006, respectively, as determined by a 
paired Student’s t-test.  
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steady	   state	  between	   rapid	  pRET	   formation	   and	  decay	   (Figure	   3.3).	   The	   study	  of	  RET	  activation	  kinetics	  described	   in	  Chapter	   3	   focused	  on	   the	   initial	  10	  min	  after	  ART	   stimulation,	  when	   effects	   of	   endocytosis	   and	   downstream	   signaling	   feedback	  loops	   are	   relatively	   small. Due	   to	   the	   significant	   degree	   of	   RET	   internalization	  observed	   upon	   ART	   stimulation,	   especially	   at	   very	   high	   ART	   levels,	   we	   were	  interested	   to	   see	   whether	   endocytosis	   or	   other	   feedback	   mechanisms	   affect	   the	  turnover	  rate	  or	  lifetime	  of	  pRET.	  As	  we	  described	  in	  Chapter	  2	  (Figure	  2.9),	  after	  stimulation	   of	   the	   cells	  with	   4	   nM	  ART	   for	   20	  min	   pRET	   levels	   start	   to	   decrease,	  indicating	   changes	   in	   the	   pRET	   turnover	   process,	   or	   the	   onset	   of	   other	   negative	  feedback	   effects,	   to	   favor	   pRET	   dephosphorylation	   over	   phosphorylation.	   To	  investigate	  whether	   the	  onset	   of	   this	  decrease	   in	  pRET	  amplitude	   results	   from	  an	  increase	   in	   the	  pRET	  dephosphorylation	   rate,	  we	   compared	   the	  pRET	  decay	   rates	  when	   adding	   the	   RET	   inhibitor	   ZD6474	   at	   different	   times	   after	   ART	   stimulation.	  Specifically,	  NB41A3-­‐mGFRα3	  cells	  were	   incubated	  with	  4	  nM	  ART	   for	  10	  min,	  30	  min,	  or	  40	  min,	  followed	  by	  addition	  of	  ZD6474	  into	  the	  culture	  medium,	  and	  then	  further	   incubation	   for	   various	   times.	   At	   the	   end	   of	   the	   treatment	   period	   the	   cells	  were	   lysed,	   and	   the	   levels	   of	   pRET	   in	   the	   cell	   lysates	   were	   determined	   by	   KIRA	  ELISA	   as	   described	   in	  Chapter	   2.	   The	   results	   (Figure	   4.5A,	   squares)	   show	   that	  pRET	  decayed	  rapidly	  to	  basal	  level	  when	  RET	  kinase	  activity	  was	  inhibited	  after	  10	  min	   of	   ART	   stimulation.	   Fitting	   the	   decay	   phase	   of	   this	   time-­‐course	   to	   a	   single	  exponential	   equation	   returned	  a	  pRET	  half-­‐life	   of	  ~1	  min,	   as	   shown	  previously	   in	  
Chapter	  3,	  Figure	  3.3.	  However,	  addition	  of	  ZD6474	  after	  stimulating	  the	  cells	  with	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ART	  for	  30	  min	  or	  40	  min	  caused	  pRET	  to	  decrease	  in	  a	  biphasic	  manner,	  consisting	  of	   a	   fast	   decay	   that	  was	   essentially	   complete	  within	  ~5	  min,	   followed	   by	   a	  much	  slower	  decay	  of	   the	  remaining	  pRET	  to	  basal	   levels	  over	   the	  subsequent	  ~60	  min.	  
Figure	   4.5B	   shows	   the	   biphasic	   decay	   normalized	   to	   the	   pRET	   levels	   prior	   to	  addition	   of	   ZD6474,	   showing	   that	   the	   slow	  phase	   of	   pRET	  decay	   comprises	   up	   to	  ~40%	   of	   total	   pRET.	   These	   results	   reveal	   the	   existence	   of	   two	   different	   forms	   of	  pRET	  that	  exhibit	  distinct	  decay	  half-­‐lives	  of	  ~1	  min	  and	  ~30	  min.	  The	  fact	  that	  cells	  stimulated	  with	  4	  nM	  ART	   for	  6	  min	  and	  40	  min	  produce	  very	   similar	   total	  pRET	  levels	   (Figure	   2.9B)	   indicates	   that	   the	   partitioning	   of	   pRET	   into	   short-­‐lived	   and	  long-­‐lived	  forms	  is	  not	  simply	  proportional	  to	  the	  total	  cellular	  pRET	  level.	  	  
  
Figure 4.5 Comparison of pRET decay when inhibited after different periods of ART 
stimulation. A. Effect on pRET levels of adding RET kinase domain inhibitor ZD6474 (50 
µM) at 10 min (squares), 30 min (circles) or 40 min (triangles) after stimulation of cells with 4 
nM ART. Data points were normalized to the values for cells treated with 4 nM ART for 10 
min. Arrows indicate the times of ZD6474 addition. B. Decay phases of the plots in A, 
normalized to the pRET level prior to inhibition in each experiment. Solid lines are 
interpolations of the data. Each plot represents the results of a separate experiment. 
Experimental data show averaged	  data	  from	  at	   least	   two	  independent	  experiments.	  Error	  bars	  are	  standard	  deviations	  of	  the	  independent	  replicate	  measurements.  
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   When	  RET	   is	   activated,	  multiple	   Tyr	   residues	   become	  phosphorylated.	   Our	  KIRA	   ELISA	   assay	   for	   pRET	   does	   not	   extinguish	   among	   Tyr	   residues	   on	   pRET,	  detecting	  all	  phosphotyrosine	  (pTyr)	  sites	   indiscriminately.	  The	  observed	  biphasic	  decrease	  in	  pTyr	  levels	  in	  RET,	  upon	  addition	  of	  RET	  inhibitors	  after	  prolonged	  ART	  stimulation,	   could	   therefore	   reflect	   full	   dephosphorylation	   of	   a	   subset	   of	   pRET	  molecules.	   Alternatively,	   this	   result	   could	   reflect	   the	   rapid,	   partial	  dephosphorylation	  of	  all	  pRET	  molecules	  at	  certain	  pTyr	  sites,	  while	  other	  sites	  on	  the	   same	   RET	   molecules	   dephosphorylate	   more	   slowly.	   To	   test	   whether	   the	  dephosphorylation	  rates	  were	  specific	   to	  particular	  pTyr	  sites	  on	  RET,	  or	  whether	  all	  pTyr	  sites	  on	  a	  given	  RET	  molecule	  are	  dephosphorylated	  with	  similar	  kinetics,	  we	   examined	   the	   decay	   kinetics	   of	   phosphorylated	   residue	  Tyr	   1062	   (pY1062)	   in	  RET	  after	  30	  min	  ART	  stimulation,	  using	  a	  detection	  antibody	  specific	   for	   this	  one	  pTyr	  site.	  Shown	  in	  Figure	  4.6,	  addition	  of	  ZD6474	  after	  30	  min	  of	  ART	  stimulation	  caused	  pY1062	  to	  dephosphorylate	  with	  identical	  biphasic	  kinetics	  to	  those	  seen	  for	  total	  pRET.	  This	  result	  proves	  that	  the	  two	  distinct	  dephosphorylation	  rates	  seen	  in	  




4.2.3. Quantification	  of	  Long-­‐lived	  and	  Short-­‐lived	  pRET	  
	   Based	   on	   the	   findings	   that	   ART	   stimulation	   triggers	   internalization	   of	   RET,	  and	   at	   later	   times	   leads	   to	   the	   accumulation	   of	   a	   more	   stable	   form	   of	   pRET,	   we	  hypothesized	   that	   a	   fraction	   of	   pRET	   might	   be	   trafficked	   to	   intracellular	  compartments	  where	  it	  becomes	  shielded	  from	  negative	  regulators	  such	  as	  protein	  tyrosine	   phosphatases,	   resulting	   in	   a	   longer	   lifetime.	   To	   further	   explore	   whether	  ligand-­‐induced	   receptor	   endocytosis	   contributes	   to	   the	   extended	   stability	   of	   a	  fraction	  of	  pRET,	  we	  examined	  the	  effects	  of	  perturbing	  endocytic	  pathways	  on	  the	  
  
Figure 4.6 Time-courses for dephosphorylation of pY1062 (squares) and total pRET (circles) 
after addition of ZD7464 to cells stimulated with ART for 30 min. Cells were incubated with 
4 nM ART for 30 min, followed by addition of RET kinase domain inhibitor ZD6474 (50 
µM). Levels of pRET and pY1062 RET in cell lysates were detected by KIRA ELISA as 
described in Chapter 2, or using the pY1062 ELISA described in Experimental Methods. 
Data points were normalized to the values from cells treated with 4 nM ART for 10 min. Data 
points show the average of duplicate wells in the ELISA assays from one representative 
experiment of three independent experiments. Error bars are differences between signals from 
duplicate well. Solid lines are smoothed interpolations of the data. The dashed line represents 
the low, basal levels of pRET and pY1062 seen in untreated cells.  
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degradation	   rate	   of	   pRET,	   by	   using	   small	   molecule	   inhibitors	   targeting	   different	  steps	  of	  receptor	  endocytosis.	  	  
	   Studies	   have	   shown	   that,	   upon	   stimulation	   by	   GDNF,	   RET	   is	   primarily	  internalized	   via	   clathrin-­‐dependent	   pathways.245	   Here,	   we	   used	  monodansylcadaverine	   (MDC)	   to	   block	   clathrin-­‐dependent	   endocytosis.	  MDC,	   and	  certain	  other	  primary	  amines,	   inhibit	  transglutaminase,	  an	  enzyme	  responsible	  for	  covalently	   cross-­‐linking	   proteins	   during	   the	   formation	   of	   clathrin-­‐coated	   pits.260	  MDC	  has	  been	  shown	  to	  efficiently	  block	  internalization	  of	  α2-­‐macroglobin	  260,261,262,	  TGFβ263,	  EGF264,	  insulin262	  and	  the	  55-­‐kDa	  receptor	  tumor	  necrosis	  facto	  (TR55)265.	  Pre-­‐incubating	  the	  cells	  with	  100	  μM	  MDC,	  followed	  by	  stimulation	  for	  20	  min	  with	  4	   nM	   ART	   in	   continued	   the	   presence	   of	   MDC,	   blocked	   ART-­‐induced	   RET	  internalization.	   Immunostaining	  for	  RET	  (Figure	  4.7	  A	  and	   B)	  showed	  that,	   in	  the	  absence	   of	  MDC,	   ART	   treatment	   caused	  most	   RET	   receptors	   to	   translocate	   to	   the	  interior	  of	  the	  cells	  from	  the	  periphery.	  
	   Wide-­‐field	   microscopy	   does	   not	   differentiate	   cell	   surface	   staining	   from	  intracellular	  staining.	  However,	  the	  minimal	  central	  staining	  and	  bright	  edges	  of	  the	  DMEM-­‐treated	   (unstimulated)	   cells	   indicates	   that	   RET	   resides	   mainly	   on	   the	   cell	  surface.	  After	  ART	  stimulation,	  most	  RET	  staining	  was	  found	  in	  the	  body	  of	  the	  cell,	  away	  from	  the	  periphery.	   Images	  captured	  by	  confocal	  microscopy,	   focused	  at	  one	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intracellular	  plane	  (Figure	  4.3),	  showed	  that	   internalized	  RET	  is	   in	  the	  cytoplasm.	  Blocking	   the	   formation	   of	   clathrin-­‐coated	   pits	  with	  MDC	   caused	  RET	   receptors	   to	  remain	   on	   the	   cell	   surface	   (Figure	   4.7C),	   suggesting	   that	   ART-­‐induced	   RET	  internalization	   occurs	   via	   clathrin-­‐dependent	   pathways.	   In	   addition,	   treating	   the	  cells	  with	  the	  RET	  kinase	  domain	  inhibitor	  ZD6474	  caused	  most	  of	  the	  RET	  to	  stay	  on	   the	   cell	   surface	   after	   subsequent	  ART	   stimulation	   (Figure	   4.7D),	   showing	   that	  
  
Figure 4.7 Inhibitory effects of MDC and ZD6474 on ART-induced RET internalization. 
NB41A3-mGFRα3 cells were pre-incubated with DMEM culture medium (A, B) for 30 min, 
100 µM MDC (C) for 30 min, or 5 µM ZD6474 (D) for 10 min, followed by 20 min 
incubation with DMEM only or with 4 nM ART, as indicated above each image. Cells were 
immunostained for RET, and imaged via a wide-field fluorescence microscope. Images are 
from one representative experiment of three independent experiments.   
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blocking	  RET	   phosphorylation	   substantially	   impaired	  ART-­‐induced	   internalization	  of	  RET.	  It	  is	  reported	  that	  AP2,	  a	  component	  of	  the	  CCP,	  interacts	  directly	  with	  wild	  type	   RET	   upon	   GDNF	   stimulation,	   but	   not	   with	   a	   kinase-­‐domain	   dead	   mutant	  RET.245	  However,	  without	  further	  experiments	  to	  determine	  the	  cellular	  localization	  of	   RET	  when	   its	   kinase	   activity	   is	   blocked,	  we	   cannot	   exclude	   the	   possibility	   that	  some	   amount	   of	   unphosphorylated	   RET	   can	   also	   be	   internalized	   upon	   ART	  stimulation,	  either	  specifically	  or	  nonspecifically.	  
	   Having	   validated	   the	   inhibitory	   effects	   of	   MDC	   on	   RET	   internalization,	   we	  investigated	   how	   blocking	   the	   formation	   of	   CCPs	   would	   affect	   the	   formation	   and	  stabilities	  of	  short-­‐lived	  and	  long-­‐lived	  pRET.	  Shown	  in	  Figure	  4.8,	  we	  found	  that	  in	  cells	  pretreated	  with	  MDC,	  pRET	  showed	  only	  fast	  decay	  in	  response	  to	  addition	  of	  ZD6474	  after	  30	  min	  of	  ART	  stimulation	  (triangles).	  This	  observation	  suggests	  that,	  if	   kept	   on	   the	   cell	   surface,	   all	   pRET	   is	   short-­‐lived	   pRET,	   indicating	   that	   clathrin-­‐dependent	  receptor	  endocytosis	  is	  required	  for	  the	  formation	  of	  long-­‐lived	  pRET.	  	  
	   Monensin,	   a	   carboxyl	   ionophore,	   can	   alkalinize	   acidic	   intracellular	  compartments	  such	  as	  endosomes	  and	  lysosomes,	  and	  thus	  interrupt	  acidification	  of	  pre-­‐lysosomal	   vesicles	   to	   become	   mature	   lysosomes.266,267,268	   Monensin	   has	   been	  shown	   to	   block	   the	   delivery	   of	   internalized	   receptor-­‐ligand	   complexes	   from	  endosomes	   to	   lysosomes	   or	   recycling	   vesicles,	   and	   thereby	   traps	   receptors	   in	  endosomes.269,270,271	  Treating	  the	  cells	  with	  monensin	  to	  block	  endosomes	  sorting	  to	  	  lysosomes	   appears	   to	   block	   or	   greatly	   slow	   the	   degradation	   of	   long-­‐lived	   pRET	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  (Figure	  4.8	  lozenges),	  suggesting	  long-­‐lived	  pRET	  accumulates	  in	  endosomes	  and	  is	  degraded	  via	  lysosomes.	  
Although	  acidification	  is	  coupled	  with	  maturation	  of	  MVBs	  and	  lysosomes,	  as	  mentioned	  earlier,	  it	   is	  not	  clear	  yet	  how	  changes	   in	  pH	  would	  affect	   formation	  of	  ILVs	   and	   MVBs.	   Chemicals	   elevating	   the	   pH	   in	   endosomes	   have	   been	   used	   as	  inhibitors	   to	  disrupt	   the	  endocytic	  pathways	  by	   interfering	  with	  the	  maturation	  of	  late	   endosomes	   and	   degradative	   activities	   of	   the	   enzymes	   in	   lysosomes.230	  Monensin,	  a	  carboxyl	  ionophore,	  elevates	  intracellular	  organelle	  pH	  by	  transporting	  protons	  out	  of	  the	  organelles	  and	  has	  been	  shown	  to	  block	  recycling	  and	  lysosomal	  
  
Figure 4.8 Effects of internalization and trafficking inhibitors on pRET decay dynamics. 
NB41A3-mGFRα3 cells were pre-incubated with 100 µM MDC (triangles) or 10 µM 
monensin (lozenges) for 30 min, then incubated with 4 nM ART for an additional 30 min, 
followed by addition of 50 µM ZD6474. As controls, cells were incubated with ART only, 
with (squares) or without (circles) addition of ZD6474 at 30 min. Data points show one 
representative experiment of three independent experiments. Experimental data are average 
measurements from duplicate ELISA wells normalized to the signal seen for cells treated with 
4 nM ART for 30 min in each treatment group. Error bars show differences between the 
duplicate ELISA measurements. The dashed line indicates the basal levels of pRET seen in 
unstimulated cells. Solid lines are smoothed interpolations of the data.  
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degradation	   of	   internalized	   receptors.	   In	  my	  work,	   I	   intended	   to	   use	  monensin	   to	  disrupt	   trafficking	  of	   internalized	  RET	  from	  endosomes	  to	   lysosomes.	  Treating	  the	  cell	  with	  monensin	  significantly	  reduced	  the	  decay	  of	  long-­‐lived	  pRET.	  If	  monensin	  inhibited	  the	  maturation	  of	  lysosomes,	  this	  result	  suggests	  that	  long-­‐lived	  pRET	  is	  in	  late	  endosomes,	  and	   the	  extended	   lifetime	  of	   long-­‐lived	  pRET	   is	  very	   likely	  due	   to	  pRET	  being	   captured	   in	   ILVs	   in	   late	   endosomes	  and	   shielded	  away	   from	  cytosolic	  phosphatases.	   However,	   there	   is	   another	   possibility	   that	   monensin	   could	   have	  blocked	   transportation	   from	  early	   to	   late	  endosomes.	   If	   this	   is	   the	  case,	   long-­‐lived	  pRET	  will	  be	  in	  early	  endosomes	  instead.	  Studies	  of	  elevating	  endosomal	  pH	  by	  small	  molecule	  inhibitors	  showed	  that	  the	  effects	  of	  pH	  modification	  on	  endocytic	  pathways	  could	  be	  cell-­‐type	  dependent.	  For	   example,	   V-­‐ATPase	   inhibitor	   bafilomycin	   was	   shown	   to	   block	   transportation	  from	  early	  endosomes	  to	  late	  endosomes	  in	  some	  studies272,273,274,275,	  but	  in	  another	  study	  it	  blocked	  the	  traffic	  from	  late	  endosomes	  to	  lysosomes276.	  Monensin	  is	  a	  mild	  trafficking	   inhibitor	   compared	   to	   V-­‐ATPase	   inhibitors.	   My	   impression	   is	   that	  monensin	   does	   not	   block	   the	   formation	   of	   ILVs,	   regardless	   of	  whether	   those	   ILVs	  can	   evolve	   into	   mature	   late	   endosomes/MVBs.	   It	   is	   very	   possible	   that	   monensin	  impairs	   the	   ability	   of	   the	   ILV-­‐containing	   vacuolar	   regions	   of	   early	   endosomes	   to	  evolve	   into	  mature	  MVBs.	   If	   this	   is	   the	  case,	  slow	  degradation	  of	  pRET,	  which	  was	  blocked	   by	  monensin,	   was	   due	   to	   deactivated	   degradative	   enzymes	   in	   lysosomes	  with	  elevated	  pH.	  In	  addition,	  monensin	  would	  also	  reduce	  the	  transportation	  from	  early	   endosomes	   to	   late	   endosomes.	   These	  hypotheses	   can	  be	   tested	  by	  detecting	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the	  cellular	  location	  of	  RET	  stimulated	  by	  ART	  in	  the	  presence	  of	  ART.	  
	   Based	   on	   the	   effects	   of	   MDC	   and	  monensin	   on	   the	   formation	   of	   long-­‐lived	  pRET,	  we	  hypothesized	  that	  pRET	  on	  the	  cell	  membrane	  and	  in	  early	  endosomes	  has	  a	  short	  lifetime	  of	  ~1	  min,	  but	  becomes	  long-­‐lived	  pRET	  when	  it	  is	  transported	  into	  late	  endosomes.	  When	  pRET	  is	  on	  the	  plasma	  membrane,	  in	  clathrin-­‐coated	  pits,	  or	  in	   early	   endosomes,	   the	   phosphorylated	   kinase	   domain	   is	   exposed	   to	   cytoplasmic	  protein	   tyrosine	  phosphatases,	   resulting	   in	   rapid	  dephosphorylate	   such	   that	  pRET	  in	   these	  membrane	   compartments	   is	   short-­‐lived.	   However,	   when	   sorted	   into	   late	  endosomes	   (so	   called	   multivesicular	   bodies	   (MVBs))	   containing	   small	   lumenal	  vesicles,	  pRET	  is	  embedded	  in	  the	  small	  vesicles	  with	   its	  kinase	  domain	  facing	  the	  endosomal	   lumen.	   We	   hypothesize	   that,	   when	   trafficked	   to	   MVBs,	   pRET	   kinase	  domain	   is	   sequestered	   from	   phosphatases,	   substantially	   increasing	   its	   lifetime.	  Alternatively,	  differences	   in	  pH	  or	   in	   the	  phosphatases	  present	   in	   late	  endosomes,	  compared	   to	   the	   cytoplasm,	  might	   cause	   the	   pRET	   in	   late	   endosomes	   to	   exhibit	   a	  longer	   lifetime.	  Eventually,	  a	   fraction	  of	  pRET	   is	  delivered	   from	  late	  endosomes	  to	  lysosomes	   for	  degradation.	   In	  conclusion,	  we	  propose	   that	   the	   fast	  decay	  of	  short-­‐lived	  pRET	  represents	  the	  rapid	  pRET	  dephosphorylation	  process	  that	  occurs	  in	  the	  cytoplasmic	   region,	   while	   the	   slow	   decay	   of	   long-­‐lived	   pRET	   represents	   the	  transportation	  from	  late	  endosomes	  to	  lysosome,	  or	  the	  pRET	  degradation	  process	  in	  lysosomes,	  whichever	  is	  rate-­‐limiting.	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Figure 4.9 Time-course for the formation of long-lived pRET compared to total pRET. 
NB41A3-mGFRα3 cells were stimulated with 4 nM ART (A) or 1 nM ART (C) for the times 
shown on the x-axis, and then incubated with 50 µM ZD6474 (squares) or with DMEM 
(circles) for 5 min, before lysing the cells and detecting pRET. Data were measured in 
duplicate, and are plotted as a percentage of the total pRET signal for cells stimulated with 4 
nM ART for 20 min. Error bars are the difference between the duplicate ELISA 
measurements. The solid lines are smoothed interpolations of the data. B and D show the 
fraction of total pRET that is long-lived (llpRET) from A and C, respectively, plotted as 
function of time. The dashed lines indicate the average fractions of llpRET observed over 20–
90 min after ART treatment. 
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4.3. Roles	  of	  Trafficking	  in	  RET	  Signaling	  
4.3.1. Signaling	  Capacity	  of	  Long-­‐lived	  pRET	  
	   In	   Chapter	   2	   we	   showed	   that	   activation	   of	   RET	   by	   ART	   triggers	   both	  transient	   and	   sustained	   activation	   of	   ERK	   and	   Akt.	   To	   investigate	   the	   extent	   to	  which	   short-­‐lived	   pRET	   and	   long-­‐lived	   pRET	   contribute	   to	   these	   downstream	  signaling	  pathways,	  we	  examined	  how	  the	  levels	  of	  pERK	  and	  pAkt	  were	  affected	  if	  RET	   phosphorylated	   was	   inhibited	   to	   deplete	   short-­‐lived	   pRET.	   To	   do	   this	   we	  incubated	  the	  cells	  with	  4	  nM	  ART	  for	  30	  min,	  added	  RET	  kinase	  inhibitor	  ZD6474	  for	  10	  min	  to	  deplete	  all	  the	  short-­‐lived	  pRET,	  and	  then	  lysed	  the	  cells	  and	  measured	  the	  levels	  of	  PRET,	  pERK	  and	  pAkt.	  Shown	  in	  Figure	  4.10,	  addition	  of	  ZD6474	  after	  
	     
Figure 4.10 Effect of depleting short-lived pRET on levels of pERK and pAkt. NB41A3-
GFRa3 cells were stimulated with 4 nM ART for 30 min, and then 50 µM of the RET kinase 
domain inhibitor ZD6474 was added for 10 min to deplete short-lived pRET. The cells were 
lysed, and the lysates analyzed for pRET, pERK or pAkt using the ELISA assays described in 
Chapter 2. Data are normalized to the phosphoprotein level measured after 30 min stimulation 
with 4 nM ART, and show the average of three independent experiments. Error bars show 
standard deviations of three independent measurements. The dashed line indicates the low, 
basal phosphoprotein levels seen in unstimulated cells.  
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30	   min	   of	   ART	   stimulation	   decreased	   total	   pRET	   by	   ~60%,	   as	   expected,	  corresponding	  to	  depletion	  of	  the	  short-­‐lived	  pRET	  to	  leave	  only	  the	  ~40%	  of	  pRET	  that	  is	  the	  long-­‐lived	  form,	  exactly	  as	  we	  showed	  in	  Figure	  4.5.	  However,	  this	  same	  treatment	  caused	  pERK	  and	  pAkt	  levels	  to	  drop	  to	  basal	  levels	  or	  below.	  The	  lack	  of	  ERK	   and	   Akt	   phosphorylation	   even	   when	   substantial	   levels	   of	   long-­‐pRET	   remain	  shows	   that	   long-­‐lived	  pRET	   is	   not	   competent	   to	   activate	  ERK	  and	  Akt.	   This	   result	  indicates	   that	   pRET	   stops	   activating	   the	   ERK	   and	   Akt	   pathways	   once	   it	   becomes	  compartmentalized	   in	   late	  endosomes	  where	   it	  became	   long-­‐lived	  pRET.	  The	  non-­‐competence	   for	   signaling	   of	   long-­‐lived	  pRET	  might	   be	   explained	  by	   its	   separation	  from	   the	   cytoplasmic	   environment	   when	   trafficked	   to	   the	   internal	   vesicles	   of	  multivesicular	  late	  endosomes,	  resulting	  in	  loss	  of	  the	  ability	  to	  access	  and	  activate	  signaling	  components	  upstream	  of	  ERK	  and	  Akt.	  Our	  results	  therefore	  suggest	  that	  that	   the	   observed	   differences	   in	   the	   functionalities	   of	   long-­‐lived	   and	   short-­‐lived	  pRET	  are	  not	  due	  to	  their	  different	  stabilities	  per	  se.	  Instead,	  their	  different	  signaling	  capacities	  and	  lifetimes	  are	  both	  consequences	  of	  the	  compartmentalization	  of	  pRET	  to	   different	   subcellular	   locations,	   due	   to	   ligand-­‐induced	   internalization	   and	  trafficking.	  	  
ERK	  and	  Akt	  are	  two	  essential	  pathways	  regulating	  cell	  survival,	  proliferation	  and	   differentiation,	   which	   are	   also	   the	   functional	   outcomes	   of	   RET	   signaling.	  Although	  we	  cannot	  rule	  out	  the	  possibility	  that	  long-­‐lived	  pRET	  can	  activate	  other	  signaling	   pathways,	   our	   results	   suggest	   that	   short-­‐lived	   pRET	   is	   primarily,	   if	   not	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completely,	  responsible	  for	  fulfilling	  the	  biological	  functions	  of	  RET.	  As	  a	  result,	  the	  actual	  signaling	  amplitudes	  of	  RET	  are	   lower	  than	  the	  detected	  total	  cellular	  pRET	  levels,	  because	  a	  portion	  of	  pRET	  is	  stored	  in	  MVBs	  where	  it	  cannot	  signal.	  
4.3.2. Effects	  of	  Trafficking	  Inhibitors	  on	  RET,	  ERK	  and	  Akt	  Activation	  
	   The	   population	   of	   short-­‐lived	   pRET	   includes	   activated	   RET	   receptors	   at	  multiples	  subcellular	  localizations,	  such	  as	  the	  cell	  surface,	  clathrin-­‐coated-­‐pits,	  and	  early	  endosomes.	  It	  has	  been	  reported	  for	  other	  systems	  that	  internalized	  activated	  receptors	  can	  continue	  to	  signal	  in	  endosomal	  compartments.227,232,233,234,277	  But	  the	  existence	  of	  signaling	  components	  that	  are	  localized	  exclusively	  in	  endosomes	  or	  on	  the	   inner	   plasma	   membrane	   can	   cause	   cell-­‐surface	   surface	   receptors	   and	  internalized	   ones	   to	   signal	   differently.278	   To	   gain	   a	   deeper	   mechanistic	  understanding	   of	   how	   RET	   signaling	   is	   regulated,	   we	   performed	   additional	  experiments	  to	  investigate	  how	  RET	  trafficking	  affects	  its	  phosphorylation	  dynamics	  and	  signaling	  outcomes.	  
To	  do	  this,	  we	  analyzed	  the	  effects	  of	  perturbing	  receptor	  internalization	  on	  the	   time-­‐course	   of	   RET	   activation	   stimulated	   by	   ART.	   The	   results	   show	   that	   cells	  pre-­‐incubated	  with	  100	  μM	  MDC,	  which	   inhibits	   formation	  of	   clathrin-­‐coated	  pits,	  produced	  lower	  levels	  of	  pRET	  in	  response	  to	  4	  nM	  ART	  stimulation	  (Figure	  4.11).	  RET	  activation	   levels	  were	  further	  decreased	  when	  a	  higher	  concentration	  of	  MDC	  was	  used.	  The	  total	  protein	  concentrations	  of	  each	  sample	  were	  monitored	  to	  make	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sure	   the	   signal	   decrease	  was	   not	   to	   due	   to	   loss	   of	   cells	   upon	   treatment	  with	   the	  inhibitor.	   Decreased	   pRET	   levels	   could	   result	   from	   a	   decrease	   in	   the	   rate	   of	   RET	  activation	  or	  phosphorylation,	  and/or	  an	  increase	  in	  the	  rate	  of	  pRET	  deactivation.	  Inhibiting	  pRET	  internalization	  with	  MDC	  might	  be	  expected	  to	  increase	  the	  overall	  pRET	   deactivation	   rate	   at	   later	   times	   after	   stimulation,	   by	   preventing	   the	  accumulation	  of	  long-­‐lived	  pRET.	  However,	  the	  fact	  that	  MDC	  decreased	  pRET	  levels	  in	   the	   first	   10	   min	   indicates	   that	   something	   else	   is	   going	   on.	   One	   possible	  explanation	  would	  be	  if	  RET	  phosphorylation	  in	  endosomes	  were	  much	  faster	  than	  on	  the	  outer	  cell	  membrane.	  When	  the	  ligand-­‐receptor	  complex	  is	  internalized	  into	  endosomes,	  the	  ligand	  concentration	  within	  the	  small	  endosome	  fluid	  volume	  might	  be	   higher	   than	   in	   the	   extracellular	   milieu,	   resulting	   in	   increased	   ligand-­‐receptor	  association.	  Therefore	  the	  lowered	  pRET	  levels	  observed	  when	  internalization	  was	  
  
Figure 4.11 Effects of monodansylcadaverine (MDC) and monensin on pRET activation 
dynamics. NB41A3-mGFRα3 cells were pre-treated with DMEM (squares), MDC at the 
stated concentrations (A), or 10 µM monensin (B), for 30 min prior to stimulation with 4 nM 
ART for 0–90 min. Data were measured in duplicate. Results are plotted as a percentage of 
pRET levels measured for cells pre-incubated in DMEM and then stimulated with 4 nM ART 
for 20 min. Error bars are the differences between the duplicate measurements. Results show 
one representative experiment out of three independent experiments. The solid lines are 
smoothed interpolations of the data. Dashed lines represent pRET levels in untreated cells.  
	  	  
128	  
blocked	   with	   MDC	   could	   result	   from	   preventing	   trafficking	   to	   endosomes	   where,	  putatively,	  RET	  phosphorylation	  is	   faster.	  However,	  this	  hypothesis	   is	  ruled	  out	  by	  our	   observations	   in	   monensin-­‐treated	   cells.	   Shown	   in	   Figure	   4.11B,	   treating	   the	  cells	  with	  monensin	   to	   block	   endosomal	   sorting	  did	  not	   affect	  ART-­‐induced	  pRET	  levels,	   which	   means	   the	   balance	   between	   RET	   phosphorylation	   and	  dephosphorylation	   remained	   the	   same	   whether	   the	   receptor	   was	   on	   the	   plasma	  membrane	  or	  in	  early	  endosomes.	  We	  cannot	  currently	  explain	  the	  effect	  of	  MDC	  on	  RET	  phosphorylation	  levels,	  and	  cannot	  say	  whether	  this	  is	  due	  to	  an	  experimental	  artifact	  or	  to	  some	  unknown	  mechanism.	  Additional	  experiments	  using	  orthogonal	  methods	  to	  perturb	  receptor	  endocytosis,	  such	  as	  using	  cells	  expressing	  a	  dominant	  dynamin-­‐deficient	  mutant,	  could	  help	  resolve	  this	  question.	  
	  We	   also	   analyzed	   the	   effects	   of	   MDC	   and	   monensin	   on	   ERK	   and	   Akt	  phosphorylation	   downstream	   of	   RET	   signaling.	   Interestingly,	   both	   MDC	   and	  monensin	  treatments	  reduced	  the	  basal	  levels	  of	  phosphorylated	  ERK	  prior	  to	  ART	  stimulation,	  but	  did	  not	  affect	  the	  amount	  of	  pRET	  induced	  by	  RET	  signaling	  (Figure	  
4.12A),	  even	  though	  in	  Figure	  4.11A	  MDC	  appeared	  to	  substantially	  decrease	  total	  pRET	  levels.	  Before	  the	  experiments	  the	  cells	  were	  cultured	  with	  10%	  fetal	  bovine	  serum	   (FBS),	   which	   contains	   a	   mixture	   of	   nutrients	   and	   growth	   factors.279	  Presumably	  ERK	  is	  constitutively	  activated	  at	  a	  low	  level	  by	  serum	  growth	  factors,	  to	   maintain	   cell	   survival	   and	   proliferation,	   which	   is	   in	   agreement	   with	   the	  observation	  that	  short-­‐term	  (≤	  2	  h)	  serum	  starvation	  can	  reduce	  basal	  ERK	  activities	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as	  has	  been	  reported	  by	  others	  in	  multiple	  cell	  lines280,281.	  For	  instance,	  insulin-­‐like	  growth	   factor	   II	   (IGF-­‐II)	   is	  present	   in	  FBS,279	   and	  has	  also	  been	   shown	   to	  activate	  ERK	   to	   promote	   cell	   survival282,283,284.	   In	   the	   experiments	   shown	   in	   Figure	   4.12,	  cells	   were	   grown	   in	   media	   containing	   10%	   FBS,	   and	   for	   the	   experiment	   were	  switched	  to	  serum-­‐free	  buffer	  with	  or	  without	  MDC/monensin	  followed	  by	  a	  30-­‐min	  incubation.	  The	   lower	  basal	  pERK	   levels	   seen	   in	  MDC	  and	  monensin	   treated	   cells,	  but	   not	   in	   cells	   treated	   with	   serum-­‐free	   buffer,	   suggests	   that	   residual	   serum	  hormones	  from	  the	  cell	  growth	  medium	  can	  activate	  ERK,	  but	  require	  endocytosis	  to	  do	  so.	  However,	  we	  observed	  the	  same	  pERK	  amplitude	  change	  induced	  by	  ART	  in	  all	   three	   treatments,	   indicating	   that	   endocytosis	   of	   RET	   is	   not	   required	   to	   fully	  activate	  ERK.	  In	  the	  same	  set	  of	  experiments	  we	  also	  observed	  that	  ART-­‐induced	  Akt	  
  
Figure 4.12 Effects of monodansylcadaverine (MDC) and monensin on ERK (A) and Akt (B) 
phosphorylation dynamics. NB41A3-mGFRα3 cells were pre-treated with DMEM (squares), 
100 µM MDC (circles), or 10 µM monensin (triangles) for 30 min prior to stimulation with 4 
nM ART for 0–90 min. Data are plotted as a percentage of the pERK or pAkt level seen in 
cells pre-treated with DMEM and then stimulated with 4 nM ART for 10 min. Results show 
averaged data from two independent experiments. Error bars are the difference between the 
duplicate experiments. The solid lines are smoothed interpolations of the data. The dashed 
lines indicate the basal levels of pERK or pAkt seen prior to ART stimulation.   
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activation	  was	  moderately	   enhanced	   by	  monensin	   but	   greatly	   decreased	   by	  MDC	  (Figure	   4.12B).	   If	   treating	   the	   cells	   with	   monensin	   to	   block	   endosomal	   sorting	  causes	   internalized	   RET	   to	   accumulate	   in	   early	   endosomes,	   the	   observation	   of	  higher	  pAkt	  levels	  with	  monensin	  treatment	  suggests	  that	  pRET	  in	  early	  endosomes	  could	  activate	  Akt	  more	  efficiently	  than	  pRET	  on	  the	  cell	  membrane.	  This	  hypothesis	  is	   in	   agreement	  with	  our	  observation	   that	   trapping	  RET	  on	   the	   cell	  membrane	  by	  treating	  the	  cells	  with	  MDC	  decreased	  pAkt	  levels.	  However,	  further	  study	  is	  needed	  to	   fully	   understand	   the	   regulatory	   mechanisms	   of	   ART-­‐induced	   RET	   endocytosis	  and	  its	  effect	  on	  RET	  signaling.	  	  
	  
4.4. Discussion	  	  
4.4.1. Development	  of	  an	  Integral	  Model	  for	  RET	  Activation	  and	  Trafficking	  	  
We	  used	  the	  above	  measurements	  of	  RET	  signaling	  and	  trafficking	  dynamics	  to	   develop	   a	  model	   representing	   the	  minimal	   network	   required	   to	   account	   for	   all	  observed	  RET	  species	  and	  their	  subcellular	  localizations.	  Shown	  in	  Figure	  4.13,	  the	  model	   contains	   five	  main	   subcellular	   localizations	   for	   RET	   in	   different	   forms:	   the	  plasma	  membrane,	  early	  endosomes,	  MVBs/late	  endosomes,	  recycling	  vesicles,	  and	  lysosomes.	  This	  model	  of	  RET	  signaling	  and	  trafficking	  expands	  on	  the	  more	  limited	  model	   for	  RET	   activation	   at	   early	   times,	   that	  was	   described	   in	  Chapter	   3.	   In	   that	  work	  we	  established	  that	  RET	  is	  activated	  upon	  ART	  binding	  in	  two	  steps:	  the	  slow	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assembly	   of	   the	   activated	   receptor	   complex,	   with	   rate	   constant	   k0,	   is	   followed	   by	  rapid	   autophosphorylation	   of	   RET	  with	   rate	   constant	   kPhos.	   Both	   steps	   in	   the	   RET	  activation	  process	  are	  reversible,	  with	  rate	  constants	  of	  k-­‐0	  and	  kDephos,	  respectively.	  The	   model	   we	   describe	   here	   additionally	   takes	   account	   of	   regulatory	   roles	   of	  receptor	   internalization	   and	   trafficking	   in	   RET	   signaling.	   Specifically,	   after	   RET	  activation	  on	  the	  cell	  membrane,	  the	  active	  ligand-­‐receptor	  complex	  is	  internalized	  
  
Figure 4.13 Trafficking dynamics of RET upon ART stimulation. ART binds to RET 
reversibly and induces RET autophosphorylation and ligand-receptor complex internalization. 
Internalized ligand-receptor complexes are transported into early endosomes and sorted to 
multivesicular bodies (MVBs)/late endosomes and then to lysosomes for degradation, or are 
sorted for recycling at different points. The equilibrium between RET phosphorylation and 
dephosphorylation that exists on the plasma membrane is maintained in early endosomes. 
Phosphorylated RET on the plasma membrane and in early endosomes can activate the 
ERK/MAPK and Akt pathways. Phosphorylated RET becomes long-lived pRET when in 
MVBs, and loses its signaling capacity.  
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and	   transported	   into	   early	   endosomes	   with	   rate	   constant	   kInt.	   RET	   in	   early	  endosomes	  can	  be	  delivered	  to	  recycling	  vesicles	  with	  rate	  constant	  kSort1	  or	  to	  MVBs	  with	   rate	   constant	   kSort2.	   The	   RET	   delivered	   to	   MVBs	   can	   be	   sorted	   to	   recycling	  vesicles	   and	   become	   unphosphorylated,	   with	   rate	   constant	   kRec2,	   or	   can	   be	  transferred	  to	  and	  degraded	  in	  lysosomes	  with	  rate	  constant	  kLysis.	  RET	  in	  recycling	  vesicles	  returns	  to	  the	  plasma	  membrane	  in	  the	  unphosphorylated,	  unoccupied	  form	  with	   rate	   constant	  kRec1,	   regardless	  of	   its	   original	   source	   from	  early	   endosomes	  or	  MVBs.	  	  
We	   previously	   observed	   that	   treatment	   with	   the	   RET	   kinase	   inhibitor	  ZD6474	  significantly	  impaired	  ART-­‐induced	  internalization	  (Figure	  4.7),	  suggesting	  that	  ART-­‐bound	  unphosphorylated	  RET	  is	  not	  efficiently	  internalized.	  However,	  the	  resolution	  of	  our	  microscopy	  data	  was	  not	  sufficient	  to	  show	  to	  what	  extent	  blocking	  RET	   phosphorylation	   inhibited	   RET	   internalization.	   Therefore	  we	   included	   in	   our	  model	   an	   internalization	   step	   for	  ART-­‐bound	  but	   inactive	  RET,	  with	   rate	   constant	  
kInt2,	  for	  further	  testing	  as	  we	  validated	  and	  refined	  the	  model.	  Since	  the	  microscopy	  results	  showed	  no	  clear	  evidence	  of	  internalization	  of	  unphosphorylated	  RET	  bound	  by	   ART,	   kInt2	   is	   presumably	   smaller	   than	   kInt.	   If	   further	   refinement	   of	   the	   model	  establishes	  that	  kInt2	  =	  0,	  this	  will	  support	  the	  hypothesis	  that	  autophosphorylation	  of	  RET	  is	  a	  prerequisite	  for	  internalization,	  as	  has	  been	  reported	  for	  RET	  stimulated	  by	  GDNF.245	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Starting	   from	  the	  model	   shown	   in	  Figure	   4.13,	  we	  made	  several	  additional	  assumptions	   and	   simplifications.	   First,	   we	   assumed	   that	   the	   rapid	   equilibrium	  between	   RET	   and	   pRET	   that	   exists	   on	   the	   plasma	   membrane	   (Chapter	   3)	   also	  occurs	   in	   early	   endosomes,	   and	   can	  be	  described	   as	   a	   reversible	   one-­‐step	  process	  with	  rate	  constants	  of	  kPhos2	  and	  kDephos2	  as	  we	  discussed	  for	  plasma	  membrane	  RET	  in	   Chapter	   3.	   However,	   the	   rate	   constants	   for	   RET	   phosphorylation	   and	  dephosphorylation	  will	   not	   necessarily	   be	   the	   same	   in	   these	   two	   environments.	   It	  has	   been	   reported	   that	   ligand-­‐receptor	   interaction	   dynamics	   change	   during	  intracellular	   trafficking,	   due	   to	   the	   decreased	   pH	   in	   endosomal	   compartments	  compared	   to	   the	   extracellular	   milieu.285	   For	   instance,	   EGF	   was	   found	   to	   remain	  bound	   to	   its	   receptor	  EGFR286	   in	   early	   endosomes,	  while	  TGFα	  mostly	   dissociated	  from	   this	   same	   receptor287,288.	   Supporting	   this	   observation,	   French	   et	   al.285	   later	  showed	   that	   EGF-­‐EGFR	   association	   and	   dissociation	   constants	   both	   decreased	   2-­‐3	  fold	  when	  the	  pH	  was	  reduced	  from	  7.4	  to	  6.0,	  which	  is	  the	  characteristic	  pH	  of	  the	  endosomal	   lumen.	  The	  TGFα-­‐EGFR	  association	   constant	  decreased	  by	  ~8	   fold	   and	  the	  dissociation	  constant	  increased	  by	  ~8	  fold,	  indicating	  that	  TGFα	  binding	  to	  EGFR	  was	  substantially	  weakened	  by	  the	  reduction	  in	  pH.	  In	  addition	  to	  the	  effects	  of	  pH,	  the	   binding	   dynamics	   between	   RET	   and	   ART	   in	   early	   endosomes	   might	   also	   be	  altered	  as	  the	  stoichiometric	  ratio	  of	  RET	  to	  ART	  changes	  in	  endosomes	  compared	  to	  on	  the	  cell	  surface.	  When	  multiple	  CCPs	  merge	  into	  early	  endosomes,	   the	  resulting	  ART	   concentration	   is	   difficult	   to	   estimate.	   This	   question	   might	   be	   answered	   by	  evaluating	   kPhos2	   by	   fitting	   our	   model	   to	   experimental	   data	   (see	   below),	   thereby	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shedding	  light	  on	  how	  ART-­‐RET	  interactions	  are	  affected	  when	  transported	  from	  the	  cell	  surface	  to	  endosomes.	  The	  dephosphorylation	  rate	  of	  pRET	  in	  endosomes	  might	  also	  differ	  from	  that	  on	  the	  cell	  surface,	  due	  to	  different	  accessibility	  to	  cytoplasmic	  phosphatases.	   Experiments	   inhibiting	   RET	   phosphorylation	   after	   various	   times	   of	  ART	   stimulation	   (Figure	   4.5)	   showed	   no	   measurable	   changes	   in	   the	   lifetime	   of	  short-­‐lived	  pRET.	  However,	  a	  faster	  pRET	  decay	  in	  early	  endosomes,	  with	  t1/2	  <<	  1	  min,	  could	  not	  be	  accurately	  detected	  using	  our	  method,	  because	  the	  first	  collected	  data	   point	   is	   2	  min	   after	   inhibition.	   Therefore,	  kDephos2	   could	   be	   equal	   to	   or	   larger	  than	  kDephos	  (~0.7	  min-­‐1),	  but	  certainly	  is	  not	  significantly	  smaller.	  
A	   second	   assumption	   is	   that	   phosphorylated	   RET	   in	   early	   endosomes	   is	  targeted	   for	   transport	   to	   late	   endosomes/MVBs	   and	   ultimately	   to	   lysosomes	   for	  degradation,	   while	   unphosphorylated	   RET	   is	   targeted	   for	   recycling,	   as	   has	   been	  observed	   in	   other	   RTK	   systems.	   French	   at	   al289	   and	   Felder	   et	   al290	   reported	   that	  ligand-­‐bound	   kinase-­‐negative	   mutant	   EGFR	   was	   targeted	   to	   a	   greater	   extent	   for	  recycling	  than	  for	  lysosomal	  degradation,	  suggesting	  that	  this	  degradation	  pathway	  predominantly	  targets	  phosphorylated	  receptors.	  Therefore,	  to	  simplify	  our	  model,	  we	  assumed	  that	  kSort1	  recycles	  unphosphorylated	  RET	  only,	  and	  kSort2	  directs	  pRET	  to	   enter	  MVBs.	   Finally,	   the	   degradation	   rate	   constant	  kLysis	   represents	   a	   simplified	  single	  step	  for	  the	  ultimate	  degradation	  of	  long-­‐lived	  pRET,	  a	  process	  that	  in	  reality	  involves	   multiple	   steps	   including	   transportation	   of	   RET	   from	   MVBs	   to	   late	  endosomes	  and	  subsequent	  lysosomal	  proteolysis.	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A	   list	   of	   the	   different	   forms	   of	   RET	   that	   are	   located	   in	   the	   different	  intracellular	   subdomains	   in	   our	   model	   is	   provided	   in	   Table	   4.1,	   including	   the	  chemical	  equations	  and	  rate	  constants	   that	   involve	  each	   form	  of	  RET.	   It	   should	  be	  noted	   that	   the	   levels	   of	   total	   pRET	   that	   we	   measure	   experimentally	   include	   cell	  surface	   pRET	   (pRET),	   internalized	   pRET	   (ipRET)	   and	   long-­‐lived	   pRET	   (llpRET).	  Similarly,	  the	  RET	  molecules	  we	  measure	  on	  the	  cell	  surface,	  by	  flow	  cytometry	  after	  staining	  with	  an	  anti-­‐RET	  antibody,	  as	   for	  example	   in	  Figure	   4.2,	  may	   include	  cell	  surface	  unbound	  RET	  (RET),	  cell	  surface	  ART-­‐bound	  unphosphorylated	  RET	  (RET’),	  
Table	  4.1	  Status	  and	  cellular	  location	  of	  different	  forms	  of	  RET	  in	  the	  model.  Form	  of	  RET	   Cellular	  location	  and	  status	   Reactions	   Rate	  constant	  RET	   Cell	  surface,	  	  unbound,	  unphosphorylated	  	   ART	  +	  RET	  à	  RET’	  +	  ART	   k0	  
RET’	   Cell	  surface,	  	  ART-­‐bound,	  unphosphorylated	  
RET’	  à	  RET	   k-­‐0	  RET’	  à	  pRET	   kPhos	  RET’	  à	  iRET	   kInt2	  
pRET	   Cell	  surface,	  	  ART-­‐bound,	  phosphorylated	   pRET	  à	  RET’	   kDephos	  pRET	  à	  ipRET	   kInt	  
iRET	   Early	  endosome,	  unphosphorylated	   iRET	  à	  ipRET	   kPhos2	  iRET	  à	  sRET	   kSort1	  
ipRET	   Early	  endosome,	  phosphorylated	   ipRET	  à	  iRET	   kDephos2	  ipRET	  à	  llpRET	   kSort2	  sRET	   Recycling	  vesicle,	  unphosphorylated	   sRET	  à	  RET	   kRec1	  




and	   cell	   surface	   phosphorylated	   RET	   (pRET).	   The	   total	   number	   of	   RET	  molecules	  was	  set	  at	  6500	  per	  cell,	  as	  we	  have	  established	  previously126,	  and	  we	  assumed	  that	  all	  RET	  was	  present	  on	  the	  cell	  surface	  in	  an	  unbound	  and	  unphosphorylated	  state	  prior	  to	  ART	  stimulation.	  
To	  test	  our	  model,	  we	  first	  used	  DynaFit	  to	  globally	  fit	  the	  model	  (Appendix	  
IV)	   to	   the	   90-­‐min	   time-­‐course	   for	   RET	   phosphorylation,	   measured	   at	   various	  different	  ART	  concentrations	  (Figure	  2.9B),	   to	  obtain	   initial	  estimates	   for	  some	  of	  the	   parameters.	   Then	   we	   manually	   optimized	   these	   and	   other	   parameters	   by	  comparing	   the	  simulation	  with	   the	  experimental	  90	  min	   time-­‐course	  data	   for	   total	  pRET,	   surface	  RET,	   and	   long-­‐lived	  pRET	   (Figure	   4.14A),	  upon	  stimulation	  of	   cells	  with	   4	   nM	   ART.	   The	   scripts	   of	   the	   program	   used	   to	   simulate	   RET	   activation	   and	  trafficking	  kinetics	  are	  described	  in	  Experimental	  Methods	  and	  Appendix	  V.	  The	  value	   of	   kDephos	  was	   set	   equal	   to	   the	   experimental	   value	   for	   the	   rapid	   pRET	   decay	  constant	  of	  0.7	  min-­‐1,	  measured	  using	  the	  RET	  kinase	  inhibitor	  ZD6474	  as	  described	  in	  Chapter	   3,	   and	  was	  held	  constant	  during	   the	  optimization.	  As	  discussed	  above,	  
kDephos2	  was	   fixed	   to	  be	  ≥	  kDephos.	  We	  also	  set	  k0,	  k-­‐0	  and	  kPhos	  to	   the	  values	  obtained	  from	   the	   studies	   analyzing	   RET	   activation	   kinetics	   in	   the	   initial	   10	  min	   after	   ART	  stimulation,	  described	  in	  Chapter	  3.	  
The	   resulting	   model,	   with	   optimized	   rate	   constants,	   agreed	   will	   with	   the	  experimentally	  measured	  RET	  phosphorylation	  and	  trafficking	  dynamics.	  As	  shown	  in	  Figure	  4.14	  A	  and	  B,	  our	  model	  is	  consistent	  with	  the	  measured	  absolute	  levels	  
	  	  
137	  
and	   dynamics	   observed	   for	   all	   three	   detected	   species	   of	   RET	   after	   4	   nM	   ART	  stimulation,	  which	  are	  the	  three	  data	  sets	  that	  were	  used	  to	  train	  the	  model.	  	  
Importantly,	  the	  same	  model,	  using	  the	  same	  values	  for	  all	  rate	  constants	  and	  protein	   concentrations,	   also	   generated	   accurate	   predictions	   for	   the	   distribution	   of	  surface	  RET,	  total	  pRET	  and	  long-­‐lived	  pRET	  seen	  upon	  treatment	  of	  cells	  with	  1	  nM	  ART,	  different	  stimulation	  conditions	  from	  those	  that	  were	  used	  to	  train	  the	  model.	  
  
Figure 4.14 Experimental (A, C) and modeled (B, D) time-courses for changes in the level of 
cell surface RET (circles, blue lines), total cellular pRET (squares, red lines), and long-lived 
pRET (triangles, green lines) after cells were stimulated with ART at the stated 
concentrations. The solid lines in A and C are smoothed interpolations of the experimental 
data. The solid lines in B and D are simulated by the model shown in Figure 4.13, using the 
values for the rate constants given in Table 4.2.  
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As	  shown	  in	  Figure	  4.14	  C	  and	  D,	  the	  model	  accurately	  predicts	  that	  internalization	  is	  slower,	  total	  pRET	  peaks	  at	  a	  later	  time	  and	  a	  lower	  amplitude,	  and	  that	  less	  long-­‐lived	  pRET	  accumulates,	  under	  1	  nM	  ART	  stimulation	  conditions.	  	  
	   To	   further	   test	   the	   model’s	   accuracy	   in	   predicting	   the	   time-­‐dependent	  behavior	   of	   RET	   in	   different	   forms	   under	   various	   ART	   stimulation	   conditions,	  we	  compared	   the	   experimentally	   measured	   time-­‐courses	   for	   pRET	   activation,	   from	  
Chapters	  2	  and	  3,	  with	  modeled	  simulations	  (Figure	  4.15).	  The	  results	  show	  that	  our	  model	  accurately	  captured	   the	  dose-­‐dependent	   features	  of	  RET	  activation	  rate	  and	  amplitude	  (Figure	  4.15	  A	  and	  B),	  across	  a	  wide	  range	  of	  ART	  concentrations.	  The	   simulated	   90-­‐min	   time-­‐course	   for	   pRET	   activation	   also	   recapitulated	   the	  experimental	   observation	   that	   the	   time	   required	   for	   pRET	   amplitude	   to	   peak	   is	  inversely	  proportional	  to	  ART	  concentration	  (Figure	  4.15	  C	  and	  D).	  	  
We	   additionally	   compared	   the	   experimentally	   measured	   RET	   trafficking	  dynamics	   with	   modeled	   simulations	   (Figure	   4.16).	   The	   model	   accurately	  recapitulated	   the	   rate	   and	   extent	   of	   the	   decrease	   in	   cell	   surface	   RET,	   and	   the	  dependence	  of	  internalization	  rate	  on	  ART	  concentration	  (Figure	  4.16	  A	  and	  B).	  The	  simulated	  time-­‐course	  for	  the	  amount	  of	  RET	  present	  in	  early	  endosomes,	  showing	  that	   accumulation	   of	   RET	   in	   early	   endosomes	   starts	   from	   a	   basal	   level	   upon	   ART	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stimulation,	  peaks	  around	  20	  min,	  and	  decreases	  to	  a	   lower	   level	   in	  the	  remaining	  40	  min,	  is	  in	  reasonable	  agreement	  with	  the	  experimental	  co-­‐localization	  analysis	  of	  RET	  with	  early	  endosome	  marker	  EEA1.	  (Figure	  4.16	  C	  and	  D).	  In	  our	  model,	  only	  ART-­‐induced	  RET	  activation	  and	  trafficking	  are	  simulated,	  so	  that	  there	  is	  no	  RET	  in	  early	  endosomes	  prior	  to	  ART	  stimulation.	  In	  the	  experimental	  data,	  we	  noticed	  that	  there	   was	   basal	   level	   of	   co-­‐localization	   between	   RET	   and	   early	   endosomes	   in	  
  
Figure 4.15 Experimental and modeled time-courses for total cellular pRET levels stimulated 
with ART at the stated concentrations for 10 min or 90 min. The solid lines in A and C are 
smoothed interpolations of the experimental data. The solid lines in B and D are simulated by 
the model shown in Figure 4.13, using the values for the rate constants given in Table 4.2. 
Experimental data in A and C were previously described in Figure 2.9. 
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untreated	  cells.	  This	  background	  level	  of	  co-­‐localization	  could	  be	  due	  to	  nonspecific	  binding	   of	   the	   anti-­‐RET	   antibody	   to	   early	   endosomal	   proteins	   during	  immunostaining.	  Alternatively,	  there	  could	  be	  some	  RET	  present	  in	  early	  endosomes	  resulting	  from	  constitutive	  trafficking	  of	  RET	  independent	  of	  ART	  stimulation.	  	  
	  
  
Figure 4.16 Experimental and modeled time-courses for RET on the cell surface and in early 
endosomes. Levels of surface RET were experimentaly measured (A) in cells stimulated with 
ART at the stated concentrations or simulated (B) by our model. C. Experimental 
measurements of the co-localization of RET with the early endosome marker EEA1 after 
stimulation of cells with 4 nM ART. D. Modeled levels of RET present in early endosomes, as 
a function of time after stimulation with 4 nM ART. The solid lines in A and C are smoothed 
interpolations of the experimental data. The solid lines in B and D are simulated by the model 
shown in Figure 4.13, using the values for the rate constants given in Table 4.2. Experimental 
data in A and C were previously described in Figure 4.2 and Figure 4.4A. 
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Rate	  constants	  for	  all	  steps	  in	  the	  final	  model	  are	  listed	  in	  Table	  4.2.	  Since	  we	  optimized	  the	  model	  by	  manually	  changing	  the	  rate	  constants,	  based	  on	  the	  values	  initially	   determined	   by	   the	   global	   fit	   to	   the	   90-­‐min	   time-­‐course	   data	   from	   Figure	  
2.9B,	  we	  do	  not	  have	  formal	  error	   limits	   for	  the	  parameters.	   Instead,	  we	  manually	  tested	   and	   defined	   a	   range	   for	   each	   constant	   that	   represents	   the	  maximum	   range	  over	  which	   its	   value	   can	   be	   varied	  without	   substantially	  worsening	   the	   fit.	   These	  approximate	   ranges	   are	   listed	   in	   Table	   4.2.	   It	   should	   be	   noted	   that	   the	   allowed
	  
Table 4.2 Rate constants for the optimized model. “Final value” indicates the best fit value. 
“Range” indicates the acceptable value range for each rate constant, without substantially 
worsening the fit to the experimental time-course data for total pRET, surface RET, and long-




range	  for	  each	  constant	  was	  determined	  while	  the	  rest	  of	  parameters	  were	  held	  at	  the	  values	  given	  in	  Table	  4.2.	  This	  flexibility	  analyses	  of	  the	  rate	  constants	  showed	  that	  the	  internalization	  rate	  constant	  kInt2	  for	  ART-­‐bound	  unphosphorylated	  RET	  is,	  at	  most,	  half	  of	  that	  for	  pRET	  (kInt).	  The	  fact	  that	  setting	  kInt2	  =	  0	  did	  not	  measurably	  affect	  the	  goodness	  of	  fit	  suggests	  pRET	  is	  the	  main	  internalized	  species,	  rather	  then	  unphosphorylated	  RET.	  The	  value	  of	  kPhos2	  was	  defined	  only	  as	  a	   lower	   limit	  of	  0.5	  min-­‐1,	  and	  therefore	  could	  be	  higher	  than,	  equal	   to,	  or	  up	  to	  ~20	  times	   lower	  than	  
kPhos	  (9.2	  min-­‐1).	  Thus,	  the	  RET	  phosphorylation	  rate	  in	  the	  acidic	  early	  endosomes	  is	  not	  necessarily	   slower	   than	  on	   the	   cell	   surface,	   as	  has	  been	   reported	   for	   the	  EGF-­‐EGFR	   system.285	   The	   upper	   limit	   of	   ≤1	   min-­‐1	   for	   kDephos2	   is	   similar	   to	   the	   directly	  determined	   value	   for	   kDephos,	   showing	   that	   the	  model	   allows	   the	   short-­‐lived	   pRET	  dephosphorylation	   rate	   to	   be	   similar	   regardless	   of	   its	   cellular	   location.	   Lastly,	   the	  small	  value	  of	  the	  rate	  constant	  for	  degradation	  of	  long-­‐lived	  pRET,	  kLysis,	  compared	  to	  recycling	  steps,	  indicates	  that	  internalized	  RET	  mainly	  partitions	  to	  recycle	  back	  to	   the	   cell	   surface,	   with	   only	   a	   small	   fraction	   partitioning	   into	   the	   lysosomal	  degradation	  pathway.	  Thus,	  down-­‐regulation	  of	  RET	  activation	  is	  mainly	  due	  to	  the	  trafficking	   of	   pRET	   to	   MVBs,	   where	   it	   cannot	   signal,	   and	   by	   storing	  unphosphorylated	  free	  RET	  in	  recycling	  vesicle	  where	  it	  does	  not	  have	  access	  to	  ART	  to	   become	   re-­‐activated.	   Although,	   to	   our	   knowledge,	   no	   such	   integrated	   and	  experimentally	   validated	   model	   of	   RTK	   activation	   and	   trafficking	   that	   has	  considered	  location-­‐specific	  signaling	  capacity	  of	  RTK	  has	  previously	  been	  reported	  for	   RET	   or	   for	   any	   other	   system,	   the	   rate	   constants	   for	   RET	   internalization	   and	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degradation	  from	  our	  model	  were	  comparable	  to	  those	  reported	  by	  others	  for	  EGFR	  endocytosis.249,253	  For	  example,	  Starbuck	  et	  al.	  reported	  that	  the	  that	  EGFR	  recycling	  rate	  constant	  as	  0.058	  min-­‐1	  and	  lysosomal	  degradation	  rate	  constant	  as	  0.022	  min-­‐1	  when	   B82	   fibroblast	   cells	   were	   stimulated	   by	   EGF,	   which	   compare	   well	   with	   the	  respective	  values	  for	  these	  two	  processes	  of	  0.02	  min-­‐1	  and	  0.03	  min-­‐1,	  reported	  in	  
Table	  4.2.249	  It	  should	  be	  noted	  that,	  in	  our	  model,	  we	  assumed	  RET	  is	  the	  limiting	  reagent.	   The	   concentration	   changes	   of	   all	   the	   RET	   species	   in	   our	   model	   are	  described	   by	   first	   order	   reactions,	   and	   therefore	   are	   insensitive	   to	   the	   initial	   RET	  concentrations.	   However,	   in	   reality,	   the	   initial	   steps	   in	   RET	   activation	   could	   be	  sensitive	  to	  RET	  expression	  levels	  on	  the	  cell	  surface,	  which	  have	  not	  been	  explored	  yet.	  
The	  flexibility	  analysis	  of	  all	  parameters	  in	  the	  model	  (Table	  4.2)	  has	  shown	  that	  not	  all	   features	  in	  this	  model	  share	  the	  same	  robustness.	  The	  fact	  that	  several	  parameters	   can	  be	  defined	  only	   as	   an	  upper	   limit,	   and	   can	  be	   set	   to	   zero	  without	  significantly	  weakening	   the	  model,	   suggests	   that	   the	  processes	  presented	  by	   these	  parameters	   are	  not	   robust	   features	   of	   the	  model	   and	   can	  be	  omitted.	  These	   steps	  include	  internalized	  of	  occupied	  but	  unphosphorylated	  RET,	  rapid	  recycling	  of	  RET	  from	   early	   endosomes,	   dephosphorylation	   of	   pRET	   in	   early	   endosomes,	   and	  lysosomal	   degradation	   of	   pRET.	   Although	   omitting	   these	   steps	   will	   not	  mathematically	  weaken	  our	  model,	   literatures	  on	  receptor	  endocytosis	  suggest	  the	  existence	  of	   these	  processes.	  All	   the	  other	  steps	  are	  robust	   features	  of	  our	  system,	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because	  setting	  the	  parameters	  for	  those	  steps	  to	  be	  zero	  significantly	  changes	  the	  model.	  The	  flexibility	  analysis	  also	  shows	  that	  rapid	  RET	  internalization	  is	  required	  to	  account	   for	  the	  rapid	  decrease	   in	  surface	  RET	  levels	  stimulated	  by	  ART	  that	  we	  measured	  by	  FACS.	  Setting	  the	  recycling	  rate	  of	  internalized	  RET	  in	  the	  appropriate	  range	   ensures	   the	   right	   amplitudes	   of	   pRET	   at	   later	   stimulation	   times,	  when	  RET	  internalization	  is	  fast.	  The	  sorting	  rate	  of	  pRET	  from	  early	  endosomes	  to	  MVBs	  must	  be	   in	   a	   range	   to	   account	   for	   the	   observed	   slow	   accumulation	   of	   long-­‐lived	   pRET.	  These	  processes	  are	  therefore	  the	  most	  robust	  features	  of	  our	  model.	  	  
4.4.2. Roles	  of	  Trafficking	  in	  RET	  Signaling	  Revealed	  by	  the	  Model	  
	  The	   above	   results	   represent,	   to	   our	   knowledge,	   the	   first	   time	   that	   a	  phosphorylated	  but	  signaling-­‐incapable	  form	  of	  RTK,	  resulting	  from	  ligand-­‐induced	  internalization	   and	   trafficking,	   has	   been	   identified	   and	   characterized.	   We	   have	  shown	  that	  activated	  RET	  can	  be	  internalized	  and	  transported	  into	  MVBs,	  where	  it	  loses	  its	  capacity	  to	  activate	  ERK	  and	  Akt	  signaling,	  while	  maintaining	  the	  same	  set	  of	  phosphorylation	  sites	  present	  on	  signaling-­‐competent	  pRET.	  The	  observation	  of	  signaling-­‐incompetent	   pRET	   suggests	   that	   phospho-­‐RTK	   signaling	   can	   be	  terminated	  before	  receptor	  dephosphorylation.	  
We	  showed	  in	  Chapter	  2	  that	  stimulation	  of	  cells	  at	  artificially	  high	  levels	  of	  growth	   factor	   could	  mislead	   about	   the	   timing	   and	   extent	   of	   intracellular	   signaling	  processes.	   We	   therefore	   considered	   the	   possibility	   that	   the	   relatively	   high	  
	  	  
145	  
concentrations	   of	   ART	   used	   in	   our	   experiments,	   relative	   to	   the	   10-­‐100	   pM	  concentrations	  required	  for	  a	  functional	  cellular	  response	  (described	  in	  Chapter	  2),	  could	  have	   initiated	  some	  unnatural	  endocytic	  mechanisms	   leading	  to	  the	  artificial	  trafficking	   of	   pRET	   to	   MVBs.	   As	   we	   discussed	   in	   Chapter	   2,	   making	   quantitative	  signaling	  measurements	  at	   low,	   functionally	  relevant	  concentrations	  of	  stimulating	  growth	   factor	   is	   very	   challenging.	   To	   investigate	   how	   trafficking	   regulates	   RET	  signaling	  at	  biologically	  relevant	  stimulation	  conditions	  we	  therefore	  used	  the	  model	  established	   above	   to	   simulate	   the	   dynamics	   of	   different	   RET	   species	   at	   low	   ART	  concentrations.	  Shown	  in	  Figure	  4.17A,	  the	  simulated	  time-­‐course	  for	  the	  evolution	  of	  long-­‐lived	  pRET	  upon	  stimulated	  by	  ART	  shows	  that	  the	  both	  initial	  accumulation	  rate	   of	   llpRET	   and	   its	   peak	   amplitude	   are	   dose-­‐dependent.	   We	   calculated	   what	  fraction	  of	  pRET	  is	  in	  the	  long-­‐lived	  form,	  as	  a	  function	  of	  time	  after	  stimulation,	  to	  see	  to	  what	  extent	  RET	  signaling	  is	  down-­‐regulated	  through	  formation	  of	  long-­‐lived	  pRET.	   Surprisingly,	   as	   shown	   in	  Figure	   4.17B,	   the	  model	   predicts	   that	   long-­‐lived	  
  
Figure 4.17 Simulated time-courses for long-lived pRET (llpRET) (A) and its fraction among 
total pRET (pRET) (B). Stimulation condition with ART at stated concentrations were 




pRET	  accumulates	  over	   the	   first	  ~30	  min	  after	  ART	  stimulation,	  and	  then	  remains	  constant	  at	  ~30%	  of	  total	  pRET,	  at	  all	  tested	  ART	  concentrations	  over	  the	  range	  of	  0.1	   –	   10	   nM.	   The	   similarity	   in	   the	   distribution	   between	   signaling-­‐capable	   and	  signaling–incapable	   pRET	   across	   this	  wide	   ART	   concentration	   range	   shows	   that	   a	  significant	   fraction	   of	   pRET	   converts	   to	   the	   long-­‐lived	   form	  even	   at	   very	   low	  ART	  stimulus	   levels.	   This	   finding	   suggests	   that	   formation	   of	   long-­‐lived	   pRET	   is	   not	   an	  artifact	   induced	   by	   artificially	   high	   ligand	   concentrations,	   but	   is	   an	   intrinsic	  mechanism	   by	   which	   RET	   signaling	   levels	   are	   down-­‐regulated	   by	   ligand-­‐induced	  internalization.	  Overall,	  we	  can	  say	  that,	  since	  phosphorylated	  RTK	  can	  be	  stored	  in	  MVBs	  and	  thus	  lose	  its	  signaling	  capacity,	  total	  cellular	  RTK	  phosphorylation	  levels	  do	   not	   necessarily	   reflect	   the	   signaling	   levels	   of	   RTK.	   In	   our	   case,	   pRET	   signaling	  levels	   are	  only	  ~70%	  of	   cellular	  pRET	   levels	   after	  30	  min	  of	  ART	  stimulation	   in	   a	  wide	  concentration	  range.	  
	   In	  Chapter	  2	  we	  showed	  that	  ART	  stimulated	  RET	  activation	  led	  to	  transient	  ERK	  activation	  at	  ~10	  min,	  followed	  by	  sustained	  pERK	  levels.	  To	  examine	  whether	  receptor	   internalization	   plays	   a	   role	   in	   transient	   ERK	   activation	   at	   biologically	  relevant	   concentration	   of	   ART	   (10–100	   pM),	  we	   simulated	   time-­‐courses	   for	   pRET	  levels	  on	  the	  cell	  surface	  and	  in	  early	  endosomes	  after	  stimulation	  of	  cells	  with	  0.1	  nM	  ART.	  Shown	  in	  Figure	  4.18,	  under	  these	  stimulation	  conditions,	  at	  10	  min	  after	  ART	   treatment	   most	   pRET	   is	   present	   on	   the	   cell	   surface,	   suggesting	   that	  internalization	   is	   not	   important	   for	   the	   transient	   activation	   of	   ERK.	   This	   result	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supports	  of	  our	  previous	  observation	  that	  inhibiting	  RET	  internalization	  by	  MDC	  did	  not	   affect	   ART-­‐induced	   ERK	   phosphorylation.	   It	   is	   also	   noteworthy	   that	   the	  simulated	  pRET	  time-­‐course	  for	  0.1	  nM	  ART	  shows	  fast	  RET	  phosphorylation	  in	  the	  initial	  20–30	  min	  which	  then	  remains	  at	  the	  same	  amplitude	  for	  another	  60	  min.	  Due	  to	   low	   sensitivity	   of	   our	   ELISA	   for	   such	   low	   stimulation	   condition,	   the	  experimentally	  measured	  pRET	  time-­‐course	  with	  0.1	  nM	  ART	  appears	  roughly	  linear	  (Figure	  4.15C).	  The	  fast	  activation	  of	  RET	  to	  reach	  its	  maximal	  stable	  amplitude	  in	  the	   initial	   30	  min	   suggests	   this	   period	   of	   time	  might	   be	   critical	   for	  RET	   signaling,	  which	  was	   not	   revealed	   using	   conventional	   biochemical	   assays.	   This	   result,	   again,	  shows	  the	  advantage	  of	  computational	  methods	  in	  revealing	  detailed	  RTK	  signaling	  dynamics	   at	   low,	   functional	   stimulation	   conditions	   that	   are	   difficult	   to	   directly	  measure.	  These	  prediction	  of	  RET	  signaling	  and	   trafficking	  dynamics	  generated	  by	  
  
Figure 4.18 Simulation of RET activation and trafficking dynamics at a biologically relevant 
ART concentration. Simulated time-courses for total pRET (red), surface pRET (blue), pRET 




the	  model	   can	   be	   tested	   experimentally.	   Our	   current	   ELISA	   assay	   is	   not	   sensitive	  enough	   to	   detect	   dynamics	   changes	   of	   RET,	   ERK	   or	   Akt	   phosphorylation	   levels	  stimulated	  by	   low	  concentrations	  of	  ART	  (e.g.	  ~	  0.1	  nM).	  By	  concentrating	  the	  cell	  lysate	   using	   spin	   columns	   with	   concentrators	   before	   loading	   to	   ELISA	   plates,	   the	  assay	  should	  be	  possible	   to	  accurately	  detect	   the	  activation	  dynamics	  of	  pRET,	   the	  formation	  of	  long-­‐lived	  pRET,	  and	  the	  activation	  levels	  of	  downstream	  effector	  (e.g.	  ERK	  or	  Akt)	  upon	  stimulation	  of	  the	  cells	  with	  low	  ART.	  Alternatively,	  we	  could	  use	  a	  higher	  number	   of	   cells	   in	   each	   treatment	   and	   lyse	   them	  with	   a	   smaller	   volume	  of	  lysis	  buffer	  to	  obtain	  a	  more	  concentrated	  cell	  lysate.	  
Computational	   models	   have	   been	   developed	   to	   investigate	   the	   trafficking	  dynamics	   of	   RTK	   and	   how	  RTK	   trafficking	   affects	   the	   activation	   dynamics	   of	   RTK	  and	  its	  downstream	  molecules,	  especially	  for	  the	  case	  of	  EGFR.	  229,249,253,291,292	  Those	  models	   mainly	   focused	   on	   illustrating	   the	   kinetics	   in	   RTK	   trafficking,	   or	   RTK	  activation	  dynamics	  affected	  by	  trafficking	  (e.g.,	  different	  activation	  kinetics	  for	  cell	  surface	   receptor	  vs.	   internalized	  receptor),	   and	  did	  not	  consider	   the	  differences	   in	  signaling	   capacity	   of	   those	   activated	  RTKs	   in	  different	   cellular	   compartments.	  Our	  results	   show	   that	   the	   activated	   RET	   trapped	   in	   MVBs	   exhibits	   distinct	   signaling	  capacity	   compared	   with	   activated	   RET	   present	   on	   the	   cell	   surface	   or	   in	   early	  endosomes.	   On	   the	   basis	   of	   these	   location-­‐specific	   signaling	   features	   of	   activated	  RET,	  our	  model	  was	  able	  to	  reveal	  both	  trafficking	  and	  signaling	  dynamics	  of	  RET	  at	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any	   given	   stimulation	   conditions,	   providing	   valuable	   information	   about	   signal	  transduction	  from	  RET	  to	  downstream	  events.	  
	  
4.5. Conclusions	  
The	  goals	  of	  the	  work	  described	  in	  this	  chapter	  were	  to	  elucidate	  how	  ligand-­‐induced	   endocytosis	   regulates	   RET	   signaling	   upon	   ART	   stimulation,	   and	   then	   to	  obtain	  a	  quantitative	  understanding	  of	  RET	  distribution	  kinetics	  due	  to	  intracellular	  trafficking.	   In	   so	   doing,	   we	   identified	   and	   characterized	   a	   long-­‐lived,	   signaling-­‐incompetent	  form	  of	  phosphorylated	  RET	  that	  accumulates	  in	  MVBs.	  By	  combining	  biochemical	  experimentation	  with	  computational	  tools,	  we	  built	  a	  model	  that	  could	  accurately	  account	  for	  the	  amounts	  and	  dynamic	  changes	  measured	  experimentally	  for	  multiple	  different	  RET	  species	  including	  surface	  RET,	  total	  pRET,	  and	  long-­‐lived	  pRET,	  over	  a	  wide	   range	  of	  ART	  stimulation	  conditions.	  From	   the	   fitted	  model	  we	  were	  able	  to	  estimate	  values	  of	  rate	  constants	  for	  key	  activation	  and	  trafficking	  steps	  that	  are	  difficult	  to	  directly	  measure	  without	  perturbing	  the	  native	  cellular	  context.	  The	   resulting	   integral	  model	   of	   RET	   activation	   and	   trafficking	   helped	   to	   elucidate	  and	   quantify	   the	   regulatory	   roles	   of	   RET	   internalization	   and	   trafficking	   in	   RET	  signaling,	   by	   providing	   information	   on	   the	   activation	   dynamics	   and	   signaling	  capacity	  of	  RET	  in	  different	  cellular	  locations.	  This	  model	  enabled	  us	  to	  quantify	  the	  amount	   of	   signaling-­‐competent	   RET,	   and	   to	   analyze	   RET	   signaling	   dynamics	   at	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biologically	   relevant	   ART	   concentrations	   at	  which	   signaling	   processes	   are	   hard	   to	  measure	   directly.	   The	   model	   shows	   that,	   at	   low,	   biologically	   relevant	   ART	  concentrations,	  most	  signaling-­‐competent	  pRET	  is	  located	  on	  the	  cell	  surface	  during	  the	   time	   when	   transient	   ERK	   activation	   occurs,	   suggesting	   that	   receptor	  internalization	  is	  not	  important	  for	  the	  transient	  activation	  of	  ERK.	  The	  existence	  of	  long-­‐lived	  pRET	  at	   low	  ART	  concentrations,	  shown	  by	  the	  model,	  suggests	  that	  the	  mechanism	  of	  deactivating	  phosphorylated	  RET	  via	  transportation	  into	  MVBs	  is	  an	  intrinsic	  mechanism	  in	  RET	  signaling	  in	  NB41A3-­‐mGFRα3	  cells,	  and	  is	  not	  merely	  an	  artifact	   caused	   by	   stimulating	   the	   cells	   with	   artificially	   high	   ART	   concentrations.	  Although	  it	  remains	  to	  be	  investigated	  whether	  such	  a	  mechanism	  operates	  in	  other	  RTK	   systems,	   the	   fact	   that	   pRET	   signaling	   can	   be	   terminated	   without	  dephosphorylation	   suggests	   RTK	   phosphorylation	   levels	   might	   not	   always	   be	   the	  best	  measure	  of	  RTK	  signaling	  levels.	  	  RET	  activation	  and	  trafficking	  dynamics	  with	  low	  ART	  predicted	  by	  our	  model	  can	  be	  tested	  by	  the	  same	  ELISA	  assays	  using	  more	  concentrated	   cell	   lysates,	   which	   can	   be	   achieved	   by	   concentrating	   the	   sample	   in	  protein	  concentrators,	  or	  using	  more	  cells	  in	  a	  smaller	  lysing	  volume.	  
Due	  to	  lack	  of	  RET	  isoform-­‐specific	  antibodies,	  we	  are	  not	  able	  to	  quantify	  the	  activation	   and	   trafficking	   kinetics	   of	   RET9	   and	   RET51	   in	   our	   system.	   It	   has	   been	  reported	  by	  others	  that	  both	  RET9	  and	  RET51	  are	  rapidly	  internalized	  via	  clathrin-­‐coated	  pits	  (CCPs)	  in	  HeLa	  cells	  stimulated	  with	  GDNF.	  The	  same	  study	  also	  showed	  that	  recruitment	  of	  RET51	  to	  CCPs	  was	  much	  more	  rapid	  and	  extensive	  compared	  to	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RET9.	   Cells	   with	   different	   expression	   ratios	   of	   these	   two	   isoforms	   can	   exhibit	  different	  signaling	  profiles	  downstream	  of	  Tyr1096,	  which	  only	  exists	  in	  RET51	  but	  not	   in	   RET9.	   Tyr1096	   can	   interact	  with	   the	   SH2	   containing	   proteins	   GRB2,	   GRB7,	  GRB10,	   and	   PLCγ,	   and	   activate	   pathways	   including	   ERK,	   Akt	   and	   PLCγ.43,44	   If	  activated	   RET	   has	   better	   signaling	   efficiency	   in	   endosomes	   or	   longer	   signaling	  lifetime,	  faster	  internalization	  of	  RET51	  then	  RET9	  will	  enhance	  Tyr1096-­‐associated	  pathways	  in	  the	  cells	  with	  higher	  expression	  level	  of	  RET51.	  
Due	  to	  limitation	  of	  commercially	  available	  antibodies	  for	  RET	  isoforms	  and	  different	  phospho-­‐Tyr	  residues	   in	  RET,	   it	   is	  difficult	   to	  quantify	   the	  activation	  and	  trafficking	   kinetics	   and	   related	   phosphorylation	   patterns	   of	   different	   isoforms	   of	  RET.	   Expressing	   a	   tagged	   version	   of	   RET	   can	   allow	   detection	   of	   RET	   trafficking	  patterns	  via	  recognition	  of	  the	  tag.	  For	  instance,	  we	  can	  express	  Myc-­‐tagged	  RET9	  in	  our	  cells	  line	  and	  detect	  accumulation	  kinetics	  and	  phosphorylation	  profiles	  of	  Myc-­‐RET9	  in	  different	  cellular	  organelles	  isolated	  by	  cellular	  fragmentation.	  In	  this	  way,	  we	  can	  compare	  the	  trafficking	  kinetics	  of	  RET9	  to	  all	  RET	  detected	  as	  a	  mixture	  and	  see	  whether	  RET	  isoforms	  are	  transported	  differently.	  Alternatively,	  we	  could	  insert	  a	  fluorescent	  tag	  into	  RET	  using	  CRISPR	  to	  visualize	  the	  trafficking	  routes	  of	  RET	  in	  its	   endogenous	   environment	   at	   the	   single	   cell	   level.	   Meanwhile,	   the	   location	   of	  phosphorylated	   RET	   among	   all	   RET	   in	   different	   cellular	   organelles	   can	   also	   be	  visualized	   by	   using	   a	   fluorescence-­‐labeled	   anti-­‐phospho	   tyrosine	   antibody	   to	  generate	  a	  FRET	  signal	  paired	  with	  the	  inserted	  fluorophores	  in	  RET.	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4.6. Experimental	  Methods	  
Materials	  
All	   salts,	   Triton	   X-­‐100,	   paraformaldehyde	   (PFA),	   bovine	   fetal	   serum	   (FBS),	  glycerol,	   Dulbecco’s	   PBS	   were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	   MO)	   or	  Thermo	   Fisher	   (Waltham,	   MA).	   RET	   inhibitor	   Vandetanib	   (ZD6474)	   (catalog	   no.	  S1046)	  was	   purchased	   from	   Selleck	   Chemicals	   (Houston,	   TX).	   The	   internalization	  inhibitors	  monensin	   (catalog	   no.	   475895)	   and	  monodansylcadaverine	   (catalog	   no.	  30432)	   were	   purchased	   from	   EMD	   Millopore	   (Billerica,	   MA)	   and	   Sigma-­‐Aldrich,	  respectively.	  For	  pY1062-­‐RET	  ELISA,	  rabbit	  polyclonal	  antibody	  anti-­‐RET	  (phospho	  Y1062)	   (catalog	  no.	   ab123544)	   and	  HRP-­‐conjugated	   goat	   anti-­‐rabbit	   IgG	   antibody	  (catalog	   no.	   6721)	   were	   purchased	   from	   Abcam	   (Cambridge,	   MA).	   For	  immunofluorescence	  microscopy,	  rabbit	  anti-­‐C-­‐terminus	  RET	  antibody	  (catalog	  no.	  ab134100)	   was	   purchased	   from	   Abcam.	   Goat	   anti-­‐EEA1	   antibody	   (catalog	   no.	  sc6414)	  was	  obtained	  from	  Santa	  Cruz	  Biotechnology	  (Santa	  Cruz,	  CA).	  Donkey	  anti-­‐rabbit	   IgG	  antibody	  with	  Alexa	  Fluor	  488	   (catalog	  no.	  A-­‐21206),	   and	  donkey	  anti-­‐goat	  IgG	  antibody	  with	  Alexa	  Fluor	  647	  (catalog	  no.	  A-­‐21447)	  were	  purchased	  from	  Life	   Technologies	   (Carlsbad,	   CA).	   The	   round	   glass	   cover	   slips	   (catalog	   no.	   89167-­‐106)	   and	   superfrost	   micro	   slides	   (catalog	   no.	   48311-­‐600)	   were	   purchased	   from	  VMR	  (Radnor,	  PA).	  For	  flow	  cytometry,	  hamster	  anti-­‐rat	  RET	  antibody	  AA.GE7.3148	  as	  the	  primary	  antibody	  was	  generous	  gifts	  from	  Biogen	  Idec	  (Cambridge,	  MA).	  Goat	  anti-­‐Armenian	   hamster	   IgG-­‐PE	   (catalog	   no.	   sc-­‐3733)	   as	   the	   secondary	   detection	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antibody	   was	   purchase	   from	   Santa	   Cruz	   Biotechnology.	   Other	   cell	   lines	   and	  materials	  used,	  were	  exactly	  as	  described	  in	  Chapter	  2.	  
pY1062-­‐RET	  ELISA	  
To	  detect	  the	  decay	  time-­‐course	  of	  pY1062	  upon	  inhibiting	  RET,	  the	  NB41A3-­‐mGFRα3cells	  were	   stimulated	  with	   4	   nM	  ART	   for	   30	  min	   followed	   by	   addition	   of	  ZD6474	   (50	   μM)	  with	   continued	  presence	   of	   ART.	   Levels	   of	   pY1062	   in	   cell	   lysate	  were	  measured	  by	  pY1062	  ELISA,	  similar	  to	  KIRA	  ELISA	  for	  pRET,	  using	  rabbit	  anti-­‐RET	  (phospho	  Y1062)	  antibody	  as	   the	  primary	  detection	  antibody.	  The	  same	   lysis	  buffer,	   ELISA	   assay	   buffers	   and	   assay	   procotol	   as	   for	   KIRA	   ELISA	   were	   used	   for	  pY1062	  ELISA,	  as	  described	  in	  Chapter	  2.	  The	  ELISA	  plate	  loaded	  with	  samples	  was	  first	   incubated	  with	   the	  primary	  detection	  antibody,	   anti-­‐pY1062	  RET	   (1:2000)	   in	  blocking	   buffer	   for	   1	   h	   while	   shaking.	   The	   plate	   is	   then	   washed	   with	   PBST	   and	  incubated	   with	   the	   secondary	   detection	   antibody,	   goat	   anti-­‐rabbit	   IgG	   antibody	  (1:2000)	   in	   blocking	   buffer	   for	   0.5	   h	   before	   washing	   and	   reacting	   with	   HRP	  substrates.	  	  
Inhibition	  of	  RET	  internalization	  
Stock	   solutions	   of	   the	   internalization	   inhibitors	   monensin	   and	  monodansylcadaverine	   (MDC)	   were	   prepared	   by	   dissolving	   each	   compound	   in	  DMSO.	  DMSO	  stocks	  were	  diluted	  into	  DMEM	  with	  L-­‐glutamine	  (DMSO	  v/v	  <	  0.1%)	  for	  treatment.	  The	  NB41A3-­‐mGFRα3	  cells	  were	  incubated	  with	  10	  μM	  monensin	  or	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100	   μM	   MDC	   for	   30	   min	   before	   the	   medium	   were	   switched	   to	   ART	   in	   stated	  concentration	  with	  10	  μM	  monensin	  or	  100	  μM	  MDC.	  
Flow	  Cytometry	  
NB41A3-­‐mGFRα3	   cells	   were	   seeded	   overnight	   in	   24-­‐well	   plates	   (Corning,	  Corning,	   NY)	   at	   a	   concentration	   of	   6	   ×	   105	   cells/mL	   in	   0.5	  mL	   growth	  media.	   To	  initiate	   ligand-­‐induced	   internalization,	   cells	  were	  stimulated	  with	  various	  doses	  of	  ART	   in	   a	   humidified	   chamber	   at	   37	   °C.	   After	   incubation	  with	  ART	   for	   the	   desired	  time,	   the	  cells	  were	  washed	  with	   ice-­‐cold	  PBS,	  and	  harvested	  with	  300	  μL	  ice-­‐cold	  FACS	   labeling	   buffer	   (2%	   FBS,	   0.2%	   sodium	   azide	   in	   PBS).	   The	   cell	   pallets	   were	  collected	  by	  centrifugation	  and	  incubated	  with	  100	  μL	  of	  5	  μg/mL	  hamster	  anti-­‐rat	  RET	  antibody	  AA.GE7.3	  in	  FACS	  labeling	  buffer	  for	  1	  h	  on	  ice.	  The	  cells	  were	  washed	  with	  500	  μL	  FACS	  labeling	  buffer,	  followed	  by	  incubation	  with	  100	  μL	  of	  1.6	  μg/mL	  goat	  anti-­‐Armenian	  hamster	  IgG-­‐PE	  in	  the	  FACS	  labeling	  buffer	  for	  30	  min	  on	  ice	  in	  the	   dark.	   After	  washing	   twice,	   the	   cells	  were	   suspended	   in	   200	   μL	   FACS	   labeling	  buffer	   for	   detection.	   The	   flow	   cytometry	   experiments	   were	   performed	   on	   a	  FACSCalibur	  (BD	  Biosciences,	  San	  Jose,	  CA).	  The	  flow	  cytometry	  data	  were	  analyzed	  using	  FlowJo	  (FlowJo,	  Ashland,	  OR)	  
Immunofluorescence	  Microscopy	  
NB41A3-­‐mGFRα3	  cells	  were	  seeded	  overnight	  on	  12	  mm	  glass	  coverslips	  in	  12-­‐well	   tissue	  culture	  plate	  at	  a	  concentration	  of	  2	  ×	  105	  cells/mL	  in	  1	  mL	  growth	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media.	  After	  2	  h	  starvation	  in	  DMEM,	  the	  cells	  were	  treated	  with	  given	  stimulation	  conditions,	  rinsed	  with	  ice-­‐cold	  PBS,	  and	  fixed	  with	  4%	  paraformaldehyde	  in	  PBS	  at	  room	  temperature	  for	  1	  h.	  After	  10	  min	  of	  permeablization	  with	  0.1%	  Triton	  X-­‐100	  in	  PBS	  (PBST),	   the	   fixed	  cells	  were	  blocked	  with	  3%	  FBS	   in	  PBS	  at	  4	  °C	  overnight.	  After	  blocking,	  the	  cells	  were	  stained	  for	  RET	  and	  for	  early	  endosomes	  by	  incubation	  with	   100	   μL	   of	   anti-­‐C-­‐terminus	   RET	   antibody	   (1:25,000)	   and	   anti-­‐EEA1	   antibody	  (1:500)	  in	  blocking	  buffer	  on	  each	  coverslip	  for	  1	  h	  at	  room	  temperature,	  followed	  by	  5	  min	  of	  washing	  with	  PBST	  for	  three	  times.	  The	  cells	  were	  blocked	  again	  for	  1	  h,	  followed	   by	   incubation	   with	   100	   μL	   of	   donkey	   anti-­‐rabbit	   IgG	   with	   Alexa	   488	  (1:250)	  and	  donkey	  anti-­‐goat	   IgG	  with	  Alexa	  647	   (1:250)	   for	  1	  h.	  After	  washing	  3	  times	  each	  with	  PBST	  and	  then	  PBS,	  the	  coverslips	  were	  mounted	  with	  50%	  glycerol	  in	   PBS	   and	   sealed	   with	   clear	   nail	   polish.	   The	   images	   were	   captured	   using	   an	  Olympus	   FV1000	   scanning	   confocal	   microscope	   (Olympus	   America	   Inc.,	   Center	  Valley	   PA),	   or	   a	   Nikon	   TE2000U	   inverted	   microscope	   (Nikon	   Instruments	   Inc.,	  Melville,	  NY).	  Raw	  fluorescence	  images	  were	  processed	  and	  analyzed	  using	  ImageJ	  (National	  Institute	  of	  Health,	  Bethesda,	  MD).258,259	  
Method	  for	  fitting	  
Experimental	  data	  of	  RET	  activation	  at	  0-­‐90	  min	  after	  ART	  stimulation	  was	  fit	   to	   the	  model	   based	  on	   the	   chemical	   reactions	   in	  Table	   4.1,  using	   the	  program	  DynaFit	   (BioKin	   Ltd.,	   Watertown,	   MA).	   The	   scripts	   of	   the	   model	   encoding	   the	  chemical	   reactions	   used	   for	   fitting	   in	   Dynafit	   are	   described	   as	   below	   (also	   see	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Appendix	  IV),	  where	  k	  represents	  the	  rate	  constant	  for	  each	  step.	  The	  value	  of	  k0,	  k-­‐
0,	  kPhos,	  and	  kDephos	  was	  set	  at	  4.6	  ×	  107	  M-­‐1	  min-­‐1,	  3.7	  min-­‐1,	  1.9	  min-­‐1	  and	  0.7	  min-­‐1,	  respectively,	   as	   established	   in	  Chapter	   3.	   Initial	   concentration	   of	   RET	  was	   set	   at	  6500	  per	  cell,	  and	  the	  initial	  concentrations	  for	  RET’	  and	  pRET	  were	  set	  at	  zero.	  	  
RET	  +	  ART	  à	  RET'	  +	  ART	   	   k0	  	   RET'	  à	  RET	   	   	   	   k-­‐0	  	   RET'	  à	  pRET	   	   	   	   kPhos	  	   pRET	  à	  RET’	  	  	   	   	   kDephos	  pRET	  à	  ipRET	   	   	   kInt	  	   RET’	  à	  iRET	   	   	   	   kInt2	  
	   iRET’	  à	  ipRET	   	   	   kPhos2	  	   ipRET	  à	  iRET	  	   	   	   kDephos2	  	   iRET	  à	  sRET	  	  	   	   	   kSort1	  ipRET	  à	  llpRET	   	   	   kSort2	  	   sRET	  à	  RET	  	   	   	   	   kRec1	  	   llpRET	  à	  sRET	  	   	   	   kSort2	  	   llpRET	  à	  lysRET	  	   	   	   kLys	  The	  model	  comprising	  the	  same	  set	  of	  reactions	  with	  rate	  constants	  obtained	  from	   the	   best	   fit	   was	  written	   in	   the	   Python	   language	   and	   ran	   on	   the	   platform	   of	  Spyder	   (Massachusetts	   Institute	   of	   Technology,	   Cambridge,	  MA)	   to	   simulate	   time-­‐courses	  for	  different	  forms	  of	  RET	  under	  various	  ART	  stimulations	  (Appendix	  V).	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Chapter	  5. Lifetimes	  of	  Key	  Signaling	  Proteins	  in	  the	  ERK	  and	  Akt	  Signaling	  
Pathways	  
5.1. Key	  Questions	  in	  Understanding	  the	  Kinetics	  of	  Ras/Raf/MEK/ERK	  and	  
PI3K/Akt	  Signaling	  Stimulated	  by	  ART	  
Ras/Raf/MEK/ERK	  and	  PI3K/Akt	  are	  two	  essential	  pathways	  downstream	  of	  RET	   for	   regulating	   cell	   proliferation,	   differentiation	   and	   apoptosis,	   as	   discussed	  earlier.	  Cell	  signaling	  is	  a	  dynamic	  process,	  and	  therefore	  temporal	  aspects	  of	  signal	  transduction	   are	   a	   potentially	   very	   important,	   but	   under-­‐explored,	   contributor	   to	  signaling	   outcomes.293,294,295	   Achieving	   a	   quantitative	   understanding	   of	   how	   ERK	  and	  Akt	  are	  activated	  by	  upstream	  molecules	  will	  help	  to	  elucidate	  the	  connections	  between	   extracellular	   stimulation	   and	   downstream	   signaling	   dynamics.	   As	  illustrated	   in	   Figure	   5.1,	   ERK	   and	   Akt	   are	   activated	   by	   a	   sequence	   of	   reactions	  
  
Figure 5.1 Simplified scheme illustrating part of the RET signaling network with key steps in 
the ERK and Akt pathways, with cross-talk and feedback loops that have been demonstrated 
for other RTK systems. 
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regulated	   by	   activators	   such	   as	   signaling	   kinases	   and	   deactivators	   such	   as	  phosphatases.	   The	   signaling	   outcomes	  of	   these	   two	  pathways	   are	   also	   affected	  by	  cross-­‐talk	   and	   feedback	   loops.296,297	   Specifically,	   negative	   feedback	   effects	   of	  activated	  ERK	  have	  been	  shown	  in	  several	  signaling	  systems.	  Activated	  RTK	  recruits	  SOS,	   via	   Grb2,	   to	   the	   plasma	  membrane	  where	   SOS	   recruits	   and	   activates	   Ras	   to	  initiate	  the	  ERK	  pathway.53	  Insulin-­‐induced	  ERK	  activation	  has	  been	  shown	  to	  cause	  phosphorylation	   of	   SOS	   and	   decrease	   the	   SOS-­‐Grb2	   interaction,	   which	   decreases	  activation	   levels	  of	  Ras.298,299,300	  Many	  computational	  models	  have	  been	  developed	  to	   analyze	   and	   predict	   how	  ERK	   signaling	   dynamics	   are	   affected	   by	   its	   upstream,	  downstream	  and	  parallel	  regulators.295,301,302,303,304	  
Interference	   of	   ERK	   and	   Akt	   activation	   with	   each	   other	   has	   also	   been	  observed	  in	  several	  RTK	  systems,	  and	  found	  to	  be	  highly	  dependent	  on	  stimulation	  conditions.296	   Since	   Ras	   is	   a	   direct	   activator	   for	   PI3K305,306,	   initiating	   the	   ERK	  signaling	   pathway	   is	   expected	   to	   activate	  Akt.	   On	   the	   other	   hand,	   phosphorylated	  ERK	  has	  been	  shown	  to	  inhibit	  PI3K.	  Studies	  showed	  that	  activated	  ERK,	  stimulated	  by	   EGF	   and	   insulin,	   could	   phosphorylate	   Grb2-­‐associated	   binder-­‐1	   (Gab1)	   and	  facilitate	   the	   dissociation	   of	   PI3K	   from	   Gab1,	   leading	   to	   decreased	   PI3K	   and	   Akt	  phosphorylation	  levels.297	  307	  Experiments	  by	  Yu	  et	  al.297	  showed	  that	  inhibiting	  ERK	  activation	  with	  MEK	  inhibitor	  U0126	  enhanced	  Akt	  phosphorylation	  stimulated	  by	  EGF.	  Inhibitory	  effects	  of	  Akt	  on	  the	  ERK	  pathway	  have	  also	  been	  observed.	  Rommel	  
et	   al.	   reported	   that	   Akt	   could	   deactivate	   Raf	   by	   phosphorylating	   Raf	   on	   Ser259,	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promoting	   the	   interaction	   of	  Raf	  with	   the	   chaperonin	  protein	   14-­‐3-­‐3	   to	   confer	   an	  inactive	  configuration	  on	  Raf.308	  In	  support	  of	  the	  negative	  effects	  of	  Akt	  on	  the	  ERK	  pathway,	  IGF-­‐induced	  ERK	  signaling	  was	  enhanced	  upon	  inhibition	  of	  Akt	  activation	  by	   a	   PI3K	   inhibitor.309	   The	   cross-­‐talk	   between	   Akt	   and	   Raf	   has	   been	   observed	   in	  several	   cell	   types,	   such	   as	   Human	   Embryonic	   Kidney	   (HEK)	   293	   and	   vascular	  smooth	  muscle	   (VSM)	   cells,	   upon	   stimulations	   by	   insulin,	   EGF	   and	   PDGF.310,311,312	  These	   cross-­‐talk	   and	   feedback	   effects	   make	   the	   signal	   transduction	   mechanism	  more	  complicated	  than	  would	  be	  the	  case	  for	  a	  simple	  linear	  series	  of	  reactions,	  and	  also	  make	  preserving	  the	  native	  cellular	  context	  essential	  for	  studying	  the	  kinetics	  of	  these	  pathways.	  	  
Here,	  we	   used	   small	  molecule	   inhibitors	   specific	   to	   different	   steps	   in	   RET-­‐dependent	  ERK	  and	  Akt	  signaling	  to	  explore	  pERK	  and	  pAkt	  decay	  dynamics,	  using	  cells	   with	   endogenous	   RET,	   ERK	   and	   Akt.	  We	   hoped	   to	   learn	   which	   steps	   would	  regulate	  the	  duration	  of	  ERK	  and	  Akt	  signaling	  when	  receptor	  stimulation	  is	  blocked	  at	  upstream	  steps.	  We	  hypothesize	  that	  individual	  components	  of	  the	  pathways	  with	  different	   lifetimes	   control	   how	   rapidly	   the	   system	   can	   respond	   to	   changes	   in	  stimulus	  levels.	  For	  instance,	  when	  stimulation	  is	  suddenly	  decreased,	  the	  existence	  of	   long-­‐lived	  species	  upstream	  of	  ERK	  or	  Akt	  can	  continue	  to	  activate	  downstream	  signaling,	   and	   can	   therefore	   lead	   to	   a	   cushioned	   decay	   dynamics	   of	   downstream	  signaling.	   Given	   the	   short	   lifetime	   of	   activated	   pRET	   demonstrated	   in	  Chapter	   3,	  pRET	  levels	  will	  respond	  rapidly	  to	  changes	   in	  stimulation	  strength.	  Without	   long-­‐
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lived	  intermediate	  species,	  ERK	  and	  Akt	  levels	  will	  decrease	  rapidly	  in	  response	  to	  decrease	   in	   ART	   and	   pRET	   levels.	   We	   hoped	   to	   characterize	   the	   lifetimes	   of	  activated	  molecules	   upstream	   of	   ERK	   and	   Akt,	   and	   identify	   ones	   that	   control	   the	  decay	  dynamics	  of	  pERK	  and	  pAkt	  in	  response	  to	  change	  in	  stimulus	  levels.	  We	  also	  tested	  how	  inhibiting	  specific	  steps	  in	  the	  ERK	  pathway	  would	  affect	  Akt	  activation	  and	  vice	  versa,	  aiming	  to	  identify	  any	  cross-­‐talk	  between	  these	  pathways	  occurring	  downstream	   of	   RET.	   We	   analyzed	   our	   data	   using	   computational	   methods,	   to	  determine	  the	  rate	  constants	  for	  key	  steps	  in	  the	  RET/Ras/Raf/MEK/ERK	  signaling	  cascade	  stimulated	  by	  ART.	  Our	  results	  establish	  that	  activated	  MEK	  has	  the	  longest	  lifetime	  of	   any	   species	   upstream	  of	   ERK,	   and	   regulates	   for	   the	   slow	  decay	  of	   ERK	  signaling	  when	  upstream	  stimulus	  decreases.	  We	  propose	  that	  the	  existence	  of	  long-­‐lived	  activated	  MEK	  can	   serve	   to	  partially	   insulate	  ERK	   from	  noisy	   fluctuations	   in	  upstream	  stimulation	  levels.	  In	  contrast,	  no	  such	  long-­‐lived	  species	  are	  observed	  in	  the	  Akt	  pathway	  	  
	  
5.2. Analysis	  of	  pERK	  Decay	  Rates	  
In	  order	  to	  understand	  how	  different	  upstream	  molecules	  contribute	  to	  ERK	  activation	   dynamics,	   such	   as	   amplitude	   and	   duration,	   we	   used	   small	   molecule	  inhibitors	   targeting	   the	   kinase	   activity	   of	   RET,	   MEK	   and	   Raf,	   individually,	   and	  examined	  the	  decay	  dynamics	  of	  ERK	  signaling	  by	  measuring	  changes	  in	  pRET	  levels	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upon	  inhibition.	  Levels	  of	  pERK	  were	  measured	  by	  our	  previously	  described	  pERK	  ELISA	  assay	  (see	  Chapter	  2,	  Experimental	  Methods).	  
We	  first	  inhibited	  MEK	  (the	  kinase	  that	  directly	  activates	  ERK)	  to	  determine	  the	   intrinsic	   lifetime	  of	  pERK.	  The	  small	  molecule	   inhibitor	  CI1040,	  also	  known	  as	  PD184352,	  inhibits	  the	  kinase	  activity	  of	  MEK1/2	  by	  binding	  to	  an	  allosteric	  binding	  pocket	   adjacent	   to	   the	   ATP	   binding	   site,	   locking	   MEK1/2	   into	   an	   inactive	  conformation.313	   CI1040	   is	   a	   highly	   selective	  MEK	   inhibitor	  with	   a	   reported	   50%	  inhibitory	  concentration	  (IC50)	  of	  17	  nM.314	  Results	  of	  the	  dose-­‐dependent	  inhibition	  of	  ERK	  phosphorylation	  by	  CI1040	  showed	  that	  addition	  of	  10	  μM	  CI1040	  after	  ART	  stimulation	  was	  sufficient	  to	  fully	  deplete	  cellular	  pERK	  (Figure	  5.2A).	  As	  shown	  in	  
Figure	   5.2B,	   addition	   of	   10	   μM	   CI1040	   after	   10	   min	   of	   ART	   stimulation	   caused	  immediate	  and	  rapid	  decay	  of	  pERK.	  Increasing	  the	  CI1040	  concentration	  to	  75	  μM	  did	  not	  further	  accelerate	  the	  pERK	  decay,	  suggesting	  that	  the	  observed	  pERK	  decay	  rate	  was	  not	  rate-­‐limited	  by	  passive	  diffusion	  of	  CI1040	  through	  the	  cell	  membrane,	  and	   thus	   truly	   reflects	   pERK	   deactivation	   kinetics.	   We	   determined	   the	   intrinsic	  lifetime	  of	  pERK	  by	  fitting	  the	  decay	  curve	  to	  an	  exponential	  decay	  equation,	  	  
Eq. 5.1 pXt	  =	  pX0	  ×	  e-­‐k	  t	  	  
where	  pX	  is	  the	  concentration	  of	  pERK	  present	  at	  the	  beginning	  (pX0)	  or	  at	  any	  given	  time	   t	  after	   inhibition	   (pXt),	   and	  k	   is	   the	   first-­‐order	   rate	   constant	   for	   pERK	  decay	  (kdephos).	  Based	  on	  t1/2	  =	  ln2	  /	  k,	  the	  best	  fit	  showed	  that	  the	  half-­‐life	  of	  pERK	  was	  t1/2	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=	  1.4	  ±	  0.1	  min	  (n	  =	  3)	  (Figure	  5.3,	  red).	  The	  short	  lifetime	  of	  pERK	  indicates	  that	  the	   continuously	   elevated	   pERK	   levels	   of	   the	   ART	   stimulation	   reflect	   a	   balance	  between	  the	  rapid	  formation	  of	  pERK	  and	  its	  comparably	  rapid	  decay.	  	  
We	   have	   previously	   shown	   that	   ART	   stimulation	   induced	   transient	   ERK	  activation,	  peaking	  at	  around	  10	  min,	  followed	  by	  sustained	  ERK	  activation	  only	  at	  a	  fraction	  of	  the	  transient	  signal	  up	  to	  at	  least	  60	  min	  (Figure	  2.11A).	  To	  investigate	  whether	  the	  decreased	  pERK	  levels	  seen	  at	  later	  time	  after	  ART	  stimulation	  was	  due	  to	   increased	  pERK	  dephosphorylation,	  we	  compared	  the	  decay	  rates	  of	  pERK	  after	  various	  periods	  of	  ART	  stimulation.	  Inhibiting	  MEK	  activity	  after	  4,	  10	  or	  60	  min	  of	  
  
Figure 5.2 Inhibition of ERK activation by MEK inhibitor CI1040. A. NB41A3-mGFRα3 
cells were incubated with 4 nM ART for 10 min, followed by addition of CI1040 for 10 min at 
the stated concentrations. Data points are plotted as percentages of the signal seen for cells 
treated with 4 nM ART only, after subtraction of the basal signal seen for untreated cells. 
Error bars are differences between duplicate ELISA wells. B. Time-course of pERK in 
NB41A3-mGFRα3 cells after stimulation with 4 nM ART followed by addition of CI1040 at 
the stated concentrations. The arrow indicates the time of addition of inhibitor into cell culture 
in the presence of 4 nM ART. Data points show average of duplicate measurements from one 
representative experiment of three independent experiments. Data are plotted as a percentage 
of the level measured for 10 min stimulation with 4 nM ART. Error bars are differences 
between duplicate ELISA wells. Solid lines are smoothed interpolations of the data. The 
dashed line indicates basal levels of pERK in untreated cells. 
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ART	   stimulation	   showed,	   unexpectedly,	   that	   pERK	  decay	   rate	   decreased	   at	   longer	  stimulation	  time.	  As	  shown	  in	  Figure	  5.3,	  half-­‐life	  of	  pERK	  increased	  from	  ~1	  min	  at	  10	  min	  after	  ART	  stimulation,	  corresponding	  to	  the	  transient	  ERK	  activation,	  to	  ~4	  min	  after	  60	  min	  of	  ART	  stimulation,	  corresponding	   to	   the	  sustained	  stage	   in	  ERK	  signaling,	  determined	  from	  the	  best	  fit	  of	  each	  decay	  curve	  to	  the	  exponential	  decay	  equation	  Eq.	   4.1.	  Accordingly,	   the	   fitted	  rate	  constant	  kdephos	  for	  pERK	  deactivation	  decreased	   from	   0.7	   min-­‐1	   to	   0.	   17	   min-­‐1,	   indicating	   decreased	   activity	   in	   pERK	  phosphatases.	   The	   lower	   pERK	   levels	   after	   60	   min	   ART	   stimulation	   with	   slower	  pERK	  decay	  rates	  can	  only	  be	  achieved	   if	   the	   formation	  rate	  of	  pERK	  at	  60	  min	   is	  substantially	   slower	   than	   that	   at	   10	   min.	   The	   comparison	   shows	   that	   pERK	  
  
Figure 5.3 Comparison of pERK decay rates upon treatment of cells with MEK inhibitor 
CI1040 after various periods of ART stimulation. NB41A3-mGFRα3 cells were incubated 
with 4 nM ART for 4 min (lozenges), 10 min (squares) or 60 min (triangles), followed by 
addition of 10 µM CI1040. Data after addition of the inhibitors are plotted as a percentage of 
that prior to addition. Data points show averaged data from three independent experiments. 
The pERK level after 30 min of inhibition in each curve was used as background and 
subtracted from all data points before normalization. Solid lines represent the best fits to an 
exponential decay equation. Values of half-life (t1/2) are from the best fit of each curve. Error 
bars are standard deviations, as are the error limits for the t1/2 values. 
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activation	   rate	  must	   have	  decreased	   to	   a	   greater	   extent	   than	   its	   decay	   rate	   in	   the	  period	  between	  after	  10	  min	  and	  60	  min	  after	  ART	  stimulation.	   	  Since	  pERK	  levels	  started	   to	   decay	   after	   10	   min	   of	   ART	   stimulation,	   when	   pRET	   levels	   were	   still	  increasing	  and	  the	  receptor	  was	  still	  located	  on	  the	  cell	  membrane	  (as	  discussed	  in	  
Chapter	  4),	  the	  decrease	  of	  transient	  pERK	  levels	  from	  the	  transient	  peak	  at	  10	  min	  is	  not	  due	  to	  any	  decrease	   in	  pRET	   levels	  or	   its	  signaling	  capacity,	  but	  result	   from	  negative	   feedback	  effects	  of	  ERK	  activation.	   Such	  negative	   feedback	  effects	  kick	   in	  after	  ~10	  min	  of	  ART	  stimulation	  regardless	  of	  stimulus	  strength	  (Figure	  2.11)	  and	  trigger	  the	  transition	  of	  transient	  pERK	  to	  sustained	  pERK	  via	  a	  reduction	  in	  the	  rate	  of	  ERK	  activation,	  not	  by	  increasing	  the	  rate	  of	  pERK	  decay.	  
	   The	   short	   intrinsic	   lifetime	   of	   pERK	   indicates	   that	   ART-­‐induced	   ERK	  signaling	   requires	   continuous	   activation	   signals	   from	   upstream	   activators.	   To	  investigate	   how	   long	   ERK	   signaling	   persists	   after	   RET	   is	   inhibited,	   we	   examined	  pERK	   decay	   kinetics	   upon	   addition	   of	   RET	   kinase	   inhibitor	   ZD6474.	   Shown	   in	  
Figure	   5.4,	   inhibiting	   RET	   kinase	   activity	   after	   10	  min	   of	   4	   nM	   ART	   stimulation	  caused	   the	   pERK	   amplitude	   to	   drop	   to	   basal	   levels	   over	   ~20	   min,	   again	  demonstrating	  that	  sustained	  pERK	  levels	  required	  continuous	  activation	  from	  RET.	  We	  noticed	   that	   pERK	   remained	   at	   the	   same	   level,	   or	   even	   increased,	   for	  ~2	  min	  before	   starting	   to	   decrease.	   This	   2-­‐min	   lag	   in	   the	   pERK	   decay	   suggests	   it	   took	  approximately	  2	  min	  for	  upstream	  ERK	  activators	  to	  decrease	  to	  a	  level	  where	  the	  ERK	   activation	   rate	   equaled	   its	   deactivation	   rate.	   We	   determined	   the	   half-­‐life	   of	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pERK	  was	  4.5	  ±	  0.3	  min	  (n	  =	  3),	  after	  the	  2-­‐min	  lag,	  by	  fitting	  the	  pERK	  decay	  data	  after	  2	  min	  of	  inhibition	  to	  the	  exponential	  decay	  equation	  Eq.	  5.1.	  	  
The	   observed	   half-­‐life	   of	   pERK	   signaling	   upon	   inhibiting	   RET	   was	   much	  longer	  than	  the	  intrinsic	  lifetimes	  of	  pRET	  (t1/2	  =	  ~1	  min)	  (see	  Chapter	  3)	  or	  pERK	  (t1/2	   =	   1.4	   ±	   0.1	   min;	   Figure	   5.2B)	   under	   the	   same	   stimulation	   condition.	   The	  observation	   that	  both	  pRET	  and	  pERK	  have	   short	   intrinsic	   lifetimes	   indicates	   that	  the	   slow	  decay	   of	   pERK	   seen	   in	  Figure	   5.4	   is	   regulated	   by	   a	   relatively	   long-­‐lived	  
 
Figure 5.4 Inhibition of ERK activation by the RET kinase inhibitor ZD6474. A. Time-course 
for pERK levels in cells stimulated with 4 nM ART, with (circles) or without (lozenges) 
addition of RET kinase inhibitor ZD6474 (50 µM) at 10 min after ART treatment. Data are 
plotted as a percentage of the pERK level seen at 10 min after stimulation with 4 nM ART, 
after subtraction of the basal signal seen for untreated cells. The arrow indicates the time of 
addition of ZD6474 into the cell culture in the presence of 4 nM ART. Data points show 
averages of duplicate ELISA measurements from one representative experiment of three 
independent experiments that were performed. Error bars are differences between the 
duplicate ELISA measurements. The solid lines are smoothed interpolations of the data. B. 
Time-course for pERK decay as a function of time after ZD6474 added, for experiments 
where inhibitor was introduced 10 min (circles) or 30 min (lozenges) after stimulation of cells 
with 4 nM ART. Data are plotted as percentages of pERK levels prior to inhibition. The 
pERK level in untreated cells was subtracted as background. Solid lines represent the best fit 
of the data to the exponential decay equation. Data points show averaged data from three 
independent experiments. Error bars represent standard deviations. 
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species	   that	   lies	   upstream	   of	   ERK	   and	   downstream	   of	   RET.   Cellular	   pERK	   is	  activated	  by	  a	  chain	  of	  reactions	  involving	  upstream	  activators	  (such	  as	  pRET,	  Ras-­‐GTP,	   pRaf	   and	   pMEK),	   and	   is	   deactivated	   by	   ERK	   phosphatases.	   When	   pRET	  formation	   is	   inhibited	   by	   ZD6474,	   accumulated	   pRET,	   Ras-­‐GTP,	   pRaf	   and	   pMEK	  prior	  to	  inhibition	  can	  continue	  activating	  the	  ERK	  pathway.	  As	  long	  as	  any	  of	  those	  activators	   is	  still	  present,	  pERK	  can	  still	  be	  produced	  and	  thus	  pERK	  levels	  will	  be	  above	   the	  basal	   level.	  The	   fact	   that	   inhibiting	  RET	  depleted	  pERK	  within	  ~20	  min	  suggests	   that	  all	   the	  upstream	  activators	  were	  also	  depleted	   in	  ≤	  20	  min	  and	   thus	  not	  able	  to	  continue	  activating	  ERK.	  Therefore,	  the	  rate	  of	  pERK	  decay	  is	  dependent	  on	  how	  fast	  pERK	  is	  dephosphorylated	  but	  its	  decay	  rate	  upon	  inhibition	  of	  RET	  is	  also	  limited	  by	  how	  slow	  its	  upstream	  activators	  decay.	  We	  showed	  in	  Figure	  5.2B	  that	  the	  intrinsic	  lifetime	  of	  pERK	  is	  much	  shorter	  than	  that	  observed	  in	  Figure	  5.4.	  




To	   investigate	  whether	   the	  retarding	  effect	  on	  pERK	  decay	   from	  such	   long-­‐lived	   specie	   also	   exists	   after	   longer	   ART	   stimulation,	   we	   examined	   pERK	   decay	  kinetics	   with	   RET	   inhibition	   after	   30	   min	   stimulation.	   As	   shown	   in	   Figure	   5.4B,	  addition	  of	  RET	  inhibitor	  after	  30	  min	  ART	  stimulation	  led	  to	  pERK	  decay	  after	  a	  ~2-­‐min	  lag	  with	  t1/2	  of	  3.6	  ±	  0.0	  min	  (n	  =	  3),	  which	  was	  very	  similar	  to	  the	  pERK	  decay	  kinetics	  seen	  upon	  inhibition	  after	  10	  min	  (2-­‐min	  lag	  followed	  by	  t1/2	  =	  4.5	  min).	  The	  2-­‐min	  lag	  period	  before	  pERK	  starting	  to	  decay	  suggests	  that	  it	  took	  2	  min	  for	  pMEK	  to	  decrease	  to	  a	  level	  where	  ERK	  activation	  by	  pMEK	  was	  equal	  to	  the	  pERK	  decay	  rate.	   Thus,	   the	   response	   of	   pERK	   to	   a	   sudden	  decrease	   in	  RET	   stimulus	   is	   similar	  during	  the	  transient	  pERK	  response	  and	  later	  on.	  
To	  test	  whether	  pMEK	  is	  the	  long-­‐lived	  species	  that	  controls	  the	  rate	  of	  pERK	  decay,	   we	   inhibited	   Raf	   kinase	   activity	   using	   small	   molecule	   SB590885	   and	  examined	  the	  pERK	  decay	  rate.	  SB590885	   is	  a	  potent,	   selective	   inhibitor	   for	  B-­‐Raf	  and	  C-­‐Raf,	  and	  inhibits	  Raf	  kinase	  activity	  by	  occupying	  the	  ATP-­‐binding	  pocket	   in	  the	   active	   conformation.315,316	   We	   performed	   similar	   inhibitory	   studies	   with	   Raf	  inhibitor	  as	  we	  did	  with	  the	  MEK	  inhibitor	  CI1040.	  Shown	  in	  Figure	  5.5	  A	  and	  B,	  10	  μM	  SB590885	  added	  after	  ART	  stimulation	  was	  sufficient	  to	  deplete	  pERK	  after	  20	  min.	   The	   pERK	   decay	   rate	   was	   not	   increased	   when	   75	   μM	   SB590885	   was	   used	  instead,	  showing	  that	  the	  observed	  pERK	  decay	  rate	  was	  not	  rate-­‐limited	  by	  passive	  diffusion	  of	  SB590885	  through	  the	  cell	  membrane.	  Inhibiting	  Raf	  led	  pERK	  levels	  to	  decay	   with	   half-­‐life	   of	   ~5min,	   very	   similar	   to	   the	   decay	   rate	   observed	   with	   RET	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inhibitor.	   This	   similarity	   is	   illustrated	   by	   Figure	   5.6,	   which	   compares	   the	   pERK	  decay	  behavior	  seen	  after	  inhibition	  of	  RET,	  Raf	  and	  MEK.	  The	  inset	  plot	  shows	  the	  same	   data	   plotted	   on	   semilogarithmic	   axes,	   on	  which	   an	   exponential	   decay	   curve	  becomes	   linear,	   and	   the	   slope	   indicates	   the	   decay	   rate	   constant.	   Comparing	   the	  steepness	  of	  the	  slopes	  in	  the	  Figure	  5.6	  inset	  plot,	  we	  see	  very	  similar	  pERK	  decay	  rate	   constants	   when	   inhibiting	   RET	   or	   Raf.	   This	   result	   indicates	   that	   the	   rate-­‐limiting	   step	   in	   pERK	   decay	   is	   downstream	   of	   Raf.	   Upon	   inhibition	   of	   Raf	   by	  SB590885,	  no	  further	  activation	  of	  MEK	  can	  occur,	  and	  the	  only	  species	  that	  can	  be	  responsible	   for	   sustaining	   pERK	   levels	   is	   pMEK.	   We	   conclude,	   therefore,	   that	  deactivation	  of	  pMEK	  is	  the	  rate-­‐limiting	  step	  in	  pERK	  decay	  in	  our	  system.    
 
Figure 5.5 Inhibition of ERK activation by Raf inhibitor SB590885. A. NB41A3-mGFRα3 
cells were incubated with 4 nM ART for 10 min, followed by addition of SB590885 for 20 
min at the stated concentrations. Data points are plotted as percent of signal from cells treated 
with 4 nM ART only, after subtraction of the basal signal seen for untreated cells. Error bars 
are differences between duplicate ELISA wells. B. Time-course of pERK in NB41A3-
mGFRα3 cells after stimulation with 4 nM ART followed by addition of SB590885 at the 
stated concentrations. The arrow indicates the time point of addition of inhibitors into the cell 
culture in the presence of 4 nM ART. Data points show average of duplicates from one 
representative experiment of three independent experiments. Data are plotted as a percentage 
of the level measured for 10 min stimulation with 4 nM ART. Error bars are differences 
between duplicate ELISA wells. Solid lines are smoothed interpolations of the data. Dashed 
lines indicate basal levels of pERK in untreated cells. 
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  Overall,	   the	   comparison	   of	   pERK	   decay	   dynamics	   after	   10	   min	   of	   ART	  stimulation	   enabled	   us	   to	   identify	   pMEK	   as	   the	   longest-­‐lived	   species	   in	   the	   ERK	  pathway,	   which	   controls	   the	   rate	   at	   which	   ERK	   signaling	   can	   respond	   when	   the	  extracellular	   stimulation	   levels	   decrease.	   In	   addition,	   we	   found	   that	   intrinsic	   the	  lifetime	  of	  activated	  ERK	  was	  short	  (t1/2	  =	  1.4	  ±	  0.1	  min)	  during	  the	  transient	  ERK	  response	  and	  increased	  to	  t1/2	  =	  4.1	  ±	  0.3	  min	  during	  the	  sustained	  ERK	  response.	  This	   decrease	   in	   pERK	   dephosphorylation	   rate	   suggests	   that	   the	   transition	   from	  transient	   ERK	   signal	   to	   the	   lower,	   sustained	   ERK	   signal	   is	   regulated	   by	   negative	  feedback	  effects	  of	  ERK	  signaling	  acting	  on	  the	  ERK	  phosphorylation	  kinetics.	  Since	  
  
Figure 5.6 Comparison of pERK decay rates upon treatment of cells with various inhibitors. 
NB41A3-mGFRα3 cells were incubated with 4 nM ART for 10 min, followed by addition of 
RET inhibitor ZD6474 (50 µM, lozenges), Raf inhibitor SB590885 (10 µM, triangles) or 
MEK inhibitor CI1040 (10 µM, circles). Data after addition of inhibitors are plotted as a 
percentage of the pERK level measured prior to adding inhibitors. The pERK level after 30 
min of inhibition in each experiment was used as background and subtracted before 
normalization. Data points show averaged data from three independent experiments. Error 
bars are standard deviations. The solid line for CI1040 represents the best fit of the data to an 
exponential decay equation. Other solid lines are smoothed interpolations of the data. The 
inset plot shows the same data plotted on a logarithmic scale. Error bars were omitted for 
clarity. Solid lines are best fits of the decay phase by linear least-squares regression.  
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ERK	   signaling	   peaks	   after	   10	   min	   of	   ART	   stimulation	   over	   the	   wide	   ART	  concentration	  range	  of	  0.1–10	  nM,	  such	  negative	  effects	  kick	  in	  before	  10	  min,	  and	  their	   timing	   is	   independent	   of	   stimulation	   strength,	   RET	   activation	   level	   or	   ERK	  activation	  level.	  
	  
5.3. Analysis	  of	  pAkt	  Decay	  Rates	  
We	  performed	  a	   similar	  analysis	  of	  phosphorylated	  Akt	  decay	  dynamics,	   in	  the	  RET/PI3K/Akt	   cascade,	   using	   the	  RET	   inhibitor	   ZD6474	  and	   the	  Akt	   inhibitor	  MK2206.	   Levels	   of	   pAkt	  were	  measured	   using	   our	   previously	   described	   the	   pAkt	  ELISA	  (see	  Chapter	  2	  Experimental	  Methods).	  Addition	  of	  ZD6474	  after	  10	  min	  of	  ART	  stimulation	  effectively	  depleted	  pAkt	  with	  t1/2	  =	  1.9	  ±	  0.1	  min	  (n	  =	  3)	  (Figure	  
5.7).	   We	   previously	   showed	   that	   Akt	   activation	   peaked	   after	   10	   min	   of	   ART	  stimulation	  and	  then	  gradually	  decreased	  over	  the	  subsequent	  80	  min	  (Chapter	  2,	  




We	   detected	   the	   intrinsic	   lifetime	   of	   phosphorylated	   Akt	   using	   the	   small	  molecule	  Akt	  inhibitor	  MK2206.	  MK2206	  is	  a	  potent,	  selective	  allosteric	  inhibitor	  of	  Akt	   that	   prevents	   Akt	   from	   being	   phosphorylated	   by	   upstream	   stimuli,	   with	   a	  reported	   IC50	  of	  5	  nM.317,318	  As	   shown	   in	  Figure	   5.8A,	   addition	  of	  10	  μM	  MK2206	  was	   sufficient	   to	   deplete	   cellular	   pAkt	   after	   ART	   stimulation.	  We	   determined	   the	  intrinsic	  half-­‐life	  of	  pAkt	  was	  ≤	  1.0	  min	  (n	  =	  3)	  by	  fitting	  the	  pAkt	  decay	  data	  to	  the	  
  
Figure 5.7  Inhibition of Akt activation by the RET kinase inhibitor ZD6474. A. Time-course 
for pAkt levels in cells stimulated with 4 nM ART, with (circles) or without (lozenges) 
addition of RET kinase inhibitor ZD6474 (50 µM) at 10 min after ART treatment. Data are 
plotted as a percentage of the pAkt level seen at 10 min after stimulation with 4 nM ART, 
after subtraction of the basal signal seen for untreated cells. The arrow indicates the time of 
addition of ZD6474 into the cell culture in the presence of 4 nM ART. Data points show 
averages of duplicate ELISA measurements from one representative experiment of three 
independent experiments that were performed. Error bars are differences between the 
duplicate ELISA measurements. The solid lines are smoothed interpolations of the data. B. 
Time-course for pAkt decay as a function of time after ZD6474 added, for experiments where 
inhibitor was introduced 10 min (circles) or 30 min (lozenges) after stimulation of cells with 4 
nM ART. Data are plotted as percentages of the pAkt level prior to inhibition. The pAkt level 
after 30 min of inhibition in each curve was used as background and subtracted from all data 
points before normalization. Solid lines represent the best fit of the data to an exponential 
decay equation. Data points show averaged data from three independent experiments. Error 
bars represent standard deviations. The dashed lines in A and B indicate basal levels of pAkt 
prior to ART stimulation.   
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exponential	  decay	  equation	  Eq.	  5.1.	  Increasing	  the	  MK2206	  concentration	  to	  50	  μM	  did	  not	  accelerate	  pAkt	  decay,	  suggesting	  that	  the	  observed	  Akt	  dephosphorylation	  was	  not	  rate-­‐limited	  by	  diffusion	  of	  MK2206	  into	  the	  cells.	  We	  also	  examined	  pAkt	  decay	  after	  60	  min	  of	  ART	  stimulation	  to	  see	  whether	  pAkt	  deactivation	  was	  faster	  at	   later	  stimulation	  times	  as	  observed	  in	  pERK.	  As	  shown	  in	   Figure	  5.9,	   inhibiting	  Akt	  activity	  after	  60	  min	  triggered	  to	  rapid	  decay	  of	  pAkt,	  again	  with	  t1/2	  ≤	  1	  min	  (n	  =	  3),	  similar	  to	  the	  decay	  kinetics	  observed	  when	  Akt	  inhibition	  after	  10	  min.	  Since	  most	   pAkt	   decayed	   in	   less	   than	   2	   min	   and	   our	   first	   data	   point	   was	   2	   min	   after	  addition	   of	   inhibitors,	   the	   actual	   pAkt	   decay	   could	   be	   even	   faster	   than	   what	   we	  
  
Figure 5.8  Inhibition of Akt activation by Akt inhibitor MK2206. A. NB41A3-mGFRα3 cells 
were incubated with 4 nM ART for 10 min, followed by addition of MK2206 for 10 min at the 
stated concentrations. Data points are plotted as percentages of the signal seen for cells treated 
with 4 nM ART only, after subtraction of the basal signal seen for untreated cells. Error bars 
are differences between duplicate ELISA wells. B. Time-course of pAkt in NB41A3-mGFRα3 
cells stimulated with 4 nM ART followed by addition of MK2206 at 10 µM (squares) or 50 
µM (crosses). The arrow indicates the time of addition of inhibitor into the cell culture in the 
presence of 4 nM ART. Data points show averages of duplicate measurements from one 
representative experiment out of three independent experiments. Data are plotted as a 
percentage of the signal seen at 10 min after stimulation with ART. Error bars are differences 
between duplicate ELISA wells. Solid lines are smoothed interpolations of the data.   
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detected.	   The	   short	   intrinsic	   lifetime	   of	   pAkt	   (t1/2	   ≤	   1	   min)	   after	   10	   and	   60	   min	  stimulation	  shows	  that	  Akt	  dephosphorylation	  remained	  rapid	  over	  this	  timeframe.	  	  
As	   shown	   in	   Figure	   5.10,	   the	   comparison	   of	   pAkt	   decay	   dynamics	   upon	  inhibition	   at	   different	   steps	   in	   the	   RET/PI3K/Akt	   cascade	   showed	   that	   inhibiting	  RET	  kinase	  activity	  led	  to	  pAkt	  decay	  at	  a	  slightly	  slower	  rate	  than	  the	  intrinsic	  rate	  of	   pAkt	   dephosphorylation.	   Compared	   to	   the	   short	   intrinsic	   half-­‐life	   of	   pRET	   and	  pAkt	  (t1/2	  ≤	  1	  min),	  the	  slightly	  longer	  half-­‐life	  of	  Akt	  signaling	  (t1/2	  =	  1.9	  ±	  0.1	  min)	  upon	  RET	  inhibition	  suggests	  that	  the	  decay	  rate	  of	  Akt	  signaling	  is	  regulated	  by	  one	  or	   more	   activators	   upstream	   of	   Akt	   that	   posses	   at	   least	   slightly	   longer	   life-­‐times	  compared	   to	   pRET	   and	   pAkt.	   Akt	   is	   phosphorylated	   on	   Thr308	   by	   the	  
  
Figure 5.9 Comparison of pAkt decay rates upon treatment of cells with Akt inhibitor 
MK2206 after various periods of ART stimulation. NB41A3-mGFRα3 cells were incubated 
with 4 nM ART for 10 min (circles) or 60 min (squares), followed by addition of 10 µM 
MK2206. Data after addition of inhibitors are plotted as a percentage of that prior to adding 
inhibitors. Data points show averaged data from three independent experiments. The pAkt 
level after 30 min of inhibition in each curve was used as background and subtracted from all 
data points before normalization. Error bars are standard deviations. Solid lines represent the 
best fits to an exponential decay equation.   
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PI3K/PIP3/PDK1	  cascade	  and	  on	  Ser473	  by	  PI3K/mTORC2	  or	  DNA-­‐PK,	   in	  order	  to	  be	  fully	  activated,	  as	  discussed	  in	  Chapter	  1.  In	  our	  pAkt	  ELISA,	  antibodies	  specific	  to	   phospho-­‐Ser473	   were	   used	   to	   detect	   cellular	   Akt	   phosphorylation	   levels.	   The	  observed	   pAkt	   decay	   therefore	   represents	   specifically	   the	   deactivation	   kinetics	   of	  Ser473	   in	   activated	  Akt.	   The	  most	   likely	   candidates	   for	   the	   long-­‐lived	   activator(s)	  responsible	   for	   the	   slightly	   slower	   pAkt	   decay	   are	   therefore	   PI3K,	   mTOR2	   or	  DNA-­‐PK.	  
	  
  
Figure 5.10  Comparison of pAkt decay rates observed with different inhibitors added after 10 
min of ART stimulation. Time-courses of pAkt decay with RET inhibitor ZD6474 (lozenges) 
or Akt inhibitor (squares) have been previously shown in Figure 5.7 B and Figure 5.9, 
respectively. Data points show averages of three independent experiments. Error bars are 
standard deviations. The solid curves represent the best fits of the data to an exponential decay 
equation. The inset plot shows the same data plotted on a logarithmic scale. Error bars were 
omitted for clarity. Solid lines are best fits by linear least-squares regression.   
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5.4. Analysis	  of	  Cross-­‐talk	  in	  the	  ERK	  and	  Akt	  Pathways	  Downstream	  of	  RET    
	   Cross-­‐talk	  between	  the	  ERK	  and	  Akt	  pathways	  have	  been	  observed	  in	  several	  RTK	   signaling	   systems.	   It	   has	   been	   reported	   that	   activated	   Akt	   can	   inactivate	   Raf	  and	   in	   turn	   decrease	   ERK	   activation.308,309,310,311,312	   Activation	   of	   ERK	   was	   also	  observed	   to	   decrease	   activation	   of	   PI3K	   and	   Akt	   by	   negatively	   regulating	   the	  activation	   of	   Ras,	  which	   is	   a	   PI3K	   activator.297	   If	   these	  mechanisms	   for	   inhibitory	  cross-­‐regulation	   are	   operative	   downstream	   of	   RET	   in	   the	   neuroblastoma	   cells	  we	  use	  in	  this	  study,	   inhibiting	  Akt	  activity	  will	  enhance	  ERK	  activation	  and	  inhibiting	  Raf,	  MEK	  or	  ERK	  activation	  in	  the	  MAPK	  pathway	  will	  enhance	  Akt	  activation.	  In	  this	  study,	   we	   used	   the	   set	   of	   small	   molecules	   inhibitors	   mentioned	   above	   to	   target	  different	  steps	  in	  each	  pathway,	  to	  explore	  possible	  feedback	  effects	  and	  cross-­‐talk	  between	  the	  ERK	  and	  Akt	  pathways	  downstream	  of	  RET.	  




Figure 5.11 Analysis of cross-talk between the ERK and Akt pathways. A. Time-course for 
pAkt levels in cells stimulated with 4 nM ART, with (circles) or without (lozenges) addition 
of MEK inhibitor CI1040 (10 µM) at 10 min after ART treatment. B. Dose-response data for 
activation of Akt after stimulation of NB41A3-mGFRα3 cells with DMEM only (lozenges) or 
DMEM contains 10 µM CI1040 (circles) for 10 min followed by stimulation with the stated 
concentration of ART for 10 min. Data are plotted as a percentage of the pAkt level seen at 10 
min after stimulation with 4 nM ART pretreated with DMEM only. C. Time-course for pAkt 
levels in cells stimulated with 4 nM ART, with (triangles) or without (lozenges) addition of 
Raf inhibitor SB590885 (10 µM) at 10 min after ART treatment. D. Time-course for pERK 
levels in cells stimulated with 4 nM ART, with (squares) or without (lozenges) addition of Akt 
inhibitor MK2206 (10 µM) at 10 min after ART treatment. Data are plotted as a percentage of 
the pAkt or pERK level seen at 10 min after stimulation with 4 nM ART without inhibitors, 
after subtraction of the basal signal seen for untreated cells. The arrow indicates the time of 
addition of inhibitors into the cell culture in the presence of 4 nM ART. Data points show 
averages of duplicate ELISA measurements from one representative experiment of two 
independent experiments that were performed. Error bars are differences between the 
duplicate ELISA measurements. The solid lines are smoothed interpolations of the data. The 
dashed lines indicate the basal levels of pERK or pAkt seen prior to ART stimulation. 
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affect	  Akt	  activation	  levels	  (Figure	  5.11	  C).	  We	  have	  previously	  established	  that	  the	  negatively	   feedback	   effects	   of	   ERK	   activation	   decrease	   pERK	   formation	   rates	   and	  lead	  to	  lower	  sustained	  pERK	  levels	  at	  later	  ART	  stimulation	  period.	  If	  ART-­‐induced	  Akt	  activation	  is	  partially	  contributed	  by	  Ras	  activating	  PI3K,	  any	  feedback	  effects	  of	  ERK	  for	  Ras	  activation	  levels	  will	  change	  PI3k/Akt	  activation.	  The	  observation	  that	  neither	   MEK	   nor	   Raf	   inhibitors	   affected	   Akt	   activation	   shows	   that	   the	   feedback	  effects	  of	  ERK	  activation	  did	  not	  affect	  Ras	  activation	   levels,	  unlike	  what	  has	  been	  observed	   in	   other	   systems298,299,300,	   instead	   targeting	   signaling	   molecules	  downstream	  of	   Ras,	   or	   Ras	   alternatively	   that	   does	   not	   contribute	   to	   ART-­‐induced	  PI3K/Akt	  activation	  in	  our	  cells.	  
We	  next	   tested	   the	   reciprocal	  question	  of	  whether	   inhibiting	  Akt	  activation	  would	   affect	   ERK	   signaling.	   In	   contrast	   to	   what	   has	   been	   observed	   by	   others,13	  inhibiting	  Akt	  phosphorylation	  using	  MK2206	  did	  not	  affect	  ERK	  activation	   in	  our	  system	  (Figure	  5.11D).	  This	  result	  suggests	  that	  the	  inhibitory	  effects	  of	  Akt	  on	  Raf	  downstream	  of	  RET,	  if	  they	  exist	  in	  our	  NB41A3-­‐mGFRα3	  cells,	  are	  not	  significant.	  	  
We	   additionally	   examined	   whether	   activation	   of	   ERK	   or	   Akt	   had	   any	  feedback	  effects	  on	  activation	  of	  RET,	  by	  monitoring	  levels	  of	  pRET	  with	  or	  without	  addition	  of	  inhibitors	  specific	  for	  the	  ERK	  or	  Akt	  pathways.	  Shown	  in	  Figure	  5.12,	  inhibiting	  ERK,	  Raf	  or	  Akt	  after	  10	  min	  of	  ART	  stimulation	  did	  not	  significantly	  affect	  subsequent	   RET	   phosphorylation	   levels.	   This	   result	   shows	   that	   ERK	   and	   Akt	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activation	  do	  not	  have	  feedback	  effects	  on	  RET	  activation	  in	  our	  system	  during	  the	  timeframe	  of	  0−40	  min.	  	  
In	   conclusion,	   we	   did	   not	   find	   any	   cross-­‐talk	   between	   the	   ERK	   and	   Akt	  pathways	  downstream	  of	  RET.	  Negative	  feedback	  effects	  of	  ERK	  and	  Akt	  activation	  exist	  in	  each	  pathway	  and	  regulate	  the	  signaling	  amplitude	  after	  ART	  stimulation,	  as	  discussed	   earlier.	   It	   is	   unclear	  whether	  Ras	   activates	   PI3K	   and	   contributes	   to	  Akt	  activation	  in	  our	  system	  as	  observed	  in	  others305,306.	   If	  yes,	  the	  lack	  of	  effects	  from	  MEK	  inhibitor	  CI1040	  for	  Akt	  activation	  would	  suggest	  that	  the	  negative	  feedback	  of	  ERK	  does	  not	  affect	  Ras	  activation	   levels.	   In	  contrast,	   if	  activated	  ERK	   inhibits	  Ras	  activation	   in	   our	   system	   as	   observed	   in	   others298,299,300,	   this	   result	  would	   suggest	  
	     
Figure 5.12  Analysis of feedback effects of ERK and Akt pathways on RET activation. Time-
courses for pRET activation were detected in cells stimulated with 4 nM ART only (lozenges) 
or with addition of 10 µM MEK inhibitor CI1040 (A), 10 µM Raf inhibitor SB590885 (A) or 
10 µM Akt inhibitor MK2206 (B). Data are plotted as a percentage of the pAkt or pERK level 
seen for 10 min stimulation with 4 nM ART. The arrow indicates the time of inhibitor 
addition. Data points show averaged duplicate ELISA measurements from one representative 
experiment out of three independent experiments. Error bars are differences between the 
duplicate measurements. The solid lines are smoothed interpolations of the data. The dashed 
lines indicate the basal levels of pRET seen prior to ART stimulation.   
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that	  the	  PI3K/Akt	  pathway	  is	  not	  activated	  by	  Ras	  upon	  ART	  stimulation.	  In	  either	  case,	  feedback	  effects	  of	  ERK	  activation	  for	  the	  ERK	  pathway	  does	  not	  cross-­‐regulate	  Akt	   activation	   in	   our	   system,	   nor	   does	   Akt	   pathway	   signaling	   cross-­‐regulate	   the	  ERK/MAPK	  pathway.	  
	  
5.5. Analysis	  of	  RET-­‐Ras-­‐MEK-­‐ERK	  Pathway	  Kinetics	  by	  Global	  Fitting	  
	   We	  hypothesized	  that	  the	  time-­‐dependent	  activation	  of	  each	  molecule	  in	  the	  RET/Ras/Raf/MEK/ERK	  signaling	  cascade	  can	  be	  described	  by	  a	  set	  of	  differential	  equations	  based	  on	  the	  reaction	  scheme	  shown	  in	  Figure	  5.13A.	  To	  determined	  rate	  
	     
Figure 5.13 Computational model of the RET/Raf/MEK/ERK  signaling  cascade. A. Kinetic 
scheme describing activation of the RET/Raf/MEK/ERK signaling cascade. The 
corresponding set of ordinary differential equations (ODEs) is shown in Table 5.1. Solid 
arrows indicate direct actions. The dashed arrow shows the indirect involvement of pRET in 
producing pRaf. B. Time-courses of pERK when RET (lozenges), Raf (triangles) or MEK 
(circles) was inhibited after 10 min of 4 nM ART stimulation, expressed in terms of average 
number of pERK molecules per cell. Data were taken from Figure 5.4, with the positive 
control normalized to the value of 142,000 pERK per cell that was determined in Chapter 2. 
The solid lines are simulated time-courses of pERK decay when RET (lozenges), Raf 




constants	   (k)	   in	   this	   scheme,	  we	   fitted	   the	   experimentally	  measured	   time-­‐courses	  for	  pERK	  decay	  when	  RET,	  Raf	  or	  MEK	  was	  inhibited	  after	  10	  min	  ART	  stimulation	  (Figure	  5.13B)	  to	  this	  model	  (Appendix	  VI).	  	  
RET	   activation	   induced	   by	   ART	   binding	   is	   a	   two-­‐step	   kinetic	   process,	   as	  described	  in	  Chapter	  3.	  Since	  we	  did	  not	  measure	  pERK	  decay	  upon	  inhibiting	  Ras,	  we	  omitted	  Ras	  from	  the	  signaling	  scheme	  and	  used	  a	  single	  step	  with	  rate	  constant	  of	  k2	  to	  represent	   the	  sequence	  of	  steps	  by	  which	  pRET	  activates	  Raf.	  The	   indirect	  involvement	  of	  pRET	  in	  Raf	  activation	  is	  represented	  by	  a	  dashed	  arrow	  in	  Figure	  
5.13A.	   The	   value	   of	   k2	   reflects	   the	   slowest	   step	   in	   the	   Raf	   activation	   process	   by	  pRET.	   The	   rate	   of	   each	   reaction	   in	   Figure	   5.13A	   can	   be	   determined	   by	   the	   rate	  constant	   and	   the	   concentration	   of	   reactants.	   The	   kinetic	   equations	   describing	   the	  concentration	  change	  of	  each	  molecule	  (Table	  5.1)	  were	  used	  build	  a	  computational	  model	  for	  the	  ERK	  pathway.	  Besides	  the	  chemical	  reactions	  shown	  in	  Figure	  5.13A,	  we	  also	  included	  the	  inhibitor-­‐induced	  deactivation	  steps	  for	  RET’,	  pRaf	  and	  pMEK	  in	   the	  ODEs	   to	   represent	   the	   situations	   in	   our	   experiments	  when	   inhibitors	  were	  added.	   The	   additional	   negative	   effects	   on	   the	   concentration	   change	   of	   target	  molecule	  X	   (X	   =	  RET’,	   pRaf	   or	  pMEK	   for	   each	   inhibitor	  used)	   can	  be	   expressed	   as	  d[X]/dt	   =	   −	   kInh	   [X]	   [Inh],	   where	   kInh	   is	   the	   rate	   constant	   for	   inhibition,	   [X]	   is	   the	  cellular	   concentration	   of	   RET’,	   pRaf	   or	   pMEK,	   and	   [Inh]	   is	   the	   concentration	   of	  inhibitors.	   Since	   we	   have	   previously	   shown	   that	   diffusion	   of	   the	   small	   molecules	  inhibitor	  into	  cells	  and	  binding	  to	  target	  proteins	  are	  not	  the	  rate-­‐limiting	  step,	  we	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made	  several	  constrains	  for	  the	  deactivation	  steps	  by	  inhibitors	  to	  ensure	  such	  steps	  remain	   fast	  enough	  and	  do	  not	  rate-­‐limit	  any	  downstream	  step.	  First,	  we	  assumed	  all	  inhibiting	  steps	  were	  irreversible	  with	  an	  artificial	  high	  rate	  constant	  kInh	  =	  1010	  molecule-­‐1	  cell	  min-­‐1.	  Secondly,	  we	  set	  an	  artificial	  high	  concentration	  [Inh]	  of	  1020	  molecule/cell	   for	   all	   three	   inhibitors	   for	   the	   fitting.	   Since	   we	   only	   tested	   one	  inhibitor	   at	   a	   time,	   the	   values	   of	   [Inh]	   and	   kInh	   were	   set	   as	   zero	   for	   uninhibited	  molecules	  during	  fitting.	  Rate	  constants	  for	  ART	  binding	  (k0),	  ART	  dissociation	  (k-­‐0),	  RET	  phosphorylation	  (k1),	  and	  RET	  dephosphorylation	  (k-­‐1)	  were	  set	  at	  3.1	  ×	  107	  M-­‐1	  min-­‐1,	  0.37	  min-­‐1,	  9.2	  min-­‐1	  and	  0.7	  min-­‐1,	  respectively,	  as	  determined	  in	  Chapter	  3.	  The	  rate	  constant	   for	  ERK	  dephosphorylation	  (k-­‐4)	  was	  set	  at	  a	  value	  of	  0.46	  min-­‐1	  and	   allowed	   to	   change	   freely	   during	   fitting,	   calculated	   from	   the	   exponential	   fit	  shown	   for	   the	   data	   in	   Figure	   5.3.	   Total	   cellular	   concentrations	   of	   the	   signaling	  molecules	  in	  Figure	  5.13A	  were	  set	  at	  values	  that	  we	  measured	  previously,	  or	  were	  
Table 5.1 Ordinary differential equations (ODEs) comprising the computational model of the 
RET/Raf/MEK/ERK signaling cascade. 
d[RET]/dt = -k0 [RET] [ART] + k-0 [RET’] 
d[RET’]/dt = k0 [RET] [ART] - k-0 [RET’] - k1 [RET’] + k-1 [pRET] – kInh [RET][Inh] 
d[pRET]/dt = k1 [RET’] - k-1 [pRET] - k2 [pRET] [Raf] + k2 [pRET] [Raf]  
d[Raf]/dt = - k2 [pRET] [Raf] + k-2 [pRaf] 
d[pRaf]/dt = k2 [pRET] [Raf] - k-2 [pRaf] - k3 [pRaf] [MEK] + k3 [pRaf] [MEK] – kInh [pRaf][Inh] 
d[MEK]/dt = - k3 [pRaf] [MEK] + k-3 [pMEK] 
d[pMEK]/dt = k3 [pRaf] [MEK] - k-3 [pMEK] - k4 [pMEK] [ERK] + k4 [pMEK] [ERK] 
                        - kInh [pMEK][Inh] 
d[ERK]/dt = - k4 [pMEK] [ERK] + k-4 [pERK] 




estimated	   based	   on	   literature.	   Specifically,	   in	  Chapter	   2,	   we	   showed	   that	   10	  min	  stimulation	   of	   4	   nM	   ART	   activated	   142,000	   pERK	   molecules	   and	   4,200	   pRET	  molecules	  per	  cell.	  Since,	  in	  the	  experiments	  shown	  in	  Figure	  5.13B,	  the	  inhibitors	  were	  added	  after	  10	  min	  stimulation	  with	  4	  nM	  ART,	  these	  numbers	  were	  used	  as	  the	   initial	   concentrations	   for	   pERK,	   pRET	   at	   time	   zero	   (the	   time	   of	   inhibitor	  addition).	   Since	   all	   three	   inhibitors	   block	   signaling	   at	   RET	   itself	   or	   at	   points	  downstream	  of	  RET,	  free	  RET	  and	  ART-­‐bound	  RET	  can’t	  continue	  to	  produce	  pRET	  or	   activate	   the	  ERK	  pathway.	  Therefore	   the	   initial	   concentrations	  of	   free	  RET	  and	  ART-­‐bound	  RET	  are	  not	  relevant	  for	  fitting	  the	  pERK	  decay	  data	  in	  Figure	  5.13B.	  So	  we	  set	   the	   initial	  concentrations	   for	   free	  RET	  (RET)	  and	  ART-­‐bound	  RET	  (RET’)	  at	  2,300	  and	  0	  molecule/cell,	  respectively.	  When	  RET	  was	  inhibited	  using	  ZD6474,	  we	  observed	  that	  pERK	  levels	  continued	  to	  increase	  for	  ~2	  min	  before	  starting	  to	  decay,	  indicating	  that,	  at	  the	  time	  of	  inhibitor	  addition,	  there	  is	  still	  unphosphorylated	  ERK	  present	   in	   the	   cell.	   We	   arbitrarily	   assumed	   4	   nM	   ART	   stimulation	   for	   10	   min	  activated	   50%	   of	   the	   total	   cellular	   ERK,	   such	   that	   there	   are	   142,000	  unphosphorylated	  ERK	  molecules	  per	   cell	   at	   time	   zero.	  We	   further	   estimated	   that	  total	   cellular	  MEK	   is	   approximately	   equal	   to	   total	   cellular	  ERK	   (284,000	  per	   cell),	  and	   that	   at	   10	   min	   after	   stimulation	   with	   4	   nM	   ART	   ~50%	   of	   cellular	   MEK	   is	  activated.	  Finally,	  we	  estimated	   that	   total	  cellular	  Raf	  was	  ~10-­‐fold	   less	   than	   total	  cellular	   ERK	   (28,400),	   and	   again	   that	   ~50%	   of	   total	   Raf	   is	   activated	   prior	   to	  inhibition.	   These	  numbers	   are	   based	  on	   reported	   values	   for	   cellular	  MEK	  and	  Raf	  concentrations	  relative	  to	  ERK	  in	  other	  cell	  types.319,320	  Figure	  5.13B	  shows	  a	  global	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nonlinear	   regression	   fit	   of	   the	   experimental	   time-­‐course	  data	   to	   this	  model,  using	  the	   program	  DynaFit.181	   The	   initial	   concentrations	   of	   different	  molecules	   prior	   to	  inhibition,	  and	  the	  rate	  constants	  obtained	  from	  the	  best	  fit,	  are	  collected	  in	  Table	  
5.2	   and	  Table	   5.3.	  The	   fit	   shown	   in	  Figure	   5.13B	   returns	  a	  best-­‐fit	   value	   for	   the	  
Table 5.2 Initial concentrations of the proteins in the RET/Raf/MEK/ERK signaling cascade 
prior to addition of inhibitors. 
Protein Concentration  (× 1000 molecules/cell) 
pRET 4.2 
Total RET 6.5 
pMEK 142 
Total MEK 284 
pRaf 14.2 
Total Raf 28.4 
pERK 142 
Total ERK 284 
Table 5.3 Rate constants for the computational RET/Raf/MEK/ERK signaling cascade model 
after 10 min of 4 nM ART stimulation. Error limits represent standard errors. Values of 
coefficient of variation (CV) for varying parameters are generated by the fit. 
Reaction Rate Constant CV (%) 
ART-RET association k0 = 3.1 × 107 M-1 min-1 Value fixed 
ART-RET dissociation k-0 = 0.37 min-1 Value fixed 
RET phosphorylation k1 = 9.2 min-1 Value fixed 
pRET dephosphorylation k-1= 0.7 min-1 Value fixed 
Raf phosphorylation k2 = 2.4 ± 2.2 × 10-7 mol-1 cell min-1 95 
pRaf dephosphorylation k-2 = 0.91 ± 0.14 min-1 15 
MEK phosphorylation k3 = 7.5 ± 2.1 × 10-5 mol-1 cell min-1 28 
pMEK dephosphorylation k-3 = 0.52 ± 0.03 min-1 6.1 
ERK phosphorylation k4 = 5.3 ± 0.5 × 10-6 mol-1 cell min-1 8.7 




rate	  constant	  (k-­‐3)	  for	  pMEK	  dephosphorylation	  of	  0.52	  min-­‐1,	  which	  is	  smaller	  than	  the	  rate	  constants	   for	  pRaf	  and	  pERK	  dephosphorylation	  (k-­‐2	  and	  k-­‐4,	   respectively).	  The	  slower	  decay	  of	  pMEK	  showed	  by	  the	  model	  supports	  our	  previous	  hypothesis	  that	  MEK	  deactivation	  is	  the	  rate-­‐limiting	  step	  in	  the	  ERK	  signaling	  decay.	  We	  also	  adjusted	   the	   initial	   concentration	   of	   total	   Raf	   to	   be	   10-­‐fold	   higher	   to	   test	   our	  assumption	  about	  how	  the	  initial	  molecule	  concentration	  would	  affect	  the	  results	  of	  our	  model.	  The	  best	  fit	  obtained	  using	  10-­‐fold	  higher	  initial	  levels	  of	  Raf	  only	  slightly	  changed	   the	   parameters,	   and	   returned	   a	   value	   for	   k-­‐3	   	   =	   0.50	   ±	   0.03	   min-­‐1,	   still	  smaller	  than	  k-­‐2	  =	  1.0	  ±	  0.2	  min-­‐1	  and	  k-­‐4	  =	  0.66	  ±	  0.03	  min-­‐1.	  This	  result	  shows	  that	  the	   qualitative	   conclusion	   from	   our	   model	   that	   pMEK	   deactivation	   is	   the	   rate-­‐limiting	  step	   from	  the	  model	   is	  not	  affected	  by	   the	  arbitrarily	  selected	  cellular	  Raf	  and	  pRaf	  concentrations,	  and	  thus	  likely	  reflects	  a	  true	  behavior	  of	  our	  system.	  
The	  rate	  constants	  provided	  by	  the	  model	  can	  help	  to	  predict	  the	  behavior	  of	  ERK	  signaling	  in	  response	  to	  sudden	  decreases	  of	  upstream	  stimulus.	  We	  compared	  the	  activation	  and	  deactivation	  rate	  of	  each	  upstream	  molecule	  prior	  to	  the	  moment	  of	  addition	  inhibitors,	  to	  explain	  the	  observed	  changes	  in	  ERK	  levels	  upon	  inhibiting	  RET,	  Raf	  or	  MEK	  by.	  As	  shown	  in	  Table	  5.4,	  we	  calculated	  the	  net	  formation	  rates	  of	  pRaf,	  pMEK	  and	  pERK	  based	  on	   the	  activation	   rates	  and	  deactivation	   rates	  of	  Raf,	  MEK	  and	  ERK	  calculated	  by	  incorporating	  the	  rate	  constants	  from	  the	  best	  fit	  (Table	  
5.2)	   and	   the	   initial	   protein	   concentrations	   (Table	   5.3)	   into	   the	  ODEs	   from	  Table	  
5.1.	   Prior	   to	   the	  moment	   of	   adding	   any	   inhibitors,	   the	   formation	   rate	   of	   pERK	   is	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slight	  higher	  than	  its	  decay	  rate,	  so	  that	  pERK	  levels	  still	   increased	  for	  a	  time	  after	  inhibitor	   addition.	   Because	   our	  model	   suggests	   pRaf	   has	   similar	   short	   lifetime	   as	  pRET	   (t1/2	   ≤	  1	  min),	   both	  pRET	  and	  pRaf	   are	   almost	   gone	   after	  ~1−2	  min	  of	  RET	  inhibition.	   Therefore,	   after	   ~1−2	   min	   of	   RET	   inhibition,	   levels	   of	   pMEK	   have	  decreased	  to	  a	   level	  where	   it	  activates	  ERK	  at	   the	  same	  rate	  as	  pERK	  decay.	  Thus,	  pERK	  levels	  start	  to	  decrease	  not	  immediately	  after	  addition	  of	  RET	  inhibitors,	  but	  after	   this	   1−2	   min	   lag	   time,	   as	   we	   observed	   experimentally	   (Figure	   5.13B).	   In	  contrast,	  if	  Raf	  is	  inhibited,	  further	  activation	  of	  MEK	  is	  blocked,	  so	  that	  pMEK	  levels	  begin	   deceasing	   immediately	   upon	  Raf	   inhibition.	   Since	   the	  ERK	   activation	   rate	   is	  only	   slightly	   bigger	   than	   its	   deactivation	   rate,	   this	   immediate	   decrease	   in	   pMEK	  levels	   causes	   an	   immediate	   decrease	   in	   the	   ERK	   activation	   rate,	   and	   results	   in	   a	  much	   shorter	   lag	   before	   the	   net	   pERK	   levels	   begin	   to	   decay.	   This	   feature	   of	   the	  model	   again	   agrees	   with	   our	   experimental	   observation	   of	   a	   much	   shorter	   lab	   in	  pERK	  decay	  after	  Raf	  inhibition	  compared	  to	  RET	  inhibition	  (Figure	  5.13B).	  
It	   is	   worth	   noting	   that,	   prior	   to	   the	   moment	   of	   inhibitor	   addition,	   the	   Raf	  activation	  rate	  is	  already	  less	  than	  its	  deactivation,	  suggesting	  that	  activation	  of	  Raf	  
Table 5.4 Reaction rates for Raf, MEK, Raf activation and deactivation after 10 min of 4 nM 
ART stimulation. Net formation rate of pX (X = Raf, MEK or ERK) is calculated from the 
activation rate minus the deactivation rate.  
Molecule Activation Rate (molecule cell-1 min-1) 
Deactivation Rate 
(molecule cell-1 min-1) 
Net Formation 
Rate of pX 
Raf 7.8 1.3 × 104 -1.3 × 104 
MEK 1.5 × 105 7.4 × 104 7.6 × 104 




itself	   is	   already	   declining	   after	   10	   min	   of	   ART	   stimulation.	   The	   negative	   net	  formation	  rate	  of	  pRaf	  might	  explain	  the	  observed	  decrease	  in	  pERK	  levels	  after	  the	  transient	  ERK	  response	  at	  10	  min	  of	  ART	  stimulation,	  seen	  even	   in	   the	  absence	  of	  any	  inhibitors	  (Figure	  2.11),	  and	  very	  likely	  result	  from	  the	  negative	  feedback	  at	  or	  downstream	   of	   pERK.	   If	   this	   is	   the	   case,	   the	   rate	   constants	   in	   this	  model	   (Figure	  
5.13A)	  would	  be	  different	  in	  the	  initial	  stage	  of	  ERK	  activation,	  before	  such	  feedback	  occurs.	  To	  investigate	  how	  the	  rate	  constants	  are	  affected	  by	  such	  negative	  feedback	  effects,	  and	  specifically	  whether	  Raf	  activation	   is	  decreased,	  we	  estimated	  the	  rate	  constants	  within	   the	   initial	   10	  min	  of	  ART	   stimulation	  by	   fitting	   the	  10-­‐min	   time-­‐course	  of	  ERK	  activation	  (Figure	  2.10A)	   to	   the	  same	  model.	  Figure	  5.14	   shows	  a	  global	  nonlinear	  regression	  fit	  of	  the	  ERK	  activation	  time-­‐course	  data	  to	  this	  model	  (Appendix	   VII),   using	   the	   program	   DynaFit.181	   The	   initial	   concentrations	   of	  different	  molecules	  prior	  to	  inhibition,	  and	  the	  rate	  constants	  obtained	  from	  the	  best	  
  
Figure 5.14 Time-courses of ERK activation stimulated by ART at the stated concentrations.  
Data  were  taken  from  Figure  2.10A.  The  solid  lines  are  fitted  time-­‐‑courses  generated  
by  our  model.  
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fit,	   are	   collected	   in	   Table	   5.5	   and	   Table	   5.6.	   Since	   the	   basal	   level	   of	   pERK	   in	  untreated	   cells	  was	   subtracted	   as	   background	   and	   the	   pERK	   levels	   only	   reflected	  ART-­‐induced	  activation,	  we	  set	  the	  initial	  concentrations	  for	  pERK	  and	  all	  activators	  in	   the	   ERK	   pathway	   (RET’,	   pRET,	   pRaf,	   pMEK)	   at	   zero	   during	   the	   fitting.	   Rate	  constants	   for	   the	   RET	   activation	   process	   (k0,	   k-­‐0,	   k1,	   and	   k-­‐1)	   and	   pERK	  dephosphorylation	  were	  set	  at	  the	  same	  values	  as	  the	  best	  fit	  of	  the	  pERK	  decay	  data	  set	  (as	  shown	  in	  Table	  5.3),	  and	  are	  omitted	  in	  Table	  5.6.	  
	   Based	   on	   the	   same	   computational	   RET/Raf/MEK/ERK	   signaling	   cascade	  model,	  we	   obtained	   two	   sets	   of	   rate	   constants	   for	   the	   steps	   in	   the	   Raf/MEK/ERK	  cascade:	  one	  from	  fitting	  the	  time-­‐course	  of	  ERK	  activation	  during	  the	  initial	  10	  min	  of	  ART	   stimulation	   in	   various	   concentrations,	   and	   the	  other	   from	   fitting	   the	   time-­‐course	  of	  pERK	  decay	  starting	  after	  10	  min	  of	  4	  nM	  ART	  stimulation	  when	  different	  steps	  were	  inhibited.	  Since	  the	  rate	  constants	  were	  assumed	  to	  be	  invariant	  during	  
Table 5.5 Initial concentrations of the proteins in the RET/Raf/MEK/ERK signaling cascade 
before ART stimulation, used to fit the data in Figure 5.14. 
Protein Concentration  (× 1000 molecules/cell) 
pRET 0 
Total RET 6.5 
pMEK 0 
Total MEK 284 
pRaf 0 
Total Raf 28.4 
pERK 0 




the	   10-­‐min	   activation	   time-­‐course,	   values	   obtained	   reflect	   the	   average	   values	  throughout	   the	   10-­‐min	   activation	   process.	   Comparison	   of	   these	   two	   sets	   of	   rate	  constants	  shows	  that	  the	  average	  Raf	  activation	  rate	  constant	  during	  initial	  stage	  of	  signaling	  was	  ~50-­‐fold	  higher	   than	  that	  seen	  after	  10	  min	  of	  stimulation,	  whereas	  other	  rate	  constants	  differed	  by	  less	  than	  5-­‐fold.	  This	  result	  suggests	  that	  negative	  feedback	   effects	   substantially	   decrease	   the	   Raf	   activation	   rate	   during	   the	   10	  min	  period	  of	  ART	  stimulation,	  leading	  to	  an	  to	  eventually	  decrease	  in	  pERK	  levels	  after	  the	  transient	  peak	  at	  10	  min.	  
	  
Table 5.6 Rate constants for the computational RET/Raf/MEK/ERK signaling cascade model 
for the first 10 min of ART stimulation. Error limits represent standard errors. Values of 
coefficient of variation (CV) for varying parameters are generated by Dynafit. Rate constants 
for the same steps after 10 min of 4 nM ART stimulation obtained from fitting the pERK 
decay data (Table 5.3) were listed for comparison. The unit for k2, k3 and k4 is mol-1 cell min-1. 
The unit for k-2, k-3 and k-4 is min-1.   
Reaction Rate Constant CV (%) Rate Constant (After 10 min) 
Raf phosphorylation k2 = 4.9 ± 20.0 × 10-5  410 k2 = 2.4 ± 2.2 × 10-7 
pRaf dephosphorylation k-2 = 0.00 ± 0.14  0 k-2 = 0.91 ± 0.14 
MEK phosphorylation k3 = 1.4 ± 7.2 × 10-4 1 520 k3 = 7.5 ± 2.1 × 10-5 
pMEK dephosphorylation k-3 = 1.9 ± 3.0  160 k-3 = 0.52 ± 0.03 
ERK phosphorylation k4 = 4.2 ± 6.6 × 10-61 160 k4 = 5.3 ± 0.5 × 10-6 




5.6. Conclusions	  	  
In	  this	  study,	  we	  analyzed	  the	  signaling	  kinetics	  of	  the	  ERK	  and	  Akt	  pathways	  stimulated	  by	  ART,	  and	  examined	   the	  possible	   cross-­‐talk	  between	   these	  pathways	  using	  selective	  small	  molecule	  inhibitors.	  Our	  results	  show	  that,	  in	  our	  experimental	  system,	   there	   is	  no	  crosstalk	  between	  ERK	  and	  Akt	  pathways	  within	   the	   initial	  60	  min	  of	  RET	  stimulation	  by	  ART.	  Analyses	  of	  different	  pERK	  decay	  rate	  in	  response	  to	  inhibiting	  different	  upstream	  steps	  in	  signaling	  suggested	  that	  activated	  MEK	  has	  a	  substantially	  longer	  lifetime	  than	  other	  molecules	  in	  the	  ERK/MAPK	  pathways,	  and	  extends	  ERK	  signaling	  when	  RET	  activation	  is	  rapidly	  reduced.	  This	  hypothesis	  was	  further	   supported	   by	   construction	   of	   a	   computational	  model	   of	   the	   ERK	   signaling	  cascade.	   Our	   results	   illustrate	   that	   employment	   of	   selective	   pathway-­‐specific	  inhibitors	  can	  provide	  detailed	  kinetic	  information	  on	  how	  signaling	  transduction	  is	  regulated.	  	  
Computational	  modeling	  based	  on	  quantitative	  data	   for	  the	  time-­‐dependent	  behavior	   of	   the	   system	   enabled	   us	   to	   quantify	   key	   rate	   constants	   in	   the	   ERK	  signaling	   cascade	   that	   are	   often	   difficult	   to	   measure	   directly	   in	   cells.	   Many	  computational	  models	   have	   been	   developed	   to	   analyze	   and	   predict	   ERK	   signaling	  dynamics301,302,303,304,321,322,323,324,325	  Most	  of	  these	  models	  were	  developed	  based	  on	  kinetic	   parameters	   obtained	   from	   experiments	   with	   purified	   recombinant	  proteins304,324,325,326,	  which	  makes	   the	  model-­‐generated	  predictions	   less	   applicable	  to	   the	   systems	   in	   their	   native	   cellular	   context.	   Models	   that	   include	   hundreds	   of	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signaling	  molecules	  and	  kinetic	  parameters	  are	   typically	  grossly	  underdetermined	  due	   to	   lack	   of	   quantitative	   systematic	   data	   on	   those	   signaling	   components	   and	  microscopic	   steps,	   which	   can	   compromise	   the	   accuracy	   of	   the	  models.304,321,323,325	  Compared	   to	   those	   models,	   our	   model	   is	   much	   smaller	   in	   scale,	   with	   just	   four	  signaling	   molecules	   (RET,	   Raf,	   MEK	   and	   ERK)	   and	   only	   focuses	   on	   the	   signaling	  kinetics	   within	   a	   short	   period	   of	   after	   stimulation	   or	   inhibition	   (≤	   30	   min).	   Our	  model	  was	  trained	  with	  quantitative	  experimental	  data	  with	  good	  accuracy,	  for	  the	  activation	   dynamics	   of	   endogenous	   ERK.	   This	   advantage	   potentially	   equips	   our	  model	   with	   good	   predictive	   ability	   for	   the	   system’s	   true	   behavior.	   Our	   model	  supports	   that	   pMEK	   is	   the	   most	   long-­‐lived	   activated	   signaling	   molecules	   in	   the	  RET/Ras/Raf/MEK/ERK	  cascade,	  and	  that	  MEK	  deactivation	  is	  the	  slowest	  step	  and	  regulated	   the	   decay	   rate	   of	   pERK	  when	   stimulation	   is	   decreased.	   The	  model	   also	  suggests	   that	   the	   negative	   feedback	   effects	   on	   ERK	   activation	   act,	   in	   part,	   by	  decreasing	   the	   activation	   rates	   of	   Raf	   rather	   than	   directly	   acting	   on	  MEK	   or	   ERK	  itself.	  
A	  possible	  biological	  advantage	  of	  having	  such	  long-­‐lived	  species	  upstream	  of	  ERK	  would	  be	   to	  prevent	  unnecessary	  oscillations	  of	  ERK	  signaling	   in	  response	   to	  rapid	   variations	   in	   upstream	   stimulation.	   When	   receptor	   stimulus	   drops,	   if	   MEK	  deactivation	   was	   not	   relatively	   slow,	   pERK	   levels	   would	   drop	  more	   quickly.	   This	  would	  potentially	  eliminate	  negative	  feedback	  effects	  regulated	  by	  pERK	  levels.	  The	  overall	  result	  would	  be	  noise	  and	  oscillation	  at	  the	  level	  of	  pERK.	  This	  putative	  noise	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in	   ERK	   signaling	   can	   be	   dampened	   if	   pERK	   decays	   at	   a	  well-­‐controlled	   slow	   rate.	  With	  MEK	  deactivation	  being	   the	   rate-­‐limiting	   step,	   any	   feedback	  effects	   targeting	  MEK	  or	  molecules	  upstream	  will	  cause	  pERK	  to	  decrease	  ~4-­‐fold	  more	  slowly	  than	  pERK	  dephosphorylation	  itself.	  On	  the	  other	  hand,	  rapid	  decay	  of	  ERK	  signaling	  can	  still	  be	  achieved	   if	  ERK	  activation	   is	  directly	   inhibited.	  The	  existence	  of	  a	   long-­‐live	  species	  upstream	  of	  ERK	  enables	   the	   system	   to	   turn	  off	   the	  ERK	  signaling	   flexibly	  depending	  on	  which	   step	   is	   affected	  by	   the	  negative	   feedback	   regulation.	  Another	  potential	  advantage	  of	  having	  this	  long-­‐lived	  molecule	  to	  activate	  ERK	  is	  to	  support	  continuous	  ERK	  signaling	  even	  with	  pulsatile	  ligand	  stimulation.	  For	  instance,	  if	  ART	  stimulation	   occurs	   in	   pulses,	   ERK	   signaling	   can	   be	   sustained	   by	   its	   long-­‐lived	  activator	   when	   ART	   stimulation	   is	   gone,	   and	   will	   remain	   elevated	   until	   the	   next	  pulse.	   Therefore,	   pulsatile	   ART	   stimulation,	   as	   long	   as	   it	   is	   within	   a	   certain	  frequency	  range,	  is	  able	  to	  trigger	  continuous	  ERK	  signaling.	  
We	  speculate	   that	   it	   is	   important	   to	  have	  pMEK	  as	   the	   long-­‐lived	  activator,	  rather	   than	   any	   upstream	  molecules,	   in	   order	   to	   maintain	   the	   sensitivity	   of	   ERK	  signaling	   in	   response	   to	   decreases	   of	   stimulation.	   For	   example,	   if	   this	   long-­‐lived	  species	  is	  not	  pMEK	  but	  pRaf,	  it	  will	  require	  a	  longer	  time	  for	  pRaf	  and	  then	  pMEK	  to	  decrease	   to	   certain	   levels	  when	   pERK	   starts	   to	   decay,	   and	   causing	   a	   lag	   between	  decrease	  in	  ERK	  signaling	  and	  stimulation	  levels.	  In	  this	  case,	  the	  system	  would	  not	  be	  as	   sensitive	   to	   changes	   in	   stimulation	   levels	  as	  having	  MEK	  deactivation	  as	   the	  slow	  step.	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Although	  we	  observed	   similar	   feedback	  effects	   of	  Akt	   activation	   stimulated	  by	  ART,	  we	  did	  not	   see	  any	   step	   in	   the	  Akt	  pathway	   that	  was	   significantly	   slower	  than	  pRET	  dephosphorylation.	  Because	  Akt	   can	  be	   activated	  by	   several	  molecules	  including	  PDK1,	  mTORC2	  and	  DNA-­‐PK	  in	  parallel,	  not	  having	  a	  particular	  long-­‐lived	  activator	   for	  Akt	  could	  help	  ensure	   that	  Akt	  signaling	  can	  respond	  quickly	  with	   to	  changes	  in	  the	  activation	  levels	  of	  any	  upstream	  activators	  of	  Akt.	  	  
	  
5.7. Experimental	  Methods	  
Materials	  Raf	   inhibitor	   SB590885	   (catalog	   no.	   S2220),	   MEK	   inhibitor	   (catalog	   no.	  S1020)	  and	  Akt	  inhibitor	  MK2206	  (catalog	  no.	  S1078)	  were	  purchased	  from	  Selleck	  Chemicals	   (Houston,	   TX).	  Materials	   used	   for	   pERK	  and	  pAkt	  ELISAs,	   and	   all	   other	  cell	  lines	  and	  materials	  used,	  were	  exactly	  as	  described	  in	  Chapter	  2.	  
Dose-­‐dependent	  inhibition	  of	  pERK	  	  
NB41A3-­‐mGFRα3	  cells	  were	  stimulated	  with	  4	  nM	  ART	   for	  10	  min	  and	   the	  medium	  were	   switched	   to	   4	   nM	   ART	   containing	   CI1040	   or	   SB590885	   at	   various	  concentrations	  (DMSO	  v/v	  ≤	  0.1%).	  The	  cells	  were	  lysed	  at	  10	  min	  after	  addition	  of	  CI1040,	   or	   20	   min	   after	   addition	   of	   SB590885,	   and	   pERK	   levels	   were	   measured	  using	  the	  pERK	  ELISA,	  as	  described	  in	  detail	  in	  Chapter	  2.	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Dose-­‐dependent	  inhibition	  of	  pAkt	  
NB41A3-­‐mGFRα3	  cells	  were	  stimulated	  with	  4	  nM	  ART	   for	  10	  min	  and	   the	  medium	  were	  switched	  to	  4	  nM	  ART	  containing	  MK2206	  at	  various	  concentrations.	  The	   cells	   were	   lysed	   at	   10	  min	   after	   addition	   of	  MK22060,	   and	   pAkt	   levels	  were	  measured	  using	  the	  pAkt	  ELISA,	  as	  described	  in	  detail	  in	  Chapter	  2.	  
Measurement	  of	  pERK	  and	  pAkt	  Decay	  Rates	  
NB41A3-­‐mGFRα3	  cells	  were	  stimulated	  with	  4	  nM	  ART	   in	  DMEM	  for	  4,	  10,	  30,	   or	   60	   min	   before	   the	   medium	   were	   changed	   to	   4	   nM	   ART	   plus	   the	   selected	  inhibitor	  at	  the	  stated	  concentrations	  (DMSO	  v/v	  ≤	  0.01%).	  The	  cells	  were	  lysed	  2,	  4,	  6,	  8,	  10,	  15	  or	  30	  min	  after	  addition	  of	  the	  inhibitor.	  Levels	  of	  pERK	  and	  pAkt	  in	  the	  cell	   lysate	  were	  measured	  by	  pERK	  and	  pAkt	  ELISAs,	   respectively,	  as	  described	   in	  
Chapter	  2.	  
Effects	  of	  CI1040	  on	  Akt	  phosphorylation	  




Method	  for	  fitting	  
Experimental	  data	  of	  ERK	  activation	  or	  pERK	  decay	  were	  fitted	  to	  the	  model	  in	   Figure	   5.13A	   (Appendix	   VII),   using	   the	   program	   DynaFit	   (BioKin	   Ltd.,	  Watertown,	  MA).	  The	  scripts	  of	  the	  model	  encoding	  the	  chemical	  reactions	  used	  for	  fitting	   in	  Dynafit	  are	  described	  as	  below,	  where	  k	   represents	   the	  rate	  constant	   for	  each	  step.	  	  	   RET	  +	  ART	  à	  RET'	  +	  ART	   	   k0	   	  	   RET'	  à	  RET	   	   	   	   k-­‐0	  	   RET'	  à	  pRET	   	   	   	   k1	  	   pRET	  à	  RET’	  	  	   	   	   k-­‐1	  	   Raf	  +	  pRET	  à	  pRaf	  +	  pRET	   	   k2	  	   pRaf	  à	  Raf	   	   	   	   k-­‐2	  	   pRaf	  +	  MEK	  à	  pMEK	  +	  pRaf	  	   k3	  	   pMEK	  à	  MEK	  	   	   	   k-­‐3	  	   pMEK	  +	  ERK	  à	  pMEK	  +	  pERK	   k4	  	   pERK	  à	  ERK	   	   	   	   k-­‐4	  
	   RET	  +	  ZD6474	  à	  RET-­‐ZD	   	   kInhRET	   	  	   pRaf	  +	  SB590885	  à	  pRaf-­‐SB	   kInhRaf	   	  	   pMEK	  +	  CI1040	  à	  pMEK-­‐CI	  	   kInhMEK	  
	   When	   fitting	   the	   pERK	   decay	   data	   after	   addition	   of	   the	   selected	   inhibitor,	  taking	   RET	   inhibitor	   ZD6474	   for	   example,	   the	   concentration	   of	   this	   inhibitor	  (ZD6474)	   is	   set	   at	   1020	   molecule/cell	   and	   the	   concentrations	   of	   the	   other	   two	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Appendix	  I.	  Dynafit	  scripts	  for	  the	  simplified	  RET	  activation	  model	  
[task] 
 task = fit | data = progress  
 
[mechanism] 
 RET + ART  ----> pRET + ART  : k1  
 pRET <---> RET   :  k-1   
 
[constants] 
 k0 = 4.46789e+007 ?  
 k-0 = 0.37 
 k1 = 2.91952 ? 
 k-1 = 0.7 
 
[concentrations] 
 RET = 6.5, ART = 10e-9, pRET = 0 
 
[data] 
 sheet ./Ret/data/Normalized/pRET10min.txt 
 column 2 | conc ART = 0.1e-9 | response pRET = 1  
 column 3 | conc ART = 0.4e-9 | response pRET = 1 
 column 4 | conc ART = 1e-9 | response pRET = 1 
 column 5 | conc ART = 4e-9 | response pRET = 1 





 XAxisLabel = Time (minutes) 
 YAxisLabel = pRET (10^3 molecules/cell) 
 





Appendix	  II.	  Dynafit	  scripts	  for	  two-­‐step	  RET	  activation	  model	  
[task] 
 task = fit | data = progress  
 
[mechanism] 
 RET + ART  ----> RET' + ART  : k0  
 RET' ---> RET    : k-0  
 RET' <---> pRET   : k1 k-1   
 
[constants] 
 k0 = 4.46789e+007 ?  
 k-0 = 0.37 
 k1 = 2.91952 ? 
 k-1 = 0.7 
 
[concentrations] 
 RET = 6.5, ART = 10e-9, RET' = 0, pRET = 0 
 
[data] 
 sheet ./Ret/data/Normalized/pRET10min.txt 
 column 2 | conc ART = 0.1e-9 | response pRET = 1  
 column 3 | conc ART = 0.4e-9 | response pRET = 1 
 column 4 | conc ART = 1e-9 | response pRET = 1 
 column 5 | conc ART = 4e-9 | response pRET = 1 





 XAxisLabel = Time (minutes) 
 YAxisLabel = pRET (10^3 molecules/cell) 
 




Appendix	  III.	  Dynafit	  scripts	  for	  two-­‐step	  RET	  activation	  model	  with	  RET	  inhibitor	  
[task] 
 task = fit | data = progress  
 
[mechanism] 
 RET + ART  ----> RET' + ART :  k0 
 RET' ---> RET   :  k-0 
 RET' <---> pRET   :  k1 k-1  
 RET + Inh ----> RETInh + Inh : ki 
 RETInh ----> RET   :  k-i 
 RET' + Inh ---> RETInh' + Inh  :  ki 
 RETInh' ----> RET'  :  k-i 
 RETInh + ART ---> RETInh' + ART : k0  
 RETInh' ----> RETInh  :  k-0 
  
[constants] 
 k0 = 6.34749e+007 ?  
 k-0 = 0.37 ? 
 ki = 1e9  
 k-i = 154.3 ? (0 .. 1e3) 
 k1 = 1.93261 ? 
 k-1 = 0.7 
 
[concentrations] 
 RET = 6.5, ART = 10e-9, RET' = 0, pRET = 0,  




 sheet ./Ret/data/pRETinh10.txt 
 column 2 | conc INH = 0.0e-6 | response pRET = 1 
 column 3 | conc INH = 0.2e-6 | response pRET = 1 
 column 4 | conc INH = 0.4e-6 | response pRET = 1 





 XAxisLabel = Time (minutes) 
 YAxisLabel = pRET (10^3 molecules/cell) 
 




Appendix	  IV.	  Dynafit	  scripts	  for	  RET	  activation	  and	  trafficking	  
[task] 
 task = fit 
 data = progress 
 
[mechanism] 
 RET + ART  ----> RET' + ART : k0  
 RET' ----> RET   : k-0 
 RET' <----> pRET  :  kp kppase  
 pRET ---> ipRET   :   kint  
 RET' --> iRET'   : kint2 
 iRET' <---> ipRET  : kp kppase  
 iRET --> sRET   : ksort1 
 ipRET ---> llRET  :  ksort2 
 llpRET ---> lysRET  : klys 
 llRET ---> sRET   :  krec2 
 sRET --> RET   : krec1 
 
[constants] 
 k0 = 4.67641e+007 
 k-0 = 0.37 
 kp = 2.15833 
 kppase = 0.7 
 kint = 0.0753669 ? (0 .. 10) 
 kint2 = 0.01 ? (0 .. 0.1) 
 ksort1 = 0.0734829 ? (0 .. 10) 
 ksort2 = 0.0495502 ? (0 .. 10) 
 krec1 = 0.02 ? 
 krec2 = 0.01 ? 




 RET = 6.5, ART = 4e-9, RET' = 0, pRET = 0, sRET = 0, 
 ipRET = 0, iRET' = 0, 
 
[data] 
 sheet ./RET/Data/pRET90timecourse.txt 
 
 column 2 | conc ART = 0.1e-9 | response pRET = 1 
 column 3 | conc ART = 0.4e-9 | response pRET = 1 
 column 4 | conc ART = 1e-9 | response pRET = 1 
 column 5 | conc ART = 4e-9 | response pRET = 1 







 XAxisLabel = Time (minutes) 
 YAxisLabel = (10^3 molecules/cell) 
 




Appendix	  V.	  Python	  scripts	  for	  RET	  activation	  and	  trafficking	  
Scripts	  of	  the	  model	  








Monomer('RET', ['s', 'c'], {'s': ['u','p'], 'c': ['i', 'g']}) 






Monomer('RAF', ['s'], {'s': ['u', 'p']}) 
Monomer('MEK', ['s'], {'s': ['u', 'p']}) 
Monomer('ERK', ['s'], {'s': ['u', 'p']}) 
Monomer('PP', ['s'], {'s': ['u', 'p']}) 
 




#proportion of pS / S at steady state  
f1 = 0.638 #pRET / RET at ss 0.72 
f2 = 0.5 #pRAF / RAF at ss 
f3 = 0.5 #pMEK / MEK at ss 
f4 = 0.5 #pERK / ERK at ss 
#***************************initial amounts***********# 
"""make sure you move iArt up here afterwards (once this is all 
done)""" 
model.iRetu = 6.5 
model.iRafu = 140.000/f2 
model.iMeku = 140.000/f3 
model.iErku = 142.000/f4 
#***************************DynaFit Global Analysis Fit 
Constants*************************# 
iArt = 4e-9 
inhibitor = 0e-6 
k0for = 2e+007 




kp = 9 
kp2 = 9 
kpp = 0.7 
kpp2 = 0.7 
kint = 0.1 
kint2 = 0.04 
kSORT1 = 0.1 
kSORT2 = 0.2 
kREC1 = 0.02 
kREC2 = 0.15 
klyse = 0.03  #0.37, 0.025 
kif = 1e9 
kirev = 154.577 #154.577 or 142.352 
 
k2rev = 3 #variable 
k3rev = 0.3 
k4rev = 0.7 
k2for = k2rev*f2/((1-f2)*f1*model.iRetu) 
k3for = k3rev*f3/((1-f3)*f2*model.iRafu) 




















Parameter('k2r', 3) #variable 
Parameter('k3r', 0.3) #fix 
































Initial(RET(s='u', c='i'), Retui0) 
Initial(RET(s='u', c='g'), Retug0) 
Initial(RET(s='p', c='g'), Retpg0) 
 
Initial(iRET(s='u'),  iRetug0) 
Initial(iRET(s='p'),  iRetpg0) 
Initial(sRET(), sRet0) 















    *+* operator to represent complRule('Rrev', RET(b=None,s='p') 
>> RET(b=None, s='u'), kppase)exation 
    *<>* operator to represent backward/forward reaction 




    *%* operator to represent a binding interaction between two 
species""" 
 
Rule('inhret', INH() + RET(s='u', c='i') >> inhRET(c='i') + 
INH(), ki) 
Rule('inhretrev', inhRET(c='i') >> RET(s='u', c='i') , kir) 
Rule('inhiret', INH() + iRET(s='u') >> iRET(s='i') + INH(), ki) 
Rule('inhiretrev', iRET(s='i') >> iRET(s='u') , kir) 
Rule('inhgret', INH() + RET(s='u', c='g') >> inhRET(c='g') + 
INH(), ki) 
Rule('inhgretrev', inhRET(c='g') >> RET(s='u', c='g'), kir) 
Rule('inhretg', inhRET(c='i') + Art() >> inhRET(c='g') + Art(), 
k0) 
Rule('inhretgrev', inhRET(c='g') >> inhRET(c='i'), k0r) 
 
Rule('retg', RET(s='u', c='i') + Art() >> RET(s='u', c='g') + 
Art(), k0)             
Rule('reti', RET(s='u', c='g') >> RET(s='u', c='i'), k0r) 
Rule('retp', RET(s='u', c='g') <> RET(s='p', c='g'), kp, kppase)  
Rule('pretint', RET(s='p',c='g') >> iRET(s='p'), kint)                              
Rule('retint', RET(s='u',c='g') >> iRET(s='u'), kint2)  
Rule('iretp', iRET(s='u') <> iRET(s='p'), kp2, kppase2)  
Rule('sortRET1', iRET(s='u') >> sRET(), ksort1)                                     
Rule('sortRET2', iRET(s='p') >> llRET(), ksort2)  
Rule('lysellRET', llRET() >> lysed(), klys)  
Rule('rec2', llRET() >> sRET(), krec2) 

















model.TotalRet = ['RETuiout', 'RETugout', 'RETpgout', 'RETugin', 
'RETpgin', 'RETs', 'RETll'] 





	  Scripts	  of	  the	  program	  to	  run	  the	  mdel	  
from pylab import * 
from pysb.integrate import odesolve 
from Model_2016 import model ###substitute “Model_2016” to file 
name 
 
time = 90 #minutes 
tspan = linspace(0,time,time*4+1) 
print "Simulating..." 
 
yfull = odesolve(model, tspan) 
 
#reterk = [] 
# 
#for x in range(0, len(tspan)): 
#    reterk.append(yfull['obsERKp'][x]/yfull['obsRETpg'][x]) 
#     
#derRET = [] 
#for x in range(0, len(tspan)-1): 
#    derRET.append((yfull['obsRETpg'][x+1]-
yfull['obsRETpg'][x])/(tspan[x+1]-tspan[x])) 
total_RET=[] 
for x in range(len(tspan)): 
    sum = 0 
    for m in model.TotalRet: 
        sum = sum + yfull[m][x]###This function will plot 
timecourse data in dcsv 
    total_RET.append(sum) 
     
tRET=[] 
for x in range(len(total_RET)): 
    tRET.append(total_RET[x]-1) 
 
pRET=[] 
for x in range(len(tspan)): 
    pRET.append(yfull['RETpgout'][x] + yfull['RETpgin'][x] + 
yfull['RETll'][x]) 
out_RET=[] 
for x in range(len(tspan)): 
    out_RET.append(yfull['RETpgout'][x] + yfull['RETugout'][x] + 
yfull['RETuiout'][x]) 
int_RET=zeros(len(tspan)) 
for x in range(len(tspan)): 




surf_RET = zeros(len(tspan)) 
for x in range(len(tspan)): 
    surf_RET[x] = out_RET[x]/6.5*100 
EE_RET = zeros(len(tspan)) 
for x in range(len(tspan)): 
    EE_RET[x] = yfull['RETugin'][x] + yfull['RETpgin'][x] 
fllpRET = zeros(len(tspan)) 
for x in range(len(tspan)): 
    fllpRET[x] = yfull['RETll'][x]*100/(yfull['RETpgout'][x] + 
yfull['RETpgin'][x] + yfull['RETll'][x]) 
## 
plot(tspan, yfull['RETll'], label = "ll-pRET", color = 'b') 
#plot(tspan, int_RET, label = "Internalized RET", color = 'b')     
plot(tspan, out_RET, label = "Surface RET", color = 'g') 
#plot(tspan, EE_RET, label = "EE RET", color = 'g') 
plot(tspan, pRET, label = "pRET", color = 'r') 
#plot(tspan, fllpRET, label = "llpRET/totalpRET", color = 'r') 
#plot(tspan, total_RET, label = 'Total RET', color = 'm') 
#plot(tspan, yfull['RETs'], label = 'sRET') 
 






for i in range(1,6): 
    print pRET[i*40] 
 
#for x in model.Obsarray: 
#    print yfull[x][len(tspan)-1] 
""" 
for x in range(1,6): 
    print yfull['RETpgout'][x*((time*4+1)/5)] 









#for t in range(len(tspan)): 
#    data[0].append(tspan[t]) 
#create time entry 
     




    data.append([model.Obsarray[x]]) 
#create species labels - i.e. row 1 of the array 
     
counter = 0  
for spec in model.Obsarray: 
    for y in range(len(yfull[spec])): 
        data[counter].append(yfull[spec][y]) 
    counter+=1 
#list values, by row columnwise.  
""" 
f = open("data.txt", 'w') 
#feel free to rename the filename "/media/kez..../data.txt" as 
you need 
#for y in range(len(data[0])): 
#    for x in range(len(data)): 
#        f.write(str(data[x][y]) + " ") 
#    f.write("\n") 
for x in range (len(out_RET)): 
     f.write(str(yfull['RETpgout'][x]) + "\n") 
f.close() 
 





Appendix	  VI.	  DynaFit	  scripts	  for	  ERK	  decay	  in	  the	  RET/Raf/MEK/ERK	  cascade	  	  
[task] 
 task = fit 
 data = progress 
 
[mechanism] 
; RET + ART  ----> RET' + ART : k0 ; ART Activation 
; RET' ----> RET   : k-0 
 RET <----> pRET  : k1 k-1 
 Raf + Ras-GTP ---> pRaf + Ras-GTP : k2   
 pRaf ---> Raf : k-2 
 pRaf + MEK ---> pMEK + pRaf : k3   
 pMEK ---> MEK : k-3 
 pMEK + ERK ---> pMEK + pERK : k4 
 pERK ---> ERK : k-4 
 
 RET + ZD6474 ----> RET-ZD : kinhRET ; inhibition of RET 
by ZD6474 
 pRaf + SB590885 ---> pRaf-SB : kinhRaf ; 
inhibition of Raf by SB590885 
 pMEK + CI1040 ---> pMEK-CI : kinhMEK ; inhibition of 
MEK by CI1040 
 
[constants] 
 k1 = 10 ?? (0 .. 20) 
 k-1 = 0.7  
 k2 = 0.1 ?? (0 .. 1) 
 k-2 = 1 ?? (0 .. 10) 
 k3 = 0.01 ?? (0.01 .. 0.1) 
 k-3 = 0.476 ?? (0 .. 1) 
 k4 = 0.0447 ?? (0 .. 0.1) 
 k-4 = 0.642 ?? 
 kinhRET = 10000000000 
 kinhRaf = 10000000000  
 kinhMEK = 10000000000  
 
[concentrations] 
 pRET = 4.2, RET = 2.3, pERK = 142, ERK = 142, Raf = 14.2 
 pRaf = 14.2, pMEK = 14.2, MEK = 142 
 
[data]  
 sheet ./ERK/Data/ERKdecay.txt 
 column 2 | concentration ZD6474 = 100000000000000000000 | 





 column 3 | concentration SB590885 = 100000000000000000000 | 
response pERK = 1 
 column 4 | concentration CI1040 = 100000000000000000000 | 






 XAxisLabel = Time (minutes) 







Appendix	  VII.	  DynaFit	  scripts	  for	  ERK	  activation	  in	  the	  RET/Raf/MEK/ERK	  cascade	  	  
[task] 
 task = fit 
 data = progress 
 
[mechanism] 
 RET + ART  ----> RET' + ART : k0 ; ART Activation 
 RET' ----> RET   : k-0 
 RET' <----> pRET  : k1 k-1 
 Raf + pRET ---> pRaf + pRET : k2   
 pRaf ---> Raf : k-2 
 pRaf + MEK ---> pMEK + pRaf : k3    
 pMEK ---> MEK : k-3 
 pMEK + ERK ---> pMEK + pERK : k4 
 pERK ---> ERK : k-4 
 
 [constants] 
 k0 = 3.1e7 
 k-0 = 0.37 
 k1 = 9.2  
 k-1 = 0.7  
 k2 = 0.37 ?? (0 .. 1) 
 k-2 = 1 ;?? (0 .. 10) 
 k3 = 0.01 ?? (0.01 .. 0.1) 
 k-3 = 0.476 ;?? (0 .. 1) 
 k4 = 0.0088 ?? (0 .. 0.1) 
 k-4 = 0.63 ;?? (0.36 .. 0.63) 
 
 [concentrations] 
 pRET = 0, RET = 6.5, pERK = 0, ERK = 284, Raf = 28.4 
 pRaf = 0, MEK = 284, pMEK = 0 
 
[data] 
 sheet ./ERK/Data/ERK10min.txt 
 
 column 2 | concentration ART = 10e-9 | response pERK = 1 
 column 3 | concentration ART = 4e-9| response pERK = 1 
 column 4 | concentration ART = 1e-9 | response pERK = 1 
 column 5 | concentration ART = 0.4e-9| response pERK = 1 










 YAxisLabel = (10^3 molecules/cell) 
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